@prefix dcterms:	<http://purl.org/dc/terms/> .
@prefix ns1:	<http://bio2rdf.org/drugbank_resource:> .
ns1:DB00231_DB00277	dcterms:title	"DDI between Temazepam and Theophylline - Theophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Theophylline is initiated, discontinued or dose changed."@en .
@prefix ns2:	<http://bio2rdf.org/drugbank_vocabulary:> .
@prefix ns3:	<http://bio2rdf.org/drugbank:> .
ns1:DB00231_DB00277	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00231 .
ns1:DB00231_DB00363	dcterms:title	"DDI between Temazepam and Clozapine - The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00231 ,
		ns3:DB00363 .
ns1:DB00231_DB00427	dcterms:title	"DDI between Temazepam and Triprolidine - The CNS depressants, Triprolidine and Temazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00231 ,
		ns3:DB00427 .
ns1:DB00231_DB00651	dcterms:title	"DDI between Temazepam and Dyphylline - Dyphylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Dyphylline is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00231 .
ns1:DB00231_DB01223	dcterms:title	"DDI between Temazepam and Aminophylline - Aminophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Aminophylline is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00231 .
ns1:DB00231_DB01322	dcterms:title	"DDI between Temazepam and Kava - Kava may increase the effect of the benzodiazepine, temazepam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01322 ,
		ns3:DB00231 .
ns1:DB00232_DB00374	dcterms:title	"DDI between Methyclothiazide and Treprostinil - Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00232 ,
		ns3:DB00374 .
ns1:DB00232_DB00390	dcterms:title	"DDI between Methyclothiazide and Digoxin - Possible electrolyte variations and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00232 ,
		ns3:DB00390 .
ns1:DB00232_DB00519	dcterms:title	"DDI between Methyclothiazide and Trandolapril - The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00232 ,
		ns3:DB00519 .
ns1:DB00232_DB01356	dcterms:title	"DDI between Methyclothiazide and Lithium - The thiazide diuretic, methyclothiazide, may increase serum levels of lithium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00232 ,
		ns3:DB01356 .
ns1:DB00233_DB00352	dcterms:title	"DDI between Aminosalicylic Acid and Thioguanine - Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00352 .
ns1:DB00233_DB00374	dcterms:title	"DDI between Aminosalicylic Acid and Treprostinil - The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00374 .
ns1:DB00233_DB00500	dcterms:title	"DDI between Aminosalicylic Acid and Tolmetin - Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00500 .
ns1:DB00233_DB00519	dcterms:title	"DDI between Aminosalicylic Acid and Trandolapril - The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00519 .
ns1:DB00233_DB00605	dcterms:title	"DDI between Aminosalicylic Acid and Sulindac - Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00605 .
ns1:DB00233_DB00682	dcterms:title	"DDI between Aminosalicylic Acid and Warfarin - The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00682 .
ns1:DB00233_DB00993	dcterms:title	"DDI between Aminosalicylic Acid and Azathioprine - Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB00993 .
ns1:DB00233_DB01033	dcterms:title	"DDI between Aminosalicylic Acid and Mercaptopurine - Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB01033 .
ns1:DB00233_DB01600	dcterms:title	"DDI between Aminosalicylic Acid and Tiaprofenic acid - Increased risk of gastrointestinal bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00233 ,
		ns3:DB01600 .
ns1:DB00236_DB00264	dcterms:title	"DDI between Pipobroman and Metoprolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00236 .
ns1:DB00236_DB00335	dcterms:title	"DDI between Pipobroman and Atenolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00335 ,
		ns3:DB00236 .
ns1:DB00236_DB00373	dcterms:title	"DDI between Pipobroman and Timolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00373 ,
		ns3:DB00236 .
ns1:DB00236_DB00489	dcterms:title	"DDI between Pipobroman and Sotalol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00489 ,
		ns3:DB00236 .
ns1:DB00236_DB00521	dcterms:title	"DDI between Pipobroman and Carteolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00521 ,
		ns3:DB00236 .
ns1:DB00236_DB00571	dcterms:title	"DDI between Pipobroman and Propranolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00571 ,
		ns3:DB00236 .
ns1:DB00236_DB00598	dcterms:title	"DDI between Pipobroman and Labetalol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00236 .
ns1:DB00236_DB00612	dcterms:title	"DDI between Pipobroman and Bisoprolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00236 .
ns1:DB00236_DB00960	dcterms:title	"DDI between Pipobroman and Pindolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00236 .
ns1:DB00236_DB01136	dcterms:title	"DDI between Pipobroman and Carvedilol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01136 ,
		ns3:DB00236 .
ns1:DB00236_DB01193	dcterms:title	"DDI between Pipobroman and Acebutolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01193 ,
		ns3:DB00236 .
ns1:DB00236_DB01203	dcterms:title	"DDI between Pipobroman and Nadolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00236 .
ns1:DB00236_DB01295	dcterms:title	"DDI between Pipobroman and Bevantolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01295 ,
		ns3:DB00236 .
ns1:DB00236_DB01297	dcterms:title	"DDI between Pipobroman and Practolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01297 ,
		ns3:DB00236 .
ns1:DB00236_DB01359	dcterms:title	"DDI between Pipobroman and Penbutolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00236 .
ns1:DB00236_DB01580	dcterms:title	"DDI between Pipobroman and Oxprenolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00236 .
ns1:DB00237_DB00254	dcterms:title	"DDI between Butabarbital and Doxycycline - The anticonvulsant, butabarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00237 .
ns1:DB00237_DB00255	dcterms:title	"DDI between Butabarbital and Diethylstilbestrol - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00255 ,
		ns3:DB00237 .
ns1:DB00237_DB00277	dcterms:title	"DDI between Butabarbital and Theophylline - The barbiturate, butabarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00277 .
ns1:DB00237_DB00280	dcterms:title	"DDI between Butabarbital and Disopyramide - arbiturates may increase the metabolism of Disopyramide. Monitor for decreased therapeutic effects of disopyramide if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00280 .
ns1:DB00237_DB00286	dcterms:title	"DDI between Butabarbital and Conjugated Estrogens - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00237 .
ns1:DB00237_DB00317	dcterms:title	"DDI between Butabarbital and Gefitinib - The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00317 .
ns1:DB00237_DB00321	dcterms:title	"DDI between Butabarbital and Amitriptyline - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00321 .
ns1:DB00237_DB00333	dcterms:title	"DDI between Butabarbital and Methadone - The barbiturate, butabarbital, decreases the effect of methadone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00333 .
ns1:DB00237_DB00344	dcterms:title	"DDI between Butabarbital and Protriptyline - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00344 .
ns1:DB00237_DB00351	dcterms:title	"DDI between Butabarbital and Megestrol acetate - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00351 ,
		ns3:DB00237 .
ns1:DB00237_DB00367	dcterms:title	"DDI between Butabarbital and Levonorgestrel - Phenobarbital decreases the effect of levonorgestrel"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00367 ,
		ns3:DB00237 .
ns1:DB00237_DB00400	dcterms:title	"DDI between Butabarbital and Griseofulvin - The barbiturate, butabarbital, decreases the effect of griseofulvin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00400 .
ns1:DB00237_DB00427	dcterms:title	"DDI between Butabarbital and Triprolidine - The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00427 .
ns1:DB00237_DB00443	dcterms:title	"DDI between Butabarbital and Betamethasone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00443 .
ns1:DB00237_DB00444	dcterms:title	"DDI between Butabarbital and Teniposide - Barbiturates like butabarbital may decrease the serum concentration of Teniposide. arbiturates may decrease the serum concentration of Teniposide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00444 .
ns1:DB00237_DB00450	dcterms:title	"DDI between Butabarbital and Droperidol - Droperidol may enhance the CNS depressant effect of CNS Depressants like butabarbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00450 .
ns1:DB00237_DB00458	dcterms:title	"DDI between Butabarbital and Imipramine - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00458 .
ns1:DB00237_DB00540	dcterms:title	"DDI between Butabarbital and Nortriptyline - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00540 .
ns1:DB00237_DB00543	dcterms:title	"DDI between Butabarbital and Amoxapine - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00543 .
ns1:DB00237_DB00555	dcterms:title	"DDI between Butabarbital and Lamotrigine - Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00555 ,
		ns3:DB00237 .
ns1:DB00237_DB00557	dcterms:title	"DDI between Butabarbital and Hydroxyzine - Hydroxyzine may enhance the CNS depressant effect of barbiturates like butabarbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00557 .
ns1:DB00237_DB00582	dcterms:title	"DDI between Butabarbital and Voriconazole - Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00582 .
ns1:DB00237_DB00603	dcterms:title	"DDI between Butabarbital and Medroxyprogesterone Acetate - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00603 ,
		ns3:DB00237 .
ns1:DB00237_DB00620	dcterms:title	"DDI between Butabarbital and Triamcinolone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00620 .
ns1:DB00237_DB00635	dcterms:title	"DDI between Butabarbital and Prednisone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00635 .
ns1:DB00237_DB00661	dcterms:title	"DDI between Butabarbital and Verapamil - Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00661 .
ns1:DB00237_DB00682	dcterms:title	"DDI between Butabarbital and Warfarin - Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00682 .
ns1:DB00237_DB00687	dcterms:title	"DDI between Butabarbital and Fludrocortisone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00687 .
ns1:DB00237_DB00717	dcterms:title	"DDI between Butabarbital and Norethindrone - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00717 .
ns1:DB00237_DB00726	dcterms:title	"DDI between Butabarbital and Trimipramine - The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00726 .
ns1:DB00237_DB00741	dcterms:title	"DDI between Butabarbital and Hydrocortisone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00741 .
ns1:DB00237_DB00783	dcterms:title	"DDI between Butabarbital and Estradiol - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00783 ,
		ns3:DB00237 .
ns1:DB00237_DB00860	dcterms:title	"DDI between Butabarbital and Prednisolone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00237 .
ns1:DB00237_DB00882	dcterms:title	"DDI between Butabarbital and Clomifene - The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00882 ,
		ns3:DB00237 .
ns1:DB00237_DB00908	dcterms:title	"DDI between Butabarbital and Quinidine - The anticonvulsant, butabarbital, decreases the effect of quinidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00908 .
ns1:DB00237_DB00916	dcterms:title	"DDI between Butabarbital and Metronidazole - The barbiturate, butabarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00916 .
ns1:DB00237_DB00977	dcterms:title	"DDI between Butabarbital and Ethinyl Estradiol - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB00977 .
ns1:DB00237_DB01023	dcterms:title	"DDI between Butabarbital and Felodipine - The barbiturate, butabarbital, decreases the effect of felodipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01023 .
ns1:DB00237_DB01115	dcterms:title	"DDI between Butabarbital and Nifedipine - The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01115 .
ns1:DB00237_DB01142	dcterms:title	"DDI between Butabarbital and Doxepin - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01142 .
ns1:DB00237_DB01151	dcterms:title	"DDI between Butabarbital and Desipramine - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01151 .
ns1:DB00237_DB01223	dcterms:title	"DDI between Butabarbital and Aminophylline - The barbiturate, butabarbital, decreases the effect of aminophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01223 .
ns1:DB00237_DB01234	dcterms:title	"DDI between Butabarbital and Dexamethasone - The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01234 .
ns1:DB00237_DB01242	dcterms:title	"DDI between Butabarbital and Clomipramine - Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01242 .
ns1:DB00237_DB01303	dcterms:title	"DDI between Butabarbital and Oxtriphylline - The barbiturate, butabarbital, decreases the effect of oxtriphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01303 .
ns1:DB00237_DB01418	dcterms:title	"DDI between Butabarbital and Acenocoumarol - Barbiturates like butabarbital may increase the metabolism of Vitamin K Antagonists like acenocoumarol. onitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB01418 .
ns1:DB00237_DB06210	dcterms:title	"DDI between Butabarbital and Eltrombopag - Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB06210 .
ns1:DB00237_DB06769	dcterms:title	"DDI between Butabarbital and Bendamustine - Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00237 ,
		ns3:DB06769 .
ns1:DB00238_DB00266	dcterms:title	"DDI between Nevirapine and Dicoumarol - Nevirapine may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00238 .
ns1:DB00238_DB00333	dcterms:title	"DDI between Nevirapine and Methadone - The antiretroviral agent decreases the effect of methadone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00333 ,
		ns3:DB00238 .
ns1:DB00238_DB00641	dcterms:title	"DDI between Nevirapine and Simvastatin - The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB00238 .
ns1:DB00238_DB00656	dcterms:title	"DDI between Nevirapine and Trazodone - The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00238 .
ns1:DB00238_DB00682	dcterms:title	"DDI between Nevirapine and Warfarin - Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00238 .
ns1:DB00238_DB00932	dcterms:title	"DDI between Nevirapine and Tipranavir - Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00238 .
ns1:DB00238_DB00976	dcterms:title	"DDI between Nevirapine and Telithromycin - Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00238 .
ns1:DB00238_DB01026	dcterms:title	"DDI between Nevirapine and Ketoconazole - Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00238 .
ns1:DB00238_DB01072	dcterms:title	"DDI between Nevirapine and Atazanavir - Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00238 .
ns1:DB00238_DB01076	dcterms:title	"DDI between Nevirapine and Atorvastatin - Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01076 ,
		ns3:DB00238 .
ns1:DB00238_DB01125	dcterms:title	"DDI between Nevirapine and Anisindione - Nevirapine may decrease the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00238 ,
		ns3:DB01125 .
ns1:DB00238_DB01232	dcterms:title	"DDI between Nevirapine and Saquinavir - Decreases the effect of saquinavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00238 .
ns1:DB00238_DB01323	dcterms:title	"DDI between Nevirapine and St. John's Wort - St. John's Wort decreases nevirapine effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01323 ,
		ns3:DB00238 .
ns1:DB00238_DB01369	dcterms:title	"DDI between Nevirapine and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00238 .
ns1:DB00238_DB01418	dcterms:title	"DDI between Nevirapine and Acenocoumarol - Nevirapine may decrease the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00238 ,
		ns3:DB01418 .
ns1:DB00238_DB01656	dcterms:title	"DDI between Nevirapine and Roflumilast - Affects CYP3A4 metabolism, decreases level or effect of roflumilast."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00238 ,
		ns3:DB01656 .
ns1:DB00238_DB05294	dcterms:title	"DDI between Nevirapine and Vandetanib - Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05294 ,
		ns3:DB00238 .
ns1:DB00238_DB06287	dcterms:title	"DDI between Nevirapine and Temsirolimus - Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06287 ,
		ns3:DB00238 .
ns1:DB00238_DB06414	dcterms:title	"DDI between Nevirapine and Etravirine - Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00238 .
ns1:DB00238_DB08866	dcterms:title	"DDI between Nevirapine and Estradiol valerate/Dienogest  - Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08866 ,
		ns3:DB00238 .
ns1:DB00241_DB00254	dcterms:title	"DDI between Butalbital and Doxycycline - The anticonvulsant, butalbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00241 .
ns1:DB00241_DB00255	dcterms:title	"DDI between Butalbital and Diethylstilbestrol - The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00255 ,
		ns3:DB00241 .
ns1:DB00241_DB00277	dcterms:title	"DDI between Butalbital and Theophylline - The barbiturate, butalbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00241 .
ns1:DB00241_DB00286	dcterms:title	"DDI between Butalbital and Conjugated Estrogens - The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00241 .
ns1:DB00241_DB00317	dcterms:title	"DDI between Butalbital and Gefitinib - The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00317 ,
		ns3:DB00241 .
ns1:DB00241_DB00321	dcterms:title	"DDI between Butalbital and Amitriptyline - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00321 ,
		ns3:DB00241 .
ns1:DB00241_DB00333	dcterms:title	"DDI between Butalbital and Methadone - The barbiturate, butalbital, decreases the effect of methadone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00333 ,
		ns3:DB00241 .
ns1:DB00241_DB00344	dcterms:title	"DDI between Butalbital and Protriptyline - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00344 ,
		ns3:DB00241 .
ns1:DB00241_DB00351	dcterms:title	"DDI between Butalbital and Megestrol acetate - The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00351 ,
		ns3:DB00241 .
ns1:DB00241_DB00367	dcterms:title	"DDI between Butalbital and Levonorgestrel - Phenobarbital decreases the effect of levonorgestrel"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00367 ,
		ns3:DB00241 .
ns1:DB00241_DB00400	dcterms:title	"DDI between Butalbital and Griseofulvin - The barbiturate, butalbital, decreases the effect of griseofulvin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00400 ,
		ns3:DB00241 .
ns1:DB00241_DB00427	dcterms:title	"DDI between Butalbital and Triprolidine - The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00427 ,
		ns3:DB00241 .
ns1:DB00241_DB00443	dcterms:title	"DDI between Butalbital and Betamethasone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00241 .
ns1:DB00241_DB00444	dcterms:title	"DDI between Butalbital and Teniposide - Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00241 .
ns1:DB00241_DB00446	dcterms:title	"DDI between Butalbital and Chloramphenicol - Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00446 ,
		ns3:DB00241 .
ns1:DB00241_DB00450	dcterms:title	"DDI between Butalbital and Droperidol - Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00241 .
ns1:DB00241_DB00458	dcterms:title	"DDI between Butalbital and Imipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00241 .
ns1:DB00241_DB00540	dcterms:title	"DDI between Butalbital and Nortriptyline - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00540 ,
		ns3:DB00241 .
ns1:DB00241_DB00543	dcterms:title	"DDI between Butalbital and Amoxapine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00543 ,
		ns3:DB00241 .
ns1:DB00241_DB00555	dcterms:title	"DDI between Butalbital and Lamotrigine - Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00555 ,
		ns3:DB00241 .
ns1:DB00241_DB00557	dcterms:title	"DDI between Butalbital and Hydroxyzine - Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00557 ,
		ns3:DB00241 .
ns1:DB00241_DB00582	dcterms:title	"DDI between Butalbital and Voriconazole - Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00241 .
ns1:DB00241_DB00603	dcterms:title	"DDI between Butalbital and Medroxyprogesterone Acetate - The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00603 ,
		ns3:DB00241 .
ns1:DB00241_DB00620	dcterms:title	"DDI between Butalbital and Triamcinolone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB00241 .
ns1:DB00241_DB00635	dcterms:title	"DDI between Butalbital and Prednisone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00241 .
ns1:DB00241_DB00661	dcterms:title	"DDI between Butalbital and Verapamil - Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00241 .
ns1:DB00241_DB00682	dcterms:title	"DDI between Butalbital and Warfarin - Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00241 .
ns1:DB00241_DB00687	dcterms:title	"DDI between Butalbital and Fludrocortisone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00687 ,
		ns3:DB00241 .
ns1:DB00241_DB00717	dcterms:title	"DDI between Butalbital and Norethindrone - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00717 ,
		ns3:DB00241 .
ns1:DB00241_DB00726	dcterms:title	"DDI between Butalbital and Trimipramine - The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00241 .
ns1:DB00241_DB00741	dcterms:title	"DDI between Butalbital and Hydrocortisone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00741 ,
		ns3:DB00241 .
ns1:DB00241_DB00783	dcterms:title	"DDI between Butalbital and Estradiol - The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00783 ,
		ns3:DB00241 .
ns1:DB00241_DB00860	dcterms:title	"DDI between Butalbital and Prednisolone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00241 .
ns1:DB00241_DB00882	dcterms:title	"DDI between Butalbital and Clomifene - The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00882 ,
		ns3:DB00241 .
ns1:DB00241_DB00908	dcterms:title	"DDI between Butalbital and Quinidine - The anticonvulsant, butalbital, decreases the effect of quinidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00241 .
ns1:DB00241_DB00916	dcterms:title	"DDI between Butalbital and Metronidazole - The barbiturate, butalbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00916 ,
		ns3:DB00241 .
ns1:DB00241_DB00977	dcterms:title	"DDI between Butalbital and Ethinyl Estradiol - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00241 .
ns1:DB00241_DB01023	dcterms:title	"DDI between Butalbital and Felodipine - The barbiturate, butalbital, decreases the effect of felodipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01023 ,
		ns3:DB00241 .
ns1:DB00241_DB01115	dcterms:title	"DDI between Butalbital and Nifedipine - The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01115 ,
		ns3:DB00241 .
ns1:DB00241_DB01142	dcterms:title	"DDI between Butalbital and Doxepin - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00241 .
ns1:DB00241_DB01151	dcterms:title	"DDI between Butalbital and Desipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01151 ,
		ns3:DB00241 .
ns1:DB00241_DB01223	dcterms:title	"DDI between Butalbital and Aminophylline - The barbiturate, butalbital, decreases the effect of aminophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00241 .
ns1:DB00241_DB01234	dcterms:title	"DDI between Butalbital and Dexamethasone - The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01234 ,
		ns3:DB00241 .
ns1:DB00241_DB01242	dcterms:title	"DDI between Butalbital and Clomipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01242 ,
		ns3:DB00241 .
ns1:DB00241_DB01303	dcterms:title	"DDI between Butalbital and Oxtriphylline - The barbiturate, butalbital, decreases the effect of oxtriphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00241 .
ns1:DB00241_DB01418	dcterms:title	"DDI between Butalbital and Acenocoumarol - Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00241 .
ns1:DB00241_DB06210	dcterms:title	"DDI between Butalbital and Eltrombopag - Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\r\nAffects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00241 .
ns1:DB00242_DB00337	dcterms:title	"DDI between Cladribine and Pimecrolimus - Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cladribine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00337 ,
		ns3:DB00242 .
ns1:DB00242_DB00864	dcterms:title	"DDI between Cladribine and Tacrolimus - Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00242 ,
		ns3:DB00864 .
ns1:DB00242_DB01097	dcterms:title	"DDI between Cladribine and Leflunomide - Immunosuppressants such as cladribine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01097 ,
		ns3:DB00242 .
ns1:DB00242_DB01656	dcterms:title	"DDI between Cladribine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01656 ,
		ns3:DB00242 .
ns1:DB00243_DB00246	dcterms:title	"DDI between Ranolazine and Ziprasidone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00246 .
ns1:DB00243_DB00257	dcterms:title	"DDI between Ranolazine and Clotrimazole - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00257 .
ns1:DB00243_DB00280	dcterms:title	"DDI between Ranolazine and Disopyramide - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00280 .
ns1:DB00243_DB00308	dcterms:title	"DDI between Ranolazine and Ibutilide - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00308 ,
		ns3:DB00243 .
ns1:DB00243_DB00343	dcterms:title	"DDI between Ranolazine and Diltiazem - Diltiazem may increase the serum concentration of ranolazine. Consider alternate therapy or limit ranolazine dose to 500 mg twice daily and monitor for changes in the therapeutic and adverse effects if diltiazem is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00343 .
ns1:DB00243_DB00390	dcterms:title	"DDI between Ranolazine and Digoxin - Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00390 .
ns1:DB00243_DB00489	dcterms:title	"DDI between Ranolazine and Sotalol - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00489 .
ns1:DB00243_DB00503	dcterms:title	"DDI between Ranolazine and Ritonavir - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00503 .
ns1:DB00243_DB00539	dcterms:title	"DDI between Ranolazine and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00539 .
ns1:DB00243_DB00582	dcterms:title	"DDI between Ranolazine and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00582 .
ns1:DB00243_DB00641	dcterms:title	"DDI between Ranolazine and Simvastatin - Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00641 .
ns1:DB00243_DB00661	dcterms:title	"DDI between Ranolazine and Verapamil - Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00661 .
ns1:DB00243_DB00675	dcterms:title	"DDI between Ranolazine and Tamoxifen - Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00675 ,
		ns3:DB00243 .
ns1:DB00243_DB00679	dcterms:title	"DDI between Ranolazine and Thioridazine - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00243 .
ns1:DB00243_DB00680	dcterms:title	"DDI between Ranolazine and Moricizine - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00680 ,
		ns3:DB00243 .
ns1:DB00243_DB00701	dcterms:title	"DDI between Ranolazine and Amprenavir - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentratin of ranolazine by inhibiting its metabolism. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00701 .
ns1:DB00243_DB00706	dcterms:title	"DDI between Ranolazine and Tamsulosin - Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00706 .
ns1:DB00243_DB00726	dcterms:title	"DDI between Ranolazine and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00726 .
ns1:DB00243_DB00864	dcterms:title	"DDI between Ranolazine and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00864 .
ns1:DB00243_DB00872	dcterms:title	"DDI between Ranolazine and Conivaptan - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors (such as the azole antifungals).1 Monitor for increased effects/toxicity of ranolazine during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00872 ,
		ns3:DB00243 .
ns1:DB00243_DB00908	dcterms:title	"DDI between Ranolazine and Quinidine - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00243 .
ns1:DB00243_DB00932	dcterms:title	"DDI between Ranolazine and Tipranavir - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00932 .
ns1:DB00243_DB00954	dcterms:title	"DDI between Ranolazine and Dirithromycin - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00954 ,
		ns3:DB00243 .
ns1:DB00243_DB00976	dcterms:title	"DDI between Ranolazine and Telithromycin - Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB00976 .
ns1:DB00243_DB01026	dcterms:title	"DDI between Ranolazine and Ketoconazole - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01026 .
ns1:DB00243_DB01030	dcterms:title	"DDI between Ranolazine and Topotecan - The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01030 .
ns1:DB00243_DB01035	dcterms:title	"DDI between Ranolazine and Procainamide - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01035 ,
		ns3:DB00243 .
ns1:DB00243_DB01036	dcterms:title	"DDI between Ranolazine and Tolterodine - Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01036 .
ns1:DB00243_DB01072	dcterms:title	"DDI between Ranolazine and Atazanavir - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01072 .
ns1:DB00243_DB01118	dcterms:title	"DDI between Ranolazine and Amiodarone - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01118 .
ns1:DB00243_DB01128	dcterms:title	"DDI between Ranolazine and Bicalutamide - CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01128 ,
		ns3:DB00243 .
ns1:DB00243_DB01158	dcterms:title	"DDI between Ranolazine and Bretylium - Possible additive effect on QT prolongation"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01158 ,
		ns3:DB00243 .
ns1:DB00243_DB01167	dcterms:title	"DDI between Ranolazine and Itraconazole - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01167 .
ns1:DB00243_DB01211	dcterms:title	"DDI between Ranolazine and Clarithromycin - Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01211 .
ns1:DB00243_DB01232	dcterms:title	"DDI between Ranolazine and Saquinavir - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01232 .
ns1:DB00243_DB01319	dcterms:title	"DDI between Ranolazine and Fosamprenavir - Increased levels of ranolazine - risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01319 .
ns1:DB00243_DB01623	dcterms:title	"DDI between Ranolazine and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01623 .
ns1:DB00243_DB01624	dcterms:title	"DDI between Ranolazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB01624 .
ns1:DB00243_DB02546	dcterms:title	"DDI between Ranolazine and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB02546 .
ns1:DB00243_DB06697	dcterms:title	"DDI between Ranolazine and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB06697 .
ns1:DB00243_DB06708	dcterms:title	"DDI between Ranolazine and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB06708 .
ns1:DB00243_DB08919	dcterms:title	"DDI between Ranolazine and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB08919 .
ns1:DB00243_DB08920	dcterms:title	"DDI between Ranolazine and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00243 ,
		ns3:DB08920 .
ns1:DB00244_DB00352	dcterms:title	"DDI between Mesalazine and Thioguanine - Mesalazine may increase the toxicity of thiopurine, thioguanine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00244 ,
		ns3:DB00352 .
ns1:DB00244_DB00993	dcterms:title	"DDI between Mesalazine and Azathioprine - Mesalazine may increase the toxicity of thiopurine, azathioprine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00244 ,
		ns3:DB00993 .
ns1:DB00244_DB01033	dcterms:title	"DDI between Mesalazine and Mercaptopurine - Mesalazine may increase the toxicity of thiopurine, mercaptopurine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00244 ,
		ns3:DB01033 .
ns1:DB00245_DB00382	dcterms:title	"DDI between Benzatropine and Tacrine - The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Benztropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00382 ,
		ns3:DB00245 .
ns1:DB00245_DB00427	dcterms:title	"DDI between Benzatropine and Triprolidine - Triprolidine and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00245 ,
		ns3:DB00427 .
ns1:DB00245_DB00502	dcterms:title	"DDI between Benzatropine and Haloperidol - The anticholinergic increases the risk of psychosis and tardive dyskinesia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00502 ,
		ns3:DB00245 .
ns1:DB00245_DB00662	dcterms:title	"DDI between Benzatropine and Trimethobenzamide - Trimethobenzamide and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00245 ,
		ns3:DB00662 .
ns1:DB00245_DB00674	dcterms:title	"DDI between Benzatropine and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00674 ,
		ns3:DB00245 .
ns1:DB00245_DB00843	dcterms:title	"DDI between Benzatropine and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00843 ,
		ns3:DB00245 .
ns1:DB00245_DB00989	dcterms:title	"DDI between Benzatropine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00245 .
ns1:DB00246_DB00268	dcterms:title	"DDI between Ziprasidone and Ropinirole - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB00246 .
ns1:DB00246_DB00270	dcterms:title	"DDI between Ziprasidone and Isradipine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00270 ,
		ns3:DB00246 .
ns1:DB00246_DB00280	dcterms:title	"DDI between Ziprasidone and Disopyramide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00280 .
ns1:DB00246_DB00308	dcterms:title	"DDI between Ziprasidone and Ibutilide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00308 ,
		ns3:DB00246 .
ns1:DB00246_DB00321	dcterms:title	"DDI between Ziprasidone and Amitriptyline - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00321 ,
		ns3:DB00246 .
ns1:DB00246_DB00333	dcterms:title	"DDI between Ziprasidone and Methadone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00333 ,
		ns3:DB00246 .
ns1:DB00246_DB00344	dcterms:title	"DDI between Ziprasidone and Protriptyline - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00344 ,
		ns3:DB00246 .
ns1:DB00246_DB00358	dcterms:title	"DDI between Ziprasidone and Mefloquine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00358 ,
		ns3:DB00246 .
ns1:DB00246_DB00382	dcterms:title	"DDI between Ziprasidone and Tacrine - Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00382 ,
		ns3:DB00246 .
ns1:DB00246_DB00408	dcterms:title	"DDI between Ziprasidone and Loxapine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00408 ,
		ns3:DB00246 .
ns1:DB00246_DB00413	dcterms:title	"DDI between Ziprasidone and Pramipexole - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00413 ,
		ns3:DB00246 .
ns1:DB00246_DB00427	dcterms:title	"DDI between Ziprasidone and Triprolidine - The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00427 ,
		ns3:DB00246 .
ns1:DB00246_DB00450	dcterms:title	"DDI between Ziprasidone and Droperidol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00246 .
ns1:DB00246_DB00458	dcterms:title	"DDI between Ziprasidone and Imipramine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00246 .
ns1:DB00246_DB00468	dcterms:title	"DDI between Ziprasidone and Quinine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00468 ,
		ns3:DB00246 .
ns1:DB00246_DB00472	dcterms:title	"DDI between Ziprasidone and Fluoxetine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00472 .
ns1:DB00246_DB00477	dcterms:title	"DDI between Ziprasidone and Chlorpromazine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00477 ,
		ns3:DB00246 .
ns1:DB00246_DB00489	dcterms:title	"DDI between Ziprasidone and Sotalol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00489 .
ns1:DB00246_DB00502	dcterms:title	"DDI between Ziprasidone and Haloperidol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00502 ,
		ns3:DB00246 .
ns1:DB00246_DB00529	dcterms:title	"DDI between Ziprasidone and Foscarnet - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00529 .
ns1:DB00246_DB00539	dcterms:title	"DDI between Ziprasidone and Toremifene - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00539 .
ns1:DB00246_DB00540	dcterms:title	"DDI between Ziprasidone and Nortriptyline - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00540 ,
		ns3:DB00246 .
ns1:DB00246_DB00543	dcterms:title	"DDI between Ziprasidone and Amoxapine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00543 ,
		ns3:DB00246 .
ns1:DB00246_DB00556	dcterms:title	"DDI between Ziprasidone and Perflutren - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00556 ,
		ns3:DB00246 .
ns1:DB00246_DB00564	dcterms:title	"DDI between Ziprasidone and Carbamazepine - Increases the effect and toxicity of ziprasidone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00564 .
ns1:DB00246_DB00582	dcterms:title	"DDI between Ziprasidone and Voriconazole - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00582 .
ns1:DB00246_DB00604	dcterms:title	"DDI between Ziprasidone and Cisapride - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00246 .
ns1:DB00246_DB00674	dcterms:title	"DDI between Ziprasidone and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00674 ,
		ns3:DB00246 .
ns1:DB00246_DB00679	dcterms:title	"DDI between Ziprasidone and Thioridazine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00246 .
ns1:DB00246_DB00714	dcterms:title	"DDI between Ziprasidone and Apomorphine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00714 ,
		ns3:DB00246 .
ns1:DB00246_DB00726	dcterms:title	"DDI between Ziprasidone and Trimipramine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00246 .
ns1:DB00246_DB00734	dcterms:title	"DDI between Ziprasidone and Risperidone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00734 ,
		ns3:DB00246 .
ns1:DB00246_DB00738	dcterms:title	"DDI between Ziprasidone and Pentamidine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00738 ,
		ns3:DB00246 .
ns1:DB00246_DB00757	dcterms:title	"DDI between Ziprasidone and Dolasetron - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00757 ,
		ns3:DB00246 .
ns1:DB00246_DB00808	dcterms:title	"DDI between Ziprasidone and Indapamide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00808 ,
		ns3:DB00246 .
ns1:DB00246_DB00843	dcterms:title	"DDI between Ziprasidone and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00843 ,
		ns3:DB00246 .
ns1:DB00246_DB00864	dcterms:title	"DDI between Ziprasidone and Tacrolimus - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00246 .
ns1:DB00246_DB00875	dcterms:title	"DDI between Ziprasidone and Flupentixol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00875 ,
		ns3:DB00246 .
ns1:DB00246_DB00908	dcterms:title	"DDI between Ziprasidone and Quinidine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00246 .
ns1:DB00246_DB00915	dcterms:title	"DDI between Ziprasidone and Amantadine - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB00246 .
ns1:DB00246_DB00933	dcterms:title	"DDI between Ziprasidone and Mesoridazine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00246 .
ns1:DB00246_DB00934	dcterms:title	"DDI between Ziprasidone and Maprotiline - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB00246 .
ns1:DB00246_DB00976	dcterms:title	"DDI between Ziprasidone and Telithromycin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00976 .
ns1:DB00246_DB01026	dcterms:title	"DDI between Ziprasidone and Ketoconazole - Ketoconazole increases the effect and toxicity of ziprasidone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01026 .
ns1:DB00246_DB01035	dcterms:title	"DDI between Ziprasidone and Procainamide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01035 ,
		ns3:DB00246 .
ns1:DB00246_DB01044	dcterms:title	"DDI between Ziprasidone and Gatifloxacin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01044 ,
		ns3:DB00246 .
ns1:DB00246_DB01059	dcterms:title	"DDI between Ziprasidone and Norfloxacin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01059 .
ns1:DB00246_DB01100	dcterms:title	"DDI between Ziprasidone and Pimozide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01100 ,
		ns3:DB00246 .
ns1:DB00246_DB01118	dcterms:title	"DDI between Ziprasidone and Amiodarone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01118 .
ns1:DB00246_DB01137	dcterms:title	"DDI between Ziprasidone and Levofloxacin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01137 .
ns1:DB00246_DB01142	dcterms:title	"DDI between Ziprasidone and Doxepin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01142 .
ns1:DB00246_DB01151	dcterms:title	"DDI between Ziprasidone and Desipramine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01151 .
ns1:DB00246_DB01169	dcterms:title	"DDI between Ziprasidone and Arsenic trioxide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01169 ,
		ns3:DB00246 .
ns1:DB00246_DB01175	dcterms:title	"DDI between Ziprasidone and Escitalopram - Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01175 .
ns1:DB00246_DB01182	dcterms:title	"DDI between Ziprasidone and Propafenone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01182 .
ns1:DB00246_DB01184	dcterms:title	"DDI between Ziprasidone and Domperidone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01184 ,
		ns3:DB00246 .
ns1:DB00246_DB01186	dcterms:title	"DDI between Ziprasidone and Pergolide - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01186 .
ns1:DB00246_DB01195	dcterms:title	"DDI between Ziprasidone and Flecainide - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01195 ,
		ns3:DB00246 .
ns1:DB00246_DB01200	dcterms:title	"DDI between Ziprasidone and Bromocriptine - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01200 .
ns1:DB00246_DB01208	dcterms:title	"DDI between Ziprasidone and Sparfloxacin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01208 .
ns1:DB00246_DB01211	dcterms:title	"DDI between Ziprasidone and Clarithromycin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01211 .
ns1:DB00246_DB01218	dcterms:title	"DDI between Ziprasidone and Halofantrine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01218 ,
		ns3:DB00246 .
ns1:DB00246_DB01224	dcterms:title	"DDI between Ziprasidone and Quetiapine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01224 .
ns1:DB00246_DB01235	dcterms:title	"DDI between Ziprasidone and L-DOPA - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01235 ,
		ns3:DB00246 .
ns1:DB00246_DB01242	dcterms:title	"DDI between Ziprasidone and Clomipramine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01242 .
ns1:DB00246_DB01254	dcterms:title	"DDI between Ziprasidone and Dasatinib - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01254 .
ns1:DB00246_DB01259	dcterms:title	"DDI between Ziprasidone and Lapatinib - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01259 .
ns1:DB00246_DB01268	dcterms:title	"DDI between Ziprasidone and Sunitinib - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01268 .
ns1:DB00246_DB01403	dcterms:title	"DDI between Ziprasidone and Methotrimeprazine - Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01403 .
ns1:DB00246_DB01599	dcterms:title	"DDI between Ziprasidone and Probucol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01599 .
ns1:DB00246_DB01623	dcterms:title	"DDI between Ziprasidone and Thiothixene - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01623 .
ns1:DB00246_DB01624	dcterms:title	"DDI between Ziprasidone and Zuclopenthixol - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB01624 .
ns1:DB00246_DB02546	dcterms:title	"DDI between Ziprasidone and Vorinostat - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB02546 .
ns1:DB00246_DB04844	dcterms:title	"DDI between Ziprasidone and Tetrabenazine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB04844 .
ns1:DB00246_DB04855	dcterms:title	"DDI between Ziprasidone and Dronedarone - Additive QTc-prolongation may occur. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB04855 .
ns1:DB00246_DB04868	dcterms:title	"DDI between Ziprasidone and Nilotinib - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB04868 .
ns1:DB00246_DB04946	dcterms:title	"DDI between Ziprasidone and Iloperidone - Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04946 ,
		ns3:DB00246 .
ns1:DB00246_DB05271	dcterms:title	"DDI between Ziprasidone and Rotigotine - The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB05271 .
ns1:DB00246_DB06176	dcterms:title	"DDI between Ziprasidone and Romidepsin - Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06176 ,
		ns3:DB00246 .
ns1:DB00246_DB06216	dcterms:title	"DDI between Ziprasidone and Asenapine - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB06216 .
ns1:DB00246_DB06402	dcterms:title	"DDI between Ziprasidone and Telavancin - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06402 ,
		ns3:DB00246 .
ns1:DB00246_DB06589	dcterms:title	"DDI between Ziprasidone and Pazopanib - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB06589 .
ns1:DB00246_DB06697	dcterms:title	"DDI between Ziprasidone and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB06697 .
ns1:DB00246_DB06708	dcterms:title	"DDI between Ziprasidone and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB06708 .
ns1:DB00246_DB08919	dcterms:title	"DDI between Ziprasidone and Zuclopenthixol acetate - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB08919 .
ns1:DB00246_DB08920	dcterms:title	"DDI between Ziprasidone and Zuclopenthixol decanoate - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB08920 .
ns1:DB00247_DB00264	dcterms:title	"DDI between Methysergide and Metoprolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00264 .
ns1:DB00247_DB00315	dcterms:title	"DDI between Methysergide and Zolmitriptan - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00315 .
ns1:DB00247_DB00335	dcterms:title	"DDI between Methysergide and Atenolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00335 .
ns1:DB00247_DB00373	dcterms:title	"DDI between Methysergide and Timolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00373 .
ns1:DB00247_DB00489	dcterms:title	"DDI between Methysergide and Sotalol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00489 .
ns1:DB00247_DB00521	dcterms:title	"DDI between Methysergide and Carteolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00521 .
ns1:DB00247_DB00571	dcterms:title	"DDI between Methysergide and Propranolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00571 .
ns1:DB00247_DB00598	dcterms:title	"DDI between Methysergide and Labetalol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00598 .
ns1:DB00247_DB00612	dcterms:title	"DDI between Methysergide and Bisoprolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00612 .
ns1:DB00247_DB00625	dcterms:title	"DDI between Methysergide and Efavirenz - The antiretroviral agent may increase the ergot derivative toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00625 .
ns1:DB00247_DB00669	dcterms:title	"DDI between Methysergide and Sumatriptan - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB00247 .
ns1:DB00247_DB00705	dcterms:title	"DDI between Methysergide and Delavirdine - The antiretroviral agent may increase the ergot derivative toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00705 ,
		ns3:DB00247 .
ns1:DB00247_DB00727	dcterms:title	"DDI between Methysergide and Nitroglycerin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00727 .
ns1:DB00247_DB00883	dcterms:title	"DDI between Methysergide and Isosorbide Dinitrate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00883 ,
		ns3:DB00247 .
ns1:DB00247_DB00918	dcterms:title	"DDI between Methysergide and Almotriptan - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00918 ,
		ns3:DB00247 .
ns1:DB00247_DB00952	dcterms:title	"DDI between Methysergide and Naratriptan - Possible severe and prolonged vasoconstriction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00952 ,
		ns3:DB00247 .
ns1:DB00247_DB00953	dcterms:title	"DDI between Methysergide and Rizatriptan - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00953 ,
		ns3:DB00247 .
ns1:DB00247_DB00960	dcterms:title	"DDI between Methysergide and Pindolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00960 .
ns1:DB00247_DB00976	dcterms:title	"DDI between Methysergide and Telithromycin - Risk of ergotism and severe ischemia with this association"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB00976 .
ns1:DB00247_DB00998	dcterms:title	"DDI between Methysergide and Frovatriptan - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB00247 .
ns1:DB00247_DB01020	dcterms:title	"DDI between Methysergide and Isosorbide Mononitrate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01020 ,
		ns3:DB00247 .
ns1:DB00247_DB01105	dcterms:title	"DDI between Methysergide and Sibutramine - Possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01105 .
ns1:DB00247_DB01136	dcterms:title	"DDI between Methysergide and Carvedilol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01136 .
ns1:DB00247_DB01193	dcterms:title	"DDI between Methysergide and Acebutolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01193 .
ns1:DB00247_DB01203	dcterms:title	"DDI between Methysergide and Nadolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01203 .
ns1:DB00247_DB01211	dcterms:title	"DDI between Methysergide and Clarithromycin - Risk of ergotism and severe ischemia with this association"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01211 .
ns1:DB00247_DB01263	dcterms:title	"DDI between Methysergide and Posaconazole - Contraindicated co-administration"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01263 .
ns1:DB00247_DB01295	dcterms:title	"DDI between Methysergide and Bevantolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01295 .
ns1:DB00247_DB01297	dcterms:title	"DDI between Methysergide and Practolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01297 .
ns1:DB00247_DB01321	dcterms:title	"DDI between Methysergide and Josamycin - Possible ergotism and severe ischemia with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01321 .
ns1:DB00247_DB01359	dcterms:title	"DDI between Methysergide and Penbutolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01359 .
ns1:DB00247_DB01361	dcterms:title	"DDI between Methysergide and Troleandomycin - Possible ergotism and severe ischemia with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01361 .
ns1:DB00247_DB01580	dcterms:title	"DDI between Methysergide and Oxprenolol - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01580 .
ns1:DB00247_DB01612	dcterms:title	"DDI between Methysergide and Amyl Nitrite - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01612 .
ns1:DB00247_DB01613	dcterms:title	"DDI between Methysergide and Erythrityl Tetranitrate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB01613 .
ns1:DB00247_DB06154	dcterms:title	"DDI between Methysergide and Pentaerythritol Tetranitrate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00247 ,
		ns3:DB06154 .
ns1:DB00248_DB00285	dcterms:title	"DDI between Cabergoline and Venlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00285 .
ns1:DB00248_DB00315	dcterms:title	"DDI between Cabergoline and Zolmitriptan - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \r\nUse of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00315 .
ns1:DB00248_DB00582	dcterms:title	"DDI between Cabergoline and Voriconazole - Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00582 .
ns1:DB00248_DB00656	dcterms:title	"DDI between Cabergoline and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00656 .
ns1:DB00248_DB00726	dcterms:title	"DDI between Cabergoline and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00726 .
ns1:DB00248_DB00752	dcterms:title	"DDI between Cabergoline and Tranylcypromine - Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00248 ,
		ns3:DB00752 .
ns1:DB00250_DB00440	dcterms:title	"DDI between Dapsone and Trimethoprim - Increased toxicity of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00440 ,
		ns3:DB00250 .
ns1:DB00250_DB00582	dcterms:title	"DDI between Dapsone and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00250 .
ns1:DB00250_DB00615	dcterms:title	"DDI between Dapsone and Rifabutin - Decreased levels of dapsone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00250 .
ns1:DB00250_DB00976	dcterms:title	"DDI between Dapsone and Telithromycin - Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00250 .
ns1:DB00250_DB01045	dcterms:title	"DDI between Dapsone and Rifampicin - Decreased levels of dapsone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00250 .
ns1:DB00250_DB01124	dcterms:title	"DDI between Dapsone and Tolbutamide - Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01124 ,
		ns3:DB00250 .
ns1:DB00250_DB01370	dcterms:title	"DDI between Dapsone and Aluminium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00250 ,
		ns3:DB01370 .
ns1:DB00250_DB01373	dcterms:title	"DDI between Dapsone and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00250 ,
		ns3:DB01373 .
ns1:DB00250_DB01377	dcterms:title	"DDI between Dapsone and Magnesium oxide - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00250 ,
		ns3:DB01377 .
ns1:DB00250_DB01378	dcterms:title	"DDI between Dapsone and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00250 ,
		ns3:DB01378 .
ns1:DB00250_DB06708	dcterms:title	"DDI between Dapsone and Lumefantrine - Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB00250 .
ns1:DB00252_DB00254	dcterms:title	"DDI between Phenytoin and Doxycycline - The anticonvulsant, phenytoin, may decrease the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00254 .
ns1:DB00252_DB00255	dcterms:title	"DDI between Phenytoin and Diethylstilbestrol - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00255 .
ns1:DB00252_DB00262	dcterms:title	"DDI between Phenytoin and Carmustine - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00262 .
ns1:DB00252_DB00266	dcterms:title	"DDI between Phenytoin and Dicoumarol - Increased hydantoin levels and risk of bleeding"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00252 .
ns1:DB00252_DB00269	dcterms:title	"DDI between Phenytoin and Chlorotrianisene - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00269 .
ns1:DB00252_DB00273	dcterms:title	"DDI between Phenytoin and Topiramate - Increased phenytoin/decreased topiramate"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00273 .
ns1:DB00252_DB00277	dcterms:title	"DDI between Phenytoin and Theophylline - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00277 .
ns1:DB00252_DB00280	dcterms:title	"DDI between Phenytoin and Disopyramide - The hydantoin decreases the effect of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00280 .
ns1:DB00252_DB00286	dcterms:title	"DDI between Phenytoin and Conjugated Estrogens - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00286 .
ns1:DB00252_DB00290	dcterms:title	"DDI between Phenytoin and Bleomycin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00290 .
ns1:DB00252_DB00317	dcterms:title	"DDI between Phenytoin and Gefitinib - The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00317 ,
		ns3:DB00252 .
ns1:DB00252_DB00333	dcterms:title	"DDI between Phenytoin and Methadone - The hydantoin decreases the effect of methadone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00333 ,
		ns3:DB00252 .
ns1:DB00252_DB00338	dcterms:title	"DDI between Phenytoin and Omeprazole - Omeprazole increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00338 ,
		ns3:DB00252 .
ns1:DB00252_DB00351	dcterms:title	"DDI between Phenytoin and Megestrol acetate - The enzyme inducer, phenytoin, may decrease the effect of megestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00351 .
ns1:DB00252_DB00359	dcterms:title	"DDI between Phenytoin and Sulfadiazine - The sulfonamide increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00359 .
ns1:DB00252_DB00363	dcterms:title	"DDI between Phenytoin and Clozapine - Phenytoin may decrease the effect of clozapine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00363 ,
		ns3:DB00252 .
ns1:DB00252_DB00364	dcterms:title	"DDI between Phenytoin and Sucralfate - Sucralfate decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00364 .
ns1:DB00252_DB00367	dcterms:title	"DDI between Phenytoin and Levonorgestrel - Phenytoin decreases the contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00367 .
ns1:DB00252_DB00370	dcterms:title	"DDI between Phenytoin and Mirtazapine - The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00370 ,
		ns3:DB00252 .
ns1:DB00252_DB00379	dcterms:title	"DDI between Phenytoin and Mexiletine - The hydantoin decreases the effect of mexiletine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00379 ,
		ns3:DB00252 .
ns1:DB00252_DB00401	dcterms:title	"DDI between Phenytoin and Nisoldipine - Phenytoin decreases the efficiency of nisoldipine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00401 .
ns1:DB00252_DB00404	dcterms:title	"DDI between Phenytoin and Alprazolam - Phenytoin may increase the metabolism of alprazolam via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00404 ,
		ns3:DB00252 .
ns1:DB00252_DB00427	dcterms:title	"DDI between Phenytoin and Triprolidine - The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00427 ,
		ns3:DB00252 .
ns1:DB00252_DB00440	dcterms:title	"DDI between Phenytoin and Trimethoprim - Trimethoprim increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00440 ,
		ns3:DB00252 .
ns1:DB00252_DB00443	dcterms:title	"DDI between Phenytoin and Betamethasone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00443 .
ns1:DB00252_DB00446	dcterms:title	"DDI between Phenytoin and Chloramphenicol - Increases phenytoin, modifies chloramphenicol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00446 .
ns1:DB00252_DB00472	dcterms:title	"DDI between Phenytoin and Fluoxetine - Fluoxetine increases the effect of phenytoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00252 .
ns1:DB00252_DB00475	dcterms:title	"DDI between Phenytoin and Chlordiazepoxide - Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00475 .
ns1:DB00252_DB00501	dcterms:title	"DDI between Phenytoin and Cimetidine - Cimetidine may increase the therapeutic effect of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00501 .
ns1:DB00252_DB00515	dcterms:title	"DDI between Phenytoin and Cisplatin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00515 ,
		ns3:DB00252 .
ns1:DB00252_DB00537	dcterms:title	"DDI between Phenytoin and Ciprofloxacin - Ciprofloxacin may decrease the therapeutic effect of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00537 ,
		ns3:DB00252 .
ns1:DB00252_DB00544	dcterms:title	"DDI between Phenytoin and Fluorouracil - Fluorouracil increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00544 ,
		ns3:DB00252 .
ns1:DB00252_DB00553	dcterms:title	"DDI between Phenytoin and Methoxsalen - The hydantoin decreases the effect of psoralene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00553 .
ns1:DB00252_DB00555	dcterms:title	"DDI between Phenytoin and Lamotrigine - Phenytoin may reduce levels of lamotrigine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00555 .
ns1:DB00252_DB00563	dcterms:title	"DDI between Phenytoin and Methotrexate - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00563 ,
		ns3:DB00252 .
ns1:DB00252_DB00570	dcterms:title	"DDI between Phenytoin and Vinblastine - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00570 ,
		ns3:DB00252 .
ns1:DB00252_DB00576	dcterms:title	"DDI between Phenytoin and Sulfamethizole - The sulfonamide increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00576 .
ns1:DB00252_DB00582	dcterms:title	"DDI between Phenytoin and Voriconazole - Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00252 .
ns1:DB00252_DB00603	dcterms:title	"DDI between Phenytoin and Medroxyprogesterone Acetate - The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00603 .
ns1:DB00252_DB00619	dcterms:title	"DDI between Phenytoin and Imatinib - The hydantoin decreases the levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00252 .
ns1:DB00252_DB00620	dcterms:title	"DDI between Phenytoin and Triamcinolone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB00252 .
ns1:DB00252_DB00628	dcterms:title	"DDI between Phenytoin and Clorazepate - Phenytoin may increase the metabolism of clorazepate via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00628 .
ns1:DB00252_DB00635	dcterms:title	"DDI between Phenytoin and Prednisone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00252 .
ns1:DB00252_DB00643	dcterms:title	"DDI between Phenytoin and Mebendazole - The hydantoin decreases the efficiency of mebendazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00643 .
ns1:DB00252_DB00651	dcterms:title	"DDI between Phenytoin and Dyphylline - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00252 .
ns1:DB00252_DB00655	dcterms:title	"DDI between Phenytoin and Estrone - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00655 .
ns1:DB00252_DB00656	dcterms:title	"DDI between Phenytoin and Trazodone - The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00252 .
ns1:DB00252_DB00661	dcterms:title	"DDI between Phenytoin and Verapamil - Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00252 .
ns1:DB00252_DB00673	dcterms:title	"DDI between Phenytoin and Aprepitant - The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00673 .
ns1:DB00252_DB00682	dcterms:title	"DDI between Phenytoin and Warfarin - Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00252 .
ns1:DB00252_DB00683	dcterms:title	"DDI between Phenytoin and Midazolam - Phenytoin may increase the metabolism of midazolam via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00683 .
ns1:DB00252_DB00684	dcterms:title	"DDI between Phenytoin and Tobramycin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00684 ,
		ns3:DB00252 .
ns1:DB00252_DB00687	dcterms:title	"DDI between Phenytoin and Fludrocortisone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00687 ,
		ns3:DB00252 .
ns1:DB00252_DB00690	dcterms:title	"DDI between Phenytoin and Flurazepam - Phenytoin may increase the metabolism of flurazepam via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00690 .
ns1:DB00252_DB00695	dcterms:title	"DDI between Phenytoin and Furosemide - The hydantoin decreases the effect of furosemide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00695 .
ns1:DB00252_DB00705	dcterms:title	"DDI between Phenytoin and Delavirdine - The anticonvulsant, phenytoin, decreases the effect of delavirdine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00705 .
ns1:DB00252_DB00717	dcterms:title	"DDI between Phenytoin and Norethindrone - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00717 .
ns1:DB00252_DB00732	dcterms:title	"DDI between Phenytoin and Atracurium - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00732 .
ns1:DB00252_DB00741	dcterms:title	"DDI between Phenytoin and Hydrocortisone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00741 .
ns1:DB00252_DB00755	dcterms:title	"DDI between Phenytoin and Tretinoin - The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00755 .
ns1:DB00252_DB00762	dcterms:title	"DDI between Phenytoin and Irinotecan - The hydantoin decreases the effect of irinotecan"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00762 .
ns1:DB00252_DB00776	dcterms:title	"DDI between Phenytoin and Oxcarbazepine - Oxcarbazepine increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00776 .
ns1:DB00252_DB00783	dcterms:title	"DDI between Phenytoin and Estradiol - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00783 .
ns1:DB00252_DB00812	dcterms:title	"DDI between Phenytoin and Phenylbutazone - The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00812 .
ns1:DB00252_DB00822	dcterms:title	"DDI between Phenytoin and Disulfiram - Disulfiram may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00822 .
ns1:DB00252_DB00829	dcterms:title	"DDI between Phenytoin and Diazepam - Phenytoin may increase the metabolism of diazepam via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00829 .
ns1:DB00252_DB00860	dcterms:title	"DDI between Phenytoin and Prednisolone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00860 .
ns1:DB00252_DB00864	dcterms:title	"DDI between Phenytoin and Tacrolimus - Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00864 .
ns1:DB00252_DB00877	dcterms:title	"DDI between Phenytoin and Sirolimus - The hydantoin decreases sirolimus levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00877 .
ns1:DB00252_DB00882	dcterms:title	"DDI between Phenytoin and Clomifene - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00882 .
ns1:DB00252_DB00897	dcterms:title	"DDI between Phenytoin and Triazolam - Phenytoin may increase the metabolism of triazolam via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00897 .
ns1:DB00252_DB00908	dcterms:title	"DDI between Phenytoin and Quinidine - The anticonvulsant, phenytoin, decreases the effect of quinidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00908 .
ns1:DB00252_DB00930	dcterms:title	"DDI between Phenytoin and Colesevelam - Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00930 .
ns1:DB00252_DB00932	dcterms:title	"DDI between Phenytoin and Tipranavir - Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00932 .
ns1:DB00252_DB00949	dcterms:title	"DDI between Phenytoin and Felbamate - Increased phenytoin levels and decreased felbamate levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00949 .
ns1:DB00252_DB00951	dcterms:title	"DDI between Phenytoin and Isoniazid - Isoniazid increases the effect of phenytoin in 20% of patients"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00951 .
ns1:DB00252_DB00958	dcterms:title	"DDI between Phenytoin and Carboplatin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00958 .
ns1:DB00252_DB00959	dcterms:title	"DDI between Phenytoin and Methylprednisolone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00959 .
ns1:DB00252_DB00976	dcterms:title	"DDI between Phenytoin and Telithromycin - Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00976 .
ns1:DB00252_DB00977	dcterms:title	"DDI between Phenytoin and Ethinyl Estradiol - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00977 .
ns1:DB00252_DB00988	dcterms:title	"DDI between Phenytoin and Dopamine - Risk of severe hypotension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00988 .
ns1:DB00252_DB00996	dcterms:title	"DDI between Phenytoin and Gabapentin - Gabapentin may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB00996 .
ns1:DB00252_DB01011	dcterms:title	"DDI between Phenytoin and Metyrapone - The combination renders the test invalid"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01011 .
ns1:DB00252_DB01023	dcterms:title	"DDI between Phenytoin and Felodipine - The hydantoin decreases the effect of felodipine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01023 .
ns1:DB00252_DB01045	dcterms:title	"DDI between Phenytoin and Rifampicin - Rifampin may decrease the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01045 .
ns1:DB00252_DB01058	dcterms:title	"DDI between Phenytoin and Praziquantel - Markedly lower praziquantel levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01058 .
ns1:DB00252_DB01080	dcterms:title	"DDI between Phenytoin and Vigabatrin - Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01080 .
ns1:DB00252_DB01101	dcterms:title	"DDI between Phenytoin and Capecitabine - Capecitabine increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01101 .
ns1:DB00252_DB01104	dcterms:title	"DDI between Phenytoin and Sertraline - Sertraline increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00252 .
ns1:DB00252_DB01114	dcterms:title	"DDI between Phenytoin and Chlorphenamine - The antihistamine increases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01114 ,
		ns3:DB00252 .
ns1:DB00252_DB01118	dcterms:title	"DDI between Phenytoin and Amiodarone - Amiodarone may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01118 .
ns1:DB00252_DB01119	dcterms:title	"DDI between Phenytoin and Diazoxide - Diazoxide decreases the efficacy of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01119 .
ns1:DB00252_DB01124	dcterms:title	"DDI between Phenytoin and Tolbutamide - Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01124 .
ns1:DB00252_DB01125	dcterms:title	"DDI between Phenytoin and Anisindione - Increased hydantoin levels and risk of bleeding"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00252 .
ns1:DB00252_DB01135	dcterms:title	"DDI between Phenytoin and Doxacurium chloride - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01135 .
ns1:DB00252_DB01167	dcterms:title	"DDI between Phenytoin and Itraconazole - Phenytoin decreases the effect of itraconazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01167 .
ns1:DB00252_DB01199	dcterms:title	"DDI between Phenytoin and Tubocurarine - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01199 .
ns1:DB00252_DB01211	dcterms:title	"DDI between Phenytoin and Clarithromycin - Clarithromycin may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01211 .
ns1:DB00252_DB01223	dcterms:title	"DDI between Phenytoin and Aminophylline - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01223 .
ns1:DB00252_DB01224	dcterms:title	"DDI between Phenytoin and Quetiapine - Phenytoin decreases the effect of quetiapine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01224 ,
		ns3:DB00252 .
ns1:DB00252_DB01226	dcterms:title	"DDI between Phenytoin and Mivacurium - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01226 .
ns1:DB00252_DB01234	dcterms:title	"DDI between Phenytoin and Dexamethasone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01234 .
ns1:DB00252_DB01235	dcterms:title	"DDI between Phenytoin and L-DOPA - The hydantoin decreases the effect of levodopa"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01235 .
ns1:DB00252_DB01254	dcterms:title	"DDI between Phenytoin and Dasatinib - Phenytoin may decrease the serum level and efficacy of dasatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01254 ,
		ns3:DB00252 .
ns1:DB00252_DB01263	dcterms:title	"DDI between Phenytoin and Posaconazole - Modifications of drug levels for both agents"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01263 .
ns1:DB00252_DB01268	dcterms:title	"DDI between Phenytoin and Sunitinib - Possible decrease in sunitinib levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01268 .
ns1:DB00252_DB01303	dcterms:title	"DDI between Phenytoin and Oxtriphylline - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01303 .
ns1:DB00252_DB01336	dcterms:title	"DDI between Phenytoin and Metocurine - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01336 .
ns1:DB00252_DB01337	dcterms:title	"DDI between Phenytoin and Pancuronium - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01337 .
ns1:DB00252_DB01339	dcterms:title	"DDI between Phenytoin and Vecuronium - Phenytoin decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01339 .
ns1:DB00252_DB01357	dcterms:title	"DDI between Phenytoin and Mestranol - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01357 .
ns1:DB00252_DB01380	dcterms:title	"DDI between Phenytoin and Cortisone acetate - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB01380 .
ns1:DB00252_DB01384	dcterms:title	"DDI between Phenytoin and Paramethasone - The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01384 ,
		ns3:DB00252 .
ns1:DB00252_DB01418	dcterms:title	"DDI between Phenytoin and Acenocoumarol - Increased hydantoin levels and risk of bleeding"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00252 .
ns1:DB00252_DB01601	dcterms:title	"DDI between Phenytoin and Lopinavir - Levels of both drugs are affected"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00252 .
ns1:DB00252_DB03585	dcterms:title	"DDI between Phenytoin and Oxyphenbutazone - The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB03585 .
ns1:DB00252_DB04571	dcterms:title	"DDI between Phenytoin and Trioxsalen - The hydantoin decreases the effect of psoralene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04571 .
ns1:DB00252_DB04572	dcterms:title	"DDI between Phenytoin and Thiotepa - Possible increase in thiotepa levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04572 .
ns1:DB00252_DB04573	dcterms:title	"DDI between Phenytoin and Estriol - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04573 .
ns1:DB00252_DB04574	dcterms:title	"DDI between Phenytoin and Estropipate - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04574 .
ns1:DB00252_DB04575	dcterms:title	"DDI between Phenytoin and Quinestrol - The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04575 .
ns1:DB00252_DB04953	dcterms:title	"DDI between Phenytoin and Ezogabine  - Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB04953 .
ns1:DB00252_DB05294	dcterms:title	"DDI between Phenytoin and Vandetanib - Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB05294 .
ns1:DB00252_DB05773	dcterms:title	"DDI between Phenytoin and ado-trastuzumab emtansine - Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB05773 .
ns1:DB00252_DB05812	dcterms:title	"DDI between Phenytoin and Abiraterone - Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05812 ,
		ns3:DB00252 .
ns1:DB00252_DB06201	dcterms:title	"DDI between Phenytoin and Rufinamide - Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB06201 .
ns1:DB00252_DB06212	dcterms:title	"DDI between Phenytoin and Tolvaptan - Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06212 ,
		ns3:DB00252 .
ns1:DB00252_DB06216	dcterms:title	"DDI between Phenytoin and Asenapine - Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06216 ,
		ns3:DB00252 .
ns1:DB00252_DB06287	dcterms:title	"DDI between Phenytoin and Temsirolimus - Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB06287 .
ns1:DB00252_DB06414	dcterms:title	"DDI between Phenytoin and Etravirine - Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB06414 .
ns1:DB00252_DB06626	dcterms:title	"DDI between Phenytoin and Axitinib - Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB06626 .
ns1:DB00252_DB06772	dcterms:title	"DDI between Phenytoin and Cabazitaxel - Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06772 ,
		ns3:DB00252 .
ns1:DB00252_DB08820	dcterms:title	"DDI between Phenytoin and Ivacaftor - Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08820 ,
		ns3:DB00252 .
ns1:DB00252_DB08864	dcterms:title	"DDI between Phenytoin and Rilpivirine - Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08864 ,
		ns3:DB00252 .
ns1:DB00252_DB08866	dcterms:title	"DDI between Phenytoin and Estradiol valerate/Dienogest  - Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08866 .
ns1:DB00252_DB08867	dcterms:title	"DDI between Phenytoin and Ulipristal - Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08867 .
ns1:DB00252_DB08873	dcterms:title	"DDI between Phenytoin and Boceprevir  - Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08873 ,
		ns3:DB00252 .
ns1:DB00252_DB08881	dcterms:title	"DDI between Phenytoin and Vemurafenib - Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08881 ,
		ns3:DB00252 .
ns1:DB00252_DB08883	dcterms:title	"DDI between Phenytoin and Perampanel - Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08883 .
ns1:DB00252_DB08895	dcterms:title	"DDI between Phenytoin and Tofacitinib - Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08895 .
ns1:DB00252_DB08896	dcterms:title	"DDI between Phenytoin and Regorafenib - Strong CYP3A4 inducers may decrease levels of regorafenib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08896 .
ns1:DB00252_DB08901	dcterms:title	"DDI between Phenytoin and Ponatinib  - Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08901 ,
		ns3:DB00252 .
ns1:DB00252_DB08907	dcterms:title	"DDI between Phenytoin and Canagliflozin - Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00252 ,
		ns3:DB08907 .
ns1:DB00252_DB08912	dcterms:title	"DDI between Phenytoin and Dabrafenib - Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08912 ,
		ns3:DB00252 .
ns1:DB00254_DB00258	dcterms:title	"DDI between Doxycycline and Calcium Acetate - Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00258 .
ns1:DB00254_DB00266	dcterms:title	"DDI between Doxycycline and Dicoumarol - The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00266 .
ns1:DB00254_DB00301	dcterms:title	"DDI between Doxycycline and Flucloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00301 .
ns1:DB00254_DB00306	dcterms:title	"DDI between Doxycycline and Talbutal - The anticonvulsant, talbutal, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00306 ,
		ns3:DB00254 .
ns1:DB00254_DB00307	dcterms:title	"DDI between Doxycycline and Bexarotene - Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00307 ,
		ns3:DB00254 .
ns1:DB00254_DB00312	dcterms:title	"DDI between Doxycycline and Pentobarbital - The anticonvulsant, pentobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00312 ,
		ns3:DB00254 .
ns1:DB00254_DB00319	dcterms:title	"DDI between Doxycycline and Piperacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00319 .
ns1:DB00254_DB00355	dcterms:title	"DDI between Doxycycline and Aztreonam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00355 .
ns1:DB00254_DB00415	dcterms:title	"DDI between Doxycycline and Ampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00415 .
ns1:DB00254_DB00417	dcterms:title	"DDI between Doxycycline and Penicillin V - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00417 ,
		ns3:DB00254 .
ns1:DB00254_DB00418	dcterms:title	"DDI between Doxycycline and Secobarbital - The anticonvulsant , secobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00418 ,
		ns3:DB00254 .
ns1:DB00254_DB00459	dcterms:title	"DDI between Doxycycline and Acitretin - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00459 ,
		ns3:DB00254 .
ns1:DB00254_DB00474	dcterms:title	"DDI between Doxycycline and Methohexital - The anticonvulsant, methohexital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00474 ,
		ns3:DB00254 .
ns1:DB00254_DB00485	dcterms:title	"DDI between Doxycycline and Dicloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00485 ,
		ns3:DB00254 .
ns1:DB00254_DB00532	dcterms:title	"DDI between Doxycycline and Mephenytoin - The anticonvulsant, mephenytoin, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00532 ,
		ns3:DB00254 .
ns1:DB00254_DB00563	dcterms:title	"DDI between Doxycycline and Methotrexate - The tetracycline, doxycycline, may increase methotrexate toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00563 ,
		ns3:DB00254 .
ns1:DB00254_DB00564	dcterms:title	"DDI between Doxycycline and Carbamazepine - The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00564 ,
		ns3:DB00254 .
ns1:DB00254_DB00578	dcterms:title	"DDI between Doxycycline and Carbenicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00578 .
ns1:DB00254_DB00599	dcterms:title	"DDI between Doxycycline and Thiopental - Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00254 .
ns1:DB00254_DB00607	dcterms:title	"DDI between Doxycycline and Nafcillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00254 .
ns1:DB00254_DB00615	dcterms:title	"DDI between Doxycycline and Rifabutin - The rifamycin decreases the effect of doxycycline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00254 .
ns1:DB00254_DB00682	dcterms:title	"DDI between Doxycycline and Warfarin - The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00254 .
ns1:DB00254_DB00706	dcterms:title	"DDI between Doxycycline and Tamsulosin - Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00706 ,
		ns3:DB00254 .
ns1:DB00254_DB00713	dcterms:title	"DDI between Doxycycline and Oxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00713 ,
		ns3:DB00254 .
ns1:DB00254_DB00739	dcterms:title	"DDI between Doxycycline and Hetacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00739 ,
		ns3:DB00254 .
ns1:DB00254_DB00754	dcterms:title	"DDI between Doxycycline and Ethotoin - The anticonvulsant, ethotoin, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00254 .
ns1:DB00254_DB00755	dcterms:title	"DDI between Doxycycline and Tretinoin - Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00755 ,
		ns3:DB00254 .
ns1:DB00254_DB00766	dcterms:title	"DDI between Doxycycline and Clavulanate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00766 ,
		ns3:DB00254 .
ns1:DB00254_DB00794	dcterms:title	"DDI between Doxycycline and Primidone - The anticonvulsant, primidone, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00254 .
ns1:DB00254_DB00849	dcterms:title	"DDI between Doxycycline and Methylphenobarbital - The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00254 .
ns1:DB00254_DB00893	dcterms:title	"DDI between Doxycycline and Iron Dextran - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00893 .
ns1:DB00254_DB00926	dcterms:title	"DDI between Doxycycline and Etretinate - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00926 ,
		ns3:DB00254 .
ns1:DB00254_DB00930	dcterms:title	"DDI between Doxycycline and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00930 ,
		ns3:DB00254 .
ns1:DB00254_DB00948	dcterms:title	"DDI between Doxycycline and Mezlocillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB00948 .
ns1:DB00254_DB00977	dcterms:title	"DDI between Doxycycline and Ethinyl Estradiol - Doxycycline may decrease the contraceptive effect of ethinyl estradiol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00254 .
ns1:DB00254_DB00982	dcterms:title	"DDI between Doxycycline and Isotretinoin - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00982 ,
		ns3:DB00254 .
ns1:DB00254_DB01000	dcterms:title	"DDI between Doxycycline and Cyclacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01000 .
ns1:DB00254_DB01036	dcterms:title	"DDI between Doxycycline and Tolterodine - Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00254 .
ns1:DB00254_DB01045	dcterms:title	"DDI between Doxycycline and Rifampicin - The rifamycin decreases the effect of doxycycline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00254 .
ns1:DB00254_DB01053	dcterms:title	"DDI between Doxycycline and Benzylpenicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01053 .
ns1:DB00254_DB01060	dcterms:title	"DDI between Doxycycline and Amoxicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01060 .
ns1:DB00254_DB01061	dcterms:title	"DDI between Doxycycline and Azlocillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01061 .
ns1:DB00254_DB01125	dcterms:title	"DDI between Doxycycline and Anisindione - The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01125 .
ns1:DB00254_DB01147	dcterms:title	"DDI between Doxycycline and Cloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01147 .
ns1:DB00254_DB01164	dcterms:title	"DDI between Doxycycline and Calcium Chloride - Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01164 .
ns1:DB00254_DB01174	dcterms:title	"DDI between Doxycycline and Phenobarbital - The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00254 .
ns1:DB00254_DB01320	dcterms:title	"DDI between Doxycycline and Fosphenytoin - The anticonvulsant, fosphenytoin, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00254 .
ns1:DB00254_DB01341	dcterms:title	"DDI between Doxycycline and Dihydroquinidine barbiturate - The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00254 .
ns1:DB00254_DB01346	dcterms:title	"DDI between Doxycycline and Quinidine barbiturate - The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00254 .
ns1:DB00254_DB01351	dcterms:title	"DDI between Doxycycline and Amobarbital - The anticonvulsant, amobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00254 .
ns1:DB00254_DB01352	dcterms:title	"DDI between Doxycycline and Aprobarbital - The anticonvulsant, aprobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00254 .
ns1:DB00254_DB01353	dcterms:title	"DDI between Doxycycline and Butethal - The anticonvulsant, butethal, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00254 .
ns1:DB00254_DB01354	dcterms:title	"DDI between Doxycycline and Heptabarbital - The anticonvulsant, heptabarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00254 .
ns1:DB00254_DB01355	dcterms:title	"DDI between Doxycycline and Hexobarbital - The anticonvulsant, hexobarbital, decreases the effect of doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00254 .
ns1:DB00254_DB01357	dcterms:title	"DDI between Doxycycline and Mestranol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00254 .
ns1:DB00254_DB01370	dcterms:title	"DDI between Doxycycline and Aluminium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01370 .
ns1:DB00254_DB01373	dcterms:title	"DDI between Doxycycline and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01373 .
ns1:DB00254_DB01377	dcterms:title	"DDI between Doxycycline and Magnesium oxide - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01377 .
ns1:DB00254_DB01378	dcterms:title	"DDI between Doxycycline and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01378 .
ns1:DB00254_DB01418	dcterms:title	"DDI between Doxycycline and Acenocoumarol - The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01418 .
ns1:DB00254_DB01574	dcterms:title	"DDI between Doxycycline and Attapulgite - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01574 ,
		ns3:DB00254 .
ns1:DB00254_DB01592	dcterms:title	"DDI between Doxycycline and Iron - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01592 ,
		ns3:DB00254 .
ns1:DB00254_DB01593	dcterms:title	"DDI between Doxycycline and Zinc - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00254 ,
		ns3:DB01593 .
ns1:DB00254_DB01602	dcterms:title	"DDI between Doxycycline and Bacampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01602 ,
		ns3:DB00254 .
ns1:DB00254_DB01603	dcterms:title	"DDI between Doxycycline and Meticillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01603 ,
		ns3:DB00254 .
ns1:DB00254_DB01604	dcterms:title	"DDI between Doxycycline and Pivampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01604 ,
		ns3:DB00254 .
ns1:DB00254_DB01605	dcterms:title	"DDI between Doxycycline and Pivmecillinam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01605 ,
		ns3:DB00254 .
ns1:DB00254_DB01606	dcterms:title	"DDI between Doxycycline and Tazobactam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01606 ,
		ns3:DB00254 .
ns1:DB00254_DB01607	dcterms:title	"DDI between Doxycycline and Ticarcillin - Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01607 ,
		ns3:DB00254 .
ns1:DB00255_DB00306	dcterms:title	"DDI between Diethylstilbestrol and Talbutal - The enzyme inducer, talbutal, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00306 ,
		ns3:DB00255 .
ns1:DB00255_DB00312	dcterms:title	"DDI between Diethylstilbestrol and Pentobarbital - The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00312 ,
		ns3:DB00255 .
ns1:DB00255_DB00400	dcterms:title	"DDI between Diethylstilbestrol and Griseofulvin - The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00400 ,
		ns3:DB00255 .
ns1:DB00255_DB00418	dcterms:title	"DDI between Diethylstilbestrol and Secobarbital - The enzyme inducer, secobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00418 ,
		ns3:DB00255 .
ns1:DB00255_DB00474	dcterms:title	"DDI between Diethylstilbestrol and Methohexital - The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00474 ,
		ns3:DB00255 .
ns1:DB00255_DB00481	dcterms:title	"DDI between Diethylstilbestrol and Raloxifene - Association not recommended"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00255 ,
		ns3:DB00481 .
ns1:DB00255_DB00532	dcterms:title	"DDI between Diethylstilbestrol and Mephenytoin - The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00532 ,
		ns3:DB00255 .
ns1:DB00255_DB00635	dcterms:title	"DDI between Diethylstilbestrol and Prednisone - The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00255 .
ns1:DB00255_DB00754	dcterms:title	"DDI between Diethylstilbestrol and Ethotoin - The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00255 .
ns1:DB00255_DB00794	dcterms:title	"DDI between Diethylstilbestrol and Primidone - The enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00255 .
ns1:DB00255_DB00849	dcterms:title	"DDI between Diethylstilbestrol and Methylphenobarbital - The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00255 .
ns1:DB00255_DB00860	dcterms:title	"DDI between Diethylstilbestrol and Prednisolone - The estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00255 .
ns1:DB00255_DB00932	dcterms:title	"DDI between Diethylstilbestrol and Tipranavir - Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00255 .
ns1:DB00255_DB01174	dcterms:title	"DDI between Diethylstilbestrol and Phenobarbital - The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00255 .
ns1:DB00255_DB01320	dcterms:title	"DDI between Diethylstilbestrol and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00255 .
ns1:DB00255_DB01351	dcterms:title	"DDI between Diethylstilbestrol and Amobarbital - The enzyme inducer, amobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00255 .
ns1:DB00255_DB01352	dcterms:title	"DDI between Diethylstilbestrol and Aprobarbital - The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00255 .
ns1:DB00255_DB01353	dcterms:title	"DDI between Diethylstilbestrol and Butethal - The enzyme inducer, butethal, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00255 .
ns1:DB00255_DB01354	dcterms:title	"DDI between Diethylstilbestrol and Heptabarbital - The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00255 .
ns1:DB00255_DB01355	dcterms:title	"DDI between Diethylstilbestrol and Hexobarbital - The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, diethylstilbestrol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00255 .
ns1:DB00255_DB01586	dcterms:title	"DDI between Diethylstilbestrol and Ursodeoxycholic acid - Estrogens decreases the effect of ursodiol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01586 ,
		ns3:DB00255 .
ns1:DB00257_DB00656	dcterms:title	"DDI between Clotrimazole and Trazodone - The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00257 .
ns1:DB00257_DB00706	dcterms:title	"DDI between Clotrimazole and Tamsulosin - Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00706 ,
		ns3:DB00257 .
ns1:DB00257_DB00813	dcterms:title	"DDI between Clotrimazole and Fentanyl - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00257 ,
		ns3:DB00813 .
ns1:DB00257_DB00864	dcterms:title	"DDI between Clotrimazole and Tacrolimus - The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00257 .
ns1:DB00257_DB01036	dcterms:title	"DDI between Clotrimazole and Tolterodine - Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00257 .
ns1:DB00257_DB01218	dcterms:title	"DDI between Clotrimazole and Halofantrine - CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01218 ,
		ns3:DB00257 .
ns1:DB00257_DB01222	dcterms:title	"DDI between Clotrimazole and Budesonide - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01222 ,
		ns3:DB00257 .
ns1:DB00257_DB01394	dcterms:title	"DDI between Clotrimazole and Colchicine - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01394 ,
		ns3:DB00257 .
ns1:DB00257_DB01590	dcterms:title	"DDI between Clotrimazole and Everolimus - CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00257 ,
		ns3:DB01590 .
ns1:DB00257_DB06212	dcterms:title	"DDI between Clotrimazole and Tolvaptan - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00257 ,
		ns3:DB06212 .
ns1:DB00257_DB06274	dcterms:title	"DDI between Clotrimazole and Alvimopan - Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00257 ,
		ns3:DB06274 .
ns1:DB00257_DB08815	dcterms:title	"DDI between Clotrimazole and Lurasidone - CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00257 ,
		ns3:DB08815 .
ns1:DB00258_DB00279	dcterms:title	"DDI between Calcium Acetate and Liothyronine - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00279 .
ns1:DB00258_DB00451	dcterms:title	"DDI between Calcium Acetate and Levothyroxine - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00451 ,
		ns3:DB00258 .
ns1:DB00258_DB00537	dcterms:title	"DDI between Calcium Acetate and Ciprofloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00537 ,
		ns3:DB00258 .
ns1:DB00258_DB00618	dcterms:title	"DDI between Calcium Acetate and Demeclocycline - Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00618 .
ns1:DB00258_DB00630	dcterms:title	"DDI between Calcium Acetate and Alendronate - Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00630 .
ns1:DB00258_DB00685	dcterms:title	"DDI between Calcium Acetate and Trovafloxacin - Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00685 .
ns1:DB00258_DB00710	dcterms:title	"DDI between Calcium Acetate and Ibandronate - Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00710 .
ns1:DB00258_DB00720	dcterms:title	"DDI between Calcium Acetate and Clodronate - Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00720 .
ns1:DB00258_DB00759	dcterms:title	"DDI between Calcium Acetate and Tetracycline - Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB00759 .
ns1:DB00258_DB00779	dcterms:title	"DDI between Calcium Acetate and Nalidixic Acid - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00779 ,
		ns3:DB00258 .
ns1:DB00258_DB00884	dcterms:title	"DDI between Calcium Acetate and Risedronate - Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00884 ,
		ns3:DB00258 .
ns1:DB00258_DB00978	dcterms:title	"DDI between Calcium Acetate and Lomefloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00978 ,
		ns3:DB00258 .
ns1:DB00258_DB01017	dcterms:title	"DDI between Calcium Acetate and Minocycline - Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01017 ,
		ns3:DB00258 .
ns1:DB00258_DB01059	dcterms:title	"DDI between Calcium Acetate and Norfloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01059 ,
		ns3:DB00258 .
ns1:DB00258_DB01077	dcterms:title	"DDI between Calcium Acetate and Etidronic acid - Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01077 ,
		ns3:DB00258 .
ns1:DB00258_DB01133	dcterms:title	"DDI between Calcium Acetate and Tiludronate - The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01133 ,
		ns3:DB00258 .
ns1:DB00258_DB01137	dcterms:title	"DDI between Calcium Acetate and Levofloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB01137 .
ns1:DB00258_DB01155	dcterms:title	"DDI between Calcium Acetate and Gemifloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01155 ,
		ns3:DB00258 .
ns1:DB00258_DB01164	dcterms:title	"DDI between Calcium Acetate and Calcium Chloride - Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01164 ,
		ns3:DB00258 .
ns1:DB00258_DB01165	dcterms:title	"DDI between Calcium Acetate and Ofloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01165 ,
		ns3:DB00258 .
ns1:DB00258_DB01196	dcterms:title	"DDI between Calcium Acetate and Estramustine - Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01196 ,
		ns3:DB00258 .
ns1:DB00258_DB01208	dcterms:title	"DDI between Calcium Acetate and Sparfloxacin - Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB01208 .
ns1:DB00258_DB01212	dcterms:title	"DDI between Calcium Acetate and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB01212 .
ns1:DB00258_DB01583	dcterms:title	"DDI between Calcium Acetate and Liotrix - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB01583 .
ns1:DB00258_DB06210	dcterms:title	"DDI between Calcium Acetate and Eltrombopag - Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB06210 .
ns1:DB00258_DB06724	dcterms:title	"DDI between Calcium Acetate and Calcium carbonate - Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB06724 .
ns1:DB00258_DB06824	dcterms:title	"DDI between Calcium Acetate and Trientine hydrochloride - Calcium salts such as calcium acetate may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of Calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00258 ,
		ns3:DB06824 .
ns1:DB00261_DB00374	dcterms:title	"DDI between Anagrelide and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00374 ,
		ns3:DB00261 .
ns1:DB00261_DB01381	dcterms:title	"DDI between Anagrelide and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00261 .
ns1:DB00262_DB00337	dcterms:title	"DDI between Carmustine and Pimecrolimus - Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB00337 .
ns1:DB00262_DB00390	dcterms:title	"DDI between Carmustine and Digoxin - The antineoplasic agent decreases the effect of digoxin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB00390 .
ns1:DB00262_DB00501	dcterms:title	"DDI between Carmustine and Cimetidine - Increases myelosuppression caused by carmustine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB00501 .
ns1:DB00262_DB00864	dcterms:title	"DDI between Carmustine and Tacrolimus - Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB00864 .
ns1:DB00262_DB01097	dcterms:title	"DDI between Carmustine and Leflunomide - Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB01097 .
ns1:DB00262_DB01320	dcterms:title	"DDI between Carmustine and Fosphenytoin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB01320 .
ns1:DB00262_DB01656	dcterms:title	"DDI between Carmustine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB01656 .
ns1:DB00262_DB06769	dcterms:title	"DDI between Carmustine and Bendamustine - Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB06769 .
ns1:DB00263_DB00440	dcterms:title	"DDI between Sulfisoxazole and Trimethoprim - The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00440 ,
		ns3:DB00263 .
ns1:DB00263_DB00549	dcterms:title	"DDI between Sulfisoxazole and Zafirlukast - Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00263 ,
		ns3:DB00549 .
ns1:DB00263_DB00563	dcterms:title	"DDI between Sulfisoxazole and Methotrexate - The sulfamide increases the toxicity of methotrexate"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00563 ,
		ns3:DB00263 .
ns1:DB00263_DB00582	dcterms:title	"DDI between Sulfisoxazole and Voriconazole - Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00263 .
ns1:DB00263_DB00672	dcterms:title	"DDI between Sulfisoxazole and Chlorpropamide - Sulfonamide/sulfonylurea: possible hypoglycemia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00672 ,
		ns3:DB00263 .
ns1:DB00263_DB00675	dcterms:title	"DDI between Sulfisoxazole and Tamoxifen - Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00675 ,
		ns3:DB00263 .
ns1:DB00263_DB00682	dcterms:title	"DDI between Sulfisoxazole and Warfarin - Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00263 .
ns1:DB00263_DB01124	dcterms:title	"DDI between Sulfisoxazole and Tolbutamide - Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01124 ,
		ns3:DB00263 .
ns1:DB00264_DB00280	dcterms:title	"DDI between Metoprolol and Disopyramide - The beta-blocker, metoprolol, may increase adverse effects of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00280 .
ns1:DB00264_DB00281	dcterms:title	"DDI between Metoprolol and Lidocaine - The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00281 .
ns1:DB00264_DB00320	dcterms:title	"DDI between Metoprolol and Dihydroergotamine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00320 .
ns1:DB00264_DB00328	dcterms:title	"DDI between Metoprolol and Indomethacin - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00328 .
ns1:DB00264_DB00343	dcterms:title	"DDI between Metoprolol and Diltiazem - Increased risk of bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00343 ,
		ns3:DB00264 .
ns1:DB00264_DB00374	dcterms:title	"DDI between Metoprolol and Treprostinil - Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00374 ,
		ns3:DB00264 .
ns1:DB00264_DB00414	dcterms:title	"DDI between Metoprolol and Acetohexamide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00414 .
ns1:DB00264_DB00457	dcterms:title	"DDI between Metoprolol and Prazosin - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00457 .
ns1:DB00264_DB00472	dcterms:title	"DDI between Metoprolol and Fluoxetine - The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00264 .
ns1:DB00264_DB00501	dcterms:title	"DDI between Metoprolol and Cimetidine - Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00501 .
ns1:DB00264_DB00554	dcterms:title	"DDI between Metoprolol and Piroxicam - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00554 ,
		ns3:DB00264 .
ns1:DB00264_DB00575	dcterms:title	"DDI between Metoprolol and Clonidine - Increased hypertension when clonidine stopped"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00575 .
ns1:DB00264_DB00661	dcterms:title	"DDI between Metoprolol and Verapamil - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00264 .
ns1:DB00264_DB00668	dcterms:title	"DDI between Metoprolol and Epinephrine - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00264 .
ns1:DB00264_DB00672	dcterms:title	"DDI between Metoprolol and Chlorpropamide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00672 ,
		ns3:DB00264 .
ns1:DB00264_DB00696	dcterms:title	"DDI between Metoprolol and Ergotamine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00696 .
ns1:DB00264_DB00715	dcterms:title	"DDI between Metoprolol and Paroxetine - The SSRI increases the effect of the beta-blocker"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00715 .
ns1:DB00264_DB00794	dcterms:title	"DDI between Metoprolol and Primidone - The barbiturate decreases the effect of metabolized beta-blocker"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00264 .
ns1:DB00264_DB00816	dcterms:title	"DDI between Metoprolol and Orciprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00816 .
ns1:DB00264_DB00839	dcterms:title	"DDI between Metoprolol and Tolazamide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00264 .
ns1:DB00264_DB00857	dcterms:title	"DDI between Metoprolol and Terbinafine - Terbinafine may reduce the metabolism and clearance of Metoprolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Metoprolol if Terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00857 .
ns1:DB00264_DB00871	dcterms:title	"DDI between Metoprolol and Terbutaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00871 .
ns1:DB00264_DB00912	dcterms:title	"DDI between Metoprolol and Repaglinide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00912 .
ns1:DB00264_DB00938	dcterms:title	"DDI between Metoprolol and Salmeterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00938 .
ns1:DB00264_DB00976	dcterms:title	"DDI between Metoprolol and Telithromycin - Telithromycin may possibly increase metoprolol effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00976 .
ns1:DB00264_DB00983	dcterms:title	"DDI between Metoprolol and Formoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00983 .
ns1:DB00264_DB01001	dcterms:title	"DDI between Metoprolol and Salbutamol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01001 .
ns1:DB00264_DB01016	dcterms:title	"DDI between Metoprolol and Glyburide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01016 .
ns1:DB00264_DB01045	dcterms:title	"DDI between Metoprolol and Rifampicin - Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01045 .
ns1:DB00264_DB01050	dcterms:title	"DDI between Metoprolol and Ibuprofen - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01050 .
ns1:DB00264_DB01064	dcterms:title	"DDI between Metoprolol and Isoprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01064 .
ns1:DB00264_DB01067	dcterms:title	"DDI between Metoprolol and Glipizide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01067 .
ns1:DB00264_DB01104	dcterms:title	"DDI between Metoprolol and Sertraline - The SSRI increases the effect of the beta-blocker"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01104 .
ns1:DB00264_DB01120	dcterms:title	"DDI between Metoprolol and Gliclazide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01120 .
ns1:DB00264_DB01124	dcterms:title	"DDI between Metoprolol and Tolbutamide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01124 .
ns1:DB00264_DB01162	dcterms:title	"DDI between Metoprolol and Terazosin - Increased risk of hypotension. Initiate concomitant therapy cautiously."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01162 .
ns1:DB00264_DB01174	dcterms:title	"DDI between Metoprolol and Phenobarbital - The barbiturate decreases the effect of the metabolized beta-blocker"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01174 .
ns1:DB00264_DB01175	dcterms:title	"DDI between Metoprolol and Escitalopram - The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01175 .
ns1:DB00264_DB01182	dcterms:title	"DDI between Metoprolol and Propafenone - Propafenone may increase the effect of beta-blocker, metoprolol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01182 .
ns1:DB00264_DB01253	dcterms:title	"DDI between Metoprolol and Ergonovine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01253 .
ns1:DB00264_DB01275	dcterms:title	"DDI between Metoprolol and Hydralazine - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01275 .
ns1:DB00264_DB01288	dcterms:title	"DDI between Metoprolol and Fenoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01288 .
ns1:DB00264_DB01289	dcterms:title	"DDI between Metoprolol and Glisoxepide - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01289 .
ns1:DB00264_DB01291	dcterms:title	"DDI between Metoprolol and Pirbuterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01291 .
ns1:DB00264_DB01366	dcterms:title	"DDI between Metoprolol and Procaterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01366 .
ns1:DB00264_DB01382	dcterms:title	"DDI between Metoprolol and Glycodiazine - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB01382 .
ns1:DB00264_DB04855	dcterms:title	"DDI between Metoprolol and Dronedarone - Metoprolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase metoprolol exposure 1.6-fold. Lower dose of metoprolol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB04855 .
ns1:DB00264_DB08893	dcterms:title	"DDI between Metoprolol and Mirabegron  - Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB08893 .
ns1:DB00266_DB00316	dcterms:title	"DDI between Dicoumarol and Acetaminophen - Acetaminophen may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00316 .
ns1:DB00266_DB00317	dcterms:title	"DDI between Dicoumarol and Gefitinib - Gefitinib may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00317 .
ns1:DB00266_DB00328	dcterms:title	"DDI between Dicoumarol and Indomethacin - The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00328 .
ns1:DB00266_DB00357	dcterms:title	"DDI between Dicoumarol and Aminoglutethimide - Aminoglutethimide may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00357 ,
		ns3:DB00266 .
ns1:DB00266_DB00358	dcterms:title	"DDI between Dicoumarol and Mefloquine - Mefloquine may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00358 .
ns1:DB00266_DB00375	dcterms:title	"DDI between Dicoumarol and Colestipol - The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00375 .
ns1:DB00266_DB00400	dcterms:title	"DDI between Dicoumarol and Griseofulvin - Griseofulvin may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00400 ,
		ns3:DB00266 .
ns1:DB00266_DB00414	dcterms:title	"DDI between Dicoumarol and Acetohexamide - Dicumarol may increase the effect of sulfonylurea, acetohexamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00414 .
ns1:DB00266_DB00437	dcterms:title	"DDI between Dicoumarol and Allopurinol - Allopurinol may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00437 ,
		ns3:DB00266 .
ns1:DB00266_DB00441	dcterms:title	"DDI between Dicoumarol and Gemcitabine - Gemcitabine may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00441 ,
		ns3:DB00266 .
ns1:DB00266_DB00443	dcterms:title	"DDI between Dicoumarol and Betamethasone - The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00266 .
ns1:DB00266_DB00451	dcterms:title	"DDI between Dicoumarol and Levothyroxine - The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00451 .
ns1:DB00266_DB00461	dcterms:title	"DDI between Dicoumarol and Nabumetone - The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00461 ,
		ns3:DB00266 .
ns1:DB00266_DB00465	dcterms:title	"DDI between Dicoumarol and Ketorolac - The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00465 .
ns1:DB00266_DB00468	dcterms:title	"DDI between Dicoumarol and Quinine - Quinine may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00468 ,
		ns3:DB00266 .
ns1:DB00266_DB00469	dcterms:title	"DDI between Dicoumarol and Tenoxicam - The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00469 ,
		ns3:DB00266 .
ns1:DB00266_DB00472	dcterms:title	"DDI between Dicoumarol and Fluoxetine - The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00266 .
ns1:DB00266_DB00482	dcterms:title	"DDI between Dicoumarol and Celecoxib - Celecoxib may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00482 .
ns1:DB00266_DB00485	dcterms:title	"DDI between Dicoumarol and Dicloxacillin - Dicloxacillin may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00485 .
ns1:DB00266_DB00501	dcterms:title	"DDI between Dicoumarol and Cimetidine - Cimetidine may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00501 ,
		ns3:DB00266 .
ns1:DB00266_DB00509	dcterms:title	"DDI between Dicoumarol and Dextrothyroxine - The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00509 .
ns1:DB00266_DB00531	dcterms:title	"DDI between Dicoumarol and Cyclophosphamide - The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00531 .
ns1:DB00266_DB00537	dcterms:title	"DDI between Dicoumarol and Ciprofloxacin - The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00537 .
ns1:DB00266_DB00544	dcterms:title	"DDI between Dicoumarol and Fluorouracil - The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00544 .
ns1:DB00266_DB00550	dcterms:title	"DDI between Dicoumarol and Propylthiouracil - The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00550 .
ns1:DB00266_DB00554	dcterms:title	"DDI between Dicoumarol and Piroxicam - The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00554 ,
		ns3:DB00266 .
ns1:DB00266_DB00559	dcterms:title	"DDI between Dicoumarol and Bosentan - Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00559 ,
		ns3:DB00266 .
ns1:DB00266_DB00560	dcterms:title	"DDI between Dicoumarol and Tigecycline - Tigecycline may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00560 .
ns1:DB00266_DB00564	dcterms:title	"DDI between Dicoumarol and Carbamazepine - Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00564 ,
		ns3:DB00266 .
ns1:DB00266_DB00573	dcterms:title	"DDI between Dicoumarol and Fenoprofen - The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00573 ,
		ns3:DB00266 .
ns1:DB00266_DB00586	dcterms:title	"DDI between Dicoumarol and Diclofenac - The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00586 ,
		ns3:DB00266 .
ns1:DB00266_DB00603	dcterms:title	"DDI between Dicoumarol and Medroxyprogesterone Acetate - Medroxyprogesterone may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00603 .
ns1:DB00266_DB00604	dcterms:title	"DDI between Dicoumarol and Cisapride - Cisapride may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00604 .
ns1:DB00266_DB00615	dcterms:title	"DDI between Dicoumarol and Rifabutin - Rifabutin may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00615 .
ns1:DB00266_DB00618	dcterms:title	"DDI between Dicoumarol and Demeclocycline - The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00618 .
ns1:DB00266_DB00619	dcterms:title	"DDI between Dicoumarol and Imatinib - Imatinib may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00619 .
ns1:DB00266_DB00620	dcterms:title	"DDI between Dicoumarol and Triamcinolone - The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00620 .
ns1:DB00266_DB00624	dcterms:title	"DDI between Dicoumarol and Testosterone - The androgen may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00624 .
ns1:DB00266_DB00635	dcterms:title	"DDI between Dicoumarol and Prednisone - The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00635 .
ns1:DB00266_DB00636	dcterms:title	"DDI between Dicoumarol and Clofibrate - The fibrate increases the anticoagulant effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00636 .
ns1:DB00266_DB00647	dcterms:title	"DDI between Dicoumarol and Dextropropoxyphene - Propoxyphene may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00647 .
ns1:DB00266_DB00648	dcterms:title	"DDI between Dicoumarol and Mitotane - Mitotane may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00648 .
ns1:DB00266_DB00672	dcterms:title	"DDI between Dicoumarol and Chlorpropamide - Dicumarol may increase the effect of sulfonylurea, chlorpropamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00672 .
ns1:DB00266_DB00673	dcterms:title	"DDI between Dicoumarol and Aprepitant - Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00673 .
ns1:DB00266_DB00687	dcterms:title	"DDI between Dicoumarol and Fludrocortisone - The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00687 .
ns1:DB00266_DB00701	dcterms:title	"DDI between Dicoumarol and Amprenavir - Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00701 .
ns1:DB00266_DB00712	dcterms:title	"DDI between Dicoumarol and Flurbiprofen - The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00712 .
ns1:DB00266_DB00715	dcterms:title	"DDI between Dicoumarol and Paroxetine - The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00715 .
ns1:DB00266_DB00741	dcterms:title	"DDI between Dicoumarol and Hydrocortisone - The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00741 .
ns1:DB00266_DB00749	dcterms:title	"DDI between Dicoumarol and Etodolac - The NSAID, etodolac, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00749 .
ns1:DB00266_DB00759	dcterms:title	"DDI between Dicoumarol and Tetracycline - Tetracycline may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00759 .
ns1:DB00266_DB00763	dcterms:title	"DDI between Dicoumarol and Methimazole - The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00763 .
ns1:DB00266_DB00779	dcterms:title	"DDI between Dicoumarol and Nalidixic Acid - The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00779 .
ns1:DB00266_DB00784	dcterms:title	"DDI between Dicoumarol and Mefenamic acid - The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00784 .
ns1:DB00266_DB00788	dcterms:title	"DDI between Dicoumarol and Naproxen - The NSAID, naproxen, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00788 .
ns1:DB00266_DB00794	dcterms:title	"DDI between Dicoumarol and Primidone - The barbiturate, primidone, decreases the anticoagulant effect, dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00794 .
ns1:DB00266_DB00806	dcterms:title	"DDI between Dicoumarol and Pentoxifylline - Pentoxifylline may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00806 .
ns1:DB00266_DB00812	dcterms:title	"DDI between Dicoumarol and Phenylbutazone - The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00812 .
ns1:DB00266_DB00814	dcterms:title	"DDI between Dicoumarol and Meloxicam - Meloxicam may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00814 .
ns1:DB00266_DB00822	dcterms:title	"DDI between Dicoumarol and Disulfiram - Disulfiram may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00822 .
ns1:DB00266_DB00848	dcterms:title	"DDI between Dicoumarol and Levamisole - Levamisole may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00848 .
ns1:DB00266_DB00860	dcterms:title	"DDI between Dicoumarol and Prednisolone - The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00860 .
ns1:DB00266_DB00861	dcterms:title	"DDI between Dicoumarol and Diflunisal - The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00861 .
ns1:DB00266_DB00863	dcterms:title	"DDI between Dicoumarol and Ranitidine - Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB00863 .
ns1:DB00266_DB00908	dcterms:title	"DDI between Dicoumarol and Quinidine - Quinidine may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00266 .
ns1:DB00266_DB00916	dcterms:title	"DDI between Dicoumarol and Metronidazole - Metronidazole may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00916 ,
		ns3:DB00266 .
ns1:DB00266_DB00945	dcterms:title	"DDI between Dicoumarol and Acetylsalicylic acid - Acetylsalicylic acid increases effect of the anticoagulant, dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB00266 .
ns1:DB00266_DB00951	dcterms:title	"DDI between Dicoumarol and Isoniazid - Isoniazid may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00266 .
ns1:DB00266_DB00976	dcterms:title	"DDI between Dicoumarol and Telithromycin - Telithromycin may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00266 .
ns1:DB00266_DB00977	dcterms:title	"DDI between Dicoumarol and Ethinyl Estradiol - Increased thrombotic risk due to estrogen"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00266 .
ns1:DB00266_DB00991	dcterms:title	"DDI between Dicoumarol and Oxaprozin - The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB00266 .
ns1:DB00266_DB00993	dcterms:title	"DDI between Dicoumarol and Azathioprine - Azathioprine may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB00266 .
ns1:DB00266_DB01009	dcterms:title	"DDI between Dicoumarol and Ketoprofen - The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00266 .
ns1:DB00266_DB01016	dcterms:title	"DDI between Dicoumarol and Glyburide - Dicumarol may increase the effect of sulfonylurea, glibenclamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01016 ,
		ns3:DB00266 .
ns1:DB00266_DB01017	dcterms:title	"DDI between Dicoumarol and Minocycline - The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01017 .
ns1:DB00266_DB01026	dcterms:title	"DDI between Dicoumarol and Ketoconazole - Ketoconazole may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00266 .
ns1:DB00266_DB01033	dcterms:title	"DDI between Dicoumarol and Mercaptopurine - Mercaptopurine may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01033 ,
		ns3:DB00266 .
ns1:DB00266_DB01039	dcterms:title	"DDI between Dicoumarol and Fenofibrate - Fenofibrate may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01039 ,
		ns3:DB00266 .
ns1:DB00266_DB01045	dcterms:title	"DDI between Dicoumarol and Rifampicin - Rifampin may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00266 .
ns1:DB00266_DB01050	dcterms:title	"DDI between Dicoumarol and Ibuprofen - The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01050 ,
		ns3:DB00266 .
ns1:DB00266_DB01059	dcterms:title	"DDI between Dicoumarol and Norfloxacin - The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01059 ,
		ns3:DB00266 .
ns1:DB00266_DB01072	dcterms:title	"DDI between Dicoumarol and Atazanavir - The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00266 .
ns1:DB00266_DB01083	dcterms:title	"DDI between Dicoumarol and Orlistat - Orlistat may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01083 ,
		ns3:DB00266 .
ns1:DB00266_DB01095	dcterms:title	"DDI between Dicoumarol and Fluvastatin - Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01095 ,
		ns3:DB00266 .
ns1:DB00266_DB01097	dcterms:title	"DDI between Dicoumarol and Leflunomide - Leflunomide may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01097 .
ns1:DB00266_DB01101	dcterms:title	"DDI between Dicoumarol and Capecitabine - Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01101 ,
		ns3:DB00266 .
ns1:DB00266_DB01110	dcterms:title	"DDI between Dicoumarol and Miconazole - Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01110 ,
		ns3:DB00266 .
ns1:DB00266_DB01118	dcterms:title	"DDI between Dicoumarol and Amiodarone - Amiodarone may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00266 .
ns1:DB00266_DB01120	dcterms:title	"DDI between Dicoumarol and Gliclazide - Dicumarol may increase the effect of sulfonylurea, gliclazide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01120 ,
		ns3:DB00266 .
ns1:DB00266_DB01137	dcterms:title	"DDI between Dicoumarol and Levofloxacin - The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01137 ,
		ns3:DB00266 .
ns1:DB00266_DB01165	dcterms:title	"DDI between Dicoumarol and Ofloxacin - The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01165 .
ns1:DB00266_DB01167	dcterms:title	"DDI between Dicoumarol and Itraconazole - Itraconazole may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00266 .
ns1:DB00266_DB01174	dcterms:title	"DDI between Dicoumarol and Phenobarbital - The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00266 .
ns1:DB00266_DB01182	dcterms:title	"DDI between Dicoumarol and Propafenone - Propafenone may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00266 .
ns1:DB00266_DB01185	dcterms:title	"DDI between Dicoumarol and Fluoxymesterone - The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01185 .
ns1:DB00266_DB01211	dcterms:title	"DDI between Dicoumarol and Clarithromycin - The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00266 .
ns1:DB00266_DB01212	dcterms:title	"DDI between Dicoumarol and Ceftriaxone - The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01212 .
ns1:DB00266_DB01234	dcterms:title	"DDI between Dicoumarol and Dexamethasone - The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01234 ,
		ns3:DB00266 .
ns1:DB00266_DB01241	dcterms:title	"DDI between Dicoumarol and Gemfibrozil - Gemfibrozil may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01241 ,
		ns3:DB00266 .
ns1:DB00266_DB01283	dcterms:title	"DDI between Dicoumarol and Lumiracoxib - Lumiracoxib may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01283 .
ns1:DB00266_DB01319	dcterms:title	"DDI between Dicoumarol and Fosamprenavir - The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00266 .
ns1:DB00266_DB01320	dcterms:title	"DDI between Dicoumarol and Fosphenytoin - Increased hydantoin levels and risk of bleeding"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00266 .
ns1:DB00266_DB01330	dcterms:title	"DDI between Dicoumarol and Cefotetan - The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01330 .
ns1:DB00266_DB01331	dcterms:title	"DDI between Dicoumarol and Cefoxitin - The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01331 .
ns1:DB00266_DB01406	dcterms:title	"DDI between Dicoumarol and Danazol - The androgen, danazol, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01406 ,
		ns3:DB00266 .
ns1:DB00266_DB01432	dcterms:title	"DDI between Dicoumarol and Cholestyramine - The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01432 .
ns1:DB00266_DB01437	dcterms:title	"DDI between Dicoumarol and Glutethimide - Glutethimide may decrease the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01437 .
ns1:DB00266_DB01628	dcterms:title	"DDI between Dicoumarol and Etoricoxib - Etoricoxib may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB01628 .
ns1:DB00266_DB03585	dcterms:title	"DDI between Dicoumarol and Oxyphenbutazone - The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00266 ,
		ns3:DB03585 .
ns1:DB00268_DB00537	dcterms:title	"DDI between Ropinirole and Ciprofloxacin - Ciprofloxacin may increase the effect and toxicity of ropinirole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00537 ,
		ns3:DB00268 .
ns1:DB00268_DB01267	dcterms:title	"DDI between Ropinirole and Paliperidone - The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB01267 .
ns1:DB00268_DB01551	dcterms:title	"DDI between Ropinirole and Dihydrocodeine - Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB01551 .
ns1:DB00268_DB01623	dcterms:title	"DDI between Ropinirole and Thiothixene - Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Ropinirole. Consider alternate therapy or monitor for decreased effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB01623 .
ns1:DB00268_DB01624	dcterms:title	"DDI between Ropinirole and Zuclopenthixol - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB01624 .
ns1:DB00268_DB08919	dcterms:title	"DDI between Ropinirole and Zuclopenthixol acetate - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB08919 .
ns1:DB00268_DB08920	dcterms:title	"DDI between Ropinirole and Zuclopenthixol decanoate - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00268 ,
		ns3:DB08920 .
ns1:DB00269_DB00400	dcterms:title	"DDI between Chlorotrianisene and Griseofulvin - The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00400 ,
		ns3:DB00269 .
ns1:DB00269_DB00481	dcterms:title	"DDI between Chlorotrianisene and Raloxifene - Association not recommended"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00481 ,
		ns3:DB00269 .
ns1:DB00269_DB00635	dcterms:title	"DDI between Chlorotrianisene and Prednisone - The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00269 .
ns1:DB00269_DB00794	dcterms:title	"DDI between Chlorotrianisene and Primidone - The enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00269 .
ns1:DB00269_DB00860	dcterms:title	"DDI between Chlorotrianisene and Prednisolone - The estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00269 .
ns1:DB00269_DB01174	dcterms:title	"DDI between Chlorotrianisene and Phenobarbital - The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00269 .
ns1:DB00269_DB01320	dcterms:title	"DDI between Chlorotrianisene and Fosphenytoin - The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00269 .
ns1:DB00270_DB00374	dcterms:title	"DDI between Isradipine and Treprostinil - Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00374 ,
		ns3:DB00270 .
ns1:DB00270_DB00539	dcterms:title	"DDI between Isradipine and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00539 ,
		ns3:DB00270 .
ns1:DB00270_DB00582	dcterms:title	"DDI between Isradipine and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00270 .
ns1:DB00270_DB00599	dcterms:title	"DDI between Isradipine and Thiopental - The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00270 .
ns1:DB00270_DB00726	dcterms:title	"DDI between Isradipine and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00270 .
ns1:DB00270_DB00864	dcterms:title	"DDI between Isradipine and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00270 .
ns1:DB00270_DB00932	dcterms:title	"DDI between Isradipine and Tipranavir - Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00270 .
ns1:DB00270_DB00976	dcterms:title	"DDI between Isradipine and Telithromycin - Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00270 .
ns1:DB00270_DB01369	dcterms:title	"DDI between Isradipine and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00270 .
ns1:DB00270_DB01623	dcterms:title	"DDI between Isradipine and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB00270 .
ns1:DB00270_DB01624	dcterms:title	"DDI between Isradipine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB00270 .
ns1:DB00270_DB02546	dcterms:title	"DDI between Isradipine and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02546 ,
		ns3:DB00270 .
ns1:DB00270_DB06697	dcterms:title	"DDI between Isradipine and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00270 .
ns1:DB00270_DB06708	dcterms:title	"DDI between Isradipine and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB00270 .
ns1:DB00270_DB08919	dcterms:title	"DDI between Isradipine and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08919 ,
		ns3:DB00270 .
ns1:DB00270_DB08920	dcterms:title	"DDI between Isradipine and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08920 ,
		ns3:DB00270 .
ns1:DB00273_DB00427	dcterms:title	"DDI between Topiramate and Triprolidine - The CNS depressants, Triprolidine and Topiramate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00427 ,
		ns3:DB00273 .
ns1:DB00273_DB00564	dcterms:title	"DDI between Topiramate and Carbamazepine - Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00564 ,
		ns3:DB00273 .
ns1:DB00273_DB00684	dcterms:title	"DDI between Topiramate and Tobramycin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00684 ,
		ns3:DB00273 .
ns1:DB00273_DB00819	dcterms:title	"DDI between Topiramate and Acetazolamide - Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00819 ,
		ns3:DB00273 .
ns1:DB00273_DB00880	dcterms:title	"DDI between Topiramate and Chlorothiazide - Thiazide diuretics such as chlorothiazide may enhance the hypokalemic effect of topiramate. Thiazide diuretics may increase the serum concentration of topiramate. Monitor for increased topiramate concentrations/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00880 ,
		ns3:DB00273 .
ns1:DB00273_DB00977	dcterms:title	"DDI between Topiramate and Ethinyl Estradiol - Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00273 .
ns1:DB00273_DB01194	dcterms:title	"DDI between Topiramate and Brinzolamide - As both brinzolamide and topiramate are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01194 ,
		ns3:DB00273 .
ns1:DB00273_DB01320	dcterms:title	"DDI between Topiramate and Fosphenytoin - Increased phenytoin/decreased topiramate"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00273 .
ns1:DB00273_DB01356	dcterms:title	"DDI between Topiramate and Lithium - Topiramate could modify lithium levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00273 .
ns1:DB00273_DB01357	dcterms:title	"DDI between Topiramate and Mestranol - Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00273 .
ns1:DB00273_DB04835	dcterms:title	"DDI between Topiramate and Maraviroc - Topiramate, a CYP3A4 inducer, may decrease the serum concentration of Maraviroc by increasing Maraviroc metabolism and clearance. A dose adjustment of Maraviroc may be required. Monitor for changes in Maraviroc therapeutic and adverse effects if Topiramate is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00273 ,
		ns3:DB04835 .
ns1:DB00273_DB08867	dcterms:title	"DDI between Topiramate and Ulipristal - Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00273 ,
		ns3:DB08867 .
ns1:DB00274_DB01032	dcterms:title	"DDI between Cefmetazole and Probenecid - Probenecid may increase the serum level of cefmatzole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00274 ,
		ns3:DB01032 .
ns1:DB00275_DB00374	dcterms:title	"DDI between Olmesartan and Treprostinil - Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00374 ,
		ns3:DB00275 .
ns1:DB00275_DB00519	dcterms:title	"DDI between Olmesartan and Trandolapril - The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00519 ,
		ns3:DB00275 .
ns1:DB00275_DB00684	dcterms:title	"DDI between Olmesartan and Tobramycin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00684 ,
		ns3:DB00275 .
ns1:DB00275_DB01395	dcterms:title	"DDI between Olmesartan and Drospirenone - Increased risk of hyperkalemia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01395 ,
		ns3:DB00275 .
ns1:DB00277_DB00306	dcterms:title	"DDI between Theophylline and Talbutal - The barbiturate, talbutal, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00306 .
ns1:DB00277_DB00312	dcterms:title	"DDI between Theophylline and Pentobarbital - The barbiturate, pentobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00312 .
ns1:DB00277_DB00365	dcterms:title	"DDI between Theophylline and Grepafloxacin - Grepafloxacin may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00365 ,
		ns3:DB00277 .
ns1:DB00277_DB00373	dcterms:title	"DDI between Theophylline and Timolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00373 .
ns1:DB00277_DB00379	dcterms:title	"DDI between Theophylline and Mexiletine - Mexiletine increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00379 ,
		ns3:DB00277 .
ns1:DB00277_DB00382	dcterms:title	"DDI between Theophylline and Tacrine - Tacrine may reduce the elimination rate of Theophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00382 ,
		ns3:DB00277 .
ns1:DB00277_DB00418	dcterms:title	"DDI between Theophylline and Secobarbital - The barbiturate, secobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00418 .
ns1:DB00277_DB00467	dcterms:title	"DDI between Theophylline and Enoxacin - Enoxacin may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00467 ,
		ns3:DB00277 .
ns1:DB00277_DB00474	dcterms:title	"DDI between Theophylline and Methohexital - The barbiturate, methohexital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00474 .
ns1:DB00277_DB00487	dcterms:title	"DDI between Theophylline and Pefloxacin - Pefloxacin may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00487 .
ns1:DB00277_DB00489	dcterms:title	"DDI between Theophylline and Sotalol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00489 .
ns1:DB00277_DB00501	dcterms:title	"DDI between Theophylline and Cimetidine - Cimetidine may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00501 .
ns1:DB00277_DB00503	dcterms:title	"DDI between Theophylline and Ritonavir - Ritonavir decreases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00503 .
ns1:DB00277_DB00521	dcterms:title	"DDI between Theophylline and Carteolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00521 .
ns1:DB00277_DB00532	dcterms:title	"DDI between Theophylline and Mephenytoin - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00532 .
ns1:DB00277_DB00533	dcterms:title	"DDI between Theophylline and Rofecoxib - Rofecoxib increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00533 .
ns1:DB00277_DB00537	dcterms:title	"DDI between Theophylline and Ciprofloxacin - Ciprofloxacin may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00537 .
ns1:DB00277_DB00549	dcterms:title	"DDI between Theophylline and Zafirlukast - Zafirlukast serum concentrations may be decreased by Theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00549 .
ns1:DB00277_DB00564	dcterms:title	"DDI between Theophylline and Carbamazepine - Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00564 .
ns1:DB00277_DB00571	dcterms:title	"DDI between Theophylline and Propranolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00571 .
ns1:DB00277_DB00582	dcterms:title	"DDI between Theophylline and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00582 .
ns1:DB00277_DB00640	dcterms:title	"DDI between Theophylline and Adenosine - Theophylline may decrease the effect of adenosine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00640 .
ns1:DB00277_DB00661	dcterms:title	"DDI between Theophylline and Verapamil - Verapamil increases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00661 .
ns1:DB00277_DB00730	dcterms:title	"DDI between Theophylline and Thiabendazole - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00730 .
ns1:DB00277_DB00732	dcterms:title	"DDI between Theophylline and Atracurium - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00732 .
ns1:DB00277_DB00744	dcterms:title	"DDI between Theophylline and Zileuton - Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00744 .
ns1:DB00277_DB00754	dcterms:title	"DDI between Theophylline and Ethotoin - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00277 .
ns1:DB00277_DB00787	dcterms:title	"DDI between Theophylline and Aciclovir - Acyclovir may increase the effect and toxicity of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00787 .
ns1:DB00277_DB00794	dcterms:title	"DDI between Theophylline and Primidone - The barbiturate, primidone, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00277 .
ns1:DB00277_DB00806	dcterms:title	"DDI between Theophylline and Pentoxifylline - Pentoxifylline increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00806 ,
		ns3:DB00277 .
ns1:DB00277_DB00822	dcterms:title	"DDI between Theophylline and Disulfiram - Disulfiram may increase the effect and toxicity of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00822 .
ns1:DB00277_DB00849	dcterms:title	"DDI between Theophylline and Methylphenobarbital - The barbiturate, methylphenobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00277 .
ns1:DB00277_DB00857	dcterms:title	"DDI between Theophylline and Terbinafine - Terbinafine increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00857 ,
		ns3:DB00277 .
ns1:DB00277_DB00932	dcterms:title	"DDI between Theophylline and Tipranavir - Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00277 .
ns1:DB00277_DB00951	dcterms:title	"DDI between Theophylline and Isoniazid - Isoniazid may increase the therapeutic and adverse effects of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00277 .
ns1:DB00277_DB00960	dcterms:title	"DDI between Theophylline and Pindolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00277 .
ns1:DB00277_DB00976	dcterms:title	"DDI between Theophylline and Telithromycin - Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00277 .
ns1:DB00277_DB00977	dcterms:title	"DDI between Theophylline and Ethinyl Estradiol - The contraceptive increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00277 .
ns1:DB00277_DB01045	dcterms:title	"DDI between Theophylline and Rifampicin - Rifampin decreases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00277 .
ns1:DB00277_DB01059	dcterms:title	"DDI between Theophylline and Norfloxacin - Norfloxacin may increase the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01059 ,
		ns3:DB00277 .
ns1:DB00277_DB01135	dcterms:title	"DDI between Theophylline and Doxacurium chloride - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01135 .
ns1:DB00277_DB01159	dcterms:title	"DDI between Theophylline and Halothane - Increased risk of cardiac arrhythmia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01159 .
ns1:DB00277_DB01174	dcterms:title	"DDI between Theophylline and Phenobarbital - The barbiturate, phenobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00277 .
ns1:DB00277_DB01182	dcterms:title	"DDI between Theophylline and Propafenone - Propafenone increases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00277 .
ns1:DB00277_DB01199	dcterms:title	"DDI between Theophylline and Tubocurarine - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01199 .
ns1:DB00277_DB01203	dcterms:title	"DDI between Theophylline and Nadolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00277 .
ns1:DB00277_DB01211	dcterms:title	"DDI between Theophylline and Clarithromycin - Clarithromycin may increase the therapeutic and adverse effects of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00277 .
ns1:DB00277_DB01226	dcterms:title	"DDI between Theophylline and Mivacurium - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01226 .
ns1:DB00277_DB01320	dcterms:title	"DDI between Theophylline and Fosphenytoin - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00277 .
ns1:DB00277_DB01321	dcterms:title	"DDI between Theophylline and Josamycin - The macrolide, josamycin, may increase the effect and toxicity of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01321 ,
		ns3:DB00277 .
ns1:DB00277_DB01323	dcterms:title	"DDI between Theophylline and St. John's Wort - St. John's Wort decreases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01323 ,
		ns3:DB00277 .
ns1:DB00277_DB01336	dcterms:title	"DDI between Theophylline and Metocurine - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01336 .
ns1:DB00277_DB01337	dcterms:title	"DDI between Theophylline and Pancuronium - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01337 .
ns1:DB00277_DB01339	dcterms:title	"DDI between Theophylline and Vecuronium - Theophylline decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB01339 .
ns1:DB00277_DB01341	dcterms:title	"DDI between Theophylline and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00277 .
ns1:DB00277_DB01346	dcterms:title	"DDI between Theophylline and Quinidine barbiturate - The barbiturate, quinidine barbiturate, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00277 .
ns1:DB00277_DB01351	dcterms:title	"DDI between Theophylline and Amobarbital - The barbiturate, amobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00277 .
ns1:DB00277_DB01352	dcterms:title	"DDI between Theophylline and Aprobarbital - The barbiturate, aprobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00277 .
ns1:DB00277_DB01353	dcterms:title	"DDI between Theophylline and Butethal - The barbiturate, butethal, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00277 .
ns1:DB00277_DB01354	dcterms:title	"DDI between Theophylline and Heptabarbital - The barbiturate, heptabarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00277 .
ns1:DB00277_DB01355	dcterms:title	"DDI between Theophylline and Hexobarbital - The barbiturate, hexobarbital, decreases the effect of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00277 .
ns1:DB00277_DB01356	dcterms:title	"DDI between Theophylline and Lithium - Theophylline decreases serum levels of lithium"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00277 .
ns1:DB00277_DB01357	dcterms:title	"DDI between Theophylline and Mestranol - The contraceptive increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00277 .
ns1:DB00277_DB01359	dcterms:title	"DDI between Theophylline and Penbutolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00277 .
ns1:DB00277_DB01361	dcterms:title	"DDI between Theophylline and Troleandomycin - The macrolide, troleandomycin, may increase the effect and toxicity of theophylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01361 ,
		ns3:DB00277 .
ns1:DB00277_DB01558	dcterms:title	"DDI between Theophylline and Bromazepam - Theophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if theophylline is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB00277 .
ns1:DB00277_DB04854	dcterms:title	"DDI between Theophylline and Febuxostat - Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB04854 .
ns1:DB00277_DB06213	dcterms:title	"DDI between Theophylline and Regadenoson - Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06213 ,
		ns3:DB00277 .
ns1:DB00278_DB00374	dcterms:title	"DDI between Argatroban and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00374 ,
		ns3:DB00278 .
ns1:DB00278_DB01381	dcterms:title	"DDI between Argatroban and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00278 .
ns1:DB00279_DB00375	dcterms:title	"DDI between Liothyronine and Colestipol - The resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00375 ,
		ns3:DB00279 .
ns1:DB00279_DB00390	dcterms:title	"DDI between Liothyronine and Digoxin - The thyroid hormone, liothyronine, decreases the effect of digoxin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00390 ,
		ns3:DB00279 .
ns1:DB00279_DB00682	dcterms:title	"DDI between Liothyronine and Warfarin - Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00279 .
ns1:DB00279_DB01164	dcterms:title	"DDI between Liothyronine and Calcium Chloride - Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00279 ,
		ns3:DB01164 .
ns1:DB00279_DB01432	dcterms:title	"DDI between Liothyronine and Cholestyramine - The resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01432 ,
		ns3:DB00279 .
ns1:DB00280_DB00335	dcterms:title	"DDI between Disopyramide and Atenolol - The beta-blocker, atenolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB00335 .
ns1:DB00280_DB00338	dcterms:title	"DDI between Disopyramide and Omeprazole - The beta-blocker increases toxicity of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB00338 .
ns1:DB00280_DB00342	dcterms:title	"DDI between Disopyramide and Terfenadine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00342 ,
		ns3:DB00280 .
ns1:DB00280_DB00365	dcterms:title	"DDI between Disopyramide and Grepafloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00365 ,
		ns3:DB00280 .
ns1:DB00280_DB00373	dcterms:title	"DDI between Disopyramide and Timolol - The beta-blocker, timolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00373 ,
		ns3:DB00280 .
ns1:DB00280_DB00489	dcterms:title	"DDI between Disopyramide and Sotalol - The beta-blocker, sotalol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00489 ,
		ns3:DB00280 .
ns1:DB00280_DB00521	dcterms:title	"DDI between Disopyramide and Carteolol - The beta-blocker, carteolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00521 ,
		ns3:DB00280 .
ns1:DB00280_DB00532	dcterms:title	"DDI between Disopyramide and Mephenytoin - The hydantoin decreases the effect of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00532 ,
		ns3:DB00280 .
ns1:DB00280_DB00539	dcterms:title	"DDI between Disopyramide and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00539 ,
		ns3:DB00280 .
ns1:DB00280_DB00571	dcterms:title	"DDI between Disopyramide and Propranolol - The beta-blocker, propranolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00571 ,
		ns3:DB00280 .
ns1:DB00280_DB00582	dcterms:title	"DDI between Disopyramide and Voriconazole - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00280 .
ns1:DB00280_DB00598	dcterms:title	"DDI between Disopyramide and Labetalol - The beta-blocker, labetolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00280 .
ns1:DB00280_DB00599	dcterms:title	"DDI between Disopyramide and Thiopental - Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00280 .
ns1:DB00280_DB00604	dcterms:title	"DDI between Disopyramide and Cisapride - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00280 .
ns1:DB00280_DB00612	dcterms:title	"DDI between Disopyramide and Bisoprolol - The beta-blocker, bisoprolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00280 .
ns1:DB00280_DB00674	dcterms:title	"DDI between Disopyramide and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00674 ,
		ns3:DB00280 .
ns1:DB00280_DB00679	dcterms:title	"DDI between Disopyramide and Thioridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00280 .
ns1:DB00280_DB00726	dcterms:title	"DDI between Disopyramide and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00280 .
ns1:DB00280_DB00754	dcterms:title	"DDI between Disopyramide and Ethotoin - The hydantoin decreases the effect of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB00754 .
ns1:DB00280_DB00843	dcterms:title	"DDI between Disopyramide and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00843 ,
		ns3:DB00280 .
ns1:DB00280_DB00864	dcterms:title	"DDI between Disopyramide and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB00864 .
ns1:DB00280_DB00933	dcterms:title	"DDI between Disopyramide and Mesoridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00280 .
ns1:DB00280_DB00960	dcterms:title	"DDI between Disopyramide and Pindolol - The beta-blocker, pindolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00280 .
ns1:DB00280_DB00976	dcterms:title	"DDI between Disopyramide and Telithromycin - Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00280 .
ns1:DB00280_DB00989	dcterms:title	"DDI between Disopyramide and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00280 .
ns1:DB00280_DB01044	dcterms:title	"DDI between Disopyramide and Gatifloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB01044 .
ns1:DB00280_DB01045	dcterms:title	"DDI between Disopyramide and Rifampicin - Rifampin decreases the effect of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00280 .
ns1:DB00280_DB01136	dcterms:title	"DDI between Disopyramide and Carvedilol - The beta-blocker, carvedilol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01136 ,
		ns3:DB00280 .
ns1:DB00280_DB01137	dcterms:title	"DDI between Disopyramide and Levofloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01137 ,
		ns3:DB00280 .
ns1:DB00280_DB01174	dcterms:title	"DDI between Disopyramide and Phenobarbital - Phenobarbital decreases levels of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00280 .
ns1:DB00280_DB01193	dcterms:title	"DDI between Disopyramide and Acebutolol - Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01193 ,
		ns3:DB00280 .
ns1:DB00280_DB01203	dcterms:title	"DDI between Disopyramide and Nadolol - The beta-blocker, nadolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00280 .
ns1:DB00280_DB01208	dcterms:title	"DDI between Disopyramide and Sparfloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01208 ,
		ns3:DB00280 .
ns1:DB00280_DB01211	dcterms:title	"DDI between Disopyramide and Clarithromycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00280 .
ns1:DB00280_DB01295	dcterms:title	"DDI between Disopyramide and Bevantolol - The beta-blocker, bevantolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01295 ,
		ns3:DB00280 .
ns1:DB00280_DB01297	dcterms:title	"DDI between Disopyramide and Practolol - The beta-blocker, practolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01297 ,
		ns3:DB00280 .
ns1:DB00280_DB01320	dcterms:title	"DDI between Disopyramide and Fosphenytoin - The hydantoin decreases the effect of disopyramide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00280 .
ns1:DB00280_DB01359	dcterms:title	"DDI between Disopyramide and Penbutolol - The beta-blocker, penbutolol,  may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00280 .
ns1:DB00280_DB01369	dcterms:title	"DDI between Disopyramide and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00280 .
ns1:DB00280_DB01580	dcterms:title	"DDI between Disopyramide and Oxprenolol - The beta-blocker, oxprenolol, may increase the toxicity of disopyramide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00280 .
ns1:DB00280_DB01623	dcterms:title	"DDI between Disopyramide and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB00280 .
ns1:DB00280_DB01624	dcterms:title	"DDI between Disopyramide and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB00280 .
ns1:DB00280_DB02546	dcterms:title	"DDI between Disopyramide and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02546 ,
		ns3:DB00280 .
ns1:DB00280_DB06402	dcterms:title	"DDI between Disopyramide and Telavancin - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB06402 .
ns1:DB00280_DB06414	dcterms:title	"DDI between Disopyramide and Etravirine - Disopyramide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for disopyramide therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00280 .
ns1:DB00280_DB06697	dcterms:title	"DDI between Disopyramide and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00280 .
ns1:DB00280_DB08865	dcterms:title	"DDI between Disopyramide and Crizotinib - Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00280 ,
		ns3:DB08865 .
ns1:DB00280_DB08868	dcterms:title	"DDI between Disopyramide and Fingolimod - Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08868 ,
		ns3:DB00280 .
ns1:DB00280_DB08919	dcterms:title	"DDI between Disopyramide and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08919 ,
		ns3:DB00280 .
ns1:DB00280_DB08920	dcterms:title	"DDI between Disopyramide and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08920 ,
		ns3:DB00280 .
ns1:DB00281_DB00335	dcterms:title	"DDI between Lidocaine and Atenolol - The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00335 .
ns1:DB00281_DB00373	dcterms:title	"DDI between Lidocaine and Timolol - The beta-blocker, timolol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00373 .
ns1:DB00281_DB00382	dcterms:title	"DDI between Lidocaine and Tacrine - The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00382 ,
		ns3:DB00281 .
ns1:DB00281_DB00501	dcterms:title	"DDI between Lidocaine and Cimetidine - Increases the effect and toxicity of lidocaine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00501 ,
		ns3:DB00281 .
ns1:DB00281_DB00571	dcterms:title	"DDI between Lidocaine and Propranolol - The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00571 .
ns1:DB00281_DB00582	dcterms:title	"DDI between Lidocaine and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00582 .
ns1:DB00281_DB00598	dcterms:title	"DDI between Lidocaine and Labetalol - The beta-blocker, labetalol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00598 .
ns1:DB00281_DB00612	dcterms:title	"DDI between Lidocaine and Bisoprolol - The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00612 .
ns1:DB00281_DB00656	dcterms:title	"DDI between Lidocaine and Trazodone - The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00656 .
ns1:DB00281_DB00675	dcterms:title	"DDI between Lidocaine and Tamoxifen - Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00675 ,
		ns3:DB00281 .
ns1:DB00281_DB00697	dcterms:title	"DDI between Lidocaine and Tizanidine - Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00697 ,
		ns3:DB00281 .
ns1:DB00281_DB00706	dcterms:title	"DDI between Lidocaine and Tamsulosin - Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00706 .
ns1:DB00281_DB00857	dcterms:title	"DDI between Lidocaine and Terbinafine - Terbinafine may reduce the metabolism and clearance of Lidocaine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lidocaine if Terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00857 .
ns1:DB00281_DB00960	dcterms:title	"DDI between Lidocaine and Pindolol - The beta-blocker increases the effect and toxicity of lidocaine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00960 .
ns1:DB00281_DB00976	dcterms:title	"DDI between Lidocaine and Telithromycin - Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB00976 .
ns1:DB00281_DB01036	dcterms:title	"DDI between Lidocaine and Tolterodine - Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01036 .
ns1:DB00281_DB01072	dcterms:title	"DDI between Lidocaine and Atazanavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01072 .
ns1:DB00281_DB01136	dcterms:title	"DDI between Lidocaine and Carvedilol - The beta-blocker, carvedilol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01136 .
ns1:DB00281_DB01193	dcterms:title	"DDI between Lidocaine and Acebutolol - The beta-blocker, acebutolol, may increase the effect and toxicity of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01193 .
ns1:DB00281_DB01203	dcterms:title	"DDI between Lidocaine and Nadolol - The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01203 .
ns1:DB00281_DB01264	dcterms:title	"DDI between Lidocaine and Darunavir - Possible increase in lidocaine levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01264 .
ns1:DB00281_DB01359	dcterms:title	"DDI between Lidocaine and Penbutolol - Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01359 .
ns1:DB00281_DB01369	dcterms:title	"DDI between Lidocaine and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01369 .
ns1:DB00281_DB01580	dcterms:title	"DDI between Lidocaine and Oxprenolol - The beta-blocker increases the effect and toxicity of lidocaine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01580 .
ns1:DB00281_DB01623	dcterms:title	"DDI between Lidocaine and Thiothixene - The strong CYP1A2 inhibitor, Lidocaine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Lidocaine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB01623 .
ns1:DB00281_DB06414	dcterms:title	"DDI between Lidocaine and Etravirine - Lidocaine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor lidocaine therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00281 ,
		ns3:DB06414 .
ns1:DB00283_DB00382	dcterms:title	"DDI between Clemastine and Tacrine - The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clemastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00382 .
ns1:DB00283_DB00427	dcterms:title	"DDI between Clemastine and Triprolidine - Concomitant therapy with triprolidine and clemastine, two anticholinergics and CNS depressants, may result in additive  adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00427 .
ns1:DB00283_DB00662	dcterms:title	"DDI between Clemastine and Trimethobenzamide - Trimethobenzamide and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00662 .
ns1:DB00283_DB00674	dcterms:title	"DDI between Clemastine and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00674 .
ns1:DB00283_DB00843	dcterms:title	"DDI between Clemastine and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00843 .
ns1:DB00283_DB00989	dcterms:title	"DDI between Clemastine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00283 ,
		ns3:DB00989 .
ns1:DB00284_DB00390	dcterms:title	"DDI between Acarbose and Digoxin - Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00284 ,
		ns3:DB00390 .
ns1:DB00285_DB00315	dcterms:title	"DDI between Venlafaxine and Zolmitriptan - Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00315 ,
		ns3:DB00285 .
ns1:DB00285_DB00320	dcterms:title	"DDI between Venlafaxine and Dihydroergotamine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00320 ,
		ns3:DB00285 .
ns1:DB00285_DB00321	dcterms:title	"DDI between Venlafaxine and Amitriptyline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00321 ,
		ns3:DB00285 .
ns1:DB00285_DB00344	dcterms:title	"DDI between Venlafaxine and Protriptyline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00344 ,
		ns3:DB00285 .
ns1:DB00285_DB00353	dcterms:title	"DDI between Venlafaxine and Methylergometrine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00353 ,
		ns3:DB00285 .
ns1:DB00285_DB00368	dcterms:title	"DDI between Venlafaxine and Norepinephrine - Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00368 ,
		ns3:DB00285 .
ns1:DB00285_DB00370	dcterms:title	"DDI between Venlafaxine and Mirtazapine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00370 ,
		ns3:DB00285 .
ns1:DB00285_DB00397	dcterms:title	"DDI between Venlafaxine and Phenylpropanolamine - Risk of serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00397 ,
		ns3:DB00285 .
ns1:DB00285_DB00427	dcterms:title	"DDI between Venlafaxine and Triprolidine - The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00427 ,
		ns3:DB00285 .
ns1:DB00285_DB00449	dcterms:title	"DDI between Venlafaxine and Dipivefrin - Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00449 .
ns1:DB00285_DB00454	dcterms:title	"DDI between Venlafaxine and Pethidine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00285 .
ns1:DB00285_DB00458	dcterms:title	"DDI between Venlafaxine and Imipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00285 .
ns1:DB00285_DB00472	dcterms:title	"DDI between Venlafaxine and Fluoxetine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00285 .
ns1:DB00285_DB00476	dcterms:title	"DDI between Venlafaxine and Duloxetine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00476 ,
		ns3:DB00285 .
ns1:DB00285_DB00477	dcterms:title	"DDI between Venlafaxine and Chlorpromazine - Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00477 ,
		ns3:DB00285 .
ns1:DB00285_DB00490	dcterms:title	"DDI between Venlafaxine and Buspirone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00490 ,
		ns3:DB00285 .
ns1:DB00285_DB00503	dcterms:title	"DDI between Venlafaxine and Ritonavir - Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00503 ,
		ns3:DB00285 .
ns1:DB00285_DB00514	dcterms:title	"DDI between Venlafaxine and Dextromethorphan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00514 ,
		ns3:DB00285 .
ns1:DB00285_DB00540	dcterms:title	"DDI between Venlafaxine and Nortriptyline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00540 ,
		ns3:DB00285 .
ns1:DB00285_DB00543	dcterms:title	"DDI between Venlafaxine and Amoxapine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00543 ,
		ns3:DB00285 .
ns1:DB00285_DB00574	dcterms:title	"DDI between Venlafaxine and Fenfluramine - Risk of serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00574 ,
		ns3:DB00285 .
ns1:DB00285_DB00579	dcterms:title	"DDI between Venlafaxine and Mazindol - Risk of serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00579 ,
		ns3:DB00285 .
ns1:DB00285_DB00582	dcterms:title	"DDI between Venlafaxine and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00285 .
ns1:DB00285_DB00601	dcterms:title	"DDI between Venlafaxine and Linezolid - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB00285 .
ns1:DB00285_DB00614	dcterms:title	"DDI between Venlafaxine and Furazolidone - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00614 ,
		ns3:DB00285 .
ns1:DB00285_DB00619	dcterms:title	"DDI between Venlafaxine and Imatinib - Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00285 .
ns1:DB00285_DB00622	dcterms:title	"DDI between Venlafaxine and Nicardipine - Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00285 .
ns1:DB00285_DB00656	dcterms:title	"DDI between Venlafaxine and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00285 .
ns1:DB00285_DB00668	dcterms:title	"DDI between Venlafaxine and Epinephrine - Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00668 .
ns1:DB00285_DB00669	dcterms:title	"DDI between Venlafaxine and Sumatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB00285 .
ns1:DB00285_DB00696	dcterms:title	"DDI between Venlafaxine and Ergotamine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00696 ,
		ns3:DB00285 .
ns1:DB00285_DB00701	dcterms:title	"DDI between Venlafaxine and Amprenavir - Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00701 .
ns1:DB00285_DB00705	dcterms:title	"DDI between Venlafaxine and Delavirdine - Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00705 ,
		ns3:DB00285 .
ns1:DB00285_DB00715	dcterms:title	"DDI between Venlafaxine and Paroxetine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00715 ,
		ns3:DB00285 .
ns1:DB00285_DB00726	dcterms:title	"DDI between Venlafaxine and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00726 .
ns1:DB00285_DB00752	dcterms:title	"DDI between Venlafaxine and Tranylcypromine - Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00752 .
ns1:DB00285_DB00780	dcterms:title	"DDI between Venlafaxine and Phenelzine - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00780 ,
		ns3:DB00285 .
ns1:DB00285_DB00852	dcterms:title	"DDI between Venlafaxine and Pseudoephedrine - Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00852 ,
		ns3:DB00285 .
ns1:DB00285_DB00857	dcterms:title	"DDI between Venlafaxine and Terbinafine - Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00857 .
ns1:DB00285_DB00872	dcterms:title	"DDI between Venlafaxine and Conivaptan - Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00872 ,
		ns3:DB00285 .
ns1:DB00285_DB00907	dcterms:title	"DDI between Venlafaxine and Cocaine - Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00907 ,
		ns3:DB00285 .
ns1:DB00285_DB00908	dcterms:title	"DDI between Venlafaxine and Quinidine - Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00285 .
ns1:DB00285_DB00918	dcterms:title	"DDI between Venlafaxine and Almotriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00918 ,
		ns3:DB00285 .
ns1:DB00285_DB00934	dcterms:title	"DDI between Venlafaxine and Maprotiline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB00285 .
ns1:DB00285_DB00937	dcterms:title	"DDI between Venlafaxine and Diethylpropion - Risk of serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB00285 .
ns1:DB00285_DB00951	dcterms:title	"DDI between Venlafaxine and Isoniazid - Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00285 .
ns1:DB00285_DB00952	dcterms:title	"DDI between Venlafaxine and Naratriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00952 ,
		ns3:DB00285 .
ns1:DB00285_DB00953	dcterms:title	"DDI between Venlafaxine and Rizatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00953 ,
		ns3:DB00285 .
ns1:DB00285_DB00976	dcterms:title	"DDI between Venlafaxine and Telithromycin - Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00976 .
ns1:DB00285_DB00998	dcterms:title	"DDI between Venlafaxine and Frovatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB00285 .
ns1:DB00285_DB01012	dcterms:title	"DDI between Venlafaxine and Cinacalcet - Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01012 ,
		ns3:DB00285 .
ns1:DB00285_DB01026	dcterms:title	"DDI between Venlafaxine and Ketoconazole - Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01026 .
ns1:DB00285_DB01037	dcterms:title	"DDI between Venlafaxine and Selegiline - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01037 ,
		ns3:DB00285 .
ns1:DB00285_DB01049	dcterms:title	"DDI between Venlafaxine and Ergoloid mesylate - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01049 ,
		ns3:DB00285 .
ns1:DB00285_DB01069	dcterms:title	"DDI between Venlafaxine and Promethazine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01069 ,
		ns3:DB00285 .
ns1:DB00285_DB01072	dcterms:title	"DDI between Venlafaxine and Atazanavir - Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01072 .
ns1:DB00285_DB01104	dcterms:title	"DDI between Venlafaxine and Sertraline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00285 .
ns1:DB00285_DB01105	dcterms:title	"DDI between Venlafaxine and Sibutramine - Increased risk of serotonin syndrome. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01105 .
ns1:DB00285_DB01110	dcterms:title	"DDI between Venlafaxine and Miconazole - Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01110 ,
		ns3:DB00285 .
ns1:DB00285_DB01142	dcterms:title	"DDI between Venlafaxine and Doxepin - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00285 .
ns1:DB00285_DB01149	dcterms:title	"DDI between Venlafaxine and Nefazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00285 .
ns1:DB00285_DB01151	dcterms:title	"DDI between Venlafaxine and Desipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01151 .
ns1:DB00285_DB01167	dcterms:title	"DDI between Venlafaxine and Itraconazole - Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00285 .
ns1:DB00285_DB01168	dcterms:title	"DDI between Venlafaxine and Procarbazine - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01168 ,
		ns3:DB00285 .
ns1:DB00285_DB01171	dcterms:title	"DDI between Venlafaxine and Moclobemide - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01171 .
ns1:DB00285_DB01175	dcterms:title	"DDI between Venlafaxine and Escitalopram - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01175 .
ns1:DB00285_DB01182	dcterms:title	"DDI between Venlafaxine and Propafenone - Propafenone increases the effect and toxicity of venlafaxine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00285 .
ns1:DB00285_DB01186	dcterms:title	"DDI between Venlafaxine and Pergolide - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01186 .
ns1:DB00285_DB01191	dcterms:title	"DDI between Venlafaxine and Dexfenfluramine - Risk of serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01191 .
ns1:DB00285_DB01200	dcterms:title	"DDI between Venlafaxine and Bromocriptine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01200 .
ns1:DB00285_DB01211	dcterms:title	"DDI between Venlafaxine and Clarithromycin - Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00285 .
ns1:DB00285_DB01232	dcterms:title	"DDI between Venlafaxine and Saquinavir - Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00285 .
ns1:DB00285_DB01233	dcterms:title	"DDI between Venlafaxine and Metoclopramide - Possible serotoninergic syndrome with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01233 ,
		ns3:DB00285 .
ns1:DB00285_DB01242	dcterms:title	"DDI between Venlafaxine and Clomipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01242 .
ns1:DB00285_DB01247	dcterms:title	"DDI between Venlafaxine and Isocarboxazid - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01247 ,
		ns3:DB00285 .
ns1:DB00285_DB01253	dcterms:title	"DDI between Venlafaxine and Ergonovine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01253 ,
		ns3:DB00285 .
ns1:DB00285_DB01263	dcterms:title	"DDI between Venlafaxine and Posaconazole - Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00285 .
ns1:DB00285_DB01264	dcterms:title	"DDI between Venlafaxine and Darunavir - Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01264 .
ns1:DB00285_DB01319	dcterms:title	"DDI between Venlafaxine and Fosamprenavir - Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00285 .
ns1:DB00285_DB01323	dcterms:title	"DDI between Venlafaxine and St. John's Wort - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01323 ,
		ns3:DB00285 .
ns1:DB00285_DB01356	dcterms:title	"DDI between Venlafaxine and Lithium - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01356 .
ns1:DB00285_DB01364	dcterms:title	"DDI between Venlafaxine and Ephedrine - Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01364 .
ns1:DB00285_DB01367	dcterms:title	"DDI between Venlafaxine and Rasagiline - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01367 .
ns1:DB00285_DB01369	dcterms:title	"DDI between Venlafaxine and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00285 .
ns1:DB00285_DB01601	dcterms:title	"DDI between Venlafaxine and Lopinavir - Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB01601 .
ns1:DB00285_DB04896	dcterms:title	"DDI between Venlafaxine and Milnacipran - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04896 ,
		ns3:DB00285 .
ns1:DB00285_DB06700	dcterms:title	"DDI between Venlafaxine and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00285 .
ns1:DB00286_DB00306	dcterms:title	"DDI between Conjugated Estrogens and Talbutal - The enzyme inducer, talbutal, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00306 .
ns1:DB00286_DB00312	dcterms:title	"DDI between Conjugated Estrogens and Pentobarbital - The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00312 .
ns1:DB00286_DB00400	dcterms:title	"DDI between Conjugated Estrogens and Griseofulvin - The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00400 .
ns1:DB00286_DB00418	dcterms:title	"DDI between Conjugated Estrogens and Secobarbital - The enzyme inducer, secobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00418 .
ns1:DB00286_DB00474	dcterms:title	"DDI between Conjugated Estrogens and Methohexital - The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00474 .
ns1:DB00286_DB00481	dcterms:title	"DDI between Conjugated Estrogens and Raloxifene - Association not recommended"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00481 ,
		ns3:DB00286 .
ns1:DB00286_DB00532	dcterms:title	"DDI between Conjugated Estrogens and Mephenytoin - The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00532 .
ns1:DB00286_DB00635	dcterms:title	"DDI between Conjugated Estrogens and Prednisone - The estrogenic agent may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00635 .
ns1:DB00286_DB00754	dcterms:title	"DDI between Conjugated Estrogens and Ethotoin - The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00754 .
ns1:DB00286_DB00794	dcterms:title	"DDI between Conjugated Estrogens and Primidone - The enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00794 .
ns1:DB00286_DB00849	dcterms:title	"DDI between Conjugated Estrogens and Methylphenobarbital - The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00849 .
ns1:DB00286_DB00860	dcterms:title	"DDI between Conjugated Estrogens and Prednisolone - The estrogenic agent may increase the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00860 .
ns1:DB00286_DB00932	dcterms:title	"DDI between Conjugated Estrogens and Tipranavir - Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB00932 .
ns1:DB00286_DB01174	dcterms:title	"DDI between Conjugated Estrogens and Phenobarbital - The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01174 .
ns1:DB00286_DB01320	dcterms:title	"DDI between Conjugated Estrogens and Fosphenytoin - The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01320 .
ns1:DB00286_DB01351	dcterms:title	"DDI between Conjugated Estrogens and Amobarbital - The enzyme inducer, amobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01351 .
ns1:DB00286_DB01352	dcterms:title	"DDI between Conjugated Estrogens and Aprobarbital - The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01352 .
ns1:DB00286_DB01353	dcterms:title	"DDI between Conjugated Estrogens and Butethal - The enzyme inducer, butethal, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01353 .
ns1:DB00286_DB01354	dcterms:title	"DDI between Conjugated Estrogens and Heptabarbital - The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01354 .
ns1:DB00286_DB01355	dcterms:title	"DDI between Conjugated Estrogens and Hexobarbital - The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, conjugated estrogens."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01355 .
ns1:DB00286_DB01586	dcterms:title	"DDI between Conjugated Estrogens and Ursodeoxycholic acid - Estrogens decreases the effect of ursodiol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00286 ,
		ns3:DB01586 .
ns1:DB00289_DB00361	dcterms:title	"DDI between Atomoxetine and Vinorelbine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00361 .
ns1:DB00289_DB00427	dcterms:title	"DDI between Atomoxetine and Triprolidine - The CNS depressants, Triprolidine and Atomoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00427 .
ns1:DB00289_DB00468	dcterms:title	"DDI between Atomoxetine and Quinine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00468 .
ns1:DB00289_DB00472	dcterms:title	"DDI between Atomoxetine and Fluoxetine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00472 .
ns1:DB00289_DB00502	dcterms:title	"DDI between Atomoxetine and Haloperidol - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00502 .
ns1:DB00289_DB00503	dcterms:title	"DDI between Atomoxetine and Ritonavir - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00503 .
ns1:DB00289_DB00608	dcterms:title	"DDI between Atomoxetine and Chloroquine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00608 .
ns1:DB00289_DB00623	dcterms:title	"DDI between Atomoxetine and Fluphenazine - Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00623 .
ns1:DB00289_DB00647	dcterms:title	"DDI between Atomoxetine and Dextropropoxyphene - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00647 .
ns1:DB00289_DB00679	dcterms:title	"DDI between Atomoxetine and Thioridazine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00679 .
ns1:DB00289_DB00715	dcterms:title	"DDI between Atomoxetine and Paroxetine - The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00715 .
ns1:DB00289_DB00752	dcterms:title	"DDI between Atomoxetine and Tranylcypromine - The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Atomoxetine. These agents should not be administered within 14 days of each other."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00752 .
ns1:DB00289_DB00780	dcterms:title	"DDI between Atomoxetine and Phenelzine - Possible severe adverse reaction with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00780 .
ns1:DB00289_DB00850	dcterms:title	"DDI between Atomoxetine and Perphenazine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00850 .
ns1:DB00289_DB00857	dcterms:title	"DDI between Atomoxetine and Terbinafine - Terbinafine, a CYP2D6 inhibitor, may reduce the metabolism and clearance of Atomoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Atomoxetine if Terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00857 .
ns1:DB00289_DB00907	dcterms:title	"DDI between Atomoxetine and Cocaine - CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00907 .
ns1:DB00289_DB00908	dcterms:title	"DDI between Atomoxetine and Quinidine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB00908 .
ns1:DB00289_DB01075	dcterms:title	"DDI between Atomoxetine and Diphenhydramine - Diphenhydramine, a moderate CYP2D6 inhibitor, may increase the therapeutic and adverse effects of atomoxetine by decreasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01075 .
ns1:DB00289_DB01103	dcterms:title	"DDI between Atomoxetine and Quinacrine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01103 .
ns1:DB00289_DB01118	dcterms:title	"DDI between Atomoxetine and Amiodarone - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01118 .
ns1:DB00289_DB01206	dcterms:title	"DDI between Atomoxetine and Lomustine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01206 .
ns1:DB00289_DB01247	dcterms:title	"DDI between Atomoxetine and Isocarboxazid - Possible severe adverse reaction with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01247 .
ns1:DB00289_DB01346	dcterms:title	"DDI between Atomoxetine and Quinidine barbiturate - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01346 .
ns1:DB00289_DB01367	dcterms:title	"DDI between Atomoxetine and Rasagiline - Possible severe adverse reaction with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00289 ,
		ns3:DB01367 .
ns1:DB00289_DB01388	dcterms:title	"DDI between Atomoxetine and Mibefradil - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01388 ,
		ns3:DB00289 .
ns1:DB00289_DB01392	dcterms:title	"DDI between Atomoxetine and Yohimbine - The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01392 ,
		ns3:DB00289 .
ns1:DB00290_DB00337	dcterms:title	"DDI between Bleomycin and Pimecrolimus - Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00337 ,
		ns3:DB00290 .
ns1:DB00290_DB00390	dcterms:title	"DDI between Bleomycin and Digoxin - The antineoplasic agent decreases the effect of digoxin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00290 ,
		ns3:DB00390 .
ns1:DB00290_DB00864	dcterms:title	"DDI between Bleomycin and Tacrolimus - Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00290 ,
		ns3:DB00864 .
ns1:DB00290_DB01097	dcterms:title	"DDI between Bleomycin and Leflunomide - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01097 ,
		ns3:DB00290 .
ns1:DB00290_DB01320	dcterms:title	"DDI between Bleomycin and Fosphenytoin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00290 .
ns1:DB00290_DB01656	dcterms:title	"DDI between Bleomycin and Roflumilast - Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00290 ,
		ns3:DB01656 .
ns1:DB00290_DB08870	dcterms:title	"DDI between Bleomycin and Brentuximab vedotin - Pulmonary toxicity of bleomycin may be increased. Avoid combination."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08870 ,
		ns3:DB00290 .
ns1:DB00291_DB00337	dcterms:title	"DDI between Chlorambucil and Pimecrolimus - Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as chlorambucil. Avoid use of pimecrolimus cream in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00337 ,
		ns3:DB00291 .
ns1:DB00291_DB00864	dcterms:title	"DDI between Chlorambucil and Tacrolimus - Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00291 ,
		ns3:DB00864 .
ns1:DB00291_DB01097	dcterms:title	"DDI between Chlorambucil and Leflunomide - Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01097 ,
		ns3:DB00291 .
ns1:DB00291_DB01656	dcterms:title	"DDI between Chlorambucil and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as chlorambucil. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00291 ,
		ns3:DB01656 .
ns1:DB00291_DB06769	dcterms:title	"DDI between Chlorambucil and Bendamustine - Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06769 ,
		ns3:DB00291 .
ns1:DB00294_DB00307	dcterms:title	"DDI between Etonogestrel and Bexarotene - Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB00307 .
ns1:DB00294_DB00599	dcterms:title	"DDI between Etonogestrel and Thiopental - Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB00599 .
ns1:DB00294_DB00682	dcterms:title	"DDI between Etonogestrel and Warfarin - Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB00682 .
ns1:DB00294_DB00755	dcterms:title	"DDI between Etonogestrel and Tretinoin - Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB00755 .
ns1:DB00294_DB00930	dcterms:title	"DDI between Etonogestrel and Colesevelam - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB00930 .
ns1:DB00294_DB06697	dcterms:title	"DDI between Etonogestrel and Artemether - Artemether may decrease the effectiveness of etonogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00294 ,
		ns3:DB06697 .
ns1:DB00295_DB00427	dcterms:title	"DDI between Morphine and Triprolidine - The CNS depressants, Triprolidine and Morphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00295 ,
		ns3:DB00427 .
ns1:DB00295_DB00685	dcterms:title	"DDI between Morphine and Trovafloxacin - Morphine may reduce serum levels of Trovafloxacin decreasing the efficacy of the antibiotic. IV doses of morphine should be administered at least 2 hours after a dose of Trovafloxacin given in a fasting state or 4 hours after if given in a fed state."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00685 ,
		ns3:DB00295 .
ns1:DB00295_DB01045	dcterms:title	"DDI between Morphine and Rifampicin - Rifampin decreases the effect of morphine/codeine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00295 ,
		ns3:DB01045 .
ns1:DB00295_DB06210	dcterms:title	"DDI between Morphine and Eltrombopag - Eltrombopag increases Morphine levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00295 ,
		ns3:DB06210 .
ns1:DB00295_DB06274	dcterms:title	"DDI between Morphine and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00295 ,
		ns3:DB06274 .
ns1:DB00595_DB00755	dcterms:title	"DDI between Oxytetracycline and Tretinoin - Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00755 ,
		ns3:DB00595 .
ns1:DB00595_DB00766	dcterms:title	"DDI between Oxytetracycline and Clavulanate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00766 ,
		ns3:DB00595 .
ns1:DB00595_DB00893	dcterms:title	"DDI between Oxytetracycline and Iron Dextran - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB00893 .
ns1:DB00595_DB00926	dcterms:title	"DDI between Oxytetracycline and Etretinate - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00926 ,
		ns3:DB00595 .
ns1:DB00595_DB00977	dcterms:title	"DDI between Oxytetracycline and Ethinyl Estradiol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00595 .
ns1:DB00595_DB00982	dcterms:title	"DDI between Oxytetracycline and Isotretinoin - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00982 ,
		ns3:DB00595 .
ns1:DB00595_DB01053	dcterms:title	"DDI between Oxytetracycline and Benzylpenicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01053 ,
		ns3:DB00595 .
ns1:DB00595_DB01060	dcterms:title	"DDI between Oxytetracycline and Amoxicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01060 ,
		ns3:DB00595 .
ns1:DB00595_DB01147	dcterms:title	"DDI between Oxytetracycline and Cloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01147 ,
		ns3:DB00595 .
ns1:DB00595_DB01373	dcterms:title	"DDI between Oxytetracycline and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB01373 .
ns1:DB00595_DB01378	dcterms:title	"DDI between Oxytetracycline and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB01378 .
ns1:DB00595_DB01604	dcterms:title	"DDI between Oxytetracycline and Pivampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB01604 .
ns1:DB00595_DB01605	dcterms:title	"DDI between Oxytetracycline and Pivmecillinam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB01605 .
ns1:DB00595_DB01607	dcterms:title	"DDI between Oxytetracycline and Ticarcillin - Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00595 ,
		ns3:DB01607 .
ns1:DB00598_DB00661	dcterms:title	"DDI between Labetalol and Verapamil - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00598 .
ns1:DB00598_DB00668	dcterms:title	"DDI between Labetalol and Epinephrine - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00598 .
ns1:DB00598_DB00672	dcterms:title	"DDI between Labetalol and Chlorpropamide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00672 ,
		ns3:DB00598 .
ns1:DB00598_DB00696	dcterms:title	"DDI between Labetalol and Ergotamine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00696 .
ns1:DB00598_DB00753	dcterms:title	"DDI between Labetalol and Isoflurane - Monitor arterial pressure closely"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00753 .
ns1:DB00598_DB00816	dcterms:title	"DDI between Labetalol and Orciprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00816 .
ns1:DB00598_DB00839	dcterms:title	"DDI between Labetalol and Tolazamide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00598 .
ns1:DB00598_DB00871	dcterms:title	"DDI between Labetalol and Terbutaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00871 .
ns1:DB00598_DB00912	dcterms:title	"DDI between Labetalol and Repaglinide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00912 ,
		ns3:DB00598 .
ns1:DB00598_DB00938	dcterms:title	"DDI between Labetalol and Salmeterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00938 .
ns1:DB00598_DB00983	dcterms:title	"DDI between Labetalol and Formoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB00983 .
ns1:DB00598_DB01001	dcterms:title	"DDI between Labetalol and Salbutamol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01001 .
ns1:DB00598_DB01016	dcterms:title	"DDI between Labetalol and Glyburide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01016 .
ns1:DB00598_DB01050	dcterms:title	"DDI between Labetalol and Ibuprofen - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01050 .
ns1:DB00598_DB01064	dcterms:title	"DDI between Labetalol and Isoprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01064 .
ns1:DB00598_DB01067	dcterms:title	"DDI between Labetalol and Glipizide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01067 .
ns1:DB00598_DB01120	dcterms:title	"DDI between Labetalol and Gliclazide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01120 .
ns1:DB00598_DB01124	dcterms:title	"DDI between Labetalol and Tolbutamide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01124 .
ns1:DB00598_DB01159	dcterms:title	"DDI between Labetalol and Halothane - Monitor arterial pressure closely"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01159 .
ns1:DB00598_DB01162	dcterms:title	"DDI between Labetalol and Terazosin - Increased risk of hypotension. Initiate concomitant therapy cautiously."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01162 .
ns1:DB00598_DB01253	dcterms:title	"DDI between Labetalol and Ergonovine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01253 .
ns1:DB00598_DB01288	dcterms:title	"DDI between Labetalol and Fenoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01288 .
ns1:DB00598_DB01289	dcterms:title	"DDI between Labetalol and Glisoxepide - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01289 .
ns1:DB00598_DB01291	dcterms:title	"DDI between Labetalol and Pirbuterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01291 .
ns1:DB00598_DB01366	dcterms:title	"DDI between Labetalol and Procaterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01366 .
ns1:DB00598_DB01382	dcterms:title	"DDI between Labetalol and Glycodiazine - The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB01382 .
ns1:DB00598_DB06704	dcterms:title	"DDI between Labetalol and Iobenguane - May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00598 ,
		ns3:DB06704 .
ns1:DB00599_DB00603	dcterms:title	"DDI between Thiopental and Medroxyprogesterone Acetate - Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00603 .
ns1:DB00599_DB00622	dcterms:title	"DDI between Thiopental and Nicardipine - The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00599 .
ns1:DB00599_DB00661	dcterms:title	"DDI between Thiopental and Verapamil - Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00661 .
ns1:DB00599_DB00682	dcterms:title	"DDI between Thiopental and Warfarin - Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00682 .
ns1:DB00599_DB00717	dcterms:title	"DDI between Thiopental and Norethindrone - Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00717 .
ns1:DB00599_DB00726	dcterms:title	"DDI between Thiopental and Trimipramine - The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00726 .
ns1:DB00599_DB00823	dcterms:title	"DDI between Thiopental and Ethynodiol - Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00823 .
ns1:DB00599_DB00908	dcterms:title	"DDI between Thiopental and Quinidine - Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00908 .
ns1:DB00599_DB00957	dcterms:title	"DDI between Thiopental and Norgestimate - Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB00957 .
ns1:DB00599_DB00977	dcterms:title	"DDI between Thiopental and Ethinyl Estradiol - Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00599 .
ns1:DB00599_DB01023	dcterms:title	"DDI between Thiopental and Felodipine - The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB01023 .
ns1:DB00599_DB01054	dcterms:title	"DDI between Thiopental and Nitrendipine - The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB01054 .
ns1:DB00599_DB01115	dcterms:title	"DDI between Thiopental and Nifedipine - The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01115 ,
		ns3:DB00599 .
ns1:DB00599_DB01182	dcterms:title	"DDI between Thiopental and Propafenone - Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00599 .
ns1:DB00599_DB01357	dcterms:title	"DDI between Thiopental and Mestranol - Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00599 .
ns1:DB00599_DB01395	dcterms:title	"DDI between Thiopental and Drospirenone - Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB01395 .
ns1:DB00599_DB01418	dcterms:title	"DDI between Thiopental and Acenocoumarol - Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00599 ,
		ns3:DB01418 .
ns1:DB00601_DB00610	dcterms:title	"DDI between Linezolid and Metaraminol - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB00610 .
ns1:DB00601_DB00656	dcterms:title	"DDI between Linezolid and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00601 .
ns1:DB00601_DB00668	dcterms:title	"DDI between Linezolid and Epinephrine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00601 .
ns1:DB00601_DB00715	dcterms:title	"DDI between Linezolid and Paroxetine - Combination associated with possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB00715 .
ns1:DB00601_DB00723	dcterms:title	"DDI between Linezolid and Methoxamine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB00723 .
ns1:DB00601_DB00726	dcterms:title	"DDI between Linezolid and Trimipramine - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00601 .
ns1:DB00601_DB00752	dcterms:title	"DDI between Linezolid and Tranylcypromine - The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00752 ,
		ns3:DB00601 .
ns1:DB00601_DB00816	dcterms:title	"DDI between Linezolid and Orciprenaline - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00816 ,
		ns3:DB00601 .
ns1:DB00601_DB00841	dcterms:title	"DDI between Linezolid and Dobutamine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00841 ,
		ns3:DB00601 .
ns1:DB00601_DB00852	dcterms:title	"DDI between Linezolid and Pseudoephedrine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00852 ,
		ns3:DB00601 .
ns1:DB00601_DB00871	dcterms:title	"DDI between Linezolid and Terbutaline - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00871 ,
		ns3:DB00601 .
ns1:DB00601_DB00921	dcterms:title	"DDI between Linezolid and Buprenorphine - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB00601 .
ns1:DB00601_DB00988	dcterms:title	"DDI between Linezolid and Dopamine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB00601 .
ns1:DB00601_DB01001	dcterms:title	"DDI between Linezolid and Salbutamol - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB01001 .
ns1:DB00601_DB01064	dcterms:title	"DDI between Linezolid and Isoprenaline - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00601 ,
		ns3:DB01064 .
ns1:DB00601_DB01104	dcterms:title	"DDI between Linezolid and Sertraline - Combination associated with possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00601 .
ns1:DB00601_DB01149	dcterms:title	"DDI between Linezolid and Nefazodone - Combination associated with possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00601 .
ns1:DB00601_DB01175	dcterms:title	"DDI between Linezolid and Escitalopram - Combination associated with possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01175 ,
		ns3:DB00601 .
ns1:DB00601_DB01288	dcterms:title	"DDI between Linezolid and Fenoterol - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01288 ,
		ns3:DB00601 .
ns1:DB00601_DB01291	dcterms:title	"DDI between Linezolid and Pirbuterol - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01291 ,
		ns3:DB00601 .
ns1:DB00601_DB01363	dcterms:title	"DDI between Linezolid and Ephedra - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01363 ,
		ns3:DB00601 .
ns1:DB00601_DB01364	dcterms:title	"DDI between Linezolid and Ephedrine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01364 ,
		ns3:DB00601 .
ns1:DB00601_DB01365	dcterms:title	"DDI between Linezolid and Mephentermine - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01365 ,
		ns3:DB00601 .
ns1:DB00601_DB01366	dcterms:title	"DDI between Linezolid and Procaterol - Possible increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01366 ,
		ns3:DB00601 .
ns1:DB00601_DB01393	dcterms:title	"DDI between Linezolid and Bezafibrate - MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01393 ,
		ns3:DB00601 .
ns1:DB00601_DB04844	dcterms:title	"DDI between Linezolid and Tetrabenazine - Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB00601 .
ns1:DB00601_DB06684	dcterms:title	"DDI between Linezolid and Vilazodone - MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06684 ,
		ns3:DB00601 .
ns1:DB00601_DB06700	dcterms:title	"DDI between Linezolid and Desvenlafaxine - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00601 .
ns1:DB00603_DB00682	dcterms:title	"DDI between Medroxyprogesterone Acetate and Warfarin - Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00603 .
ns1:DB00603_DB00754	dcterms:title	"DDI between Medroxyprogesterone Acetate and Ethotoin - The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00603 .
ns1:DB00603_DB00794	dcterms:title	"DDI between Medroxyprogesterone Acetate and Primidone - The enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00603 .
ns1:DB00603_DB00849	dcterms:title	"DDI between Medroxyprogesterone Acetate and Methylphenobarbital - The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00603 .
ns1:DB00603_DB00930	dcterms:title	"DDI between Medroxyprogesterone Acetate and Colesevelam - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00603 ,
		ns3:DB00930 .
ns1:DB00603_DB01125	dcterms:title	"DDI between Medroxyprogesterone Acetate and Anisindione - Medroxyprogesterone may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00603 ,
		ns3:DB01125 .
ns1:DB00603_DB01174	dcterms:title	"DDI between Medroxyprogesterone Acetate and Phenobarbital - The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00603 .
ns1:DB00603_DB01320	dcterms:title	"DDI between Medroxyprogesterone Acetate and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00603 .
ns1:DB00603_DB01351	dcterms:title	"DDI between Medroxyprogesterone Acetate and Amobarbital - The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00603 .
ns1:DB00603_DB01352	dcterms:title	"DDI between Medroxyprogesterone Acetate and Aprobarbital - The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00603 .
ns1:DB00603_DB01353	dcterms:title	"DDI between Medroxyprogesterone Acetate and Butethal - The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00603 .
ns1:DB00603_DB01354	dcterms:title	"DDI between Medroxyprogesterone Acetate and Heptabarbital - The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00603 .
ns1:DB00603_DB01355	dcterms:title	"DDI between Medroxyprogesterone Acetate and Hexobarbital - The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00603 .
ns1:DB00603_DB01418	dcterms:title	"DDI between Medroxyprogesterone Acetate and Acenocoumarol - Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00603 ,
		ns3:DB01418 .
ns1:DB00603_DB06697	dcterms:title	"DDI between Medroxyprogesterone Acetate and Artemether - Artemether may decrease the effectiveness of medroxyprogesterone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00603 .
ns1:DB00604_DB00623	dcterms:title	"DDI between Cisapride and Fluphenazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00623 ,
		ns3:DB00604 .
ns1:DB00604_DB00625	dcterms:title	"DDI between Cisapride and Efavirenz - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00604 .
ns1:DB00604_DB00637	dcterms:title	"DDI between Cisapride and Astemizole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00637 .
ns1:DB00604_DB00673	dcterms:title	"DDI between Cisapride and Aprepitant - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00673 ,
		ns3:DB00604 .
ns1:DB00604_DB00679	dcterms:title	"DDI between Cisapride and Thioridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00604 .
ns1:DB00604_DB00682	dcterms:title	"DDI between Cisapride and Warfarin - Cisapride may increase the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00604 .
ns1:DB00604_DB00701	dcterms:title	"DDI between Cisapride and Amprenavir - Amprenavir may increase the effect and toxicity of cisapride."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00701 ,
		ns3:DB00604 .
ns1:DB00604_DB00705	dcterms:title	"DDI between Cisapride and Delavirdine - Delavirdine, a strong CYP3A4 inhibitor, may increase the metabolism of cisapride. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cisapride if delavirdine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00705 .
ns1:DB00604_DB00726	dcterms:title	"DDI between Cisapride and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00604 .
ns1:DB00604_DB00777	dcterms:title	"DDI between Cisapride and Propiomazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00777 .
ns1:DB00604_DB00831	dcterms:title	"DDI between Cisapride and Trifluoperazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00831 .
ns1:DB00604_DB00850	dcterms:title	"DDI between Cisapride and Perphenazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00850 .
ns1:DB00604_DB00864	dcterms:title	"DDI between Cisapride and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00604 .
ns1:DB00604_DB00902	dcterms:title	"DDI between Cisapride and Methdilazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00902 .
ns1:DB00604_DB00908	dcterms:title	"DDI between Cisapride and Quinidine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00908 .
ns1:DB00604_DB00932	dcterms:title	"DDI between Cisapride and Tipranavir - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00604 .
ns1:DB00604_DB00933	dcterms:title	"DDI between Cisapride and Mesoridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00933 .
ns1:DB00604_DB00934	dcterms:title	"DDI between Cisapride and Maprotiline - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00934 .
ns1:DB00604_DB00950	dcterms:title	"DDI between Cisapride and Fexofenadine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB00950 .
ns1:DB00604_DB00976	dcterms:title	"DDI between Cisapride and Telithromycin - Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00604 .
ns1:DB00604_DB01026	dcterms:title	"DDI between Cisapride and Ketoconazole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00604 .
ns1:DB00604_DB01035	dcterms:title	"DDI between Cisapride and Procainamide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01035 ,
		ns3:DB00604 .
ns1:DB00604_DB01063	dcterms:title	"DDI between Cisapride and Acetophenazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01063 .
ns1:DB00604_DB01069	dcterms:title	"DDI between Cisapride and Promethazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01069 ,
		ns3:DB00604 .
ns1:DB00604_DB01072	dcterms:title	"DDI between Cisapride and Atazanavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00604 .
ns1:DB00604_DB01115	dcterms:title	"DDI between Cisapride and Nifedipine - Cisapride may increase the effect and toxicity of nifedipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01115 ,
		ns3:DB00604 .
ns1:DB00604_DB01118	dcterms:title	"DDI between Cisapride and Amiodarone - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00604 .
ns1:DB00604_DB01125	dcterms:title	"DDI between Cisapride and Anisindione - Cisapride may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00604 .
ns1:DB00604_DB01142	dcterms:title	"DDI between Cisapride and Doxepin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00604 .
ns1:DB00604_DB01149	dcterms:title	"DDI between Cisapride and Nefazodone - Nefazodone increases serum levels of cisapride"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00604 .
ns1:DB00604_DB01151	dcterms:title	"DDI between Cisapride and Desipramine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01151 ,
		ns3:DB00604 .
ns1:DB00604_DB01158	dcterms:title	"DDI between Cisapride and Bretylium - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01158 ,
		ns3:DB00604 .
ns1:DB00604_DB01167	dcterms:title	"DDI between Cisapride and Itraconazole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00604 .
ns1:DB00604_DB01182	dcterms:title	"DDI between Cisapride and Propafenone - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00604 .
ns1:DB00604_DB01195	dcterms:title	"DDI between Cisapride and Flecainide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01195 ,
		ns3:DB00604 .
ns1:DB00604_DB01211	dcterms:title	"DDI between Cisapride and Clarithromycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00604 .
ns1:DB00604_DB01228	dcterms:title	"DDI between Cisapride and Encainide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01228 .
ns1:DB00604_DB01232	dcterms:title	"DDI between Cisapride and Saquinavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00604 .
ns1:DB00604_DB01242	dcterms:title	"DDI between Cisapride and Clomipramine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01242 ,
		ns3:DB00604 .
ns1:DB00604_DB01244	dcterms:title	"DDI between Cisapride and Bepridil - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01244 .
ns1:DB00604_DB01246	dcterms:title	"DDI between Cisapride and Alimemazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01246 .
ns1:DB00604_DB01263	dcterms:title	"DDI between Cisapride and Posaconazole - Contraindicated co-administration"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00604 .
ns1:DB00604_DB01319	dcterms:title	"DDI between Cisapride and Fosamprenavir - Amprenavir increases the effect and toxicity of cisapride"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00604 .
ns1:DB00604_DB01321	dcterms:title	"DDI between Cisapride and Josamycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01321 ,
		ns3:DB00604 .
ns1:DB00604_DB01341	dcterms:title	"DDI between Cisapride and Dihydroquinidine barbiturate - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00604 .
ns1:DB00604_DB01346	dcterms:title	"DDI between Cisapride and Quinidine barbiturate - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00604 .
ns1:DB00604_DB01361	dcterms:title	"DDI between Cisapride and Troleandomycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01361 ,
		ns3:DB00604 .
ns1:DB00604_DB01369	dcterms:title	"DDI between Cisapride and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00604 .
ns1:DB00604_DB01388	dcterms:title	"DDI between Cisapride and Mibefradil - Mibefradil increases levels of cisapride"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01388 ,
		ns3:DB00604 .
ns1:DB00604_DB01403	dcterms:title	"DDI between Cisapride and Methotrimeprazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01403 .
ns1:DB00604_DB01418	dcterms:title	"DDI between Cisapride and Acenocoumarol - Cisapride may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB01418 .
ns1:DB00604_DB01623	dcterms:title	"DDI between Cisapride and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB00604 .
ns1:DB00604_DB01624	dcterms:title	"DDI between Cisapride and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB00604 .
ns1:DB00604_DB02546	dcterms:title	"DDI between Cisapride and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02546 ,
		ns3:DB00604 .
ns1:DB00604_DB05521	dcterms:title	"DDI between Cisapride and Telaprevir - Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05521 ,
		ns3:DB00604 .
ns1:DB00604_DB06402	dcterms:title	"DDI between Cisapride and Telavancin - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06402 ,
		ns3:DB00604 .
ns1:DB00604_DB06697	dcterms:title	"DDI between Cisapride and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00604 .
ns1:DB00604_DB06708	dcterms:title	"DDI between Cisapride and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB00604 .
ns1:DB00604_DB08865	dcterms:title	"DDI between Cisapride and Crizotinib - Concurrent use with drugs that prolong QTc interval is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08865 ,
		ns3:DB00604 .
ns1:DB00604_DB08873	dcterms:title	"DDI between Cisapride and Boceprevir  - Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00604 ,
		ns3:DB08873 .
ns1:DB00604_DB08919	dcterms:title	"DDI between Cisapride and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08919 ,
		ns3:DB00604 .
ns1:DB00604_DB08920	dcterms:title	"DDI between Cisapride and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08920 ,
		ns3:DB00604 .
ns1:DB00605_DB00642	dcterms:title	"DDI between Sulindac and Pemetrexed - The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00642 ,
		ns3:DB00605 .
ns1:DB00605_DB00682	dcterms:title	"DDI between Sulindac and Warfarin - The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00682 .
ns1:DB00605_DB00695	dcterms:title	"DDI between Sulindac and Furosemide - The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00695 .
ns1:DB00605_DB00887	dcterms:title	"DDI between Sulindac and Bumetanide - The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00887 .
ns1:DB00605_DB00903	dcterms:title	"DDI between Sulindac and Ethacrynic acid - The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacryninc acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00903 .
ns1:DB00605_DB00930	dcterms:title	"DDI between Sulindac and Colesevelam - The bile acid sequestrant, colesevelam, may decrease the absorption of the NSAID, sulindac. Sulindac should be administered at least 1 hour before or 4 hours after colesevelam. Monitor for changes in the therapeutic and adverse effects of sulindac if colesevelam is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00930 .
ns1:DB00605_DB00945	dcterms:title	"DDI between Sulindac and Acetylsalicylic acid - Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00945 .
ns1:DB00605_DB00966	dcterms:title	"DDI between Sulindac and Telmisartan - Concomitant use of Telmisartan and Sulindac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB00966 .
ns1:DB00605_DB01381	dcterms:title	"DDI between Sulindac and Ginkgo biloba - Ginkgo biloba may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01381 .
ns1:DB00605_DB01398	dcterms:title	"DDI between Sulindac and Salicylate-sodium - Risk of additive toxicity (e.g. bleed risk). Salicylate-sodium may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01398 .
ns1:DB00605_DB01399	dcterms:title	"DDI between Sulindac and Salsalate - Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01399 .
ns1:DB00605_DB01404	dcterms:title	"DDI between Sulindac and Ginseng - Ginseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01404 .
ns1:DB00605_DB01418	dcterms:title	"DDI between Sulindac and Acenocoumarol - The NSAID, sulindac, may increase the anticoagulant effect of acenocoumarol. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01418 .
ns1:DB00605_DB01432	dcterms:title	"DDI between Sulindac and Cholestyramine - The bile acid sequestrant, cholestyramine, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if cholestyramine is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB01432 .
ns1:DB00605_DB06813	dcterms:title	"DDI between Sulindac and Pralatrexate - NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB06813 .
ns1:DB00605_DB08822	dcterms:title	"DDI between Sulindac and Azilsartan medoxomil - Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00605 ,
		ns3:DB08822 .
ns1:DB00606_DB01356	dcterms:title	"DDI between Cyclothiazide and Lithium - The thiazide diuretic, cyclothiazide, may increase serum levels of lithium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00606 ,
		ns3:DB01356 .
ns1:DB00607_DB00618	dcterms:title	"DDI between Nafcillin and Demeclocycline - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00618 .
ns1:DB00607_DB00656	dcterms:title	"DDI between Nafcillin and Trazodone - The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00656 .
ns1:DB00607_DB00661	dcterms:title	"DDI between Nafcillin and Verapamil - Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00661 .
ns1:DB00607_DB00682	dcterms:title	"DDI between Nafcillin and Warfarin - Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00682 .
ns1:DB00607_DB00759	dcterms:title	"DDI between Nafcillin and Tetracycline - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00759 .
ns1:DB00607_DB00976	dcterms:title	"DDI between Nafcillin and Telithromycin - Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00976 .
ns1:DB00607_DB00977	dcterms:title	"DDI between Nafcillin and Ethinyl Estradiol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB00977 .
ns1:DB00607_DB01017	dcterms:title	"DDI between Nafcillin and Minocycline - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB01017 .
ns1:DB00607_DB01656	dcterms:title	"DDI between Nafcillin and Roflumilast - Affects CYP3A4 metabolism, decreases level or effect of roflumilast."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB01656 .
ns1:DB00607_DB05294	dcterms:title	"DDI between Nafcillin and Vandetanib - Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB05294 .
ns1:DB00607_DB06287	dcterms:title	"DDI between Nafcillin and Temsirolimus - Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB06287 .
ns1:DB00607_DB08815	dcterms:title	"DDI between Nafcillin and Lurasidone - Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB08815 .
ns1:DB00607_DB08866	dcterms:title	"DDI between Nafcillin and Estradiol valerate/Dienogest  - Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00607 ,
		ns3:DB08866 .
ns1:DB00608_DB00675	dcterms:title	"DDI between Chloroquine and Tamoxifen - Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB00675 .
ns1:DB00608_DB00679	dcterms:title	"DDI between Chloroquine and Thioridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB00679 .
ns1:DB00608_DB00706	dcterms:title	"DDI between Chloroquine and Tamsulosin - Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00706 ,
		ns3:DB00608 .
ns1:DB00608_DB00857	dcterms:title	"DDI between Chloroquine and Terbinafine - Terbinafine may reduce the metabolism and clearance of Chloroquine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chloroquine if Terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00857 ,
		ns3:DB00608 .
ns1:DB00608_DB00933	dcterms:title	"DDI between Chloroquine and Mesoridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB00933 .
ns1:DB00608_DB00976	dcterms:title	"DDI between Chloroquine and Telithromycin - Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB00976 .
ns1:DB00608_DB01058	dcterms:title	"DDI between Chloroquine and Praziquantel - Markedly lower praziquantel levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01058 .
ns1:DB00608_DB01370	dcterms:title	"DDI between Chloroquine and Aluminium - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01370 .
ns1:DB00608_DB01373	dcterms:title	"DDI between Chloroquine and Calcium - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01373 .
ns1:DB00608_DB01375	dcterms:title	"DDI between Chloroquine and Dihydroxyaluminium - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01375 ,
		ns3:DB00608 .
ns1:DB00608_DB01377	dcterms:title	"DDI between Chloroquine and Magnesium oxide - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01377 .
ns1:DB00608_DB01378	dcterms:title	"DDI between Chloroquine and Magnesium - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01378 .
ns1:DB00608_DB01574	dcterms:title	"DDI between Chloroquine and Attapulgite - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01574 .
ns1:DB00608_DB01575	dcterms:title	"DDI between Chloroquine and Kaolin - The antiacid decreases the absorption of chloroquine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB01575 .
ns1:DB00608_DB06697	dcterms:title	"DDI between Chloroquine and Artemether - Chloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB06697 .
ns1:DB00608_DB06708	dcterms:title	"DDI between Chloroquine and Lumefantrine - Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00608 ,
		ns3:DB06708 .
ns1:DB00610_DB00780	dcterms:title	"DDI between Metaraminol and Phenelzine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00780 ,
		ns3:DB00610 .
ns1:DB00610_DB00968	dcterms:title	"DDI between Metaraminol and Methyldopa - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00968 ,
		ns3:DB00610 .
ns1:DB00610_DB01142	dcterms:title	"DDI between Metaraminol and Doxepin - The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01142 .
ns1:DB00610_DB01151	dcterms:title	"DDI between Metaraminol and Desipramine - The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01151 .
ns1:DB00610_DB01170	dcterms:title	"DDI between Metaraminol and Guanethidine - Metaraminol may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01170 .
ns1:DB00610_DB01171	dcterms:title	"DDI between Metaraminol and Moclobemide - Moclobemide increases the sympathomimetic effect of metaraminol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01171 .
ns1:DB00610_DB01242	dcterms:title	"DDI between Metaraminol and Clomipramine - The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01242 .
ns1:DB00610_DB01247	dcterms:title	"DDI between Metaraminol and Isocarboxazid - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01247 .
ns1:DB00610_DB01367	dcterms:title	"DDI between Metaraminol and Rasagiline - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00610 ,
		ns3:DB01367 .
ns1:DB00611_DB06274	dcterms:title	"DDI between Butorphanol and Alvimopan - Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00611 ,
		ns3:DB06274 .
ns1:DB00612_DB00661	dcterms:title	"DDI between Bisoprolol and Verapamil - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00661 .
ns1:DB00612_DB00668	dcterms:title	"DDI between Bisoprolol and Epinephrine - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00612 .
ns1:DB00612_DB00672	dcterms:title	"DDI between Bisoprolol and Chlorpropamide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00672 .
ns1:DB00612_DB00696	dcterms:title	"DDI between Bisoprolol and Ergotamine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00696 .
ns1:DB00612_DB00816	dcterms:title	"DDI between Bisoprolol and Orciprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00816 .
ns1:DB00612_DB00839	dcterms:title	"DDI between Bisoprolol and Tolazamide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00612 .
ns1:DB00612_DB00871	dcterms:title	"DDI between Bisoprolol and Terbutaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00871 ,
		ns3:DB00612 .
ns1:DB00612_DB00912	dcterms:title	"DDI between Bisoprolol and Repaglinide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00912 .
ns1:DB00612_DB00938	dcterms:title	"DDI between Bisoprolol and Salmeterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB00612 .
ns1:DB00612_DB00976	dcterms:title	"DDI between Bisoprolol and Telithromycin - Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00612 .
ns1:DB00612_DB00983	dcterms:title	"DDI between Bisoprolol and Formoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00983 ,
		ns3:DB00612 .
ns1:DB00612_DB01001	dcterms:title	"DDI between Bisoprolol and Salbutamol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01001 ,
		ns3:DB00612 .
ns1:DB00612_DB01016	dcterms:title	"DDI between Bisoprolol and Glyburide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01016 ,
		ns3:DB00612 .
ns1:DB00612_DB01045	dcterms:title	"DDI between Bisoprolol and Rifampicin - Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00612 .
ns1:DB00612_DB01050	dcterms:title	"DDI between Bisoprolol and Ibuprofen - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01050 ,
		ns3:DB00612 .
ns1:DB00612_DB01064	dcterms:title	"DDI between Bisoprolol and Isoprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01064 ,
		ns3:DB00612 .
ns1:DB00612_DB01067	dcterms:title	"DDI between Bisoprolol and Glipizide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01067 ,
		ns3:DB00612 .
ns1:DB00612_DB01120	dcterms:title	"DDI between Bisoprolol and Gliclazide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01120 ,
		ns3:DB00612 .
ns1:DB00612_DB01124	dcterms:title	"DDI between Bisoprolol and Tolbutamide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01124 ,
		ns3:DB00612 .
ns1:DB00612_DB01162	dcterms:title	"DDI between Bisoprolol and Terazosin - Increased risk of hypotension. Initiate concomitant therapy cautiously."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01162 ,
		ns3:DB00612 .
ns1:DB00612_DB01253	dcterms:title	"DDI between Bisoprolol and Ergonovine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01253 ,
		ns3:DB00612 .
ns1:DB00612_DB01288	dcterms:title	"DDI between Bisoprolol and Fenoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01288 ,
		ns3:DB00612 .
ns1:DB00612_DB01289	dcterms:title	"DDI between Bisoprolol and Glisoxepide - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01289 ,
		ns3:DB00612 .
ns1:DB00612_DB01291	dcterms:title	"DDI between Bisoprolol and Pirbuterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01291 ,
		ns3:DB00612 .
ns1:DB00612_DB01306	dcterms:title	"DDI between Bisoprolol and Insulin Aspart - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01306 ,
		ns3:DB00612 .
ns1:DB00612_DB01307	dcterms:title	"DDI between Bisoprolol and Insulin Detemir - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01307 ,
		ns3:DB00612 .
ns1:DB00612_DB01309	dcterms:title	"DDI between Bisoprolol and Insulin Glulisine - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01309 ,
		ns3:DB00612 .
ns1:DB00612_DB01366	dcterms:title	"DDI between Bisoprolol and Procaterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01366 ,
		ns3:DB00612 .
ns1:DB00612_DB01382	dcterms:title	"DDI between Bisoprolol and Glycodiazine - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01382 ,
		ns3:DB00612 .
ns1:DB00612_DB05039	dcterms:title	"DDI between Bisoprolol and Indacaterol - Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05039 ,
		ns3:DB00612 .
ns1:DB00614_DB00656	dcterms:title	"DDI between Furazolidone and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00614 ,
		ns3:DB00656 .
ns1:DB00614_DB00726	dcterms:title	"DDI between Furazolidone and Trimipramine - Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00614 ,
		ns3:DB00726 .
ns1:DB00614_DB00752	dcterms:title	"DDI between Furazolidone and Tranylcypromine - Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00614 ,
		ns3:DB00752 .
ns1:DB00614_DB04844	dcterms:title	"DDI between Furazolidone and Tetrabenazine - Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB00614 .
ns1:DB00614_DB04896	dcterms:title	"DDI between Furazolidone and Milnacipran - Increase serotonin levels. Combination therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04896 ,
		ns3:DB00614 .
ns1:DB00615_DB00641	dcterms:title	"DDI between Rifabutin and Simvastatin - Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00641 .
ns1:DB00615_DB00656	dcterms:title	"DDI between Rifabutin and Trazodone - The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00656 .
ns1:DB00615_DB00661	dcterms:title	"DDI between Rifabutin and Verapamil - Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00615 .
ns1:DB00615_DB00675	dcterms:title	"DDI between Rifabutin and Tamoxifen - The rifamycin decreases the effect of anti-estrogen"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00675 .
ns1:DB00615_DB00682	dcterms:title	"DDI between Rifabutin and Warfarin - Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00615 .
ns1:DB00615_DB00701	dcterms:title	"DDI between Rifabutin and Amprenavir - Amprenavir may increase the effect and toxicity of rifabutin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00701 ,
		ns3:DB00615 .
ns1:DB00615_DB00705	dcterms:title	"DDI between Rifabutin and Delavirdine - Rifabutin decreases the effect of delavirdine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00705 .
ns1:DB00615_DB00717	dcterms:title	"DDI between Rifabutin and Norethindrone - Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00717 .
ns1:DB00615_DB00726	dcterms:title	"DDI between Rifabutin and Trimipramine - The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00726 .
ns1:DB00615_DB00857	dcterms:title	"DDI between Rifabutin and Terbinafine - Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00615 ,
		ns3:DB00857 .
ns1:DB00615_DB00864	dcterms:title	"DDI between Rifabutin and Tacrolimus - Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00615 .
ns1:DB00615_DB00877	dcterms:title	"DDI between Rifabutin and Sirolimus - The rifamycin decreases the effect of sirolimus"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00877 ,
		ns3:DB00615 .
ns1:DB00615_DB00932	dcterms:title	"DDI between Rifabutin and Tipranavir - Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00615 .
ns1:DB00615_DB00976	dcterms:title	"DDI between Rifabutin and Telithromycin - Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00615 .
ns1:DB00615_DB00977	dcterms:title	"DDI between Rifabutin and Ethinyl Estradiol - Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00615 .
ns1:DB00615_DB01072	dcterms:title	"DDI between Rifabutin and Atazanavir - Atazanavir may increase levels/toxicity of rifabutin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00615 .
ns1:DB00615_DB01076	dcterms:title	"DDI between Rifabutin and Atorvastatin - Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01076 ,
		ns3:DB00615 .
ns1:DB00615_DB01095	dcterms:title	"DDI between Rifabutin and Fluvastatin - Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01095 ,
		ns3:DB00615 .
ns1:DB00615_DB01117	dcterms:title	"DDI between Rifabutin and Atovaquone - Rifabutin decreases the effect of atovaquone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01117 ,
		ns3:DB00615 .
ns1:DB00615_DB01125	dcterms:title	"DDI between Rifabutin and Anisindione - Rifabutin, may decrease the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00615 .
ns1:DB00615_DB01142	dcterms:title	"DDI between Rifabutin and Doxepin - The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00615 .
ns1:DB00615_DB01151	dcterms:title	"DDI between Rifabutin and Desipramine - The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01151 ,
		ns3:DB00615 .
ns1:DB00615_DB01156	dcterms:title	"DDI between Rifabutin and Bupropion - Rifampin reduces bupropion levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01156 ,
		ns3:DB00615 .
ns1:DB00615_DB01167	dcterms:title	"DDI between Rifabutin and Itraconazole - Rifabutin decreases the effect of itraconazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00615 .
ns1:DB00615_DB01182	dcterms:title	"DDI between Rifabutin and Propafenone - Rifampin decreases the effect of propafenone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00615 .
ns1:DB00615_DB01211	dcterms:title	"DDI between Rifabutin and Clarithromycin - The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00615 .
ns1:DB00615_DB01232	dcterms:title	"DDI between Rifabutin and Saquinavir - Rifabutin decreases the effect of saquinavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00615 .
ns1:DB00615_DB01242	dcterms:title	"DDI between Rifabutin and Clomipramine - The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01242 ,
		ns3:DB00615 .
ns1:DB00615_DB01263	dcterms:title	"DDI between Rifabutin and Posaconazole - Modification of drug levels for both agents"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00615 .
ns1:DB00615_DB01268	dcterms:title	"DDI between Rifabutin and Sunitinib - Possible decrease in sunitinib levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01268 ,
		ns3:DB00615 .
ns1:DB00615_DB01319	dcterms:title	"DDI between Rifabutin and Fosamprenavir - Amprenavir increases the effect and toxicity of rifabutin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00615 .
ns1:DB00615_DB01321	dcterms:title	"DDI between Rifabutin and Josamycin - The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01321 ,
		ns3:DB00615 .
ns1:DB00615_DB01357	dcterms:title	"DDI between Rifabutin and Mestranol - This product may cause a slight decrease of the contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00615 .
ns1:DB00615_DB01418	dcterms:title	"DDI between Rifabutin and Acenocoumarol - Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00615 .
ns1:DB00615_DB01558	dcterms:title	"DDI between Rifabutin and Bromazepam - Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB00615 .
ns1:DB00615_DB01656	dcterms:title	"DDI between Rifabutin and Roflumilast - Affects CYP3A4 metabolism, decreases level or effect of roflumilast."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01656 ,
		ns3:DB00615 .
ns1:DB00615_DB05294	dcterms:title	"DDI between Rifabutin and Vandetanib - Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05294 ,
		ns3:DB00615 .
ns1:DB00615_DB05812	dcterms:title	"DDI between Rifabutin and Abiraterone - Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05812 ,
		ns3:DB00615 .
ns1:DB00615_DB06212	dcterms:title	"DDI between Rifabutin and Tolvaptan - Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06212 ,
		ns3:DB00615 .
ns1:DB00615_DB06287	dcterms:title	"DDI between Rifabutin and Temsirolimus - Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06287 ,
		ns3:DB00615 .
ns1:DB00615_DB06414	dcterms:title	"DDI between Rifabutin and Etravirine - Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00615 .
ns1:DB00615_DB06589	dcterms:title	"DDI between Rifabutin and Pazopanib - Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06589 ,
		ns3:DB00615 .
ns1:DB00615_DB06772	dcterms:title	"DDI between Rifabutin and Cabazitaxel - Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06772 ,
		ns3:DB00615 .
ns1:DB00615_DB08820	dcterms:title	"DDI between Rifabutin and Ivacaftor - Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08820 ,
		ns3:DB00615 .
ns1:DB00615_DB08864	dcterms:title	"DDI between Rifabutin and Rilpivirine - Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08864 ,
		ns3:DB00615 .
ns1:DB00615_DB08866	dcterms:title	"DDI between Rifabutin and Estradiol valerate/Dienogest  - Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08866 ,
		ns3:DB00615 .
ns1:DB00615_DB08881	dcterms:title	"DDI between Rifabutin and Vemurafenib - Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08881 ,
		ns3:DB00615 .
ns1:DB00618_DB00682	dcterms:title	"DDI between Demeclocycline and Warfarin - The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00682 .
ns1:DB00618_DB00713	dcterms:title	"DDI between Demeclocycline and Oxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00713 .
ns1:DB00618_DB00739	dcterms:title	"DDI between Demeclocycline and Hetacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00739 ,
		ns3:DB00618 .
ns1:DB00618_DB00755	dcterms:title	"DDI between Demeclocycline and Tretinoin - Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00755 .
ns1:DB00618_DB00766	dcterms:title	"DDI between Demeclocycline and Clavulanate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00766 ,
		ns3:DB00618 .
ns1:DB00618_DB00893	dcterms:title	"DDI between Demeclocycline and Iron Dextran - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00893 .
ns1:DB00618_DB00926	dcterms:title	"DDI between Demeclocycline and Etretinate - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00926 .
ns1:DB00618_DB00930	dcterms:title	"DDI between Demeclocycline and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00930 .
ns1:DB00618_DB00948	dcterms:title	"DDI between Demeclocycline and Mezlocillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00948 ,
		ns3:DB00618 .
ns1:DB00618_DB00977	dcterms:title	"DDI between Demeclocycline and Ethinyl Estradiol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00977 .
ns1:DB00618_DB00982	dcterms:title	"DDI between Demeclocycline and Isotretinoin - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB00982 .
ns1:DB00618_DB01000	dcterms:title	"DDI between Demeclocycline and Cyclacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01000 .
ns1:DB00618_DB01028	dcterms:title	"DDI between Demeclocycline and Methoxyflurane - The tetracycline, demeclocycline, may increase the renal toxicity of methoxyflurane."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01028 ,
		ns3:DB00618 .
ns1:DB00618_DB01053	dcterms:title	"DDI between Demeclocycline and Benzylpenicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01053 .
ns1:DB00618_DB01060	dcterms:title	"DDI between Demeclocycline and Amoxicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01060 .
ns1:DB00618_DB01061	dcterms:title	"DDI between Demeclocycline and Azlocillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01061 .
ns1:DB00618_DB01125	dcterms:title	"DDI between Demeclocycline and Anisindione - The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01125 .
ns1:DB00618_DB01147	dcterms:title	"DDI between Demeclocycline and Cloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01147 .
ns1:DB00618_DB01164	dcterms:title	"DDI between Demeclocycline and Calcium Chloride - Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01164 ,
		ns3:DB00618 .
ns1:DB00618_DB01357	dcterms:title	"DDI between Demeclocycline and Mestranol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01357 .
ns1:DB00618_DB01370	dcterms:title	"DDI between Demeclocycline and Aluminium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01370 .
ns1:DB00618_DB01373	dcterms:title	"DDI between Demeclocycline and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01373 .
ns1:DB00618_DB01377	dcterms:title	"DDI between Demeclocycline and Magnesium oxide - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01377 .
ns1:DB00618_DB01378	dcterms:title	"DDI between Demeclocycline and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01378 .
ns1:DB00618_DB01418	dcterms:title	"DDI between Demeclocycline and Acenocoumarol - The tetracycline, demeclocycline, may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01418 .
ns1:DB00618_DB01574	dcterms:title	"DDI between Demeclocycline and Attapulgite - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01574 ,
		ns3:DB00618 .
ns1:DB00618_DB01592	dcterms:title	"DDI between Demeclocycline and Iron - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01592 .
ns1:DB00618_DB01593	dcterms:title	"DDI between Demeclocycline and Zinc - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01593 .
ns1:DB00618_DB01602	dcterms:title	"DDI between Demeclocycline and Bacampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01602 .
ns1:DB00618_DB01603	dcterms:title	"DDI between Demeclocycline and Meticillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01603 .
ns1:DB00618_DB01604	dcterms:title	"DDI between Demeclocycline and Pivampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01604 .
ns1:DB00618_DB01605	dcterms:title	"DDI between Demeclocycline and Pivmecillinam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01605 .
ns1:DB00618_DB01606	dcterms:title	"DDI between Demeclocycline and Tazobactam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01606 .
ns1:DB00618_DB01607	dcterms:title	"DDI between Demeclocycline and Ticarcillin - Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00618 ,
		ns3:DB01607 .
ns1:DB00619_DB00641	dcterms:title	"DDI between Imatinib and Simvastatin - Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB00619 .
ns1:DB00619_DB00656	dcterms:title	"DDI between Imatinib and Trazodone - The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00619 .
ns1:DB00619_DB00661	dcterms:title	"DDI between Imatinib and Verapamil - Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00661 .
ns1:DB00619_DB00673	dcterms:title	"DDI between Imatinib and Aprepitant - Aprepitant may change levels of the chemotherapy agent, imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00673 ,
		ns3:DB00619 .
ns1:DB00619_DB00675	dcterms:title	"DDI between Imatinib and Tamoxifen - Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00675 ,
		ns3:DB00619 .
ns1:DB00619_DB00682	dcterms:title	"DDI between Imatinib and Warfarin - Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00682 .
ns1:DB00619_DB00706	dcterms:title	"DDI between Imatinib and Tamsulosin - Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00706 .
ns1:DB00619_DB00726	dcterms:title	"DDI between Imatinib and Trimipramine - The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00726 .
ns1:DB00619_DB00754	dcterms:title	"DDI between Imatinib and Ethotoin - The hydantoin decreases the levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00619 .
ns1:DB00619_DB00820	dcterms:title	"DDI between Imatinib and Tadalafil - Imatinib may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00820 ,
		ns3:DB00619 .
ns1:DB00619_DB00862	dcterms:title	"DDI between Imatinib and Vardenafil - Imatinib, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00862 ,
		ns3:DB00619 .
ns1:DB00619_DB00864	dcterms:title	"DDI between Imatinib and Tacrolimus - The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00619 .
ns1:DB00619_DB00906	dcterms:title	"DDI between Imatinib and Tiagabine - The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00906 ,
		ns3:DB00619 .
ns1:DB00619_DB00909	dcterms:title	"DDI between Imatinib and Zonisamide - Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00909 ,
		ns3:DB00619 .
ns1:DB00619_DB00976	dcterms:title	"DDI between Imatinib and Telithromycin - Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB00976 .
ns1:DB00619_DB01026	dcterms:title	"DDI between Imatinib and Ketoconazole - Ketoconazole may increase the levels of imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01026 .
ns1:DB00619_DB01030	dcterms:title	"DDI between Imatinib and Topotecan - The BCRP/ABCG2 inhibitor, Imatinib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01030 .
ns1:DB00619_DB01036	dcterms:title	"DDI between Imatinib and Tolterodine - Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01036 .
ns1:DB00619_DB01045	dcterms:title	"DDI between Imatinib and Rifampicin - Rifampin decreases levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01045 .
ns1:DB00619_DB01076	dcterms:title	"DDI between Imatinib and Atorvastatin - Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01076 .
ns1:DB00619_DB01100	dcterms:title	"DDI between Imatinib and Pimozide - Imatinib may increase the effect and toxicity of pimozide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01100 .
ns1:DB00619_DB01115	dcterms:title	"DDI between Imatinib and Nifedipine - Imatinib increases the effect and toxicity of nifedipine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01115 .
ns1:DB00619_DB01125	dcterms:title	"DDI between Imatinib and Anisindione - Imatinib may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01125 .
ns1:DB00619_DB01167	dcterms:title	"DDI between Imatinib and Itraconazole - Itraconazole may increase the levels of imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01167 .
ns1:DB00619_DB01174	dcterms:title	"DDI between Imatinib and Phenobarbital - Phenobarbital decreases levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01174 .
ns1:DB00619_DB01198	dcterms:title	"DDI between Imatinib and Zopiclone - Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01198 .
ns1:DB00619_DB01211	dcterms:title	"DDI between Imatinib and Clarithromycin - The macrolide, clarithromycin, may increase the serum concentration of imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01211 .
ns1:DB00619_DB01219	dcterms:title	"DDI between Imatinib and Dantrolene - Imatinib may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01219 .
ns1:DB00619_DB01234	dcterms:title	"DDI between Imatinib and Dexamethasone - Dexamethasone may decrease levels of imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01234 .
ns1:DB00619_DB01320	dcterms:title	"DDI between Imatinib and Fosphenytoin - The hydantoin decreases the levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01320 .
ns1:DB00619_DB01321	dcterms:title	"DDI between Imatinib and Josamycin - The macrolide, josamycin, may increase the serum concentration of imatinib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01321 .
ns1:DB00619_DB01323	dcterms:title	"DDI between Imatinib and St. John's Wort - St. John's Wort decreases levels of imatinib"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01323 .
ns1:DB00619_DB01418	dcterms:title	"DDI between Imatinib and Acenocoumarol - Imatinib may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01418 .
ns1:DB00619_DB01558	dcterms:title	"DDI between Imatinib and Bromazepam - Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if imatinib is initiated, discontinued or dose changed. Dosage adjustments may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB01558 .
ns1:DB00619_DB06287	dcterms:title	"DDI between Imatinib and Temsirolimus - Imatinib may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB06287 .
ns1:DB00619_DB06414	dcterms:title	"DDI between Imatinib and Etravirine - Imatinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by a minimum of 50%, and to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB06414 .
ns1:DB00619_DB08815	dcterms:title	"DDI between Imatinib and Lurasidone - Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00619 ,
		ns3:DB08815 .
ns1:DB00620_DB00682	dcterms:title	"DDI between Triamcinolone and Warfarin - The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00620 .
ns1:DB00620_DB00754	dcterms:title	"DDI between Triamcinolone and Ethotoin - The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00620 .
ns1:DB00620_DB00794	dcterms:title	"DDI between Triamcinolone and Primidone - The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00620 .
ns1:DB00620_DB00849	dcterms:title	"DDI between Triamcinolone and Methylphenobarbital - The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00620 .
ns1:DB00620_DB00945	dcterms:title	"DDI between Triamcinolone and Acetylsalicylic acid - The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB00620 .
ns1:DB00620_DB01010	dcterms:title	"DDI between Triamcinolone and Edrophonium - The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01010 ,
		ns3:DB00620 .
ns1:DB00620_DB01045	dcterms:title	"DDI between Triamcinolone and Rifampicin - The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01045 .
ns1:DB00620_DB01122	dcterms:title	"DDI between Triamcinolone and Ambenonium - The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01122 ,
		ns3:DB00620 .
ns1:DB00620_DB01125	dcterms:title	"DDI between Triamcinolone and Anisindione - The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01125 .
ns1:DB00620_DB01174	dcterms:title	"DDI between Triamcinolone and Phenobarbital - The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01174 .
ns1:DB00620_DB01294	dcterms:title	"DDI between Triamcinolone and Bismuth Subsalicylate - The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01294 ,
		ns3:DB00620 .
ns1:DB00620_DB01320	dcterms:title	"DDI between Triamcinolone and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01320 .
ns1:DB00620_DB01339	dcterms:title	"DDI between Triamcinolone and Vecuronium - Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01339 ,
		ns3:DB00620 .
ns1:DB00620_DB01341	dcterms:title	"DDI between Triamcinolone and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01341 .
ns1:DB00620_DB01346	dcterms:title	"DDI between Triamcinolone and Quinidine barbiturate - The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01346 .
ns1:DB00620_DB01351	dcterms:title	"DDI between Triamcinolone and Amobarbital - The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01351 .
ns1:DB00620_DB01352	dcterms:title	"DDI between Triamcinolone and Aprobarbital - The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01352 .
ns1:DB00620_DB01353	dcterms:title	"DDI between Triamcinolone and Butethal - The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01353 .
ns1:DB00620_DB01354	dcterms:title	"DDI between Triamcinolone and Heptabarbital - The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01354 .
ns1:DB00620_DB01355	dcterms:title	"DDI between Triamcinolone and Hexobarbital - The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01355 .
ns1:DB00620_DB01397	dcterms:title	"DDI between Triamcinolone and Magnesium salicylate - The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01397 ,
		ns3:DB00620 .
ns1:DB00620_DB01398	dcterms:title	"DDI between Triamcinolone and Salicylate-sodium - The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01398 ,
		ns3:DB00620 .
ns1:DB00620_DB01399	dcterms:title	"DDI between Triamcinolone and Salsalate - The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01399 ,
		ns3:DB00620 .
ns1:DB00620_DB01400	dcterms:title	"DDI between Triamcinolone and Neostigmine - The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01400 .
ns1:DB00620_DB01401	dcterms:title	"DDI between Triamcinolone and Trisalicylate-choline - The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01401 ,
		ns3:DB00620 .
ns1:DB00620_DB01418	dcterms:title	"DDI between Triamcinolone and Acenocoumarol - The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00620 ,
		ns3:DB01418 .
ns1:DB00621_DB00682	dcterms:title	"DDI between Oxandrolone and Warfarin - Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00621 .
ns1:DB00622_DB00656	dcterms:title	"DDI between Nicardipine and Trazodone - The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00656 .
ns1:DB00622_DB00661	dcterms:title	"DDI between Nicardipine and Verapamil - Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00661 .
ns1:DB00622_DB00675	dcterms:title	"DDI between Nicardipine and Tamoxifen - Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00675 .
ns1:DB00622_DB00682	dcterms:title	"DDI between Nicardipine and Warfarin - Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00622 .
ns1:DB00622_DB00706	dcterms:title	"DDI between Nicardipine and Tamsulosin - Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00706 ,
		ns3:DB00622 .
ns1:DB00622_DB00726	dcterms:title	"DDI between Nicardipine and Trimipramine - The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00622 .
ns1:DB00622_DB00820	dcterms:title	"DDI between Nicardipine and Tadalafil - Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00820 .
ns1:DB00622_DB00862	dcterms:title	"DDI between Nicardipine and Vardenafil - Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00862 .
ns1:DB00622_DB00864	dcterms:title	"DDI between Nicardipine and Tacrolimus - The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00864 .
ns1:DB00622_DB00906	dcterms:title	"DDI between Nicardipine and Tiagabine - The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00906 .
ns1:DB00622_DB00909	dcterms:title	"DDI between Nicardipine and Zonisamide - Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00909 .
ns1:DB00622_DB00932	dcterms:title	"DDI between Nicardipine and Tipranavir - Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00932 .
ns1:DB00622_DB00976	dcterms:title	"DDI between Nicardipine and Telithromycin - Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB00976 .
ns1:DB00622_DB01030	dcterms:title	"DDI between Nicardipine and Topotecan - The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01030 .
ns1:DB00622_DB01036	dcterms:title	"DDI between Nicardipine and Tolterodine - Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01036 .
ns1:DB00622_DB01124	dcterms:title	"DDI between Nicardipine and Tolbutamide - Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01124 .
ns1:DB00622_DB01198	dcterms:title	"DDI between Nicardipine and Zopiclone - Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01198 .
ns1:DB00622_DB01219	dcterms:title	"DDI between Nicardipine and Dantrolene - Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01219 .
ns1:DB00622_DB01369	dcterms:title	"DDI between Nicardipine and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01369 .
ns1:DB00622_DB01558	dcterms:title	"DDI between Nicardipine and Bromazepam - Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB01558 .
ns1:DB00622_DB06287	dcterms:title	"DDI between Nicardipine and Temsirolimus - Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00622 ,
		ns3:DB06287 .
ns1:DB00623_DB00662	dcterms:title	"DDI between Fluphenazine and Trimethobenzamide - Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB00623 .
ns1:DB00623_DB00830	dcterms:title	"DDI between Fluphenazine and Phenmetrazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00830 ,
		ns3:DB00623 .
ns1:DB00623_DB00857	dcterms:title	"DDI between Fluphenazine and Terbinafine - Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00857 ,
		ns3:DB00623 .
ns1:DB00623_DB00865	dcterms:title	"DDI between Fluphenazine and Benzphetamine - Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00865 ,
		ns3:DB00623 .
ns1:DB00623_DB00937	dcterms:title	"DDI between Fluphenazine and Diethylpropion - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB00623 .
ns1:DB00623_DB01044	dcterms:title	"DDI between Fluphenazine and Gatifloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01044 ,
		ns3:DB00623 .
ns1:DB00623_DB01137	dcterms:title	"DDI between Fluphenazine and Levofloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01137 ,
		ns3:DB00623 .
ns1:DB00623_DB01170	dcterms:title	"DDI between Fluphenazine and Guanethidine - Fluphenazine may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01170 ,
		ns3:DB00623 .
ns1:DB00623_DB01191	dcterms:title	"DDI between Fluphenazine and Dexfenfluramine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01191 ,
		ns3:DB00623 .
ns1:DB00623_DB01200	dcterms:title	"DDI between Fluphenazine and Bromocriptine - The phenothiazine decreases the effect of bromocriptine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01200 ,
		ns3:DB00623 .
ns1:DB00623_DB01208	dcterms:title	"DDI between Fluphenazine and Sparfloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01208 ,
		ns3:DB00623 .
ns1:DB00623_DB01576	dcterms:title	"DDI between Fluphenazine and Dextroamphetamine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01576 ,
		ns3:DB00623 .
ns1:DB00623_DB01577	dcterms:title	"DDI between Fluphenazine and Methamphetamine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01577 ,
		ns3:DB00623 .
ns1:DB00623_DB01578	dcterms:title	"DDI between Fluphenazine and Metrizamide - Increased risk of convulsions"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01578 ,
		ns3:DB00623 .
ns1:DB00623_DB01579	dcterms:title	"DDI between Fluphenazine and Phendimetrazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01579 ,
		ns3:DB00623 .
ns1:DB00623_DB04844	dcterms:title	"DDI between Fluphenazine and Tetrabenazine - May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB00623 .
ns1:DB00624_DB00682	dcterms:title	"DDI between Testosterone and Warfarin - Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00624 ,
		ns3:DB00682 .
ns1:DB00624_DB01125	dcterms:title	"DDI between Testosterone and Anisindione - The androgen may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00624 ,
		ns3:DB01125 .
ns1:DB00624_DB01248	dcterms:title	"DDI between Testosterone and Docetaxel - Testosterone may increase the serum levels and toxicity of docetaxel."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01248 ,
		ns3:DB00624 .
ns1:DB00624_DB01418	dcterms:title	"DDI between Testosterone and Acenocoumarol - The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00624 ,
		ns3:DB01418 .
ns1:DB00625_DB00637	dcterms:title	"DDI between Efavirenz and Astemizole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00637 .
ns1:DB00625_DB00641	dcterms:title	"DDI between Efavirenz and Simvastatin - Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB00625 .
ns1:DB00625_DB00656	dcterms:title	"DDI between Efavirenz and Trazodone - The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00625 .
ns1:DB00625_DB00683	dcterms:title	"DDI between Efavirenz and Midazolam - The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00683 .
ns1:DB00625_DB00696	dcterms:title	"DDI between Efavirenz and Ergotamine - The antiretroviral agent may increase the ergot derivative toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00696 .
ns1:DB00625_DB00706	dcterms:title	"DDI between Efavirenz and Tamsulosin - Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00706 .
ns1:DB00625_DB00897	dcterms:title	"DDI between Efavirenz and Triazolam - The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB00897 .
ns1:DB00625_DB00932	dcterms:title	"DDI between Efavirenz and Tipranavir - Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00625 .
ns1:DB00625_DB00976	dcterms:title	"DDI between Efavirenz and Telithromycin - Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00625 .
ns1:DB00625_DB01036	dcterms:title	"DDI between Efavirenz and Tolterodine - Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00625 .
ns1:DB00625_DB01072	dcterms:title	"DDI between Efavirenz and Atazanavir - Efavirenz decreases the levels/effects of atazanavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00625 .
ns1:DB00625_DB01076	dcterms:title	"DDI between Efavirenz and Atorvastatin - Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01076 ,
		ns3:DB00625 .
ns1:DB00625_DB01211	dcterms:title	"DDI between Efavirenz and Clarithromycin - Efavirenz decreases levels of clarithromycin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00625 .
ns1:DB00625_DB01232	dcterms:title	"DDI between Efavirenz and Saquinavir - Efavirenz decreases the effect of saquinavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00625 .
ns1:DB00625_DB01323	dcterms:title	"DDI between Efavirenz and St. John's Wort - St. John's Wort decreases the antiretroviral effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01323 ,
		ns3:DB00625 .
ns1:DB00625_DB01656	dcterms:title	"DDI between Efavirenz and Roflumilast - Affects CYP3A4 metabolism, decreases level or effect of roflumilast."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB01656 .
ns1:DB00625_DB05294	dcterms:title	"DDI between Efavirenz and Vandetanib - Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB05294 .
ns1:DB00625_DB05521	dcterms:title	"DDI between Efavirenz and Telaprevir - Inducers of CYP3A enzymes will decrease telaprevir levels."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05521 ,
		ns3:DB00625 .
ns1:DB00625_DB06210	dcterms:title	"DDI between Efavirenz and Eltrombopag - Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB06210 .
ns1:DB00625_DB06287	dcterms:title	"DDI between Efavirenz and Temsirolimus - Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06287 ,
		ns3:DB00625 .
ns1:DB00625_DB06414	dcterms:title	"DDI between Efavirenz and Etravirine - Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. \r\nCombination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00625 .
ns1:DB00625_DB08864	dcterms:title	"DDI between Efavirenz and Rilpivirine - Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB08864 .
ns1:DB00625_DB08866	dcterms:title	"DDI between Efavirenz and Estradiol valerate/Dienogest  - Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00625 ,
		ns3:DB08866 .
ns1:DB00627_DB00930	dcterms:title	"DDI between Niacin and Colesevelam - Bile Acid Sequestrants may decrease the absorption of Niacin. It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00930 ,
		ns3:DB00627 .
ns1:DB00627_DB08860	dcterms:title	"DDI between Niacin and Pitavastatin - Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08860 ,
		ns3:DB00627 .
ns1:DB00628_DB00701	dcterms:title	"DDI between Clorazepate and Amprenavir - Amprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00701 ,
		ns3:DB00628 .
ns1:DB00628_DB00754	dcterms:title	"DDI between Clorazepate and Ethotoin - Ethotoin may increase the metabolism of clorazepate via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00628 .
ns1:DB00628_DB00932	dcterms:title	"DDI between Clorazepate and Tipranavir - Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00628 .
ns1:DB00628_DB00976	dcterms:title	"DDI between Clorazepate and Telithromycin - Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00628 .
ns1:DB00628_DB01026	dcterms:title	"DDI between Clorazepate and Ketoconazole - Ketoconazole may increase the effect of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00628 .
ns1:DB00628_DB01167	dcterms:title	"DDI between Clorazepate and Itraconazole - Itraconazole may increase the effect of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00628 .
ns1:DB00628_DB01232	dcterms:title	"DDI between Clorazepate and Saquinavir - The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00628 .
ns1:DB00628_DB01319	dcterms:title	"DDI between Clorazepate and Fosamprenavir - Fosamprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00628 .
ns1:DB00628_DB01320	dcterms:title	"DDI between Clorazepate and Fosphenytoin - Fosphenytoin may increase the metabolism of clorazepate via CYP3A4."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00628 .
ns1:DB00628_DB01322	dcterms:title	"DDI between Clorazepate and Kava - Kava may increase the effect of the benzodiazepine, clorazepate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00628 ,
		ns3:DB01322 .
ns1:DB00629_DB00726	dcterms:title	"DDI between Guanabenz and Trimipramine - Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanabenz. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanabenz should be withdrawn very gradually to reduce the risk of hypertensive crisis."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00629 .
ns1:DB00629_DB00730	dcterms:title	"DDI between Guanabenz and Thiabendazole - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00629 ,
		ns3:DB00730 .
ns1:DB00630_DB00712	dcterms:title	"DDI between Alendronate and Flurbiprofen - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00712 ,
		ns3:DB00630 .
ns1:DB00630_DB00749	dcterms:title	"DDI between Alendronate and Etodolac - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00749 ,
		ns3:DB00630 .
ns1:DB00630_DB00784	dcterms:title	"DDI between Alendronate and Mefenamic acid - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00784 ,
		ns3:DB00630 .
ns1:DB00630_DB00788	dcterms:title	"DDI between Alendronate and Naproxen - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00788 ,
		ns3:DB00630 .
ns1:DB00630_DB00861	dcterms:title	"DDI between Alendronate and Diflunisal - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00861 ,
		ns3:DB00630 .
ns1:DB00630_DB00893	dcterms:title	"DDI between Alendronate and Iron Dextran - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00630 ,
		ns3:DB00893 .
ns1:DB00630_DB00991	dcterms:title	"DDI between Alendronate and Oxaprozin - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB00630 .
ns1:DB00630_DB01050	dcterms:title	"DDI between Alendronate and Ibuprofen - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01050 ,
		ns3:DB00630 .
ns1:DB00630_DB01164	dcterms:title	"DDI between Alendronate and Calcium Chloride - Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00630 ,
		ns3:DB01164 .
ns1:DB00630_DB01373	dcterms:title	"DDI between Alendronate and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00630 ,
		ns3:DB01373 .
ns1:DB00630_DB01378	dcterms:title	"DDI between Alendronate and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00630 ,
		ns3:DB01378 .
ns1:DB00630_DB03585	dcterms:title	"DDI between Alendronate and Oxyphenbutazone - Increased risk of gastric toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00630 ,
		ns3:DB03585 .
ns1:DB00631_DB00864	dcterms:title	"DDI between Clofarabine and Tacrolimus - Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00631 .
ns1:DB00631_DB01097	dcterms:title	"DDI between Clofarabine and Leflunomide - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00631 ,
		ns3:DB01097 .
ns1:DB00631_DB01656	dcterms:title	"DDI between Clofarabine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00631 ,
		ns3:DB01656 .
ns1:DB00633_DB00726	dcterms:title	"DDI between Dexmedetomidine and Trimipramine - Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Dexmedetomidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Dexmedetomidine should be withdrawn very gradually to reduce the risk of hypertensive crisis."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00633 .
ns1:DB00633_DB00752	dcterms:title	"DDI between Dexmedetomidine and Tranylcypromine - Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Dexmedetomidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00752 ,
		ns3:DB00633 .
ns1:DB00635_DB00655	dcterms:title	"DDI between Prednisone and Estrone - The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00655 .
ns1:DB00635_DB00682	dcterms:title	"DDI between Prednisone and Warfarin - The corticosteroid, prednisone, alters the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00682 .
ns1:DB00635_DB00754	dcterms:title	"DDI between Prednisone and Ethotoin - The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00754 .
ns1:DB00635_DB00783	dcterms:title	"DDI between Prednisone and Estradiol - The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00783 .
ns1:DB00635_DB00794	dcterms:title	"DDI between Prednisone and Primidone - The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00794 .
ns1:DB00635_DB00849	dcterms:title	"DDI between Prednisone and Methylphenobarbital - The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00635 .
ns1:DB00635_DB00882	dcterms:title	"DDI between Prednisone and Clomifene - The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00882 .
ns1:DB00635_DB00945	dcterms:title	"DDI between Prednisone and Acetylsalicylic acid - The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00945 .
ns1:DB00635_DB00977	dcterms:title	"DDI between Prednisone and Ethinyl Estradiol - The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00977 .
ns1:DB00635_DB01010	dcterms:title	"DDI between Prednisone and Edrophonium - The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB01010 .
ns1:DB00635_DB01026	dcterms:title	"DDI between Prednisone and Ketoconazole - The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB01026 .
ns1:DB00635_DB01045	dcterms:title	"DDI between Prednisone and Rifampicin - The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB01045 .
ns1:DB00635_DB01122	dcterms:title	"DDI between Prednisone and Ambenonium - The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB01122 .
ns1:DB00635_DB01125	dcterms:title	"DDI between Prednisone and Anisindione - The corticosteroid, prednisone, alters the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00635 .
ns1:DB00635_DB01167	dcterms:title	"DDI between Prednisone and Itraconazole - The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00635 .
ns1:DB00635_DB01174	dcterms:title	"DDI between Prednisone and Phenobarbital - The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00635 .
ns1:DB00635_DB01294	dcterms:title	"DDI between Prednisone and Bismuth Subsalicylate - The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01294 ,
		ns3:DB00635 .
ns1:DB00635_DB01320	dcterms:title	"DDI between Prednisone and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00635 .
ns1:DB00635_DB01339	dcterms:title	"DDI between Prednisone and Vecuronium - Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01339 ,
		ns3:DB00635 .
ns1:DB00635_DB01341	dcterms:title	"DDI between Prednisone and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00635 .
ns1:DB00635_DB01346	dcterms:title	"DDI between Prednisone and Quinidine barbiturate - The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00635 .
ns1:DB00635_DB01351	dcterms:title	"DDI between Prednisone and Amobarbital - The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00635 .
ns1:DB00635_DB01352	dcterms:title	"DDI between Prednisone and Aprobarbital - The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00635 .
ns1:DB00635_DB01353	dcterms:title	"DDI between Prednisone and Butethal - The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00635 .
ns1:DB00635_DB01354	dcterms:title	"DDI between Prednisone and Heptabarbital - The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00635 .
ns1:DB00635_DB01355	dcterms:title	"DDI between Prednisone and Hexobarbital - The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00635 .
ns1:DB00635_DB01357	dcterms:title	"DDI between Prednisone and Mestranol - The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00635 .
ns1:DB00635_DB01397	dcterms:title	"DDI between Prednisone and Magnesium salicylate - The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01397 ,
		ns3:DB00635 .
ns1:DB00635_DB01398	dcterms:title	"DDI between Prednisone and Salicylate-sodium - The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01398 ,
		ns3:DB00635 .
ns1:DB00635_DB01399	dcterms:title	"DDI between Prednisone and Salsalate - The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01399 ,
		ns3:DB00635 .
ns1:DB00635_DB01400	dcterms:title	"DDI between Prednisone and Neostigmine - The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01400 ,
		ns3:DB00635 .
ns1:DB00635_DB01401	dcterms:title	"DDI between Prednisone and Trisalicylate-choline - The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01401 ,
		ns3:DB00635 .
ns1:DB00635_DB01418	dcterms:title	"DDI between Prednisone and Acenocoumarol - The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00635 .
ns1:DB00635_DB04573	dcterms:title	"DDI between Prednisone and Estriol - The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04573 ,
		ns3:DB00635 .
ns1:DB00635_DB04574	dcterms:title	"DDI between Prednisone and Estropipate - The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04574 ,
		ns3:DB00635 .
ns1:DB00635_DB04575	dcterms:title	"DDI between Prednisone and Quinestrol - The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04575 ,
		ns3:DB00635 .
ns1:DB00635_DB05039	dcterms:title	"DDI between Prednisone and Indacaterol - Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05039 ,
		ns3:DB00635 .
ns1:DB00635_DB06223	dcterms:title	"DDI between Prednisone and F - decreases the effect of cortisone by metabolism alteration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06223 ,
		ns3:DB00635 .
ns1:DB00635_DB08882	dcterms:title	"DDI between Prednisone and Linagliptin  - CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08882 ,
		ns3:DB00635 .
ns1:DB00635_DB08909	dcterms:title	"DDI between Prednisone and Glycerol Phenylbutyrate - Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08909 ,
		ns3:DB00635 .
ns1:DB00636_DB00672	dcterms:title	"DDI between Clofibrate and Chlorpropamide - Clofibrate may increase the effect of sulfonylurea, chlorpropamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB00672 .
ns1:DB00636_DB00682	dcterms:title	"DDI between Clofibrate and Warfarin - The fibrate increases the anticoagulant effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB00682 .
ns1:DB00636_DB00839	dcterms:title	"DDI between Clofibrate and Tolazamide - Clofibrate may increase the effect of sulfonylurea, tolazamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB00839 .
ns1:DB00636_DB01016	dcterms:title	"DDI between Clofibrate and Glyburide - Clofibrate may increase the effect of sulfonylurea, glibenclamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01016 ,
		ns3:DB00636 .
ns1:DB00636_DB01067	dcterms:title	"DDI between Clofibrate and Glipizide - Clofibrate may increase the effect of sulfonylurea, glipizide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01067 ,
		ns3:DB00636 .
ns1:DB00636_DB01120	dcterms:title	"DDI between Clofibrate and Gliclazide - Clofibrate may increase the effect of sulfonylurea, gliclazide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01120 ,
		ns3:DB00636 .
ns1:DB00636_DB01124	dcterms:title	"DDI between Clofibrate and Tolbutamide - Clofibrate may increase the effect of sulfonylurea, tolbutamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01124 ,
		ns3:DB00636 .
ns1:DB00636_DB01125	dcterms:title	"DDI between Clofibrate and Anisindione - The fibrate increases the anticoagulant effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB01125 .
ns1:DB00636_DB01289	dcterms:title	"DDI between Clofibrate and Glisoxepide - Clofibrate may increase the effect of sulfonylurea, glisoxepide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB01289 .
ns1:DB00636_DB01306	dcterms:title	"DDI between Clofibrate and Insulin Aspart - Increases the effect of insulin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01306 ,
		ns3:DB00636 .
ns1:DB00636_DB01307	dcterms:title	"DDI between Clofibrate and Insulin Detemir - Increases the effect of insulin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01307 ,
		ns3:DB00636 .
ns1:DB00636_DB01309	dcterms:title	"DDI between Clofibrate and Insulin Glulisine - Increases the effect of insulin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01309 ,
		ns3:DB00636 .
ns1:DB00636_DB01382	dcterms:title	"DDI between Clofibrate and Glycodiazine - Clofibrate may increase the effect of sulfonylurea, glycodiazine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB01382 .
ns1:DB00636_DB01418	dcterms:title	"DDI between Clofibrate and Acenocoumarol - The fibrate increases the anticoagulant effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00636 ,
		ns3:DB01418 .
ns1:DB00636_DB01586	dcterms:title	"DDI between Clofibrate and Ursodeoxycholic acid - The fibric acid derivative decreases the effect of ursodiol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01586 ,
		ns3:DB00636 .
ns1:DB00637_DB00673	dcterms:title	"DDI between Astemizole and Aprepitant - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00637 ,
		ns3:DB00673 .
ns1:DB00637_DB00679	dcterms:title	"DDI between Astemizole and Thioridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00637 .
ns1:DB00637_DB00701	dcterms:title	"DDI between Astemizole and Amprenavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00637 ,
		ns3:DB00701 .
ns1:DB00637_DB00705	dcterms:title	"DDI between Astemizole and Delavirdine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00705 ,
		ns3:DB00637 .
ns1:DB00637_DB00932	dcterms:title	"DDI between Astemizole and Tipranavir - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00637 .
ns1:DB00637_DB00933	dcterms:title	"DDI between Astemizole and Mesoridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00637 .
ns1:DB00637_DB00976	dcterms:title	"DDI between Astemizole and Telithromycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00637 .
ns1:DB00637_DB01026	dcterms:title	"DDI between Astemizole and Ketoconazole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00637 .
ns1:DB00637_DB01149	dcterms:title	"DDI between Astemizole and Nefazodone - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00637 .
ns1:DB00637_DB01167	dcterms:title	"DDI between Astemizole and Itraconazole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00637 .
ns1:DB00637_DB01208	dcterms:title	"DDI between Astemizole and Sparfloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01208 ,
		ns3:DB00637 .
ns1:DB00637_DB01211	dcterms:title	"DDI between Astemizole and Clarithromycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00637 .
ns1:DB00637_DB01232	dcterms:title	"DDI between Astemizole and Saquinavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00637 .
ns1:DB00637_DB01244	dcterms:title	"DDI between Astemizole and Bepridil - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01244 ,
		ns3:DB00637 .
ns1:DB00637_DB01263	dcterms:title	"DDI between Astemizole and Posaconazole - Contraindicated co-administration"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00637 .
ns1:DB00637_DB01319	dcterms:title	"DDI between Astemizole and Fosamprenavir - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00637 .
ns1:DB00637_DB01321	dcterms:title	"DDI between Astemizole and Josamycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01321 ,
		ns3:DB00637 .
ns1:DB00637_DB01361	dcterms:title	"DDI between Astemizole and Troleandomycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01361 ,
		ns3:DB00637 .
ns1:DB00637_DB01369	dcterms:title	"DDI between Astemizole and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00637 .
ns1:DB00637_DB01388	dcterms:title	"DDI between Astemizole and Mibefradil - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00637 ,
		ns3:DB01388 .
ns1:DB00637_DB06402	dcterms:title	"DDI between Astemizole and Telavancin - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00637 ,
		ns3:DB06402 .
ns1:DB00640_DB00651	dcterms:title	"DDI between Adenosine and Dyphylline - This xanthine decreases the effect of adenosine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00640 .
ns1:DB00640_DB00975	dcterms:title	"DDI between Adenosine and Dipyridamole - Dipyridamole may increase the effect/toxicity of adenosine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00640 ,
		ns3:DB00975 .
ns1:DB00640_DB01223	dcterms:title	"DDI between Adenosine and Aminophylline - This xanthine decreases the effect of adenosine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00640 .
ns1:DB00640_DB01303	dcterms:title	"DDI between Adenosine and Oxtriphylline - This xanthine decreases the effect of adenosine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00640 .
ns1:DB00641_DB00661	dcterms:title	"DDI between Simvastatin and Verapamil - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00641 .
ns1:DB00641_DB00701	dcterms:title	"DDI between Simvastatin and Amprenavir - Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB00701 .
ns1:DB00641_DB00705	dcterms:title	"DDI between Simvastatin and Delavirdine - Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB00705 .
ns1:DB00641_DB00932	dcterms:title	"DDI between Simvastatin and Tipranavir - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00641 .
ns1:DB00641_DB00976	dcterms:title	"DDI between Simvastatin and Telithromycin - Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00641 .
ns1:DB00641_DB01026	dcterms:title	"DDI between Simvastatin and Ketoconazole - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00641 .
ns1:DB00641_DB01039	dcterms:title	"DDI between Simvastatin and Fenofibrate - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01039 ,
		ns3:DB00641 .
ns1:DB00641_DB01045	dcterms:title	"DDI between Simvastatin and Rifampicin - Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00641 .
ns1:DB00641_DB01072	dcterms:title	"DDI between Simvastatin and Atazanavir - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00641 .
ns1:DB00641_DB01118	dcterms:title	"DDI between Simvastatin and Amiodarone - Increased risk of rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00641 .
ns1:DB00641_DB01149	dcterms:title	"DDI between Simvastatin and Nefazodone - Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00641 .
ns1:DB00641_DB01167	dcterms:title	"DDI between Simvastatin and Itraconazole - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00641 .
ns1:DB00641_DB01211	dcterms:title	"DDI between Simvastatin and Clarithromycin - The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00641 .
ns1:DB00641_DB01241	dcterms:title	"DDI between Simvastatin and Gemfibrozil - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB01241 .
ns1:DB00641_DB01319	dcterms:title	"DDI between Simvastatin and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00641 .
ns1:DB00641_DB01369	dcterms:title	"DDI between Simvastatin and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00641 .
ns1:DB00641_DB01394	dcterms:title	"DDI between Simvastatin and Colchicine - Increased risk of rhabdomyolysis with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01394 ,
		ns3:DB00641 .
ns1:DB00641_DB02703	dcterms:title	"DDI between Simvastatin and Fusidic Acid - Increased risk of myopathy/rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB02703 .
ns1:DB00641_DB04855	dcterms:title	"DDI between Simvastatin and Dronedarone - Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04855 ,
		ns3:DB00641 .
ns1:DB00641_DB05521	dcterms:title	"DDI between Simvastatin and Telaprevir - Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05521 ,
		ns3:DB00641 .
ns1:DB00641_DB06273	dcterms:title	"DDI between Simvastatin and Tocilizumab - Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06273 ,
		ns3:DB00641 .
ns1:DB00641_DB06335	dcterms:title	"DDI between Simvastatin and Saxagliptin - Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06335 ,
		ns3:DB00641 .
ns1:DB00641_DB06414	dcterms:title	"DDI between Simvastatin and Etravirine - Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00641 .
ns1:DB00641_DB06589	dcterms:title	"DDI between Simvastatin and Pazopanib - Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB06589 .
ns1:DB00641_DB08816	dcterms:title	"DDI between Simvastatin and Ticagrelor - Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB08816 .
ns1:DB00641_DB08827	dcterms:title	"DDI between Simvastatin and Lomitapide - Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00641 ,
		ns3:DB08827 .
ns1:DB00642_DB01009	dcterms:title	"DDI between Pemetrexed and Ketoprofen - The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00642 .
ns1:DB00642_DB01600	dcterms:title	"DDI between Pemetrexed and Tiaprofenic acid - Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01600 ,
		ns3:DB00642 .
ns1:DB00643_DB00754	dcterms:title	"DDI between Mebendazole and Ethotoin - The hydantoin decreases the efficiency of mebendazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00643 .
ns1:DB00643_DB01320	dcterms:title	"DDI between Mebendazole and Fosphenytoin - The hydantoin decreases the efficiency of mebendazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00643 .
ns1:DB00647_DB00682	dcterms:title	"DDI between Dextropropoxyphene and Warfarin - Propoxyphene may increase the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00647 .
ns1:DB00647_DB00752	dcterms:title	"DDI between Dextropropoxyphene and Tranylcypromine - Increased risk of serotonin syndrome. Concomitant use should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00647 ,
		ns3:DB00752 .
ns1:DB00647_DB01125	dcterms:title	"DDI between Dextropropoxyphene and Anisindione - Propoxyphene may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00647 ,
		ns3:DB01125 .
ns1:DB00647_DB01418	dcterms:title	"DDI between Dextropropoxyphene and Acenocoumarol - Propoxyphene may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00647 ,
		ns3:DB01418 .
ns1:DB00647_DB06274	dcterms:title	"DDI between Dextropropoxyphene and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00647 ,
		ns3:DB06274 .
ns1:DB00648_DB00682	dcterms:title	"DDI between Mitotane and Warfarin - Mitotane may decrease the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00648 ,
		ns3:DB00682 .
ns1:DB00648_DB01125	dcterms:title	"DDI between Mitotane and Anisindione - Mitotane may decrease the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00648 ,
		ns3:DB01125 .
ns1:DB00648_DB01418	dcterms:title	"DDI between Mitotane and Acenocoumarol - Mitotane may decrease the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00648 ,
		ns3:DB01418 .
ns1:DB00650_DB08898	dcterms:title	"DDI between Leucovorin and Glucarpidase - Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08898 ,
		ns3:DB00650 .
ns1:DB00651_DB00787	dcterms:title	"DDI between Dyphylline and Aciclovir - Acyclovir increases the effect and toxicity of dyphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00787 ,
		ns3:DB00651 .
ns1:DB00651_DB00794	dcterms:title	"DDI between Dyphylline and Primidone - The barbiturate, primidone, decreases the effect of dyphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00651 .
ns1:DB00651_DB00806	dcterms:title	"DDI between Dyphylline and Pentoxifylline - Pentoxifylline increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00806 .
ns1:DB00651_DB00822	dcterms:title	"DDI between Dyphylline and Disulfiram - Increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00822 .
ns1:DB00651_DB00857	dcterms:title	"DDI between Dyphylline and Terbinafine - Terbinafine increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00857 .
ns1:DB00651_DB00951	dcterms:title	"DDI between Dyphylline and Isoniazid - Increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00951 .
ns1:DB00651_DB00960	dcterms:title	"DDI between Dyphylline and Pindolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00960 .
ns1:DB00651_DB00977	dcterms:title	"DDI between Dyphylline and Ethinyl Estradiol - The contraceptive increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00977 .
ns1:DB00651_DB01045	dcterms:title	"DDI between Dyphylline and Rifampicin - Rifampin decreases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01045 .
ns1:DB00651_DB01059	dcterms:title	"DDI between Dyphylline and Norfloxacin - Norfloxacin may increase the effect of dyphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01059 .
ns1:DB00651_DB01174	dcterms:title	"DDI between Dyphylline and Phenobarbital - The barbiturate, phenobarbital, decreases the effect of dyphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01174 .
ns1:DB00651_DB01182	dcterms:title	"DDI between Dyphylline and Propafenone - Propafenone increases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01182 .
ns1:DB00651_DB01203	dcterms:title	"DDI between Dyphylline and Nadolol - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01203 .
ns1:DB00651_DB01211	dcterms:title	"DDI between Dyphylline and Clarithromycin - Increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01211 .
ns1:DB00651_DB01320	dcterms:title	"DDI between Dyphylline and Fosphenytoin - Decreased effect of both products"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01320 .
ns1:DB00651_DB01356	dcterms:title	"DDI between Dyphylline and Lithium - Theophylline decreases serum levels of lithium"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01356 .
ns1:DB00651_DB01558	dcterms:title	"DDI between Dyphylline and Bromazepam - Dyphylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if dyphylline is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB01558 .
ns1:DB00652_DB06274	dcterms:title	"DDI between Pentazocine and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06274 ,
		ns3:DB00652 .
ns1:DB00653_DB00685	dcterms:title	"DDI between Magnesium Sulfate and Trovafloxacin - Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00653 ,
		ns3:DB00685 .
ns1:DB00653_DB01072	dcterms:title	"DDI between Magnesium Sulfate and Atazanavir - This gastric pH modifier decreases the levels/effects of atazanavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00653 .
ns1:DB00653_DB01133	dcterms:title	"DDI between Magnesium Sulfate and Tiludronate - The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00653 ,
		ns3:DB01133 .
ns1:DB00653_DB01551	dcterms:title	"DDI between Magnesium Sulfate and Dihydrocodeine - May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00653 .
ns1:DB00653_DB06210	dcterms:title	"DDI between Magnesium Sulfate and Eltrombopag - Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00653 .
ns1:DB00654_DB00905	dcterms:title	"DDI between Latanoprost and Bimatoprost - The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00905 ,
		ns3:DB00654 .
ns1:DB00655_DB00794	dcterms:title	"DDI between Estrone and Primidone - The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00655 .
ns1:DB00655_DB00860	dcterms:title	"DDI between Estrone and Prednisolone - The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00655 .
ns1:DB00655_DB00932	dcterms:title	"DDI between Estrone and Tipranavir - Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00655 .
ns1:DB00655_DB01174	dcterms:title	"DDI between Estrone and Phenobarbital - The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00655 .
ns1:DB00655_DB01320	dcterms:title	"DDI between Estrone and Fosphenytoin - The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00655 .
ns1:DB00656_DB00661	dcterms:title	"DDI between Trazodone and Verapamil - The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00661 .
ns1:DB00656_DB00669	dcterms:title	"DDI between Trazodone and Sumatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00669 .
ns1:DB00656_DB00673	dcterms:title	"DDI between Trazodone and Aprepitant - The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00673 .
ns1:DB00656_DB00674	dcterms:title	"DDI between Trazodone and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00674 .
ns1:DB00656_DB00675	dcterms:title	"DDI between Trazodone and Tamoxifen - Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00675 .
ns1:DB00656_DB00696	dcterms:title	"DDI between Trazodone and Ergotamine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00696 .
ns1:DB00656_DB00701	dcterms:title	"DDI between Trazodone and Amprenavir - The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00701 ,
		ns3:DB00656 .
ns1:DB00656_DB00705	dcterms:title	"DDI between Trazodone and Delavirdine - The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00705 .
ns1:DB00656_DB00706	dcterms:title	"DDI between Trazodone and Tamsulosin - Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00706 .
ns1:DB00656_DB00715	dcterms:title	"DDI between Trazodone and Paroxetine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00715 .
ns1:DB00656_DB00726	dcterms:title	"DDI between Trazodone and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00726 .
ns1:DB00656_DB00752	dcterms:title	"DDI between Trazodone and Tranylcypromine - Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00752 ,
		ns3:DB00656 .
ns1:DB00656_DB00759	dcterms:title	"DDI between Trazodone and Tetracycline - The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00759 .
ns1:DB00656_DB00776	dcterms:title	"DDI between Trazodone and Oxcarbazepine - The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00776 .
ns1:DB00656_DB00780	dcterms:title	"DDI between Trazodone and Phenelzine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00780 .
ns1:DB00656_DB00794	dcterms:title	"DDI between Trazodone and Primidone - The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00794 .
ns1:DB00656_DB00843	dcterms:title	"DDI between Trazodone and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00843 .
ns1:DB00656_DB00872	dcterms:title	"DDI between Trazodone and Conivaptan - The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00872 .
ns1:DB00656_DB00908	dcterms:title	"DDI between Trazodone and Quinidine - The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00908 .
ns1:DB00656_DB00916	dcterms:title	"DDI between Trazodone and Metronidazole - The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00916 .
ns1:DB00656_DB00918	dcterms:title	"DDI between Trazodone and Almotriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00918 .
ns1:DB00656_DB00932	dcterms:title	"DDI between Trazodone and Tipranavir - The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00932 .
ns1:DB00656_DB00934	dcterms:title	"DDI between Trazodone and Maprotiline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00934 .
ns1:DB00656_DB00951	dcterms:title	"DDI between Trazodone and Isoniazid - The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00951 .
ns1:DB00656_DB00952	dcterms:title	"DDI between Trazodone and Naratriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00952 .
ns1:DB00656_DB00953	dcterms:title	"DDI between Trazodone and Rizatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00953 .
ns1:DB00656_DB00976	dcterms:title	"DDI between Trazodone and Telithromycin - The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00976 .
ns1:DB00656_DB00989	dcterms:title	"DDI between Trazodone and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00989 .
ns1:DB00656_DB00998	dcterms:title	"DDI between Trazodone and Frovatriptan - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB00998 .
ns1:DB00656_DB01026	dcterms:title	"DDI between Trazodone and Ketoconazole - The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01026 .
ns1:DB00656_DB01037	dcterms:title	"DDI between Trazodone and Selegiline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01037 .
ns1:DB00656_DB01045	dcterms:title	"DDI between Trazodone and Rifampicin - The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01045 .
ns1:DB00656_DB01049	dcterms:title	"DDI between Trazodone and Ergoloid mesylate - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01049 .
ns1:DB00656_DB01059	dcterms:title	"DDI between Trazodone and Norfloxacin - The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01059 .
ns1:DB00656_DB01069	dcterms:title	"DDI between Trazodone and Promethazine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01069 .
ns1:DB00656_DB01072	dcterms:title	"DDI between Trazodone and Atazanavir - The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01072 .
ns1:DB00656_DB01104	dcterms:title	"DDI between Trazodone and Sertraline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01104 .
ns1:DB00656_DB01105	dcterms:title	"DDI between Trazodone and Sibutramine - Increased risk of serotonin syndrome. Avoid concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01105 .
ns1:DB00656_DB01110	dcterms:title	"DDI between Trazodone and Miconazole - The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01110 .
ns1:DB00656_DB01118	dcterms:title	"DDI between Trazodone and Amiodarone - The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01118 .
ns1:DB00656_DB01142	dcterms:title	"DDI between Trazodone and Doxepin - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01142 .
ns1:DB00656_DB01149	dcterms:title	"DDI between Trazodone and Nefazodone - Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01149 .
ns1:DB00656_DB01151	dcterms:title	"DDI between Trazodone and Desipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01151 .
ns1:DB00656_DB01167	dcterms:title	"DDI between Trazodone and Itraconazole - The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01167 .
ns1:DB00656_DB01168	dcterms:title	"DDI between Trazodone and Procarbazine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01168 .
ns1:DB00656_DB01171	dcterms:title	"DDI between Trazodone and Moclobemide - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01171 .
ns1:DB00656_DB01174	dcterms:title	"DDI between Trazodone and Phenobarbital - The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01174 .
ns1:DB00656_DB01175	dcterms:title	"DDI between Trazodone and Escitalopram - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01175 .
ns1:DB00656_DB01186	dcterms:title	"DDI between Trazodone and Pergolide - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01186 .
ns1:DB00656_DB01200	dcterms:title	"DDI between Trazodone and Bromocriptine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01200 .
ns1:DB00656_DB01201	dcterms:title	"DDI between Trazodone and Rifapentine - The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01201 .
ns1:DB00656_DB01211	dcterms:title	"DDI between Trazodone and Clarithromycin - The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01211 .
ns1:DB00656_DB01232	dcterms:title	"DDI between Trazodone and Saquinavir - The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01232 .
ns1:DB00656_DB01234	dcterms:title	"DDI between Trazodone and Dexamethasone - The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01234 .
ns1:DB00656_DB01242	dcterms:title	"DDI between Trazodone and Clomipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01242 .
ns1:DB00656_DB01247	dcterms:title	"DDI between Trazodone and Isocarboxazid - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01247 .
ns1:DB00656_DB01253	dcterms:title	"DDI between Trazodone and Ergonovine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01253 .
ns1:DB00656_DB01259	dcterms:title	"DDI between Trazodone and Lapatinib - The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01259 .
ns1:DB00656_DB01263	dcterms:title	"DDI between Trazodone and Posaconazole - The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01263 .
ns1:DB00656_DB01264	dcterms:title	"DDI between Trazodone and Darunavir - The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00656 ,
		ns3:DB01264 .
ns1:DB00656_DB01319	dcterms:title	"DDI between Trazodone and Fosamprenavir - The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00656 .
ns1:DB00656_DB01320	dcterms:title	"DDI between Trazodone and Fosphenytoin - The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00656 .
ns1:DB00656_DB01323	dcterms:title	"DDI between Trazodone and St. John's Wort - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01323 ,
		ns3:DB00656 .
ns1:DB00656_DB01356	dcterms:title	"DDI between Trazodone and Lithium - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00656 .
ns1:DB00656_DB01367	dcterms:title	"DDI between Trazodone and Rasagiline - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01367 ,
		ns3:DB00656 .
ns1:DB00656_DB01381	dcterms:title	"DDI between Trazodone and Ginkgo biloba - Increased effect and toxicity of both agents"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00656 .
ns1:DB00656_DB01601	dcterms:title	"DDI between Trazodone and Lopinavir - The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00656 .
ns1:DB00656_DB06268	dcterms:title	"DDI between Trazodone and Sitaxentan - The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06268 ,
		ns3:DB00656 .
ns1:DB00656_DB06414	dcterms:title	"DDI between Trazodone and Etravirine - The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00656 .
ns1:DB00656_DB06695	dcterms:title	"DDI between Trazodone and Dabigatran etexilate - P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06695 ,
		ns3:DB00656 .
ns1:DB00656_DB06700	dcterms:title	"DDI between Trazodone and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00656 .
ns1:DB00658_DB00685	dcterms:title	"DDI between Sevelamer and Trovafloxacin - Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00658 ,
		ns3:DB00685 .
ns1:DB00661_DB00683	dcterms:title	"DDI between Verapamil and Midazolam - Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00683 ,
		ns3:DB00661 .
ns1:DB00661_DB00700	dcterms:title	"DDI between Verapamil and Eplerenone - This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00700 ,
		ns3:DB00661 .
ns1:DB00661_DB00701	dcterms:title	"DDI between Verapamil and Amprenavir - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00701 ,
		ns3:DB00661 .
ns1:DB00661_DB00705	dcterms:title	"DDI between Verapamil and Delavirdine - Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00705 ,
		ns3:DB00661 .
ns1:DB00661_DB00706	dcterms:title	"DDI between Verapamil and Tamsulosin - Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00706 .
ns1:DB00661_DB00794	dcterms:title	"DDI between Verapamil and Primidone - The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00661 .
ns1:DB00661_DB00849	dcterms:title	"DDI between Verapamil and Methylphenobarbital - Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00661 .
ns1:DB00661_DB00864	dcterms:title	"DDI between Verapamil and Tacrolimus - The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00864 .
ns1:DB00661_DB00872	dcterms:title	"DDI between Verapamil and Conivaptan - Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00872 ,
		ns3:DB00661 .
ns1:DB00661_DB00897	dcterms:title	"DDI between Verapamil and Triazolam - Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00897 ,
		ns3:DB00661 .
ns1:DB00661_DB00908	dcterms:title	"DDI between Verapamil and Quinidine - Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00661 .
ns1:DB00661_DB00932	dcterms:title	"DDI between Verapamil and Tipranavir - Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB00661 .
ns1:DB00661_DB00951	dcterms:title	"DDI between Verapamil and Isoniazid - Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00661 .
ns1:DB00661_DB00960	dcterms:title	"DDI between Verapamil and Pindolol - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00661 .
ns1:DB00661_DB00976	dcterms:title	"DDI between Verapamil and Telithromycin - Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00661 .
ns1:DB00661_DB01026	dcterms:title	"DDI between Verapamil and Ketoconazole - Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00661 .
ns1:DB00661_DB01030	dcterms:title	"DDI between Verapamil and Topotecan - The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01030 ,
		ns3:DB00661 .
ns1:DB00661_DB01036	dcterms:title	"DDI between Verapamil and Tolterodine - Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00661 .
ns1:DB00661_DB01045	dcterms:title	"DDI between Verapamil and Rifampicin - Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00661 .
ns1:DB00661_DB01072	dcterms:title	"DDI between Verapamil and Atazanavir - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00661 .
ns1:DB00661_DB01076	dcterms:title	"DDI between Verapamil and Atorvastatin - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01076 ,
		ns3:DB00661 .
ns1:DB00661_DB01110	dcterms:title	"DDI between Verapamil and Miconazole - Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01110 ,
		ns3:DB00661 .
ns1:DB00661_DB01118	dcterms:title	"DDI between Verapamil and Amiodarone - Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00661 .
ns1:DB00661_DB01136	dcterms:title	"DDI between Verapamil and Carvedilol - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01136 ,
		ns3:DB00661 .
ns1:DB00661_DB01143	dcterms:title	"DDI between Verapamil and Amifostine - Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01143 ,
		ns3:DB00661 .
ns1:DB00661_DB01149	dcterms:title	"DDI between Verapamil and Nefazodone - Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00661 .
ns1:DB00661_DB01167	dcterms:title	"DDI between Verapamil and Itraconazole - Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00661 .
ns1:DB00661_DB01174	dcterms:title	"DDI between Verapamil and Phenobarbital - Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00661 .
ns1:DB00661_DB01193	dcterms:title	"DDI between Verapamil and Acebutolol - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01193 ,
		ns3:DB00661 .
ns1:DB00661_DB01201	dcterms:title	"DDI between Verapamil and Rifapentine - Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01201 ,
		ns3:DB00661 .
ns1:DB00661_DB01203	dcterms:title	"DDI between Verapamil and Nadolol - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00661 .
ns1:DB00661_DB01211	dcterms:title	"DDI between Verapamil and Clarithromycin - Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00661 .
ns1:DB00661_DB01218	dcterms:title	"DDI between Verapamil and Halofantrine - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB01218 .
ns1:DB00661_DB01223	dcterms:title	"DDI between Verapamil and Aminophylline - Verapamil increases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00661 .
ns1:DB00661_DB01232	dcterms:title	"DDI between Verapamil and Saquinavir - Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00661 .
ns1:DB00661_DB01263	dcterms:title	"DDI between Verapamil and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00661 .
ns1:DB00661_DB01264	dcterms:title	"DDI between Verapamil and Darunavir - Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01264 ,
		ns3:DB00661 .
ns1:DB00661_DB01303	dcterms:title	"DDI between Verapamil and Oxtriphylline - Verapamil increases the effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00661 .
ns1:DB00661_DB01319	dcterms:title	"DDI between Verapamil and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00661 .
ns1:DB00661_DB01351	dcterms:title	"DDI between Verapamil and Amobarbital - Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00661 .
ns1:DB00661_DB01356	dcterms:title	"DDI between Verapamil and Lithium - Signs of lithium toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00661 .
ns1:DB00661_DB01369	dcterms:title	"DDI between Verapamil and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00661 .
ns1:DB00661_DB01394	dcterms:title	"DDI between Verapamil and Colchicine - Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01394 ,
		ns3:DB00661 .
ns1:DB00661_DB01396	dcterms:title	"DDI between Verapamil and Digitoxin - Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01396 ,
		ns3:DB00661 .
ns1:DB00661_DB01558	dcterms:title	"DDI between Verapamil and Bromazepam - Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB00661 .
ns1:DB00661_DB01580	dcterms:title	"DDI between Verapamil and Oxprenolol - Increased effect of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00661 .
ns1:DB00661_DB01590	dcterms:title	"DDI between Verapamil and Everolimus - Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01590 ,
		ns3:DB00661 .
ns1:DB00661_DB01601	dcterms:title	"DDI between Verapamil and Lopinavir - Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00661 .
ns1:DB00661_DB04855	dcterms:title	"DDI between Verapamil and Dronedarone - Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04855 ,
		ns3:DB00661 .
ns1:DB00661_DB05039	dcterms:title	"DDI between Verapamil and Indacaterol - Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05039 ,
		ns3:DB00661 .
ns1:DB00661_DB06207	dcterms:title	"DDI between Verapamil and Silodosin - Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06207 ,
		ns3:DB00661 .
ns1:DB00661_DB06212	dcterms:title	"DDI between Verapamil and Tolvaptan - Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06212 ,
		ns3:DB00661 .
ns1:DB00661_DB06695	dcterms:title	"DDI between Verapamil and Dabigatran etexilate - Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06695 ,
		ns3:DB00661 .
ns1:DB00662_DB00674	dcterms:title	"DDI between Trimethobenzamide and Galantamine - The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00674 ,
		ns3:DB00662 .
ns1:DB00662_DB00679	dcterms:title	"DDI between Trimethobenzamide and Thioridazine - Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00679 ,
		ns3:DB00662 .
ns1:DB00662_DB00725	dcterms:title	"DDI between Trimethobenzamide and Homatropine Methylbromide - Trimethobenzamide and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00725 ,
		ns3:DB00662 .
ns1:DB00662_DB00726	dcterms:title	"DDI between Trimethobenzamide and Trimipramine - Trimethobenzamide and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00662 .
ns1:DB00662_DB00734	dcterms:title	"DDI between Trimethobenzamide and Risperidone - Trimethobenzamide and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00734 ,
		ns3:DB00662 .
ns1:DB00662_DB00737	dcterms:title	"DDI between Trimethobenzamide and Meclizine - Trimethobenzamide and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00737 ,
		ns3:DB00662 .
ns1:DB00662_DB00747	dcterms:title	"DDI between Trimethobenzamide and Scopolamine - Trimethobenzamide and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00747 ,
		ns3:DB00662 .
ns1:DB00662_DB00748	dcterms:title	"DDI between Trimethobenzamide and Carbinoxamine - Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00748 ,
		ns3:DB00662 .
ns1:DB00662_DB00752	dcterms:title	"DDI between Trimethobenzamide and Tranylcypromine - Trimethobenzamide and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB00752 .
ns1:DB00662_DB00761	dcterms:title	"DDI between Trimethobenzamide and Potassium Chloride - The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00761 ,
		ns3:DB00662 .
ns1:DB00662_DB00771	dcterms:title	"DDI between Trimethobenzamide and Clidinium - Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00771 ,
		ns3:DB00662 .
ns1:DB00662_DB00780	dcterms:title	"DDI between Trimethobenzamide and Phenelzine - Trimethobenzamide and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00780 ,
		ns3:DB00662 .
ns1:DB00662_DB00782	dcterms:title	"DDI between Trimethobenzamide and Propantheline - Trimethobenzamide and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00782 ,
		ns3:DB00662 .
ns1:DB00662_DB00804	dcterms:title	"DDI between Trimethobenzamide and Dicyclomine - Trimethobenzamide and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00804 ,
		ns3:DB00662 .
ns1:DB00662_DB00810	dcterms:title	"DDI between Trimethobenzamide and Biperiden - Trimethobenzamide and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00810 ,
		ns3:DB00662 .
ns1:DB00662_DB00831	dcterms:title	"DDI between Trimethobenzamide and Trifluoperazine - Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00831 ,
		ns3:DB00662 .
ns1:DB00662_DB00835	dcterms:title	"DDI between Trimethobenzamide and Brompheniramine - Trimethobenzamide and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00835 ,
		ns3:DB00662 .
ns1:DB00662_DB00843	dcterms:title	"DDI between Trimethobenzamide and Donepezil - The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00843 ,
		ns3:DB00662 .
ns1:DB00662_DB00850	dcterms:title	"DDI between Trimethobenzamide and Perphenazine - Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00850 ,
		ns3:DB00662 .
ns1:DB00662_DB00875	dcterms:title	"DDI between Trimethobenzamide and Flupentixol - Trimethobenzamide and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00875 ,
		ns3:DB00662 .
ns1:DB00662_DB00920	dcterms:title	"DDI between Trimethobenzamide and Ketotifen - Trimethobenzamide and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00920 ,
		ns3:DB00662 .
ns1:DB00662_DB00933	dcterms:title	"DDI between Trimethobenzamide and Mesoridazine - Trimethobenzamide and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00662 .
ns1:DB00662_DB00934	dcterms:title	"DDI between Trimethobenzamide and Maprotiline - Trimethobenzamide and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB00662 .
ns1:DB00662_DB00940	dcterms:title	"DDI between Trimethobenzamide and Methantheline - Trimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00940 ,
		ns3:DB00662 .
ns1:DB00662_DB00950	dcterms:title	"DDI between Trimethobenzamide and Fexofenadine - Trimethobenzamide and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00950 ,
		ns3:DB00662 .
ns1:DB00662_DB00972	dcterms:title	"DDI between Trimethobenzamide and Azelastine - Trimethobenzamide and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00972 ,
		ns3:DB00662 .
ns1:DB00662_DB00985	dcterms:title	"DDI between Trimethobenzamide and Dimenhydrinate - Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00985 ,
		ns3:DB00662 .
ns1:DB00662_DB00986	dcterms:title	"DDI between Trimethobenzamide and Glycopyrrolate - Trimethobenzamide and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00986 ,
		ns3:DB00662 .
ns1:DB00662_DB00989	dcterms:title	"DDI between Trimethobenzamide and Rivastigmine - The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00662 .
ns1:DB00662_DB01036	dcterms:title	"DDI between Trimethobenzamide and Tolterodine - Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01036 .
ns1:DB00662_DB01062	dcterms:title	"DDI between Trimethobenzamide and Oxybutynin - Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01062 ,
		ns3:DB00662 .
ns1:DB00662_DB01063	dcterms:title	"DDI between Trimethobenzamide and Acetophenazine - Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01063 ,
		ns3:DB00662 .
ns1:DB00662_DB01069	dcterms:title	"DDI between Trimethobenzamide and Promethazine - Trimethobenzamide and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01069 ,
		ns3:DB00662 .
ns1:DB00662_DB01075	dcterms:title	"DDI between Trimethobenzamide and Diphenhydramine - Trimethobenzamide and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01075 ,
		ns3:DB00662 .
ns1:DB00662_DB01100	dcterms:title	"DDI between Trimethobenzamide and Pimozide - Trimethobenzamide and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01100 ,
		ns3:DB00662 .
ns1:DB00662_DB01114	dcterms:title	"DDI between Trimethobenzamide and Chlorphenamine - Trimethobenzamide and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01114 ,
		ns3:DB00662 .
ns1:DB00662_DB01142	dcterms:title	"DDI between Trimethobenzamide and Doxepin - Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00662 .
ns1:DB00662_DB01148	dcterms:title	"DDI between Trimethobenzamide and Flavoxate - Trimethobenzamide and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01148 ,
		ns3:DB00662 .
ns1:DB00662_DB01171	dcterms:title	"DDI between Trimethobenzamide and Moclobemide - Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01171 ,
		ns3:DB00662 .
ns1:DB00662_DB01173	dcterms:title	"DDI between Trimethobenzamide and Orphenadrine - Trimethobenzamide and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01173 ,
		ns3:DB00662 .
ns1:DB00662_DB01176	dcterms:title	"DDI between Trimethobenzamide and Cyclizine - Trimethobenzamide and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01176 ,
		ns3:DB00662 .
ns1:DB00662_DB01224	dcterms:title	"DDI between Trimethobenzamide and Quetiapine - Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01224 ,
		ns3:DB00662 .
ns1:DB00662_DB01237	dcterms:title	"DDI between Trimethobenzamide and Bromodiphenhydramine - Trimethobenzamide and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01237 ,
		ns3:DB00662 .
ns1:DB00662_DB01242	dcterms:title	"DDI between Trimethobenzamide and Clomipramine - Trimethobenzamide and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01242 ,
		ns3:DB00662 .
ns1:DB00662_DB01246	dcterms:title	"DDI between Trimethobenzamide and Alimemazine - Trimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01246 ,
		ns3:DB00662 .
ns1:DB00662_DB01247	dcterms:title	"DDI between Trimethobenzamide and Isocarboxazid - Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01247 .
ns1:DB00662_DB01278	dcterms:title	"DDI between Trimethobenzamide and Pramlintide - The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01278 .
ns1:DB00662_DB01409	dcterms:title	"DDI between Trimethobenzamide and Tiotropium - Trimethobenzamide and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01409 .
ns1:DB00662_DB01591	dcterms:title	"DDI between Trimethobenzamide and Solifenacin - Trimethobenzamide and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01591 ,
		ns3:DB00662 .
ns1:DB00662_DB01618	dcterms:title	"DDI between Trimethobenzamide and Molindone - Trimethobenzamide and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01618 ,
		ns3:DB00662 .
ns1:DB00662_DB01619	dcterms:title	"DDI between Trimethobenzamide and Phenindamine - Trimethobenzamide and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01619 ,
		ns3:DB00662 .
ns1:DB00662_DB01623	dcterms:title	"DDI between Trimethobenzamide and Thiothixene - Trimethobenzamide and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01623 .
ns1:DB00662_DB01624	dcterms:title	"DDI between Trimethobenzamide and Zuclopenthixol - Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB01624 .
ns1:DB00662_DB04843	dcterms:title	"DDI between Trimethobenzamide and Mepenzolate - Trimethobenzamide and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04843 ,
		ns3:DB00662 .
ns1:DB00662_DB06153	dcterms:title	"DDI between Trimethobenzamide and Pizotifen - Trimethobenzamide and Pizotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06153 ,
		ns3:DB00662 .
ns1:DB00662_DB08919	dcterms:title	"DDI between Trimethobenzamide and Zuclopenthixol acetate - Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB08919 .
ns1:DB00662_DB08920	dcterms:title	"DDI between Trimethobenzamide and Zuclopenthixol decanoate - Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB08920 .
ns1:DB00668_DB00726	dcterms:title	"DDI between Epinephrine and Trimipramine - Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00726 .
ns1:DB00668_DB00752	dcterms:title	"DDI between Epinephrine and Tranylcypromine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00752 ,
		ns3:DB00668 .
ns1:DB00668_DB00780	dcterms:title	"DDI between Epinephrine and Phenelzine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00780 ,
		ns3:DB00668 .
ns1:DB00668_DB00960	dcterms:title	"DDI between Epinephrine and Pindolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00960 .
ns1:DB00668_DB00968	dcterms:title	"DDI between Epinephrine and Methyldopa - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00968 .
ns1:DB00668_DB01089	dcterms:title	"DDI between Epinephrine and Deserpidine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01089 .
ns1:DB00668_DB01136	dcterms:title	"DDI between Epinephrine and Carvedilol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01136 .
ns1:DB00668_DB01142	dcterms:title	"DDI between Epinephrine and Doxepin - The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01142 .
ns1:DB00668_DB01151	dcterms:title	"DDI between Epinephrine and Desipramine - Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01151 .
ns1:DB00668_DB01170	dcterms:title	"DDI between Epinephrine and Guanethidine - Epinephrine may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01170 .
ns1:DB00668_DB01171	dcterms:title	"DDI between Epinephrine and Moclobemide - Moclobemide increases the sympathomimetic effect of epinephrine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01171 .
ns1:DB00668_DB01193	dcterms:title	"DDI between Epinephrine and Acebutolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01193 .
ns1:DB00668_DB01203	dcterms:title	"DDI between Epinephrine and Nadolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01203 .
ns1:DB00668_DB01242	dcterms:title	"DDI between Epinephrine and Clomipramine - The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of epinephrine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01242 .
ns1:DB00668_DB01247	dcterms:title	"DDI between Epinephrine and Isocarboxazid - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01247 .
ns1:DB00668_DB01253	dcterms:title	"DDI between Epinephrine and Ergonovine - Possible marked increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01253 .
ns1:DB00668_DB01295	dcterms:title	"DDI between Epinephrine and Bevantolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01295 .
ns1:DB00668_DB01297	dcterms:title	"DDI between Epinephrine and Practolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01297 .
ns1:DB00668_DB01359	dcterms:title	"DDI between Epinephrine and Penbutolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01359 .
ns1:DB00668_DB01367	dcterms:title	"DDI between Epinephrine and Rasagiline - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01367 .
ns1:DB00668_DB01580	dcterms:title	"DDI between Epinephrine and Oxprenolol - Hypertension, then bradycardia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01580 .
ns1:DB00668_DB01626	dcterms:title	"DDI between Epinephrine and Pargyline - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB01626 .
ns1:DB00668_DB06700	dcterms:title	"DDI between Epinephrine and Desvenlafaxine - Desvenlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB06700 .
ns1:DB00668_DB08815	dcterms:title	"DDI between Epinephrine and Lurasidone - Epinephrine increases toxicity (enhance hypotensive effects) of lurasidone by pharmacodynamic synergism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08815 ,
		ns3:DB00668 .
ns1:DB00669_DB00696	dcterms:title	"DDI between Sumatriptan and Ergotamine - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00696 ,
		ns3:DB00669 .
ns1:DB00669_DB00715	dcterms:title	"DDI between Sumatriptan and Paroxetine - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00715 ,
		ns3:DB00669 .
ns1:DB00669_DB00726	dcterms:title	"DDI between Sumatriptan and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB00726 .
ns1:DB00669_DB00752	dcterms:title	"DDI between Sumatriptan and Tranylcypromine - The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Sumatriptan. Risk of serotonin syndrome and Sumatriptan toxicity. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB00752 .
ns1:DB00669_DB00780	dcterms:title	"DDI between Sumatriptan and Phenelzine - The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB00780 .
ns1:DB00669_DB01149	dcterms:title	"DDI between Sumatriptan and Nefazodone - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB01149 .
ns1:DB00669_DB01175	dcterms:title	"DDI between Sumatriptan and Escitalopram - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB01175 .
ns1:DB00669_DB01247	dcterms:title	"DDI between Sumatriptan and Isocarboxazid - The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB01247 .
ns1:DB00669_DB01356	dcterms:title	"DDI between Sumatriptan and Lithium - Possible serotoninergic syndrome with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB01356 .
ns1:DB00669_DB06684	dcterms:title	"DDI between Sumatriptan and Vilazodone - Increased risk of serotonin syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB06684 .
ns1:DB00669_DB06700	dcterms:title	"DDI between Sumatriptan and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00669 ,
		ns3:DB06700 .
ns1:DB00909_DB00951	dcterms:title	"DDI between Zonisamide and Isoniazid - Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00909 .
ns1:DB00909_DB00976	dcterms:title	"DDI between Zonisamide and Telithromycin - Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00909 .
ns1:DB00909_DB01026	dcterms:title	"DDI between Zonisamide and Ketoconazole - Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00909 .
ns1:DB00909_DB01072	dcterms:title	"DDI between Zonisamide and Atazanavir - Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00909 .
ns1:DB00909_DB01149	dcterms:title	"DDI between Zonisamide and Nefazodone - Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00909 .
ns1:DB00909_DB01167	dcterms:title	"DDI between Zonisamide and Itraconazole - Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00909 .
ns1:DB00909_DB01194	dcterms:title	"DDI between Zonisamide and Brinzolamide - As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01194 ,
		ns3:DB00909 .
ns1:DB00909_DB01211	dcterms:title	"DDI between Zonisamide and Clarithromycin - Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00909 .
ns1:DB00909_DB01232	dcterms:title	"DDI between Zonisamide and Saquinavir - Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00909 .
ns1:DB00909_DB01263	dcterms:title	"DDI between Zonisamide and Posaconazole - Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00909 .
ns1:DB00909_DB01264	dcterms:title	"DDI between Zonisamide and Darunavir - Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01264 ,
		ns3:DB00909 .
ns1:DB00909_DB01319	dcterms:title	"DDI between Zonisamide and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00909 .
ns1:DB00909_DB01403	dcterms:title	"DDI between Zonisamide and Methotrimeprazine - Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01403 ,
		ns3:DB00909 .
ns1:DB00909_DB01601	dcterms:title	"DDI between Zonisamide and Lopinavir - Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00909 .
ns1:DB00910_DB00930	dcterms:title	"DDI between Paricalcitol and Colesevelam - Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00910 ,
		ns3:DB00930 .
ns1:DB00912_DB00960	dcterms:title	"DDI between Repaglinide and Pindolol - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00912 .
ns1:DB00912_DB00976	dcterms:title	"DDI between Repaglinide and Telithromycin - Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00912 .
ns1:DB00912_DB01045	dcterms:title	"DDI between Repaglinide and Rifampicin - Rifampin decreases the effect of repaglinide"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00912 .
ns1:DB00912_DB01095	dcterms:title	"DDI between Repaglinide and Fluvastatin - Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01095 ,
		ns3:DB00912 .
ns1:DB00912_DB01136	dcterms:title	"DDI between Repaglinide and Carvedilol - The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01136 ,
		ns3:DB00912 .
ns1:DB00912_DB01193	dcterms:title	"DDI between Repaglinide and Acebutolol - Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01193 ,
		ns3:DB00912 .
ns1:DB00912_DB01203	dcterms:title	"DDI between Repaglinide and Nadolol - The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00912 .
ns1:DB00912_DB01211	dcterms:title	"DDI between Repaglinide and Clarithromycin - Clarithromycin may increase the effect of repaglinide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00912 .
ns1:DB00912_DB01241	dcterms:title	"DDI between Repaglinide and Gemfibrozil - Gemfibrozil may increase the effect and toxicity of repaglinide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00912 ,
		ns3:DB01241 .
ns1:DB00912_DB01295	dcterms:title	"DDI between Repaglinide and Bevantolol - The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01295 ,
		ns3:DB00912 .
ns1:DB00912_DB01296	dcterms:title	"DDI between Repaglinide and Glucosamine - Possible hyperglycemia"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00912 ,
		ns3:DB01296 .
ns1:DB00912_DB01297	dcterms:title	"DDI between Repaglinide and Practolol - The beta-blocker, practolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01297 ,
		ns3:DB00912 .
ns1:DB00912_DB01321	dcterms:title	"DDI between Repaglinide and Josamycin - The macrolide, josamycin, may increase the effect of repaglinide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01321 ,
		ns3:DB00912 .
ns1:DB00912_DB01359	dcterms:title	"DDI between Repaglinide and Penbutolol - The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00912 .
ns1:DB00912_DB01580	dcterms:title	"DDI between Repaglinide and Oxprenolol - The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00912 .
ns1:DB00915_DB00989	dcterms:title	"DDI between Amantadine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB00989 .
ns1:DB00915_DB01043	dcterms:title	"DDI between Amantadine and Memantine - Increased risk of CNS adverse effects with this association"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB01043 .
ns1:DB00915_DB01267	dcterms:title	"DDI between Amantadine and Paliperidone - The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, amantadine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01267 ,
		ns3:DB00915 .
ns1:DB00915_DB01623	dcterms:title	"DDI between Amantadine and Thiothixene - Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Amantadine. Consider alternate therapy or monitor for decreased effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB01623 .
ns1:DB00915_DB01624	dcterms:title	"DDI between Amantadine and Zuclopenthixol - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB01624 .
ns1:DB00915_DB08919	dcterms:title	"DDI between Amantadine and Zuclopenthixol acetate - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB08919 .
ns1:DB00915_DB08920	dcterms:title	"DDI between Amantadine and Zuclopenthixol decanoate - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00915 ,
		ns3:DB08920 .
ns1:DB00916_DB01008	dcterms:title	"DDI between Metronidazole and Busulfan - Metronidazole increases the effect/toxicity of busulfan"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01008 ,
		ns3:DB00916 .
ns1:DB00916_DB01036	dcterms:title	"DDI between Metronidazole and Tolterodine - Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00916 .
ns1:DB00916_DB01125	dcterms:title	"DDI between Metronidazole and Anisindione - Metronidazole may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00916 .
ns1:DB00916_DB01174	dcterms:title	"DDI between Metronidazole and Phenobarbital - The barbiturate, phenobarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00916 .
ns1:DB00916_DB01341	dcterms:title	"DDI between Metronidazole and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00916 .
ns1:DB00916_DB01346	dcterms:title	"DDI between Metronidazole and Quinidine barbiturate - The barbiturate, quinidine barbiturate, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00916 .
ns1:DB00916_DB01351	dcterms:title	"DDI between Metronidazole and Amobarbital - The barbiturate, amobarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00916 .
ns1:DB00916_DB01352	dcterms:title	"DDI between Metronidazole and Aprobarbital - The barbiturate, aprobarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00916 .
ns1:DB00916_DB01353	dcterms:title	"DDI between Metronidazole and Butethal - The barbiturate, butethal, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00916 .
ns1:DB00916_DB01354	dcterms:title	"DDI between Metronidazole and Heptabarbital - The barbiturate, heptabarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00916 .
ns1:DB00916_DB01355	dcterms:title	"DDI between Metronidazole and Hexobarbital - The barbiturate, hexobarbital, decreases the effect of metronidazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00916 .
ns1:DB00916_DB01356	dcterms:title	"DDI between Metronidazole and Lithium - Metronidazole increases the effect and toxicity of lithium"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00916 .
ns1:DB00916_DB01418	dcterms:title	"DDI between Metronidazole and Acenocoumarol - Metronidazole may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00916 .
ns1:DB00917_DB01282	dcterms:title	"DDI between Dinoprostone and Carbetocin - Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01282 ,
		ns3:DB00917 .
ns1:DB00918_DB01026	dcterms:title	"DDI between Almotriptan and Ketoconazole - This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00918 .
ns1:DB00918_DB01104	dcterms:title	"DDI between Almotriptan and Sertraline - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00918 ,
		ns3:DB01104 .
ns1:DB00918_DB01105	dcterms:title	"DDI between Almotriptan and Sibutramine - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01105 ,
		ns3:DB00918 .
ns1:DB00918_DB01149	dcterms:title	"DDI between Almotriptan and Nefazodone - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00918 .
ns1:DB00918_DB01167	dcterms:title	"DDI between Almotriptan and Itraconazole - This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00918 .
ns1:DB00918_DB01175	dcterms:title	"DDI between Almotriptan and Escitalopram - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00918 ,
		ns3:DB01175 .
ns1:DB00918_DB01247	dcterms:title	"DDI between Almotriptan and Isocarboxazid - The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00918 ,
		ns3:DB01247 .
ns1:DB00918_DB01253	dcterms:title	"DDI between Almotriptan and Ergonovine - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01253 ,
		ns3:DB00918 .
ns1:DB00918_DB06700	dcterms:title	"DDI between Almotriptan and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00918 .
ns1:DB00921_DB00976	dcterms:title	"DDI between Buprenorphine and Telithromycin - Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB00976 .
ns1:DB00921_DB01037	dcterms:title	"DDI between Buprenorphine and Selegiline - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01037 .
ns1:DB00921_DB01072	dcterms:title	"DDI between Buprenorphine and Atazanavir - Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01072 .
ns1:DB00921_DB01168	dcterms:title	"DDI between Buprenorphine and Procarbazine - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01168 .
ns1:DB00921_DB01171	dcterms:title	"DDI between Buprenorphine and Moclobemide - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01171 .
ns1:DB00921_DB01247	dcterms:title	"DDI between Buprenorphine and Isocarboxazid - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01247 .
ns1:DB00921_DB01367	dcterms:title	"DDI between Buprenorphine and Rasagiline - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB01367 .
ns1:DB00921_DB06274	dcterms:title	"DDI between Buprenorphine and Alvimopan - Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB06274 .
ns1:DB00921_DB06414	dcterms:title	"DDI between Buprenorphine and Etravirine - Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00921 ,
		ns3:DB06414 .
ns1:DB00923_DB00955	dcterms:title	"DDI between Ceforanide and Netilmicin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00923 ,
		ns3:DB00955 .
ns1:DB00924_DB00989	dcterms:title	"DDI between Cyclobenzaprine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00924 .
ns1:DB00924_DB01367	dcterms:title	"DDI between Cyclobenzaprine and Rasagiline - Increased risk of toxicity with this association"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00924 ,
		ns3:DB01367 .
ns1:DB00924_DB05039	dcterms:title	"DDI between Cyclobenzaprine and Indacaterol - Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00924 ,
		ns3:DB05039 .
ns1:DB00926_DB00931	dcterms:title	"DDI between Etretinate and Methacycline - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00926 ,
		ns3:DB00931 .
ns1:DB00926_DB01017	dcterms:title	"DDI between Etretinate and Minocycline - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00926 ,
		ns3:DB01017 .
ns1:DB00926_DB01301	dcterms:title	"DDI between Etretinate and Rolitetracycline - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00926 ,
		ns3:DB01301 .
ns1:DB00927_DB01026	dcterms:title	"DDI between Famotidine and Ketoconazole - The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00927 ,
		ns3:DB01026 .
ns1:DB00927_DB01066	dcterms:title	"DDI between Famotidine and Cefditoren - H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00927 ,
		ns3:DB01066 .
ns1:DB00927_DB01072	dcterms:title	"DDI between Famotidine and Atazanavir - This gastric pH modifier decreases the levels/effects of atazanavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00927 ,
		ns3:DB01072 .
ns1:DB00927_DB01167	dcterms:title	"DDI between Famotidine and Itraconazole - The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00927 ,
		ns3:DB01167 .
ns1:DB00927_DB08864	dcterms:title	"DDI between Famotidine and Rilpivirine - Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00927 ,
		ns3:DB08864 .
ns1:DB00929_DB01282	dcterms:title	"DDI between Misoprostol and Carbetocin - Misoprostol may enhance the therapeutic effect of Carbetocin. Avoid the concomitant use of carbetocin and misoprostol. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00929 ,
		ns3:DB01282 .
ns1:DB00930_DB00939	dcterms:title	"DDI between Colesevelam and Meclofenamic acid - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00939 ,
		ns3:DB00930 .
ns1:DB00930_DB00957	dcterms:title	"DDI between Colesevelam and Norgestimate - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00957 ,
		ns3:DB00930 .
ns1:DB00930_DB00977	dcterms:title	"DDI between Colesevelam and Ethinyl Estradiol - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00930 .
ns1:DB00930_DB00991	dcterms:title	"DDI between Colesevelam and Oxaprozin - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB00930 .
ns1:DB00930_DB01009	dcterms:title	"DDI between Colesevelam and Ketoprofen - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00930 .
ns1:DB00930_DB01016	dcterms:title	"DDI between Colesevelam and Glyburide - Colesevelam may decrease the serum concentration of Glyburide. Glyburide should be administered at least 4 hours before colesevelam to minimize the risk of an interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01016 ,
		ns3:DB00930 .
ns1:DB00930_DB01017	dcterms:title	"DDI between Colesevelam and Minocycline - Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01017 ,
		ns3:DB00930 .
ns1:DB00930_DB01021	dcterms:title	"DDI between Colesevelam and Trichlormethiazide - The bile acid sequestrant, Colesevelam, may inhibit the absorption of Trichlormethiazide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01021 ,
		ns3:DB00930 .
ns1:DB00930_DB01050	dcterms:title	"DDI between Colesevelam and Ibuprofen - Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01050 ,
		ns3:DB00930 .
ns1:DB00930_DB01097	dcterms:title	"DDI between Colesevelam and Leflunomide - Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide. Unless using cholestyramine (or another bile acid sequestrant) together with leflunomide to intentionally enhance the removal/elimination of leflunomide, consider using an alternative to the bile acid sequestrants whenever possible. Separating the administration of these agents is unlikely to be an effective means of avoiding the interaction."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01097 ,
		ns3:DB00930 .
ns1:DB00930_DB01118	dcterms:title	"DDI between Colesevelam and Amiodarone - Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00930 .
ns1:DB00930_DB01132	dcterms:title	"DDI between Colesevelam and Pioglitazone - Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01132 ,
		ns3:DB00930 .
ns1:DB00930_DB01357	dcterms:title	"DDI between Colesevelam and Mestranol - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01357 ,
		ns3:DB00930 .
ns1:DB00930_DB01395	dcterms:title	"DDI between Colesevelam and Drospirenone - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01395 ,
		ns3:DB00930 .
ns1:DB00930_DB01436	dcterms:title	"DDI between Colesevelam and Alfacalcidol - Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01436 ,
		ns3:DB00930 .
ns1:DB00930_DB01586	dcterms:title	"DDI between Colesevelam and Ursodeoxycholic acid - Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01586 ,
		ns3:DB00930 .
ns1:DB00930_DB01600	dcterms:title	"DDI between Colesevelam and Tiaprofenic acid - The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01600 ,
		ns3:DB00930 .
ns1:DB00930_DB06410	dcterms:title	"DDI between Colesevelam and Doxercalciferol - Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00930 ,
		ns3:DB06410 .
ns1:DB00930_DB06713	dcterms:title	"DDI between Colesevelam and Norelgestromin - Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06713 ,
		ns3:DB00930 .
ns1:DB00930_DB06777	dcterms:title	"DDI between Colesevelam and Chenodeoxycholic acid - Bile Acid Sequestrants may decrease the serum concentration of Chenodiol. Consider administration of chenodiol 5 hours or more after bile acid sequestrants to reduce chenodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06777 ,
		ns3:DB00930 .
ns1:DB00931_DB00977	dcterms:title	"DDI between Methacycline and Ethinyl Estradiol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00931 ,
		ns3:DB00977 .
ns1:DB00931_DB00982	dcterms:title	"DDI between Methacycline and Isotretinoin - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00931 ,
		ns3:DB00982 .
ns1:DB00931_DB01053	dcterms:title	"DDI between Methacycline and Benzylpenicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01053 ,
		ns3:DB00931 .
ns1:DB00931_DB01060	dcterms:title	"DDI between Methacycline and Amoxicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01060 ,
		ns3:DB00931 .
ns1:DB00931_DB01147	dcterms:title	"DDI between Methacycline and Cloxacillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01147 ,
		ns3:DB00931 .
ns1:DB00931_DB01373	dcterms:title	"DDI between Methacycline and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01373 ,
		ns3:DB00931 .
ns1:DB00931_DB01378	dcterms:title	"DDI between Methacycline and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01378 ,
		ns3:DB00931 .
ns1:DB00931_DB01604	dcterms:title	"DDI between Methacycline and Pivampicillin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01604 ,
		ns3:DB00931 .
ns1:DB00931_DB01605	dcterms:title	"DDI between Methacycline and Pivmecillinam - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01605 ,
		ns3:DB00931 .
ns1:DB00932_DB00977	dcterms:title	"DDI between Tipranavir and Ethinyl Estradiol - Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB00932 .
ns1:DB00932_DB01023	dcterms:title	"DDI between Tipranavir and Felodipine - Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01023 .
ns1:DB00932_DB01026	dcterms:title	"DDI between Tipranavir and Ketoconazole - Tipranavir may increase the serum concentration of Ketoconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00932 .
ns1:DB00932_DB01045	dcterms:title	"DDI between Tipranavir and Rifampicin - Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00932 .
ns1:DB00932_DB01048	dcterms:title	"DDI between Tipranavir and Abacavir - The serum concentration of Abacavir may be decreased by protease inhibitors such as Tipranavir. The antiviral response should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01048 .
ns1:DB00932_DB01049	dcterms:title	"DDI between Tipranavir and Ergoloid mesylate - Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01049 .
ns1:DB00932_DB01054	dcterms:title	"DDI between Tipranavir and Nitrendipine - Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01054 ,
		ns3:DB00932 .
ns1:DB00932_DB01068	dcterms:title	"DDI between Tipranavir and Clonazepam - Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01068 .
ns1:DB00932_DB01072	dcterms:title	"DDI between Tipranavir and Atazanavir - Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01072 .
ns1:DB00932_DB01076	dcterms:title	"DDI between Tipranavir and Atorvastatin - Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01076 .
ns1:DB00932_DB01098	dcterms:title	"DDI between Tipranavir and Rosuvastatin - Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01098 .
ns1:DB00932_DB01100	dcterms:title	"DDI between Tipranavir and Pimozide - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01100 .
ns1:DB00932_DB01104	dcterms:title	"DDI between Tipranavir and Sertraline - Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00932 .
ns1:DB00932_DB01115	dcterms:title	"DDI between Tipranavir and Nifedipine - Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01115 .
ns1:DB00932_DB01118	dcterms:title	"DDI between Tipranavir and Amiodarone - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01118 .
ns1:DB00932_DB01151	dcterms:title	"DDI between Tipranavir and Desipramine - Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01151 ,
		ns3:DB00932 .
ns1:DB00932_DB01167	dcterms:title	"DDI between Tipranavir and Itraconazole - Tipranavir may increase the serum concentration of Itraconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00932 .
ns1:DB00932_DB01174	dcterms:title	"DDI between Tipranavir and Phenobarbital - Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00932 .
ns1:DB00932_DB01182	dcterms:title	"DDI between Tipranavir and Propafenone - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01182 ,
		ns3:DB00932 .
ns1:DB00932_DB01186	dcterms:title	"DDI between Tipranavir and Pergolide - Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01186 ,
		ns3:DB00932 .
ns1:DB00932_DB01195	dcterms:title	"DDI between Tipranavir and Flecainide - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01195 ,
		ns3:DB00932 .
ns1:DB00932_DB01200	dcterms:title	"DDI between Tipranavir and Bromocriptine - Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01200 ,
		ns3:DB00932 .
ns1:DB00932_DB01201	dcterms:title	"DDI between Tipranavir and Rifapentine - Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01201 ,
		ns3:DB00932 .
ns1:DB00932_DB01211	dcterms:title	"DDI between Tipranavir and Clarithromycin - The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00932 .
ns1:DB00932_DB01215	dcterms:title	"DDI between Tipranavir and Estazolam - Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01215 ,
		ns3:DB00932 .
ns1:DB00932_DB01222	dcterms:title	"DDI between Tipranavir and Budesonide - Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01222 ,
		ns3:DB00932 .
ns1:DB00932_DB01232	dcterms:title	"DDI between Tipranavir and Saquinavir - Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01232 .
ns1:DB00932_DB01244	dcterms:title	"DDI between Tipranavir and Bepridil - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01244 ,
		ns3:DB00932 .
ns1:DB00932_DB01253	dcterms:title	"DDI between Tipranavir and Ergonovine - Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01253 .
ns1:DB00932_DB01263	dcterms:title	"DDI between Tipranavir and Posaconazole - Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01263 .
ns1:DB00932_DB01319	dcterms:title	"DDI between Tipranavir and Fosamprenavir - Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01319 .
ns1:DB00932_DB01323	dcterms:title	"DDI between Tipranavir and St. John's Wort - St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01323 .
ns1:DB00932_DB01357	dcterms:title	"DDI between Tipranavir and Mestranol - Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB01357 .
ns1:DB00932_DB01390	dcterms:title	"DDI between Tipranavir and Sodium bicarbonate - Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01390 ,
		ns3:DB00932 .
ns1:DB00932_DB01558	dcterms:title	"DDI between Tipranavir and Bromazepam - Tipranavir may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if tipranavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB00932 .
ns1:DB00932_DB01588	dcterms:title	"DDI between Tipranavir and Prazepam - Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01588 ,
		ns3:DB00932 .
ns1:DB00932_DB01589	dcterms:title	"DDI between Tipranavir and Quazepam - Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01589 ,
		ns3:DB00932 .
ns1:DB00932_DB01601	dcterms:title	"DDI between Tipranavir and Lopinavir - Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00932 .
ns1:DB00932_DB02703	dcterms:title	"DDI between Tipranavir and Fusidic Acid - Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02703 ,
		ns3:DB00932 .
ns1:DB00932_DB06287	dcterms:title	"DDI between Tipranavir and Temsirolimus - Tipranavir may affect the efficacy/toxicity of Temsirolimus."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB06287 .
ns1:DB00932_DB06414	dcterms:title	"DDI between Tipranavir and Etravirine - Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00932 ,
		ns3:DB06414 .
ns1:DB00932_DB06695	dcterms:title	"DDI between Tipranavir and Dabigatran etexilate - P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06695 ,
		ns3:DB00932 .
ns1:DB00933_DB00934	dcterms:title	"DDI between Mesoridazine and Maprotiline - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00934 .
ns1:DB00933_DB00937	dcterms:title	"DDI between Mesoridazine and Diethylpropion - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00937 .
ns1:DB00933_DB00960	dcterms:title	"DDI between Mesoridazine and Pindolol - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00933 .
ns1:DB00933_DB00989	dcterms:title	"DDI between Mesoridazine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00933 .
ns1:DB00933_DB01035	dcterms:title	"DDI between Mesoridazine and Procainamide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01035 ,
		ns3:DB00933 .
ns1:DB00933_DB01044	dcterms:title	"DDI between Mesoridazine and Gatifloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01044 ,
		ns3:DB00933 .
ns1:DB00933_DB01053	dcterms:title	"DDI between Mesoridazine and Benzylpenicillin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01053 ,
		ns3:DB00933 .
ns1:DB00933_DB01075	dcterms:title	"DDI between Mesoridazine and Diphenhydramine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01075 ,
		ns3:DB00933 .
ns1:DB00933_DB01100	dcterms:title	"DDI between Mesoridazine and Pimozide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01100 ,
		ns3:DB00933 .
ns1:DB00933_DB01118	dcterms:title	"DDI between Mesoridazine and Amiodarone - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00933 .
ns1:DB00933_DB01137	dcterms:title	"DDI between Mesoridazine and Levofloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01137 ,
		ns3:DB00933 .
ns1:DB00933_DB01142	dcterms:title	"DDI between Mesoridazine and Doxepin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01142 ,
		ns3:DB00933 .
ns1:DB00933_DB01158	dcterms:title	"DDI between Mesoridazine and Bretylium - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01158 ,
		ns3:DB00933 .
ns1:DB00933_DB01170	dcterms:title	"DDI between Mesoridazine and Guanethidine - Mesoridazine may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01170 ,
		ns3:DB00933 .
ns1:DB00933_DB01182	dcterms:title	"DDI between Mesoridazine and Propafenone - Increased risk of cardiotoxicity and arrhythmias."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB01182 .
ns1:DB00933_DB01191	dcterms:title	"DDI between Mesoridazine and Dexfenfluramine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01191 ,
		ns3:DB00933 .
ns1:DB00933_DB01195	dcterms:title	"DDI between Mesoridazine and Flecainide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01195 ,
		ns3:DB00933 .
ns1:DB00933_DB01200	dcterms:title	"DDI between Mesoridazine and Bromocriptine - The phenothiazine decreases the effect of bromocriptine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01200 ,
		ns3:DB00933 .
ns1:DB00933_DB01208	dcterms:title	"DDI between Mesoridazine and Sparfloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01208 ,
		ns3:DB00933 .
ns1:DB00933_DB01218	dcterms:title	"DDI between Mesoridazine and Halofantrine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01218 ,
		ns3:DB00933 .
ns1:DB00933_DB01321	dcterms:title	"DDI between Mesoridazine and Josamycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB01321 .
ns1:DB00933_DB01346	dcterms:title	"DDI between Mesoridazine and Quinidine barbiturate - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB01346 .
ns1:DB00933_DB01576	dcterms:title	"DDI between Mesoridazine and Dextroamphetamine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01576 ,
		ns3:DB00933 .
ns1:DB00933_DB01577	dcterms:title	"DDI between Mesoridazine and Methamphetamine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01577 ,
		ns3:DB00933 .
ns1:DB00933_DB01578	dcterms:title	"DDI between Mesoridazine and Metrizamide - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01578 ,
		ns3:DB00933 .
ns1:DB00933_DB01579	dcterms:title	"DDI between Mesoridazine and Phendimetrazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01579 ,
		ns3:DB00933 .
ns1:DB00933_DB01623	dcterms:title	"DDI between Mesoridazine and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB01623 .
ns1:DB00933_DB01624	dcterms:title	"DDI between Mesoridazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB01624 .
ns1:DB00933_DB02546	dcterms:title	"DDI between Mesoridazine and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB02546 .
ns1:DB00933_DB04844	dcterms:title	"DDI between Mesoridazine and Tetrabenazine - May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB00933 .
ns1:DB00933_DB06144	dcterms:title	"DDI between Mesoridazine and Sertindole - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB06144 .
ns1:DB00933_DB06145	dcterms:title	"DDI between Mesoridazine and Spiramycin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB06145 .
ns1:DB00933_DB06697	dcterms:title	"DDI between Mesoridazine and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB06697 .
ns1:DB00933_DB06708	dcterms:title	"DDI between Mesoridazine and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB06708 .
ns1:DB00933_DB08919	dcterms:title	"DDI between Mesoridazine and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB08919 .
ns1:DB00933_DB08920	dcterms:title	"DDI between Mesoridazine and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB08920 .
ns1:DB00934_DB00989	dcterms:title	"DDI between Maprotiline and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB00989 .
ns1:DB00934_DB01623	dcterms:title	"DDI between Maprotiline and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB01623 .
ns1:DB00934_DB01624	dcterms:title	"DDI between Maprotiline and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB01624 .
ns1:DB00934_DB02546	dcterms:title	"DDI between Maprotiline and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB02546 .
ns1:DB00934_DB06697	dcterms:title	"DDI between Maprotiline and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB06697 .
ns1:DB00934_DB06700	dcterms:title	"DDI between Maprotiline and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB06700 .
ns1:DB00934_DB06708	dcterms:title	"DDI between Maprotiline and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB06708 .
ns1:DB00934_DB08919	dcterms:title	"DDI between Maprotiline and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB08919 .
ns1:DB00934_DB08920	dcterms:title	"DDI between Maprotiline and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00934 ,
		ns3:DB08920 .
ns1:DB00937_DB01063	dcterms:title	"DDI between Diethylpropion and Acetophenazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01063 ,
		ns3:DB00937 .
ns1:DB00937_DB01069	dcterms:title	"DDI between Diethylpropion and Promethazine - Decreased anorexic effect, may increase psychotic symptoms."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01069 .
ns1:DB00937_DB01170	dcterms:title	"DDI between Diethylpropion and Guanethidine - Diethylpropion may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01170 .
ns1:DB00937_DB01246	dcterms:title	"DDI between Diethylpropion and Alimemazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01246 .
ns1:DB00937_DB01247	dcterms:title	"DDI between Diethylpropion and Isocarboxazid - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01247 .
ns1:DB00937_DB01367	dcterms:title	"DDI between Diethylpropion and Rasagiline - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01367 .
ns1:DB00937_DB01403	dcterms:title	"DDI between Diethylpropion and Methotrimeprazine - Decreased anorexic effect, may increase psychotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01403 .
ns1:DB00937_DB01608	dcterms:title	"DDI between Diethylpropion and Propericiazine - Decreased anorexic effect, may increase psychotic symptoms."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00937 ,
		ns3:DB01608 .
ns1:DB00938_DB00960	dcterms:title	"DDI between Salmeterol and Pindolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB00960 .
ns1:DB00938_DB00976	dcterms:title	"DDI between Salmeterol and Telithromycin - Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB00976 .
ns1:DB00938_DB01136	dcterms:title	"DDI between Salmeterol and Carvedilol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB01136 .
ns1:DB00938_DB01193	dcterms:title	"DDI between Salmeterol and Acebutolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB01193 .
ns1:DB00938_DB01203	dcterms:title	"DDI between Salmeterol and Nadolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB01203 .
ns1:DB00938_DB01369	dcterms:title	"DDI between Salmeterol and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB01369 .
ns1:DB00938_DB01580	dcterms:title	"DDI between Salmeterol and Oxprenolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB01580 .
ns1:DB00938_DB05039	dcterms:title	"DDI between Salmeterol and Indacaterol - Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00938 ,
		ns3:DB05039 .
ns1:DB00939_DB00966	dcterms:title	"DDI between Meclofenamic acid and Telmisartan - Concomitant use of Telmisartan and Meclofenamic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB00939 .
ns1:DB00939_DB01381	dcterms:title	"DDI between Meclofenamic acid and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00939 .
ns1:DB00939_DB06210	dcterms:title	"DDI between Meclofenamic acid and Eltrombopag - Increases levels of Meclofenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00939 .
ns1:DB00939_DB06813	dcterms:title	"DDI between Meclofenamic acid and Pralatrexate - NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06813 ,
		ns3:DB00939 .
ns1:DB00939_DB08822	dcterms:title	"DDI between Meclofenamic acid and Azilsartan medoxomil - Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08822 ,
		ns3:DB00939 .
ns1:DB00945_DB00959	dcterms:title	"DDI between Acetylsalicylic acid and Methylprednisolone - The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB00959 .
ns1:DB00945_DB00966	dcterms:title	"DDI between Acetylsalicylic acid and Telmisartan - Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB00966 .
ns1:DB00945_DB01009	dcterms:title	"DDI between Acetylsalicylic acid and Ketoprofen - Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01009 .
ns1:DB00945_DB01016	dcterms:title	"DDI between Acetylsalicylic acid and Glyburide - Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01016 .
ns1:DB00945_DB01032	dcterms:title	"DDI between Acetylsalicylic acid and Probenecid - Acetylsalicylic acid decreases the uricosuric effect of probenecid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01032 ,
		ns3:DB00945 .
ns1:DB00945_DB01050	dcterms:title	"DDI between Acetylsalicylic acid and Ibuprofen - Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01050 .
ns1:DB00945_DB01067	dcterms:title	"DDI between Acetylsalicylic acid and Glipizide - Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01067 .
ns1:DB00945_DB01109	dcterms:title	"DDI between Acetylsalicylic acid and Heparin - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01109 .
ns1:DB00945_DB01120	dcterms:title	"DDI between Acetylsalicylic acid and Gliclazide - Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01120 .
ns1:DB00945_DB01124	dcterms:title	"DDI between Acetylsalicylic acid and Tolbutamide - Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01124 .
ns1:DB00945_DB01125	dcterms:title	"DDI between Acetylsalicylic acid and Anisindione - Acetylsalicylic acid increases effect of the anticoagulant, anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01125 .
ns1:DB00945_DB01144	dcterms:title	"DDI between Acetylsalicylic acid and Dichlorphenamide - Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01144 ,
		ns3:DB00945 .
ns1:DB00945_DB01234	dcterms:title	"DDI between Acetylsalicylic acid and Dexamethasone - The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01234 .
ns1:DB00945_DB01289	dcterms:title	"DDI between Acetylsalicylic acid and Glisoxepide - Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01289 .
ns1:DB00945_DB01380	dcterms:title	"DDI between Acetylsalicylic acid and Cortisone acetate - The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01380 .
ns1:DB00945_DB01381	dcterms:title	"DDI between Acetylsalicylic acid and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01381 .
ns1:DB00945_DB01382	dcterms:title	"DDI between Acetylsalicylic acid and Glycodiazine - Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01382 .
ns1:DB00945_DB01384	dcterms:title	"DDI between Acetylsalicylic acid and Paramethasone - The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01384 .
ns1:DB00945_DB01418	dcterms:title	"DDI between Acetylsalicylic acid and Acenocoumarol - Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01418 .
ns1:DB00945_DB01600	dcterms:title	"DDI between Acetylsalicylic acid and Tiaprofenic acid - Increased risk of gastrointestinal bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB01600 .
ns1:DB00945_DB04865	dcterms:title	"DDI between Acetylsalicylic acid and Homoharringtonine - Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB04865 .
ns1:DB00945_DB06210	dcterms:title	"DDI between Acetylsalicylic acid and Eltrombopag - Decreases metabolism, will increase effect/level of eltrombopag."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB06210 .
ns1:DB00945_DB08822	dcterms:title	"DDI between Acetylsalicylic acid and Azilsartan medoxomil - Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB08822 .
ns1:DB00948_DB00977	dcterms:title	"DDI between Mezlocillin and Ethinyl Estradiol - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00948 ,
		ns3:DB00977 .
ns1:DB00948_DB01017	dcterms:title	"DDI between Mezlocillin and Minocycline - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01017 ,
		ns3:DB00948 .
ns1:DB00949_DB00976	dcterms:title	"DDI between Felbamate and Telithromycin - Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00949 ,
		ns3:DB00976 .
ns1:DB00949_DB01174	dcterms:title	"DDI between Felbamate and Phenobarbital - Felbamate increases the effect and toxicity of phenobarbital/primidone"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00949 ,
		ns3:DB01174 .
ns1:DB00949_DB01320	dcterms:title	"DDI between Felbamate and Fosphenytoin - Increased phenytoin levels and decreased felbamate levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00949 ,
		ns3:DB01320 .
ns1:DB00949_DB01369	dcterms:title	"DDI between Felbamate and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00949 ,
		ns3:DB01369 .
ns1:DB00949_DB08867	dcterms:title	"DDI between Felbamate and Ulipristal - Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00949 ,
		ns3:DB08867 .
ns1:DB00951_DB00976	dcterms:title	"DDI between Isoniazid and Telithromycin - Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00976 .
ns1:DB00951_DB01026	dcterms:title	"DDI between Isoniazid and Ketoconazole - Isoniazid decreases the effect of ketoconazole"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB01026 .
ns1:DB00951_DB01036	dcterms:title	"DDI between Isoniazid and Tolterodine - Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00951 .
ns1:DB00951_DB01125	dcterms:title	"DDI between Isoniazid and Anisindione - Isoniazid may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00951 .
ns1:DB00951_DB01198	dcterms:title	"DDI between Isoniazid and Zopiclone - Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01198 ,
		ns3:DB00951 .
ns1:DB00951_DB01219	dcterms:title	"DDI between Isoniazid and Dantrolene - Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01219 ,
		ns3:DB00951 .
ns1:DB00951_DB01223	dcterms:title	"DDI between Isoniazid and Aminophylline - Isoniazid may increase the effect and toxicity of oxtriphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00951 .
ns1:DB00951_DB01303	dcterms:title	"DDI between Isoniazid and Oxtriphylline - Isoniazid may increase the effect and toxicity of oxtriphylline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00951 .
ns1:DB00951_DB01320	dcterms:title	"DDI between Isoniazid and Fosphenytoin - Isoniazid may increase the effect of phenytoin in 20% of patients."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00951 .
ns1:DB00951_DB01418	dcterms:title	"DDI between Isoniazid and Acenocoumarol - Isoniazid may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00951 .
ns1:DB00951_DB01558	dcterms:title	"DDI between Isoniazid and Bromazepam - Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB00951 .
ns1:DB00951_DB06210	dcterms:title	"DDI between Isoniazid and Eltrombopag - Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00951 .
ns1:DB00951_DB06287	dcterms:title	"DDI between Isoniazid and Temsirolimus - Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06287 ,
		ns3:DB00951 .
ns1:DB00952_DB01104	dcterms:title	"DDI between Naratriptan and Sertraline - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00952 .
ns1:DB00952_DB01105	dcterms:title	"DDI between Naratriptan and Sibutramine - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01105 ,
		ns3:DB00952 .
ns1:DB00952_DB01149	dcterms:title	"DDI between Naratriptan and Nefazodone - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00952 .
ns1:DB00952_DB01175	dcterms:title	"DDI between Naratriptan and Escitalopram - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01175 ,
		ns3:DB00952 .
ns1:DB00952_DB01247	dcterms:title	"DDI between Naratriptan and Isocarboxazid - The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00952 ,
		ns3:DB01247 .
ns1:DB00952_DB01253	dcterms:title	"DDI between Naratriptan and Ergonovine - Possible severe and prolonged vasocontriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01253 ,
		ns3:DB00952 .
ns1:DB00952_DB06684	dcterms:title	"DDI between Naratriptan and Vilazodone - Increased risk of serotonin syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06684 ,
		ns3:DB00952 .
ns1:DB00952_DB06700	dcterms:title	"DDI between Naratriptan and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00952 .
ns1:DB00953_DB01149	dcterms:title	"DDI between Rizatriptan and Nefazodone - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00953 .
ns1:DB00953_DB01171	dcterms:title	"DDI between Rizatriptan and Moclobemide - The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01171 ,
		ns3:DB00953 .
ns1:DB00953_DB01175	dcterms:title	"DDI between Rizatriptan and Escitalopram - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01175 ,
		ns3:DB00953 .
ns1:DB00953_DB01247	dcterms:title	"DDI between Rizatriptan and Isocarboxazid - The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00953 ,
		ns3:DB01247 .
ns1:DB00953_DB06700	dcterms:title	"DDI between Rizatriptan and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00953 .
ns1:DB00955_DB01041	dcterms:title	"DDI between Netilmicin and Thalidomide - Thalidomide increases the renal toxicity of the aminoglycoside"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01041 ,
		ns3:DB00955 .
ns1:DB00955_DB01112	dcterms:title	"DDI between Netilmicin and Cefuroxime - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01112 ,
		ns3:DB00955 .
ns1:DB00955_DB01135	dcterms:title	"DDI between Netilmicin and Doxacurium chloride - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01135 .
ns1:DB00955_DB01139	dcterms:title	"DDI between Netilmicin and Cefapirin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01139 ,
		ns3:DB00955 .
ns1:DB00955_DB01199	dcterms:title	"DDI between Netilmicin and Tubocurarine - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01199 .
ns1:DB00955_DB01212	dcterms:title	"DDI between Netilmicin and Ceftriaxone - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01212 .
ns1:DB00955_DB01226	dcterms:title	"DDI between Netilmicin and Mivacurium - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01226 .
ns1:DB00955_DB01326	dcterms:title	"DDI between Netilmicin and Cefamandole - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01326 ,
		ns3:DB00955 .
ns1:DB00955_DB01327	dcterms:title	"DDI between Netilmicin and Cefazolin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01327 ,
		ns3:DB00955 .
ns1:DB00955_DB01328	dcterms:title	"DDI between Netilmicin and Cefonicid - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01328 ,
		ns3:DB00955 .
ns1:DB00955_DB01329	dcterms:title	"DDI between Netilmicin and Cefoperazone - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01329 ,
		ns3:DB00955 .
ns1:DB00955_DB01330	dcterms:title	"DDI between Netilmicin and Cefotetan - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01330 .
ns1:DB00955_DB01331	dcterms:title	"DDI between Netilmicin and Cefoxitin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01331 .
ns1:DB00955_DB01332	dcterms:title	"DDI between Netilmicin and Ceftizoxime - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01332 ,
		ns3:DB00955 .
ns1:DB00955_DB01333	dcterms:title	"DDI between Netilmicin and Cefradine - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01333 ,
		ns3:DB00955 .
ns1:DB00955_DB01336	dcterms:title	"DDI between Netilmicin and Metocurine - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01336 .
ns1:DB00955_DB01337	dcterms:title	"DDI between Netilmicin and Pancuronium - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01337 .
ns1:DB00955_DB01338	dcterms:title	"DDI between Netilmicin and Pipecuronium - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01338 .
ns1:DB00955_DB01339	dcterms:title	"DDI between Netilmicin and Vecuronium - The agent increases the effect of muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB01339 .
ns1:DB00955_DB03450	dcterms:title	"DDI between Netilmicin and Cephalothin Group - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00955 ,
		ns3:DB03450 .
ns1:DB00956_DB06210	dcterms:title	"DDI between Hydrocodone and Eltrombopag - Increases levels of Hydrocodone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00956 .
ns1:DB00956_DB06274	dcterms:title	"DDI between Hydrocodone and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06274 ,
		ns3:DB00956 .
ns1:DB00957_DB06697	dcterms:title	"DDI between Norgestimate and Artemether - Artemether may decrease the effectiveness of norgestimate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00957 .
ns1:DB00958_DB01030	dcterms:title	"DDI between Carboplatin and Topotecan - Administration of Topotecan after Carboplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01030 ,
		ns3:DB00958 .
ns1:DB00958_DB01097	dcterms:title	"DDI between Carboplatin and Leflunomide - Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00958 ,
		ns3:DB01097 .
ns1:DB00958_DB01229	dcterms:title	"DDI between Carboplatin and Paclitaxel - Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01229 ,
		ns3:DB00958 .
ns1:DB00958_DB01248	dcterms:title	"DDI between Carboplatin and Docetaxel - Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01248 ,
		ns3:DB00958 .
ns1:DB00958_DB01320	dcterms:title	"DDI between Carboplatin and Fosphenytoin - The antineoplasic agent decreases the effect of hydantoin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00958 .
ns1:DB00958_DB01656	dcterms:title	"DDI between Carboplatin and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carboplatin. he Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00958 ,
		ns3:DB01656 .
ns1:DB00958_DB06769	dcterms:title	"DDI between Carboplatin and Bendamustine - Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06769 ,
		ns3:DB00958 .
ns1:DB00959_DB01026	dcterms:title	"DDI between Methylprednisolone and Ketoconazole - The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01026 .
ns1:DB00959_DB01045	dcterms:title	"DDI between Methylprednisolone and Rifampicin - The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01045 .
ns1:DB00959_DB01167	dcterms:title	"DDI between Methylprednisolone and Itraconazole - The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00959 .
ns1:DB00959_DB01174	dcterms:title	"DDI between Methylprednisolone and Phenobarbital - The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01174 .
ns1:DB00959_DB01211	dcterms:title	"DDI between Methylprednisolone and Clarithromycin - The macrolide, clarithromycin, may increase the effect of corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01211 .
ns1:DB00959_DB01320	dcterms:title	"DDI between Methylprednisolone and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01320 .
ns1:DB00959_DB01339	dcterms:title	"DDI between Methylprednisolone and Vecuronium - Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01339 .
ns1:DB00959_DB01369	dcterms:title	"DDI between Methylprednisolone and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00959 ,
		ns3:DB01369 .
ns1:DB00960_DB00968	dcterms:title	"DDI between Pindolol and Methyldopa - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00968 .
ns1:DB00960_DB00983	dcterms:title	"DDI between Pindolol and Formoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB00983 .
ns1:DB00960_DB01001	dcterms:title	"DDI between Pindolol and Salbutamol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01001 .
ns1:DB00960_DB01016	dcterms:title	"DDI between Pindolol and Glyburide - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01016 .
ns1:DB00960_DB01050	dcterms:title	"DDI between Pindolol and Ibuprofen - Risk of inhibition of renal prostaglandins"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01050 .
ns1:DB00960_DB01064	dcterms:title	"DDI between Pindolol and Isoprenaline - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01064 .
ns1:DB00960_DB01067	dcterms:title	"DDI between Pindolol and Glipizide - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01067 .
ns1:DB00960_DB01120	dcterms:title	"DDI between Pindolol and Gliclazide - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01120 .
ns1:DB00960_DB01124	dcterms:title	"DDI between Pindolol and Tolbutamide - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01124 .
ns1:DB00960_DB01162	dcterms:title	"DDI between Pindolol and Terazosin - Increased risk of hypotension. Initiate concomitant therapy cautiously."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01162 .
ns1:DB00960_DB01223	dcterms:title	"DDI between Pindolol and Aminophylline - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00960 .
ns1:DB00960_DB01253	dcterms:title	"DDI between Pindolol and Ergonovine - Ischemia with risk of gangrene"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01253 ,
		ns3:DB00960 .
ns1:DB00960_DB01288	dcterms:title	"DDI between Pindolol and Fenoterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01288 .
ns1:DB00960_DB01289	dcterms:title	"DDI between Pindolol and Glisoxepide - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01289 .
ns1:DB00960_DB01291	dcterms:title	"DDI between Pindolol and Pirbuterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01291 .
ns1:DB00960_DB01303	dcterms:title	"DDI between Pindolol and Oxtriphylline - Antagonism of action and increased effect of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00960 .
ns1:DB00960_DB01366	dcterms:title	"DDI between Pindolol and Procaterol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01366 .
ns1:DB00960_DB01382	dcterms:title	"DDI between Pindolol and Glycodiazine - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00960 ,
		ns3:DB01382 .
ns1:DB00962_DB01045	dcterms:title	"DDI between Zaleplon and Rifampicin - Rifampin decreases the effect of zaleplon"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00962 .
ns1:DB00962_DB01403	dcterms:title	"DDI between Zaleplon and Methotrimeprazine - Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01403 ,
		ns3:DB00962 .
ns1:DB00963_DB06210	dcterms:title	"DDI between Bromfenac and Eltrombopag - Eltrombopag increases levels of Bromfenac via metabolism decrease."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00963 .
ns1:DB00963_DB06781	dcterms:title	"DDI between Bromfenac and Difluprednate - NSAIDs may slow healing."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06781 ,
		ns3:DB00963 .
ns1:DB00966_DB00991	dcterms:title	"DDI between Telmisartan and Oxaprozin - Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB00966 .
ns1:DB00966_DB01009	dcterms:title	"DDI between Telmisartan and Ketoprofen - Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00966 .
ns1:DB00966_DB01143	dcterms:title	"DDI between Telmisartan and Amifostine - Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB01143 .
ns1:DB00966_DB01283	dcterms:title	"DDI between Telmisartan and Lumiracoxib - Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB01283 .
ns1:DB00966_DB01345	dcterms:title	"DDI between Telmisartan and Potassium - Potassium may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB01345 .
ns1:DB00966_DB01356	dcterms:title	"DDI between Telmisartan and Lithium - Telmisartan may increase serum Lithium concentrations. Monitor serum Lithium levels during concomitant therapy to avoid Lithium toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB01356 .
ns1:DB00966_DB01395	dcterms:title	"DDI between Telmisartan and Drospirenone - Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00966 ,
		ns3:DB01395 .
ns1:DB00966_DB01600	dcterms:title	"DDI between Telmisartan and Tiaprofenic acid - Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01600 ,
		ns3:DB00966 .
ns1:DB00968_DB00988	dcterms:title	"DDI between Methyldopa and Dopamine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB00968 .
ns1:DB00968_DB01001	dcterms:title	"DDI between Methyldopa and Salbutamol - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01001 ,
		ns3:DB00968 .
ns1:DB00968_DB01064	dcterms:title	"DDI between Methyldopa and Isoprenaline - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01064 ,
		ns3:DB00968 .
ns1:DB00968_DB01203	dcterms:title	"DDI between Methyldopa and Nadolol - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00968 .
ns1:DB00968_DB01235	dcterms:title	"DDI between Methyldopa and L-DOPA - Methyldopa increases the effect and toxicity of levodopa"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00968 ,
		ns3:DB01235 .
ns1:DB00968_DB01288	dcterms:title	"DDI between Methyldopa and Fenoterol - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01288 ,
		ns3:DB00968 .
ns1:DB00968_DB01291	dcterms:title	"DDI between Methyldopa and Pirbuterol - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01291 ,
		ns3:DB00968 .
ns1:DB00968_DB01356	dcterms:title	"DDI between Methyldopa and Lithium - Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00968 .
ns1:DB00968_DB01359	dcterms:title	"DDI between Methyldopa and Penbutolol - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00968 .
ns1:DB00968_DB01363	dcterms:title	"DDI between Methyldopa and Ephedra - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01363 ,
		ns3:DB00968 .
ns1:DB00968_DB01364	dcterms:title	"DDI between Methyldopa and Ephedrine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01364 ,
		ns3:DB00968 .
ns1:DB00968_DB01365	dcterms:title	"DDI between Methyldopa and Mephentermine - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01365 ,
		ns3:DB00968 .
ns1:DB00968_DB01366	dcterms:title	"DDI between Methyldopa and Procaterol - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01366 ,
		ns3:DB00968 .
ns1:DB00968_DB01580	dcterms:title	"DDI between Methyldopa and Oxprenolol - Possible hypertensive crisis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00968 .
ns1:DB00968_DB01592	dcterms:title	"DDI between Methyldopa and Iron - Iron decreases the absorption of dopa derivatives"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01592 ,
		ns3:DB00968 .
ns1:DB00971_DB06210	dcterms:title	"DDI between Selenium Sulfide and Eltrombopag - Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06210 ,
		ns3:DB00971 .
ns1:DB00972_DB01551	dcterms:title	"DDI between Azelastine and Dihydrocodeine - Enhanced CNS depressant effects contraindicates concurrent use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00972 .
ns1:DB00972_DB08872	dcterms:title	"DDI between Azelastine and gabapentin enacarbil - Avoid combination due to increased CNS depression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00972 ,
		ns3:DB08872 .
ns1:DB00972_DB08883	dcterms:title	"DDI between Azelastine and Perampanel - Avoid combination with azelastine or other CNS depressants due to the combined increase of CNS depression."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00972 ,
		ns3:DB08883 .
ns1:DB00973_DB01432	dcterms:title	"DDI between Ezetimibe and Cholestyramine - Cholestyramine may decrease the levels of ezetimibe."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00973 ,
		ns3:DB01432 .
ns1:DB00975_DB01030	dcterms:title	"DDI between Dipyridamole and Topotecan - The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01030 ,
		ns3:DB00975 .
ns1:DB00975_DB01073	dcterms:title	"DDI between Dipyridamole and Fludarabine - Dipyridamole may decrease the effect of fludarabine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01073 ,
		ns3:DB00975 .
ns1:DB00975_DB01381	dcterms:title	"DDI between Dipyridamole and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00975 .
ns1:DB00975_DB06213	dcterms:title	"DDI between Dipyridamole and Regadenoson - Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06213 ,
		ns3:DB00975 .
ns1:DB00976_DB00997	dcterms:title	"DDI between Telithromycin and Doxorubicin - Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00997 ,
		ns3:DB00976 .
ns1:DB00976_DB01008	dcterms:title	"DDI between Telithromycin and Busulfan - Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01008 .
ns1:DB00976_DB01012	dcterms:title	"DDI between Telithromycin and Cinacalcet - Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01012 .
ns1:DB00976_DB01020	dcterms:title	"DDI between Telithromycin and Isosorbide Mononitrate - Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01020 .
ns1:DB00976_DB01023	dcterms:title	"DDI between Telithromycin and Felodipine - Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01023 .
ns1:DB00976_DB01026	dcterms:title	"DDI between Telithromycin and Ketoconazole - Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00976 .
ns1:DB00976_DB01036	dcterms:title	"DDI between Telithromycin and Tolterodine - Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00976 .
ns1:DB00976_DB01045	dcterms:title	"DDI between Telithromycin and Rifampicin - Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01045 .
ns1:DB00976_DB01049	dcterms:title	"DDI between Telithromycin and Ergoloid mesylate - Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01049 .
ns1:DB00976_DB01054	dcterms:title	"DDI between Telithromycin and Nitrendipine - Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01054 .
ns1:DB00976_DB01058	dcterms:title	"DDI between Telithromycin and Praziquantel - Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01058 .
ns1:DB00976_DB01068	dcterms:title	"DDI between Telithromycin and Clonazepam - Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01068 .
ns1:DB00976_DB01072	dcterms:title	"DDI between Telithromycin and Atazanavir - Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01072 .
ns1:DB00976_DB01076	dcterms:title	"DDI between Telithromycin and Atorvastatin - The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01076 .
ns1:DB00976_DB01100	dcterms:title	"DDI between Telithromycin and Pimozide - Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01100 .
ns1:DB00976_DB01105	dcterms:title	"DDI between Telithromycin and Sibutramine - Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01105 .
ns1:DB00976_DB01110	dcterms:title	"DDI between Telithromycin and Miconazole - Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01110 .
ns1:DB00976_DB01114	dcterms:title	"DDI between Telithromycin and Chlorphenamine - Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01114 .
ns1:DB00976_DB01115	dcterms:title	"DDI between Telithromycin and Nifedipine - Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01115 .
ns1:DB00976_DB01118	dcterms:title	"DDI between Telithromycin and Amiodarone - Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01118 ,
		ns3:DB00976 .
ns1:DB00976_DB01125	dcterms:title	"DDI between Telithromycin and Anisindione - Telithromycin may increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01125 .
ns1:DB00976_DB01142	dcterms:title	"DDI between Telithromycin and Doxepin - Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01142 .
ns1:DB00976_DB01149	dcterms:title	"DDI between Telithromycin and Nefazodone - Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00976 .
ns1:DB00976_DB01158	dcterms:title	"DDI between Telithromycin and Bretylium - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01158 .
ns1:DB00976_DB01166	dcterms:title	"DDI between Telithromycin and Cilostazol - Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01166 .
ns1:DB00976_DB01167	dcterms:title	"DDI between Telithromycin and Itraconazole - Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00976 .
ns1:DB00976_DB01174	dcterms:title	"DDI between Telithromycin and Phenobarbital - Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00976 .
ns1:DB00976_DB01175	dcterms:title	"DDI between Telithromycin and Escitalopram - Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01175 .
ns1:DB00976_DB01181	dcterms:title	"DDI between Telithromycin and Ifosfamide - Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01181 .
ns1:DB00976_DB01186	dcterms:title	"DDI between Telithromycin and Pergolide - Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01186 .
ns1:DB00976_DB01198	dcterms:title	"DDI between Telithromycin and Zopiclone - Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01198 .
ns1:DB00976_DB01200	dcterms:title	"DDI between Telithromycin and Bromocriptine - Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01200 .
ns1:DB00976_DB01201	dcterms:title	"DDI between Telithromycin and Rifapentine - Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01201 .
ns1:DB00976_DB01211	dcterms:title	"DDI between Telithromycin and Clarithromycin - Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00976 .
ns1:DB00976_DB01218	dcterms:title	"DDI between Telithromycin and Halofantrine - Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01218 .
ns1:DB00976_DB01219	dcterms:title	"DDI between Telithromycin and Dantrolene - Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01219 .
ns1:DB00976_DB01221	dcterms:title	"DDI between Telithromycin and Ketamine - Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01221 .
ns1:DB00976_DB01222	dcterms:title	"DDI between Telithromycin and Budesonide - Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01222 .
ns1:DB00976_DB01224	dcterms:title	"DDI between Telithromycin and Quetiapine - Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01224 .
ns1:DB00976_DB01229	dcterms:title	"DDI between Telithromycin and Paclitaxel - Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01229 ,
		ns3:DB00976 .
ns1:DB00976_DB01232	dcterms:title	"DDI between Telithromycin and Saquinavir - Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00976 .
ns1:DB00976_DB01234	dcterms:title	"DDI between Telithromycin and Dexamethasone - Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01234 ,
		ns3:DB00976 .
ns1:DB00976_DB01238	dcterms:title	"DDI between Telithromycin and Aripiprazole - Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01238 .
ns1:DB00976_DB01248	dcterms:title	"DDI between Telithromycin and Docetaxel - Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01248 .
ns1:DB00976_DB01253	dcterms:title	"DDI between Telithromycin and Ergonovine - Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01253 .
ns1:DB00976_DB01254	dcterms:title	"DDI between Telithromycin and Dasatinib - Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01254 .
ns1:DB00976_DB01259	dcterms:title	"DDI between Telithromycin and Lapatinib - Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01259 .
ns1:DB00976_DB01263	dcterms:title	"DDI between Telithromycin and Posaconazole - Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01263 .
ns1:DB00976_DB01264	dcterms:title	"DDI between Telithromycin and Darunavir - Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01264 .
ns1:DB00976_DB01268	dcterms:title	"DDI between Telithromycin and Sunitinib - Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01268 .
ns1:DB00976_DB01319	dcterms:title	"DDI between Telithromycin and Fosamprenavir - Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01319 .
ns1:DB00976_DB01320	dcterms:title	"DDI between Telithromycin and Fosphenytoin - Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01320 .
ns1:DB00976_DB01346	dcterms:title	"DDI between Telithromycin and Quinidine barbiturate - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01346 .
ns1:DB00976_DB01394	dcterms:title	"DDI between Telithromycin and Colchicine - Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01394 .
ns1:DB00976_DB01396	dcterms:title	"DDI between Telithromycin and Digitoxin - Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01396 .
ns1:DB00976_DB01410	dcterms:title	"DDI between Telithromycin and Ciclesonide - Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01410 .
ns1:DB00976_DB01418	dcterms:title	"DDI between Telithromycin and Acenocoumarol - Telithromycin may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01418 .
ns1:DB00976_DB01558	dcterms:title	"DDI between Telithromycin and Bromazepam - Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01558 .
ns1:DB00976_DB01591	dcterms:title	"DDI between Telithromycin and Solifenacin - Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01591 .
ns1:DB00976_DB01601	dcterms:title	"DDI between Telithromycin and Lopinavir - Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01601 .
ns1:DB00976_DB01621	dcterms:title	"DDI between Telithromycin and Pipotiazine - Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB01621 .
ns1:DB00976_DB01623	dcterms:title	"DDI between Telithromycin and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB00976 .
ns1:DB00976_DB01624	dcterms:title	"DDI between Telithromycin and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB00976 .
ns1:DB00976_DB02546	dcterms:title	"DDI between Telithromycin and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02546 ,
		ns3:DB00976 .
ns1:DB00976_DB03575	dcterms:title	"DDI between Telithromycin and Phencyclidine - Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB03575 .
ns1:DB00976_DB04835	dcterms:title	"DDI between Telithromycin and Maraviroc - Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB04835 .
ns1:DB00976_DB04844	dcterms:title	"DDI between Telithromycin and Tetrabenazine - Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB04844 .
ns1:DB00976_DB04845	dcterms:title	"DDI between Telithromycin and Ixabepilone - Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB04845 .
ns1:DB00976_DB04855	dcterms:title	"DDI between Telithromycin and Dronedarone - Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04855 ,
		ns3:DB00976 .
ns1:DB00976_DB04868	dcterms:title	"DDI between Telithromycin and Nilotinib - Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB04868 .
ns1:DB00976_DB05331	dcterms:title	"DDI between Telithromycin and doxorubicin TransDrug - Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB05331 .
ns1:DB00976_DB05812	dcterms:title	"DDI between Telithromycin and Abiraterone - Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB05812 .
ns1:DB00976_DB06145	dcterms:title	"DDI between Telithromycin and Spiramycin - Telithromycin may reduce clearance of Spiramycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Spiramycin if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06145 .
ns1:DB00976_DB06228	dcterms:title	"DDI between Telithromycin and Rivaroxaban - Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06228 .
ns1:DB00976_DB06287	dcterms:title	"DDI between Telithromycin and Temsirolimus - Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06287 .
ns1:DB00976_DB06403	dcterms:title	"DDI between Telithromycin and ambrisentan - Telithromycin may reduce clearance of Ambrisentan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ambrisentan if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06403 .
ns1:DB00976_DB06413	dcterms:title	"DDI between Telithromycin and armodafinil - Telithromycin may reduce clearance of Armodafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Armodafinil if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06413 .
ns1:DB00976_DB06697	dcterms:title	"DDI between Telithromycin and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB00976 .
ns1:DB00976_DB06708	dcterms:title	"DDI between Telithromycin and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB00976 .
ns1:DB00976_DB06772	dcterms:title	"DDI between Telithromycin and Cabazitaxel - Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB06772 .
ns1:DB00976_DB08820	dcterms:title	"DDI between Telithromycin and Ivacaftor - Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB08820 .
ns1:DB00976_DB08881	dcterms:title	"DDI between Telithromycin and Vemurafenib - Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB08881 .
ns1:DB00976_DB08896	dcterms:title	"DDI between Telithromycin and Regorafenib - Strong CYP3A4 inhibitors may increase levels of regorafenib."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB08896 .
ns1:DB00976_DB08901	dcterms:title	"DDI between Telithromycin and Ponatinib  - Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB08901 .
ns1:DB00976_DB08919	dcterms:title	"DDI between Telithromycin and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08919 ,
		ns3:DB00976 .
ns1:DB00976_DB08920	dcterms:title	"DDI between Telithromycin and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08920 ,
		ns3:DB00976 .
ns1:DB00977_DB01000	dcterms:title	"DDI between Ethinyl Estradiol and Cyclacillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01000 .
ns1:DB00977_DB01017	dcterms:title	"DDI between Ethinyl Estradiol and Minocycline - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01017 .
ns1:DB00977_DB01026	dcterms:title	"DDI between Ethinyl Estradiol and Ketoconazole - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01026 .
ns1:DB00977_DB01045	dcterms:title	"DDI between Ethinyl Estradiol and Rifampicin - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01045 .
ns1:DB00977_DB01060	dcterms:title	"DDI between Ethinyl Estradiol and Amoxicillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01060 .
ns1:DB00977_DB01061	dcterms:title	"DDI between Ethinyl Estradiol and Azlocillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01061 .
ns1:DB00977_DB01125	dcterms:title	"DDI between Ethinyl Estradiol and Anisindione - Increased thrombotic risk due to estrogen"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01125 .
ns1:DB00977_DB01147	dcterms:title	"DDI between Ethinyl Estradiol and Cloxacillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01147 .
ns1:DB00977_DB01174	dcterms:title	"DDI between Ethinyl Estradiol and Phenobarbital - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00977 .
ns1:DB00977_DB01201	dcterms:title	"DDI between Ethinyl Estradiol and Rifapentine - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01201 .
ns1:DB00977_DB01223	dcterms:title	"DDI between Ethinyl Estradiol and Aminophylline - The contraceptive increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00977 .
ns1:DB00977_DB01301	dcterms:title	"DDI between Ethinyl Estradiol and Rolitetracycline - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01301 .
ns1:DB00977_DB01303	dcterms:title	"DDI between Ethinyl Estradiol and Oxtriphylline - The contraceptive increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00977 .
ns1:DB00977_DB01320	dcterms:title	"DDI between Ethinyl Estradiol and Fosphenytoin - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01320 .
ns1:DB00977_DB01323	dcterms:title	"DDI between Ethinyl Estradiol and St. John's Wort - St. John's Wort could reduce the contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01323 .
ns1:DB00977_DB01351	dcterms:title	"DDI between Ethinyl Estradiol and Amobarbital - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01351 .
ns1:DB00977_DB01352	dcterms:title	"DDI between Ethinyl Estradiol and Aprobarbital - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01352 .
ns1:DB00977_DB01353	dcterms:title	"DDI between Ethinyl Estradiol and Butethal - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01353 .
ns1:DB00977_DB01354	dcterms:title	"DDI between Ethinyl Estradiol and Heptabarbital - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01354 .
ns1:DB00977_DB01355	dcterms:title	"DDI between Ethinyl Estradiol and Hexobarbital - This product may cause a slight decrease of contraceptive effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01355 .
ns1:DB00977_DB01418	dcterms:title	"DDI between Ethinyl Estradiol and Acenocoumarol - Increased thrombotic risk due to estrogen"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01418 .
ns1:DB00977_DB01586	dcterms:title	"DDI between Ethinyl Estradiol and Ursodeoxycholic acid - Estrogens decreases the effect of ursodiol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01586 .
ns1:DB00977_DB01602	dcterms:title	"DDI between Ethinyl Estradiol and Bacampicillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01602 .
ns1:DB00977_DB01603	dcterms:title	"DDI between Ethinyl Estradiol and Meticillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01603 .
ns1:DB00977_DB01604	dcterms:title	"DDI between Ethinyl Estradiol and Pivampicillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01604 .
ns1:DB00977_DB01606	dcterms:title	"DDI between Ethinyl Estradiol and Tazobactam - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01606 .
ns1:DB00977_DB01607	dcterms:title	"DDI between Ethinyl Estradiol and Ticarcillin - This anti-infectious agent could decrease the effect of the oral contraceptive"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01607 .
ns1:DB00977_DB01628	dcterms:title	"DDI between Ethinyl Estradiol and Etoricoxib - Etoricoxib may increase the levels of ethinyl estradiol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB01628 .
ns1:DB00977_DB06201	dcterms:title	"DDI between Ethinyl Estradiol and Rufinamide - Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB06201 .
ns1:DB00977_DB06210	dcterms:title	"DDI between Ethinyl Estradiol and Eltrombopag - Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB06210 .
ns1:DB00977_DB06697	dcterms:title	"DDI between Ethinyl Estradiol and Artemether - Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB06697 .
ns1:DB00977_DB06769	dcterms:title	"DDI between Ethinyl Estradiol and Bendamustine - Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00977 ,
		ns3:DB06769 .
ns1:DB00978_DB01373	dcterms:title	"DDI between Lomefloxacin and Calcium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01373 ,
		ns3:DB00978 .
ns1:DB00978_DB01378	dcterms:title	"DDI between Lomefloxacin and Magnesium - Formation of non-absorbable complexes"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01378 ,
		ns3:DB00978 .
ns1:DB00980_DB01026	dcterms:title	"DDI between Ramelteon and Ketoconazole - Ketoconazole may increase the serum levels and toxicity of ramelteon."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00980 .
ns1:DB00980_DB01045	dcterms:title	"DDI between Ramelteon and Rifampicin - Rifampin reduces the levels/effect of ramelteon"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00980 .
ns1:DB00980_DB01072	dcterms:title	"DDI between Ramelteon and Atazanavir - Atazanavir increases levels/toxicity of ramelteon"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00980 .
ns1:DB00982_DB01017	dcterms:title	"DDI between Isotretinoin and Minocycline - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01017 ,
		ns3:DB00982 .
ns1:DB00982_DB01301	dcterms:title	"DDI between Isotretinoin and Rolitetracycline - Increased risk of intracranial hypertension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01301 ,
		ns3:DB00982 .
ns1:DB00983_DB01136	dcterms:title	"DDI between Formoterol and Carvedilol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01136 ,
		ns3:DB00983 .
ns1:DB00983_DB01193	dcterms:title	"DDI between Formoterol and Acebutolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01193 ,
		ns3:DB00983 .
ns1:DB00983_DB01203	dcterms:title	"DDI between Formoterol and Nadolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01203 ,
		ns3:DB00983 .
ns1:DB00983_DB01295	dcterms:title	"DDI between Formoterol and Bevantolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01295 ,
		ns3:DB00983 .
ns1:DB00983_DB01297	dcterms:title	"DDI between Formoterol and Practolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01297 ,
		ns3:DB00983 .
ns1:DB00983_DB01359	dcterms:title	"DDI between Formoterol and Penbutolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01359 ,
		ns3:DB00983 .
ns1:DB00983_DB01580	dcterms:title	"DDI between Formoterol and Oxprenolol - Antagonism"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01580 ,
		ns3:DB00983 .
ns1:DB00983_DB05039	dcterms:title	"DDI between Formoterol and Indacaterol - Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00983 ,
		ns3:DB05039 .
ns1:DB00985_DB00989	dcterms:title	"DDI between Dimenhydrinate and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00985 .
ns1:DB00986_DB00989	dcterms:title	"DDI between Glycopyrrolate and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00986 .
ns1:DB00988_DB01142	dcterms:title	"DDI between Dopamine and Doxepin - The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01142 .
ns1:DB00988_DB01151	dcterms:title	"DDI between Dopamine and Desipramine - The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dopamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01151 .
ns1:DB00988_DB01170	dcterms:title	"DDI between Dopamine and Guanethidine - Dopamine may decrease the effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01170 .
ns1:DB00988_DB01171	dcterms:title	"DDI between Dopamine and Moclobemide - Moclobemide increases the sympathomimetic effect of dopamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01171 .
ns1:DB00988_DB01242	dcterms:title	"DDI between Dopamine and Clomipramine - The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dopamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01242 .
ns1:DB00988_DB01247	dcterms:title	"DDI between Dopamine and Isocarboxazid - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01247 .
ns1:DB00988_DB01320	dcterms:title	"DDI between Dopamine and Fosphenytoin - Risk of severe hypotension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01320 .
ns1:DB00988_DB01367	dcterms:title	"DDI between Dopamine and Rasagiline - Increased arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB01367 .
ns1:DB00988_DB08815	dcterms:title	"DDI between Dopamine and Lurasidone - Dopamine increases toxicity (enhanced hypotensive effects) of lurasidone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB08815 .
ns1:DB00989_DB01035	dcterms:title	"DDI between Rivastigmine and Procainamide - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01035 .
ns1:DB00989_DB01062	dcterms:title	"DDI between Rivastigmine and Oxybutynin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01062 ,
		ns3:DB00989 .
ns1:DB00989_DB01069	dcterms:title	"DDI between Rivastigmine and Promethazine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01069 ,
		ns3:DB00989 .
ns1:DB00989_DB01075	dcterms:title	"DDI between Rivastigmine and Diphenhydramine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01075 ,
		ns3:DB00989 .
ns1:DB00989_DB01100	dcterms:title	"DDI between Rivastigmine and Pimozide - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01100 ,
		ns3:DB00989 .
ns1:DB00989_DB01114	dcterms:title	"DDI between Rivastigmine and Chlorphenamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01114 .
ns1:DB00989_DB01142	dcterms:title	"DDI between Rivastigmine and Doxepin - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01142 .
ns1:DB00989_DB01148	dcterms:title	"DDI between Rivastigmine and Flavoxate - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01148 .
ns1:DB00989_DB01151	dcterms:title	"DDI between Rivastigmine and Desipramine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01151 .
ns1:DB00989_DB01171	dcterms:title	"DDI between Rivastigmine and Moclobemide - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01171 .
ns1:DB00989_DB01173	dcterms:title	"DDI between Rivastigmine and Orphenadrine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01173 .
ns1:DB00989_DB01176	dcterms:title	"DDI between Rivastigmine and Cyclizine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01176 .
ns1:DB00989_DB01224	dcterms:title	"DDI between Rivastigmine and Quetiapine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01224 .
ns1:DB00989_DB01239	dcterms:title	"DDI between Rivastigmine and Chlorprothixene - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01239 .
ns1:DB00989_DB01242	dcterms:title	"DDI between Rivastigmine and Clomipramine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01242 .
ns1:DB00989_DB01247	dcterms:title	"DDI between Rivastigmine and Isocarboxazid - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01247 .
ns1:DB00989_DB01403	dcterms:title	"DDI between Rivastigmine and Methotrimeprazine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01403 .
ns1:DB00989_DB01437	dcterms:title	"DDI between Rivastigmine and Glutethimide - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01437 .
ns1:DB00989_DB01608	dcterms:title	"DDI between Rivastigmine and Propericiazine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01608 .
ns1:DB00989_DB01622	dcterms:title	"DDI between Rivastigmine and Thioproperazine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB01622 .
ns1:DB00990_DB06414	dcterms:title	"DDI between Exemestane and Etravirine - Exemestane, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dosage of exemestane and to closely monitor therapy for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB00990 .
ns1:DB00991_DB01125	dcterms:title	"DDI between Oxaprozin and Anisindione - The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB01125 .
ns1:DB00991_DB01381	dcterms:title	"DDI between Oxaprozin and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB01381 .
ns1:DB00991_DB01418	dcterms:title	"DDI between Oxaprozin and Acenocoumarol - The NSAID, oxaprozin, may increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB01418 .
ns1:DB00991_DB06813	dcterms:title	"DDI between Oxaprozin and Pralatrexate - NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB06813 .
ns1:DB00991_DB08822	dcterms:title	"DDI between Oxaprozin and Azilsartan medoxomil - Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00991 ,
		ns3:DB08822 .
ns1:DB00993_DB01125	dcterms:title	"DDI between Azathioprine and Anisindione - Azathioprine may decrease the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01125 .
ns1:DB00993_DB01135	dcterms:title	"DDI between Azathioprine and Doxacurium chloride - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01135 .
ns1:DB00993_DB01199	dcterms:title	"DDI between Azathioprine and Tubocurarine - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01199 .
ns1:DB00993_DB01226	dcterms:title	"DDI between Azathioprine and Mivacurium - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01226 .
ns1:DB00993_DB01250	dcterms:title	"DDI between Azathioprine and Olsalazine - Olsalazine may increase the toxicity of thiopurine, azathioprine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01250 .
ns1:DB00993_DB01336	dcterms:title	"DDI between Azathioprine and Metocurine - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01336 .
ns1:DB00993_DB01337	dcterms:title	"DDI between Azathioprine and Pancuronium - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01337 .
ns1:DB00993_DB01339	dcterms:title	"DDI between Azathioprine and Vecuronium - The agent decreases the effect of the muscle relaxant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01339 .
ns1:DB00993_DB01418	dcterms:title	"DDI between Azathioprine and Acenocoumarol - Azathioprine may decrease the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB01418 .
ns1:DB00993_DB04854	dcterms:title	"DDI between Azathioprine and Febuxostat - Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB04854 .
ns1:DB00993_DB06168	dcterms:title	"DDI between Azathioprine and Canakinumab - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB06168 .
ns1:DB00993_DB06372	dcterms:title	"DDI between Azathioprine and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00993 ,
		ns3:DB06372 .
ns1:DB00994_DB01111	dcterms:title	"DDI between Neomycin and Colistimethate - Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01111 ,
		ns3:DB00994 .
ns1:DB00994_DB01212	dcterms:title	"DDI between Neomycin and Ceftriaxone - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00994 ,
		ns3:DB01212 .
ns1:DB00994_DB01330	dcterms:title	"DDI between Neomycin and Cefotetan - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00994 ,
		ns3:DB01330 .
ns1:DB00994_DB01331	dcterms:title	"DDI between Neomycin and Cefoxitin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00994 ,
		ns3:DB01331 .
ns1:DB00994_DB01607	dcterms:title	"DDI between Neomycin and Ticarcillin - Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00994 ,
		ns3:DB01607 .
ns1:DB00996_DB01320	dcterms:title	"DDI between Gabapentin and Fosphenytoin - Gabapentin may increase the effect of fosphenytoin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00996 ,
		ns3:DB01320 .
ns1:DB00997_DB06695	dcterms:title	"DDI between Doxorubicin and Dabigatran etexilate - P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06695 ,
		ns3:DB00997 .
ns1:DB00998_DB01104	dcterms:title	"DDI between Frovatriptan and Sertraline - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01104 ,
		ns3:DB00998 .
ns1:DB00998_DB01105	dcterms:title	"DDI between Frovatriptan and Sibutramine - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB01105 .
ns1:DB00998_DB01149	dcterms:title	"DDI between Frovatriptan and Nefazodone - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB01149 .
ns1:DB00998_DB01175	dcterms:title	"DDI between Frovatriptan and Escitalopram - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01175 ,
		ns3:DB00998 .
ns1:DB00998_DB01253	dcterms:title	"DDI between Frovatriptan and Ergonovine - Possible severe and prolonged vasoconstriction"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB01253 .
ns1:DB00998_DB06700	dcterms:title	"DDI between Frovatriptan and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00998 ,
		ns3:DB06700 .
ns1:DB00999_DB01078	dcterms:title	"DDI between Hydrochlorothiazide and Deslanoside - Possible electrolyte variations and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01078 ,
		ns3:DB00999 .
ns1:DB00999_DB01119	dcterms:title	"DDI between Hydrochlorothiazide and Diazoxide - Significant hyperglycemic effect"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01119 ,
		ns3:DB00999 .
ns1:DB00999_DB01356	dcterms:title	"DDI between Hydrochlorothiazide and Lithium - The thiazide diuretic, hydrochlorothiazide, may increase serum levels of lithium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01356 ,
		ns3:DB00999 .
ns1:DB00999_DB01396	dcterms:title	"DDI between Hydrochlorothiazide and Digitoxin - Possible electrolyte variations and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01396 ,
		ns3:DB00999 .
ns1:DB00999_DB01551	dcterms:title	"DDI between Hydrochlorothiazide and Dihydrocodeine - Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. \r\nIt is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00999 .
ns1:DB00999_DB05039	dcterms:title	"DDI between Hydrochlorothiazide and Indacaterol - Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05039 ,
		ns3:DB00999 .
ns1:DB01000_DB01017	dcterms:title	"DDI between Cyclacillin and Minocycline - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01000 ,
		ns3:DB01017 .
ns1:DB01483_DB06212	dcterms:title	"DDI between Barbital and Tolvaptan - Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06212 ,
		ns3:DB01483 .
ns1:DB01483_DB08867	dcterms:title	"DDI between Barbital and Ulipristal - Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08867 ,
		ns3:DB01483 .
ns1:DB01491_DB06274	dcterms:title	"DDI between Dipipanone and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06274 ,
		ns3:DB01491 .
ns1:DB01501_DB06274	dcterms:title	"DDI between Difenoxin and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01501 ,
		ns3:DB06274 .
ns1:DB01529_DB06274	dcterms:title	"DDI between Dextromoramide and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01529 ,
		ns3:DB06274 .
ns1:DB01551_DB05271	dcterms:title	"DDI between Dihydrocodeine and Rotigotine - Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB05271 .
ns1:DB01551_DB06274	dcterms:title	"DDI between Dihydrocodeine and Alvimopan - Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB06274 .
ns1:DB01551_DB06767	dcterms:title	"DDI between Dihydrocodeine and Ammonium chloride - May enhance excretion of dihydrocodeine. Recommended to monitor for reduced therapeutic effect."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06767 ,
		ns3:DB01551 .
ns1:DB01551_DB08883	dcterms:title	"DDI between Dihydrocodeine and Perampanel - Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB08883 .
ns1:DB01558_DB01601	dcterms:title	"DDI between Bromazepam and Lopinavir - Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if lopinavir is initiated, discontinued or dose changed. Dosage adjustments may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01558 ,
		ns3:DB01601 .
ns1:DB01574_DB01627	dcterms:title	"DDI between Attapulgite and Lincomycin - The aluminium salt decreases the absorption of lincosamides"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01627 ,
		ns3:DB01574 .
ns1:DB01575_DB01627	dcterms:title	"DDI between Kaolin and Lincomycin - The aluminium salt decreases the absorption of lincosamides"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01627 ,
		ns3:DB01575 .
ns1:DB01576_DB01608	dcterms:title	"DDI between Dextroamphetamine and Propericiazine - Decreased anorexic effect, may increase pyschotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01608 ,
		ns3:DB01576 .
ns1:DB01577_DB01608	dcterms:title	"DDI between Methamphetamine and Propericiazine - Decreased anorexic effect, may increase pyschotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01577 ,
		ns3:DB01608 .
ns1:DB01578_DB01608	dcterms:title	"DDI between Metrizamide and Propericiazine - Increased risk of convulsions"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01608 ,
		ns3:DB01578 .
ns1:DB01579_DB01608	dcterms:title	"DDI between Phendimetrazine and Propericiazine - Decreased anorexic effect, may increase pyschotic symptoms"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01608 ,
		ns3:DB01579 .
ns1:DB01590_DB06372	dcterms:title	"DDI between Everolimus and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06372 ,
		ns3:DB01590 .
ns1:DB01590_DB06414	dcterms:title	"DDI between Everolimus and Etravirine - Everolimus, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. If concurrent therapy cannot be avoided, a gradual dosage increase of everolimus is recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB01590 .
ns1:DB01592_DB08826	dcterms:title	"DDI between Iron and Deferiprone - Deferiprone serum concentrations may be decreased by iron salts except for ferric gluconate, ferumoxytol, iron dextran complex, and iron sucrose."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01592 ,
		ns3:DB08826 .
ns1:DB01593_DB08826	dcterms:title	"DDI between Zinc and Deferiprone - Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01593 ,
		ns3:DB08826 .
ns1:DB01597_DB01610	dcterms:title	"DDI between Cilastatin and Valganciclovir - Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01610 ,
		ns3:DB01597 .
ns1:DB01598_DB01610	dcterms:title	"DDI between Imipenem and Valganciclovir - Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01610 ,
		ns3:DB01598 .
ns1:DB01599_DB01623	dcterms:title	"DDI between Probucol and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01599 ,
		ns3:DB01623 .
ns1:DB01599_DB01624	dcterms:title	"DDI between Probucol and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB01599 .
ns1:DB01599_DB02546	dcterms:title	"DDI between Probucol and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02546 ,
		ns3:DB01599 .
ns1:DB01599_DB06697	dcterms:title	"DDI between Probucol and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01599 ,
		ns3:DB06697 .
ns1:DB01599_DB06708	dcterms:title	"DDI between Probucol and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01599 ,
		ns3:DB06708 .
ns1:DB01599_DB08919	dcterms:title	"DDI between Probucol and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01599 ,
		ns3:DB08919 .
ns1:DB01599_DB08920	dcterms:title	"DDI between Probucol and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01599 ,
		ns3:DB08920 .
ns1:DB01601_DB01624	dcterms:title	"DDI between Lopinavir and Zuclopenthixol - Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB01624 .
ns1:DB01601_DB01656	dcterms:title	"DDI between Lopinavir and Roflumilast - Affects CYP1A2 metabolism; decreases level or effect of roflumilast."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01656 ,
		ns3:DB01601 .
ns1:DB01601_DB06287	dcterms:title	"DDI between Lopinavir and Temsirolimus - Lopinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB06287 .
ns1:DB01601_DB06414	dcterms:title	"DDI between Lopinavir and Etravirine - Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \r\n\r\nProtease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \r\n\r\nRitonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB06414 .
ns1:DB01601_DB08860	dcterms:title	"DDI between Lopinavir and Pitavastatin - Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB08860 .
ns1:DB01601_DB08901	dcterms:title	"DDI between Lopinavir and Ponatinib  - Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08901 ,
		ns3:DB01601 .
ns1:DB01601_DB08919	dcterms:title	"DDI between Lopinavir and Zuclopenthixol acetate - Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB08919 .
ns1:DB01601_DB08920	dcterms:title	"DDI between Lopinavir and Zuclopenthixol decanoate - Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB08920 .
ns1:DB01607_DB02703	dcterms:title	"DDI between Ticarcillin and Fusidic Acid - Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB02703 ,
		ns3:DB01607 .
ns1:DB01609_DB06414	dcterms:title	"DDI between Deferasirox and Etravirine - Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06414 ,
		ns3:DB01609 .
ns1:DB01609_DB08895	dcterms:title	"DDI between Deferasirox and Tofacitinib - Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08895 ,
		ns3:DB01609 .
ns1:DB01611_DB06372	dcterms:title	"DDI between Hydroxychloroquine and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06372 ,
		ns3:DB01611 .
ns1:DB01611_DB06697	dcterms:title	"DDI between Hydroxychloroquine and Artemether - Hydroxychloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB01611 .
ns1:DB01611_DB06708	dcterms:title	"DDI between Hydroxychloroquine and Lumefantrine - Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB01611 .
ns1:DB01618_DB04844	dcterms:title	"DDI between Molindone and Tetrabenazine - May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB01618 .
ns1:DB01623_DB01624	dcterms:title	"DDI between Thiothixene and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB01624 .
ns1:DB01623_DB02546	dcterms:title	"DDI between Thiothixene and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01623 ,
		ns3:DB02546 .
ns1:DB01623_DB04844	dcterms:title	"DDI between Thiothixene and Tetrabenazine - Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB01623 .
ns1:DB01623_DB04868	dcterms:title	"DDI between Thiothixene and Nilotinib - May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04868 ,
		ns3:DB01623 .
ns1:DB01623_DB05271	dcterms:title	"DDI between Thiothixene and Rotigotine - Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Rotigotine. Consider alternate therapy or monitor for decreased effects of both agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05271 ,
		ns3:DB01623 .
ns1:DB01623_DB06697	dcterms:title	"DDI between Thiothixene and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06697 ,
		ns3:DB01623 .
ns1:DB01623_DB06708	dcterms:title	"DDI between Thiothixene and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06708 ,
		ns3:DB01623 .
ns1:DB01623_DB08919	dcterms:title	"DDI between Thiothixene and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08919 ,
		ns3:DB01623 .
ns1:DB01623_DB08920	dcterms:title	"DDI between Thiothixene and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08920 ,
		ns3:DB01623 .
ns1:DB01624_DB02546	dcterms:title	"DDI between Zuclopenthixol and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB02546 .
ns1:DB01624_DB04844	dcterms:title	"DDI between Zuclopenthixol and Tetrabenazine - Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04844 ,
		ns3:DB01624 .
ns1:DB01624_DB04855	dcterms:title	"DDI between Zuclopenthixol and Dronedarone - Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB04855 .
ns1:DB01624_DB04868	dcterms:title	"DDI between Zuclopenthixol and Nilotinib - Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04868 ,
		ns3:DB01624 .
ns1:DB01624_DB04946	dcterms:title	"DDI between Zuclopenthixol and Iloperidone - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB04946 .
ns1:DB01624_DB05271	dcterms:title	"DDI between Zuclopenthixol and Rotigotine - Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05271 ,
		ns3:DB01624 .
ns1:DB01624_DB06176	dcterms:title	"DDI between Zuclopenthixol and Romidepsin - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB06176 .
ns1:DB01624_DB06216	dcterms:title	"DDI between Zuclopenthixol and Asenapine - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06216 ,
		ns3:DB01624 .
ns1:DB01624_DB06402	dcterms:title	"DDI between Zuclopenthixol and Telavancin - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB06402 .
ns1:DB01624_DB06414	dcterms:title	"DDI between Zuclopenthixol and Etravirine - Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB06414 .
ns1:DB01624_DB06589	dcterms:title	"DDI between Zuclopenthixol and Pazopanib - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06589 ,
		ns3:DB01624 .
ns1:DB01624_DB06708	dcterms:title	"DDI between Zuclopenthixol and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01624 ,
		ns3:DB06708 .
ns1:DB01626_DB04896	dcterms:title	"DDI between Pargyline and Milnacipran - Increase serotonin levels. Combination therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01626 ,
		ns3:DB04896 .
ns1:DB00001_DB00374	dcterms:title	"DDI between Lepirudin and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00001 ,
		ns3:DB00374 .
ns1:DB00001_DB01381	dcterms:title	"DDI between Lepirudin and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00001 ,
		ns3:DB01381 .
ns1:DB00004_DB00072	dcterms:title	"DDI between Denileukin diftitox and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00004 ,
		ns3:DB00072 .
ns1:DB00004_DB06372	dcterms:title	"DDI between Denileukin diftitox and Rilonacept - decreases effects of toxoids by pharmacodynamic antagonism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00004 ,
		ns3:DB06372 .
ns1:DB00005_DB00072	dcterms:title	"DDI between Etanercept and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00005 ,
		ns3:DB00072 .
ns1:DB00005_DB06372	dcterms:title	"DDI between Etanercept and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00005 ,
		ns3:DB06372 .
ns1:DB00005_DB08895	dcterms:title	"DDI between Etanercept and Tofacitinib - Etanercept increases the risk of added immunosuppression. It is recommended to avoid concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00005 ,
		ns3:DB08895 .
ns1:DB00006_DB00374	dcterms:title	"DDI between Bivalirudin and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00006 ,
		ns3:DB00374 .
ns1:DB00006_DB00441	dcterms:title	"DDI between Bivalirudin and Gemcitabine - Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00006 ,
		ns3:DB00441 .
ns1:DB00006_DB01381	dcterms:title	"DDI between Bivalirudin and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00006 ,
		ns3:DB01381 .
ns1:DB00006_DB01609	dcterms:title	"DDI between Bivalirudin and Deferasirox - Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00006 ,
		ns3:DB01609 .
ns1:DB00006_DB06228	dcterms:title	"DDI between Bivalirudin and Rivaroxaban - Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00006 ,
		ns3:DB06228 .
ns1:DB00008_DB00277	dcterms:title	"DDI between Peginterferon alfa-2a and Theophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00008 .
ns1:DB00008_DB00651	dcterms:title	"DDI between Peginterferon alfa-2a and Dyphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00008 .
ns1:DB00008_DB01223	dcterms:title	"DDI between Peginterferon alfa-2a and Aminophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00008 ,
		ns3:DB01223 .
ns1:DB00008_DB01265	dcterms:title	"DDI between Peginterferon alfa-2a and Telbivudine - Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00008 ,
		ns3:DB01265 .
ns1:DB00008_DB01303	dcterms:title	"DDI between Peginterferon alfa-2a and Oxtriphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00008 ,
		ns3:DB01303 .
ns1:DB00008_DB06414	dcterms:title	"DDI between Peginterferon alfa-2a and Etravirine - Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00008 ,
		ns3:DB06414 .
ns1:DB00009_DB00208	dcterms:title	"DDI between Alteplase and Ticlopidine - Increased bleeding risk. Monitor for signs of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00208 ,
		ns3:DB00009 .
ns1:DB00009_DB00727	dcterms:title	"DDI between Alteplase and Nitroglycerin - IV nitroglycerin may decrease the effect of alteplase."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00727 ,
		ns3:DB00009 .
ns1:DB00009_DB01381	dcterms:title	"DDI between Alteplase and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00009 ,
		ns3:DB01381 .
ns1:DB00011_DB00277	dcterms:title	"DDI between Interferon alfa-n1 and Theophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00011 .
ns1:DB00011_DB00651	dcterms:title	"DDI between Interferon alfa-n1 and Dyphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00011 .
ns1:DB00011_DB01223	dcterms:title	"DDI between Interferon alfa-n1 and Aminophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00011 ,
		ns3:DB01223 .
ns1:DB00011_DB01303	dcterms:title	"DDI between Interferon alfa-n1 and Oxtriphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00011 ,
		ns3:DB01303 .
ns1:DB00013_DB00055	dcterms:title	"DDI between Urokinase and Drotrecogin alfa - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00013 .
ns1:DB00013_DB01381	dcterms:title	"DDI between Urokinase and Ginkgo biloba - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00013 ,
		ns3:DB01381 .
ns1:DB00013_DB01404	dcterms:title	"DDI between Urokinase and Ginseng - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00013 ,
		ns3:DB01404 .
ns1:DB00013_DB06692	dcterms:title	"DDI between Urokinase and Aprotinin - Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00013 ,
		ns3:DB06692 .
ns1:DB00015_DB00208	dcterms:title	"DDI between Reteplase and Ticlopidine - Increased bleeding risk. Monitor for signs of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00208 ,
		ns3:DB00015 .
ns1:DB00015_DB01381	dcterms:title	"DDI between Reteplase and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00015 ,
		ns3:DB01381 .
ns1:DB00021_DB00209	dcterms:title	"DDI between Secretin and Trospium - The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00209 ,
		ns3:DB00021 .
ns1:DB00021_DB00376	dcterms:title	"DDI between Secretin and Trihexyphenidyl - The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00376 ,
		ns3:DB00021 .
ns1:DB00021_DB00662	dcterms:title	"DDI between Secretin and Trimethobenzamide - The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00662 ,
		ns3:DB00021 .
ns1:DB00021_DB00771	dcterms:title	"DDI between Secretin and Clidinium - Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00021 ,
		ns3:DB00771 .
ns1:DB00021_DB01036	dcterms:title	"DDI between Secretin and Tolterodine - The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01036 ,
		ns3:DB00021 .
ns1:DB00021_DB01409	dcterms:title	"DDI between Secretin and Tiotropium - The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01409 ,
		ns3:DB00021 .
ns1:DB00022_DB00277	dcterms:title	"DDI between Peginterferon alfa-2b and Theophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00022 ,
		ns3:DB00277 .
ns1:DB00022_DB00651	dcterms:title	"DDI between Peginterferon alfa-2b and Dyphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00022 ,
		ns3:DB00651 .
ns1:DB00022_DB01223	dcterms:title	"DDI between Peginterferon alfa-2b and Aminophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00022 .
ns1:DB00022_DB01303	dcterms:title	"DDI between Peginterferon alfa-2b and Oxtriphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00022 .
ns1:DB00023_DB00072	dcterms:title	"DDI between Asparaginase and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00023 ,
		ns3:DB00072 .
ns1:DB00026_DB00072	dcterms:title	"DDI between Anakinra and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00026 ,
		ns3:DB00072 .
ns1:DB00026_DB01041	dcterms:title	"DDI between Anakinra and Thalidomide - Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01041 ,
		ns3:DB00026 .
ns1:DB00026_DB06168	dcterms:title	"DDI between Anakinra and Canakinumab - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06168 ,
		ns3:DB00026 .
ns1:DB00026_DB06372	dcterms:title	"DDI between Anakinra and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06372 ,
		ns3:DB00026 .
ns1:DB00026_DB06674	dcterms:title	"DDI between Anakinra and golimumab - Avoid combination with anakinra due to the increased chance of serious infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06674 ,
		ns3:DB00026 .
ns1:DB00026_DB08895	dcterms:title	"DDI between Anakinra and Tofacitinib - Avoid combination due to the potential increase in tofacitinib related adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08895 ,
		ns3:DB00026 .
ns1:DB00026_DB08904	dcterms:title	"DDI between Anakinra and Certolizumab pegol - Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08904 ,
		ns3:DB00026 .
ns1:DB00030_DB06655	dcterms:title	"DDI between Insulin Regular  and Liraglutide - Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06655 ,
		ns3:DB00030 .
ns1:DB00031_DB00055	dcterms:title	"DDI between Tenecteplase and Drotrecogin alfa - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00031 .
ns1:DB00031_DB00208	dcterms:title	"DDI between Tenecteplase and Ticlopidine - Increased bleeding risk. Monitor for signs of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00208 ,
		ns3:DB00031 .
ns1:DB00031_DB01381	dcterms:title	"DDI between Tenecteplase and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00031 .
ns1:DB00031_DB01404	dcterms:title	"DDI between Tenecteplase and Ginseng - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01404 ,
		ns3:DB00031 .
ns1:DB00031_DB06692	dcterms:title	"DDI between Tenecteplase and Aprotinin - Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06692 ,
		ns3:DB00031 .
ns1:DB00034_DB00277	dcterms:title	"DDI between Interferon Alfa-2a, Recombinant and Theophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00034 .
ns1:DB00034_DB00651	dcterms:title	"DDI between Interferon Alfa-2a, Recombinant and Dyphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00034 .
ns1:DB00034_DB01223	dcterms:title	"DDI between Interferon Alfa-2a, Recombinant and Aminophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01223 ,
		ns3:DB00034 .
ns1:DB00034_DB01303	dcterms:title	"DDI between Interferon Alfa-2a, Recombinant and Oxtriphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01303 ,
		ns3:DB00034 .
ns1:DB00035_DB01551	dcterms:title	"DDI between Desmopressin and Dihydrocodeine - Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00035 .
ns1:DB00038_DB01551	dcterms:title	"DDI between Oprelvekin and Dihydrocodeine - May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00038 .
ns1:DB00039_DB06769	dcterms:title	"DDI between Palifermin and Bendamustine - Increases toxicity of bendamustine. Should not be administered within a 24 hour time period of antineoplastic agent administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06769 ,
		ns3:DB00039 .
ns1:DB00039_DB06813	dcterms:title	"DDI between Palifermin and Pralatrexate - Increases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06813 ,
		ns3:DB00039 .
ns1:DB00041_DB00838	dcterms:title	"DDI between Aldesleukin and Clocortolone - Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00041 ,
		ns3:DB00838 .
ns1:DB00041_DB01013	dcterms:title	"DDI between Aldesleukin and Clobetasol propionate - Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01013 ,
		ns3:DB00041 .
ns1:DB00041_DB01285	dcterms:title	"DDI between Aldesleukin and Corticotropin - Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01285 ,
		ns3:DB00041 .
ns1:DB00046_DB00104	dcterms:title	"DDI between Insulin Lispro and Octreotide - Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00104 .
ns1:DB00046_DB00178	dcterms:title	"DDI between Insulin Lispro and Ramipril - Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00178 .
ns1:DB00046_DB00187	dcterms:title	"DDI between Insulin Lispro and Esmolol - The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00187 .
ns1:DB00046_DB00280	dcterms:title	"DDI between Insulin Lispro and Disopyramide - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00280 .
ns1:DB00046_DB00335	dcterms:title	"DDI between Insulin Lispro and Atenolol - The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00335 .
ns1:DB00046_DB00472	dcterms:title	"DDI between Insulin Lispro and Fluoxetine - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00046 .
ns1:DB00046_DB00584	dcterms:title	"DDI between Insulin Lispro and Enalapril - Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00584 ,
		ns3:DB00046 .
ns1:DB00046_DB00612	dcterms:title	"DDI between Insulin Lispro and Bisoprolol - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00612 ,
		ns3:DB00046 .
ns1:DB00046_DB00635	dcterms:title	"DDI between Insulin Lispro and Prednisone - Concomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00046 .
ns1:DB00046_DB00647	dcterms:title	"DDI between Insulin Lispro and Dextropropoxyphene - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00647 ,
		ns3:DB00046 .
ns1:DB00046_DB00668	dcterms:title	"DDI between Insulin Lispro and Epinephrine - Concomitant therapy with sympathomimetic agents may reduce the blood-glucose-lowering effect of insulin lispro."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00668 ,
		ns3:DB00046 .
ns1:DB00046_DB00678	dcterms:title	"DDI between Insulin Lispro and Losartan - Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00678 ,
		ns3:DB00046 .
ns1:DB00046_DB00806	dcterms:title	"DDI between Insulin Lispro and Pentoxifylline - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00806 ,
		ns3:DB00046 .
ns1:DB00046_DB00999	dcterms:title	"DDI between Insulin Lispro and Hydrochlorothiazide - Concomitant therapy with diuretics may reduce the blood-glucose-lowering effect of insulin lispro."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB00999 .
ns1:DB00046_DB01039	dcterms:title	"DDI between Insulin Lispro and Fenofibrate - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB01039 .
ns1:DB00046_DB01136	dcterms:title	"DDI between Insulin Lispro and Carvedilol - The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB01136 .
ns1:DB00046_DB01193	dcterms:title	"DDI between Insulin Lispro and Acebutolol - The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB01193 .
ns1:DB00046_DB01278	dcterms:title	"DDI between Insulin Lispro and Pramlintide - Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00046 ,
		ns3:DB01278 .
ns1:DB00047_DB00052	dcterms:title	"DDI between Insulin Glargine and Somatropin recombinant - Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00052 .
ns1:DB00047_DB00187	dcterms:title	"DDI between Insulin Glargine and Esmolol - The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00187 ,
		ns3:DB00047 .
ns1:DB00047_DB00195	dcterms:title	"DDI between Insulin Glargine and Betaxolol - The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00195 ,
		ns3:DB00047 .
ns1:DB00047_DB00264	dcterms:title	"DDI between Insulin Glargine and Metoprolol - The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00264 ,
		ns3:DB00047 .
ns1:DB00047_DB00335	dcterms:title	"DDI between Insulin Glargine and Atenolol - The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00335 .
ns1:DB00047_DB00373	dcterms:title	"DDI between Insulin Glargine and Timolol - The beta-blocker, timolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00373 .
ns1:DB00047_DB00489	dcterms:title	"DDI between Insulin Glargine and Sotalol - The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00489 .
ns1:DB00047_DB00521	dcterms:title	"DDI between Insulin Glargine and Carteolol - The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00521 .
ns1:DB00047_DB00571	dcterms:title	"DDI between Insulin Glargine and Propranolol - The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00571 .
ns1:DB00047_DB00598	dcterms:title	"DDI between Insulin Glargine and Labetalol - The beta-blocker, labetolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00598 .
ns1:DB00047_DB00612	dcterms:title	"DDI between Insulin Glargine and Bisoprolol - The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00612 .
ns1:DB00047_DB00960	dcterms:title	"DDI between Insulin Glargine and Pindolol - The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB00960 .
ns1:DB00047_DB01136	dcterms:title	"DDI between Insulin Glargine and Carvedilol - The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01136 .
ns1:DB00047_DB01193	dcterms:title	"DDI between Insulin Glargine and Acebutolol - The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01193 .
ns1:DB00047_DB01203	dcterms:title	"DDI between Insulin Glargine and Nadolol - The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01203 .
ns1:DB00047_DB01295	dcterms:title	"DDI between Insulin Glargine and Bevantolol - The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01295 .
ns1:DB00047_DB01297	dcterms:title	"DDI between Insulin Glargine and Practolol - The beta-blocker, practolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01297 .
ns1:DB00047_DB01359	dcterms:title	"DDI between Insulin Glargine and Penbutolol - The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01359 .
ns1:DB00047_DB01580	dcterms:title	"DDI between Insulin Glargine and Oxprenolol - The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00047 ,
		ns3:DB01580 .
ns1:DB00051_DB00072	dcterms:title	"DDI between Adalimumab and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00051 ,
		ns3:DB00072 .
ns1:DB00051_DB06168	dcterms:title	"DDI between Adalimumab and Canakinumab - Increases immunosuppressive effects and risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00051 ,
		ns3:DB06168 .
ns1:DB00051_DB06372	dcterms:title	"DDI between Adalimumab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00051 ,
		ns3:DB06372 .
ns1:DB00051_DB08895	dcterms:title	"DDI between Adalimumab and Tofacitinib - Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00051 ,
		ns3:DB08895 .
ns1:DB00052_DB00222	dcterms:title	"DDI between Somatropin recombinant and Glimepiride - Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB00222 .
ns1:DB00052_DB00284	dcterms:title	"DDI between Somatropin recombinant and Acarbose - Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB00284 .
ns1:DB00052_DB00331	dcterms:title	"DDI between Somatropin recombinant and Metformin - Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB00331 .
ns1:DB00052_DB00412	dcterms:title	"DDI between Somatropin recombinant and Rosiglitazone - Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00412 ,
		ns3:DB00052 .
ns1:DB00052_DB00491	dcterms:title	"DDI between Somatropin recombinant and Miglitol - Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00491 ,
		ns3:DB00052 .
ns1:DB00052_DB00672	dcterms:title	"DDI between Somatropin recombinant and Chlorpropamide - Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00672 ,
		ns3:DB00052 .
ns1:DB00052_DB00731	dcterms:title	"DDI between Somatropin recombinant and Nateglinide - Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00731 ,
		ns3:DB00052 .
ns1:DB00052_DB00839	dcterms:title	"DDI between Somatropin recombinant and Tolazamide - Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00052 .
ns1:DB00052_DB01016	dcterms:title	"DDI between Somatropin recombinant and Glyburide - Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01016 .
ns1:DB00052_DB01067	dcterms:title	"DDI between Somatropin recombinant and Glipizide - Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01067 .
ns1:DB00052_DB01120	dcterms:title	"DDI between Somatropin recombinant and Gliclazide - Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01120 .
ns1:DB00052_DB01124	dcterms:title	"DDI between Somatropin recombinant and Tolbutamide - Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01124 .
ns1:DB00052_DB01132	dcterms:title	"DDI between Somatropin recombinant and Pioglitazone - Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01132 .
ns1:DB00052_DB01261	dcterms:title	"DDI between Somatropin recombinant and Sitagliptin - Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01261 .
ns1:DB00052_DB01276	dcterms:title	"DDI between Somatropin recombinant and Exenatide - Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01276 .
ns1:DB00052_DB01306	dcterms:title	"DDI between Somatropin recombinant and Insulin Aspart - Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01306 .
ns1:DB00052_DB01307	dcterms:title	"DDI between Somatropin recombinant and Insulin Detemir - Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01307 .
ns1:DB00052_DB01309	dcterms:title	"DDI between Somatropin recombinant and Insulin Glulisine - Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB01309 .
ns1:DB00052_DB06335	dcterms:title	"DDI between Somatropin recombinant and Saxagliptin - Somatropin may antagonize the hypoglycemic effect of saxagliptin. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB06335 .
ns1:DB00052_DB06655	dcterms:title	"DDI between Somatropin recombinant and Liraglutide - Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00052 ,
		ns3:DB06655 .
ns1:DB00054_DB00072	dcterms:title	"DDI between Abciximab and Trastuzumab - Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00054 .
ns1:DB00054_DB00374	dcterms:title	"DDI between Abciximab and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00054 ,
		ns3:DB00374 .
ns1:DB00054_DB00775	dcterms:title	"DDI between Abciximab and Tirofiban - Additive effects. Concomitant use is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00054 ,
		ns3:DB00775 .
ns1:DB00054_DB01381	dcterms:title	"DDI between Abciximab and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00054 ,
		ns3:DB01381 .
ns1:DB00055_DB00374	dcterms:title	"DDI between Drotrecogin alfa and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00374 .
ns1:DB00055_DB00500	dcterms:title	"DDI between Drotrecogin alfa and Tolmetin - Increased risk of bleeding. Monitor for increased bleeding during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00500 .
ns1:DB00055_DB00569	dcterms:title	"DDI between Drotrecogin alfa and Fondaparinux sodium - Drotrecogin alfa may increase the adverse effects of fondaparinux, resulting in excessive bleeding. Concomitant use should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00569 .
ns1:DB00055_DB00682	dcterms:title	"DDI between Drotrecogin alfa and Warfarin - Increased risk of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00682 .
ns1:DB00055_DB00758	dcterms:title	"DDI between Drotrecogin alfa and Clopidogrel - Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00055 ,
		ns3:DB00758 .
ns1:DB00055_DB01009	dcterms:title	"DDI between Drotrecogin alfa and Ketoprofen - The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00055 .
ns1:DB00055_DB01109	dcterms:title	"DDI between Drotrecogin alfa and Heparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01109 ,
		ns3:DB00055 .
ns1:DB00055_DB01225	dcterms:title	"DDI between Drotrecogin alfa and Enoxaparin - Combination should be used with caution after weighing advantages and disadvantages. Low molecular weight heparins such as enoxaparin may increase the adverse effects of drotrecogin. Monitor for bleeding if used concomitantly."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01225 ,
		ns3:DB00055 .
ns1:DB00055_DB06684	dcterms:title	"DDI between Drotrecogin alfa and Vilazodone - Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06684 ,
		ns3:DB00055 .
ns1:DB00055_DB06779	dcterms:title	"DDI between Drotrecogin alfa and Dalteparin - Low molecular weight heparin (LMWH) such as dalteparin may enhance the adverse/toxic effect of drotrecogin alfa. Bleeding may occur."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06779 ,
		ns3:DB00055 .
ns1:DB00055_DB06822	dcterms:title	"DDI between Drotrecogin alfa and Tinzaparin - Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06822 ,
		ns3:DB00055 .
ns1:DB00055_DB08813	dcterms:title	"DDI between Drotrecogin alfa and Nadroparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08813 ,
		ns3:DB00055 .
ns1:DB00059_DB00072	dcterms:title	"DDI between Pegaspargase and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00059 ,
		ns3:DB00072 .
ns1:DB00063_DB00374	dcterms:title	"DDI between Eptifibatide and Treprostinil - The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00063 ,
		ns3:DB00374 .
ns1:DB00063_DB00775	dcterms:title	"DDI between Eptifibatide and Tirofiban - Additive effects. Concomitant use is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00063 ,
		ns3:DB00775 .
ns1:DB00063_DB01381	dcterms:title	"DDI between Eptifibatide and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00063 .
ns1:DB00065_DB00072	dcterms:title	"DDI between Infliximab and Trastuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00065 .
ns1:DB00065_DB06372	dcterms:title	"DDI between Infliximab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06372 ,
		ns3:DB00065 .
ns1:DB00065_DB06674	dcterms:title	"DDI between Infliximab and golimumab - Avoid combination with infliximab due to the potential increased immunosuppression of infliximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06674 ,
		ns3:DB00065 .
ns1:DB00065_DB08895	dcterms:title	"DDI between Infliximab and Tofacitinib - Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08895 ,
		ns3:DB00065 .
ns1:DB00068_DB00495	dcterms:title	"DDI between Interferon beta-1b and Zidovudine - The interferon increases the effect and toxicity of zidovudine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00068 ,
		ns3:DB00495 .
ns1:DB00072_DB00073	dcterms:title	"DDI between Trastuzumab and Rituximab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00073 .
ns1:DB00072_DB00074	dcterms:title	"DDI between Trastuzumab and Basiliximab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00074 ,
		ns3:DB00072 .
ns1:DB00072_DB00075	dcterms:title	"DDI between Trastuzumab and Muromonab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00075 ,
		ns3:DB00072 .
ns1:DB00072_DB00078	dcterms:title	"DDI between Trastuzumab and Ibritumomab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00078 .
ns1:DB00072_DB00081	dcterms:title	"DDI between Trastuzumab and Tositumomab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00081 .
ns1:DB00072_DB00087	dcterms:title	"DDI between Trastuzumab and Alemtuzumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00087 .
ns1:DB00072_DB00091	dcterms:title	"DDI between Trastuzumab and Cyclosporine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00091 .
ns1:DB00072_DB00095	dcterms:title	"DDI between Trastuzumab and Efalizumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00095 .
ns1:DB00072_DB00108	dcterms:title	"DDI between Trastuzumab and Natalizumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00108 ,
		ns3:DB00072 .
ns1:DB00072_DB00111	dcterms:title	"DDI between Trastuzumab and Daclizumab - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00111 .
ns1:DB00072_DB00242	dcterms:title	"DDI between Trastuzumab and Cladribine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00242 .
ns1:DB00072_DB00262	dcterms:title	"DDI between Trastuzumab and Carmustine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00262 .
ns1:DB00072_DB00276	dcterms:title	"DDI between Trastuzumab and Amsacrine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00276 .
ns1:DB00072_DB00290	dcterms:title	"DDI between Trastuzumab and Bleomycin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00290 .
ns1:DB00072_DB00291	dcterms:title	"DDI between Trastuzumab and Chlorambucil - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00291 .
ns1:DB00072_DB00305	dcterms:title	"DDI between Trastuzumab and Mitomycin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00305 .
ns1:DB00072_DB00317	dcterms:title	"DDI between Trastuzumab and Gefitinib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00317 .
ns1:DB00072_DB00322	dcterms:title	"DDI between Trastuzumab and Floxuridine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00322 .
ns1:DB00072_DB00352	dcterms:title	"DDI between Trastuzumab and Thioguanine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00352 .
ns1:DB00072_DB00361	dcterms:title	"DDI between Trastuzumab and Vinorelbine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00361 .
ns1:DB00072_DB00385	dcterms:title	"DDI between Trastuzumab and Valrubicin - Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00385 .
ns1:DB00072_DB00398	dcterms:title	"DDI between Trastuzumab and Sorafenib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00398 .
ns1:DB00072_DB00428	dcterms:title	"DDI between Trastuzumab and Streptozocin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00428 .
ns1:DB00072_DB00441	dcterms:title	"DDI between Trastuzumab and Gemcitabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00441 .
ns1:DB00072_DB00443	dcterms:title	"DDI between Trastuzumab and Betamethasone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00443 .
ns1:DB00072_DB00444	dcterms:title	"DDI between Trastuzumab and Teniposide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00444 .
ns1:DB00072_DB00445	dcterms:title	"DDI between Trastuzumab and Epirubicin - Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00445 .
ns1:DB00072_DB00480	dcterms:title	"DDI between Trastuzumab and Lenalidomide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00480 .
ns1:DB00072_DB00488	dcterms:title	"DDI between Trastuzumab and Altretamine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00488 .
ns1:DB00072_DB00515	dcterms:title	"DDI between Trastuzumab and Cisplatin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00515 .
ns1:DB00072_DB00526	dcterms:title	"DDI between Trastuzumab and Oxaliplatin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00526 .
ns1:DB00072_DB00530	dcterms:title	"DDI between Trastuzumab and Erlotinib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00530 .
ns1:DB00072_DB00531	dcterms:title	"DDI between Trastuzumab and Cyclophosphamide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00531 .
ns1:DB00072_DB00541	dcterms:title	"DDI between Trastuzumab and Vincristine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00541 .
ns1:DB00072_DB00544	dcterms:title	"DDI between Trastuzumab and Fluorouracil - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00544 .
ns1:DB00072_DB00552	dcterms:title	"DDI between Trastuzumab and Pentostatin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00552 .
ns1:DB00072_DB00563	dcterms:title	"DDI between Trastuzumab and Methotrexate - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00563 .
ns1:DB00072_DB00570	dcterms:title	"DDI between Trastuzumab and Vinblastine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00570 .
ns1:DB00072_DB00619	dcterms:title	"DDI between Trastuzumab and Imatinib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00619 .
ns1:DB00072_DB00620	dcterms:title	"DDI between Trastuzumab and Triamcinolone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00620 .
ns1:DB00072_DB00631	dcterms:title	"DDI between Trastuzumab and Clofarabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00631 .
ns1:DB00072_DB00635	dcterms:title	"DDI between Trastuzumab and Prednisone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00635 ,
		ns3:DB00072 .
ns1:DB00072_DB00687	dcterms:title	"DDI between Trastuzumab and Fludrocortisone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00687 ,
		ns3:DB00072 .
ns1:DB00072_DB00688	dcterms:title	"DDI between Trastuzumab and Mycophenolate mofetil - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00688 ,
		ns3:DB00072 .
ns1:DB00072_DB00694	dcterms:title	"DDI between Trastuzumab and Daunorubicin - Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00694 ,
		ns3:DB00072 .
ns1:DB00072_DB00741	dcterms:title	"DDI between Trastuzumab and Hydrocortisone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00741 ,
		ns3:DB00072 .
ns1:DB00072_DB00755	dcterms:title	"DDI between Trastuzumab and Tretinoin - Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00755 ,
		ns3:DB00072 .
ns1:DB00072_DB00762	dcterms:title	"DDI between Trastuzumab and Irinotecan - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00762 ,
		ns3:DB00072 .
ns1:DB00072_DB00773	dcterms:title	"DDI between Trastuzumab and Etoposide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00773 ,
		ns3:DB00072 .
ns1:DB00072_DB00851	dcterms:title	"DDI between Trastuzumab and Dacarbazine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00851 ,
		ns3:DB00072 .
ns1:DB00072_DB00853	dcterms:title	"DDI between Trastuzumab and Temozolomide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00853 ,
		ns3:DB00072 .
ns1:DB00072_DB00860	dcterms:title	"DDI between Trastuzumab and Prednisolone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00860 ,
		ns3:DB00072 .
ns1:DB00072_DB00864	dcterms:title	"DDI between Trastuzumab and Tacrolimus - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00072 .
ns1:DB00072_DB00877	dcterms:title	"DDI between Trastuzumab and Sirolimus - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00877 ,
		ns3:DB00072 .
ns1:DB00072_DB00888	dcterms:title	"DDI between Trastuzumab and Mechlorethamine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00888 ,
		ns3:DB00072 .
ns1:DB00072_DB00928	dcterms:title	"DDI between Trastuzumab and Azacitidine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00928 ,
		ns3:DB00072 .
ns1:DB00072_DB00958	dcterms:title	"DDI between Trastuzumab and Carboplatin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00958 .
ns1:DB00072_DB00959	dcterms:title	"DDI between Trastuzumab and Methylprednisolone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00959 .
ns1:DB00072_DB00970	dcterms:title	"DDI between Trastuzumab and Dactinomycin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00970 .
ns1:DB00072_DB00987	dcterms:title	"DDI between Trastuzumab and Cytarabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00987 .
ns1:DB00072_DB00993	dcterms:title	"DDI between Trastuzumab and Azathioprine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00993 .
ns1:DB00072_DB00997	dcterms:title	"DDI between Trastuzumab and Doxorubicin - Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB00997 .
ns1:DB00072_DB01005	dcterms:title	"DDI between Trastuzumab and Hydroxyurea - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01005 .
ns1:DB00072_DB01008	dcterms:title	"DDI between Trastuzumab and Busulfan - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01008 .
ns1:DB00072_DB01024	dcterms:title	"DDI between Trastuzumab and Mycophenolic acid - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01024 .
ns1:DB00072_DB01030	dcterms:title	"DDI between Trastuzumab and Topotecan - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01030 .
ns1:DB00072_DB01033	dcterms:title	"DDI between Trastuzumab and Mercaptopurine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01033 .
ns1:DB00072_DB01041	dcterms:title	"DDI between Trastuzumab and Thalidomide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01041 .
ns1:DB00072_DB01042	dcterms:title	"DDI between Trastuzumab and Melphalan - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01042 .
ns1:DB00072_DB01073	dcterms:title	"DDI between Trastuzumab and Fludarabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01073 .
ns1:DB00072_DB01101	dcterms:title	"DDI between Trastuzumab and Capecitabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01101 .
ns1:DB00072_DB01168	dcterms:title	"DDI between Trastuzumab and Procarbazine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01168 .
ns1:DB00072_DB01177	dcterms:title	"DDI between Trastuzumab and Idarubicin - Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01177 .
ns1:DB00072_DB01181	dcterms:title	"DDI between Trastuzumab and Ifosfamide - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01181 .
ns1:DB00072_DB01196	dcterms:title	"DDI between Trastuzumab and Estramustine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01196 .
ns1:DB00072_DB01204	dcterms:title	"DDI between Trastuzumab and Mitoxantrone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01204 .
ns1:DB00072_DB01206	dcterms:title	"DDI between Trastuzumab and Lomustine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01206 .
ns1:DB00072_DB01229	dcterms:title	"DDI between Trastuzumab and Paclitaxel - Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01229 .
ns1:DB00072_DB01234	dcterms:title	"DDI between Trastuzumab and Dexamethasone - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01234 .
ns1:DB00072_DB01248	dcterms:title	"DDI between Trastuzumab and Docetaxel - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01248 .
ns1:DB00072_DB01268	dcterms:title	"DDI between Trastuzumab and Sunitinib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01268 .
ns1:DB00072_DB01280	dcterms:title	"DDI between Trastuzumab and Nelarabine - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01280 .
ns1:DB00072_DB01281	dcterms:title	"DDI between Trastuzumab and Abatacept - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01281 .
ns1:DB00072_DB01285	dcterms:title	"DDI between Trastuzumab and Corticotropin - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01285 .
ns1:DB00072_DB01380	dcterms:title	"DDI between Trastuzumab and Cortisone acetate - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB01380 .
ns1:DB00072_DB04572	dcterms:title	"DDI between Trastuzumab and Thiotepa - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB04572 .
ns1:DB00072_DB04868	dcterms:title	"DDI between Trastuzumab and Nilotinib - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB04868 .
ns1:DB00072_DB06287	dcterms:title	"DDI between Trastuzumab and Temsirolimus - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB06287 .
ns1:DB00072_DB06372	dcterms:title	"DDI between Trastuzumab and Rilonacept - Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB06372 .
ns1:DB00072_DB08895	dcterms:title	"DDI between Trastuzumab and Tofacitinib - Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00072 ,
		ns3:DB08895 .
ns1:DB00073_DB00177	dcterms:title	"DDI between Rituximab and Valsartan - Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00177 ,
		ns3:DB00073 .
ns1:DB00073_DB00195	dcterms:title	"DDI between Rituximab and Betaxolol - Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00195 ,
		ns3:DB00073 .
ns1:DB00073_DB00214	dcterms:title	"DDI between Rituximab and Torasemide - Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00214 ,
		ns3:DB00073 .
ns1:DB00073_DB00519	dcterms:title	"DDI between Rituximab and Trandolapril - Trandolapril may incresae the hypotensive effect of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00519 ,
		ns3:DB00073 .
ns1:DB00073_DB00661	dcterms:title	"DDI between Rituximab and Verapamil - Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00661 ,
		ns3:DB00073 .
ns1:DB00073_DB00839	dcterms:title	"DDI between Rituximab and Tolazamide - Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00073 .
ns1:DB00073_DB00880	dcterms:title	"DDI between Rituximab and Chlorothiazide - Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00880 ,
		ns3:DB00073 .
ns1:DB00073_DB00966	dcterms:title	"DDI between Rituximab and Telmisartan - Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB00966 .
ns1:DB00073_DB01021	dcterms:title	"DDI between Rituximab and Trichlormethiazide - Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB01021 .
ns1:DB00073_DB01162	dcterms:title	"DDI between Rituximab and Terazosin - Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB01162 .
ns1:DB00073_DB08822	dcterms:title	"DDI between Rituximab and Azilsartan medoxomil - Azilsartan medoxomil used in combination with rituximab may lead to hypotension."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB08822 .
ns1:DB00073_DB08895	dcterms:title	"DDI between Rituximab and Tofacitinib - Avoid combination due to the potential increase in tofacitinib related adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB08895 .
ns1:DB00073_DB08904	dcterms:title	"DDI between Rituximab and Certolizumab pegol - Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00073 ,
		ns3:DB08904 .
ns1:DB00074_DB06168	dcterms:title	"DDI between Basiliximab and Canakinumab - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00074 ,
		ns3:DB06168 .
ns1:DB00074_DB06372	dcterms:title	"DDI between Basiliximab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00074 ,
		ns3:DB06372 .
ns1:DB00075_DB00091	dcterms:title	"DDI between Muromonab and Cyclosporine - Muromonab increases the levels of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00075 .
ns1:DB00075_DB06372	dcterms:title	"DDI between Muromonab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00075 ,
		ns3:DB06372 .
ns1:DB00076_DB08810	dcterms:title	"DDI between Digoxin Immune Fab (Ovine) and Cinitapride - Cinitapride can alter the absorption of digoxin as it simulates gastric emptying."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00076 ,
		ns3:DB08810 .
ns1:DB00081_DB00108	dcterms:title	"DDI between Tositumomab and Natalizumab - The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00081 ,
		ns3:DB00108 .
ns1:DB00082_DB01551	dcterms:title	"DDI between Pegvisomant and Dihydrocodeine - Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01551 ,
		ns3:DB00082 .
ns1:DB00085_DB01592	dcterms:title	"DDI between Pancrelipase and Iron - If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01592 ,
		ns3:DB00085 .
ns1:DB00086_DB00208	dcterms:title	"DDI between Streptokinase and Ticlopidine - Increased bleeding risk. Monitor for signs of bleeding."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00208 ,
		ns3:DB00086 .
ns1:DB00091_DB00104	dcterms:title	"DDI between Cyclosporine and Octreotide - Octreotide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB00091 .
ns1:DB00091_DB00175	dcterms:title	"DDI between Cyclosporine and Pravastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00175 ,
		ns3:DB00091 .
ns1:DB00091_DB00193	dcterms:title	"DDI between Cyclosporine and Tramadol - Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00193 ,
		ns3:DB00091 .
ns1:DB00091_DB00196	dcterms:title	"DDI between Cyclosporine and Fluconazole - Fluconazole may increase the therapeutic and adverse effects of the cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00196 .
ns1:DB00091_DB00197	dcterms:title	"DDI between Cyclosporine and Troglitazone - Troglitazone decreases the effect of the immunosuppressant"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00197 .
ns1:DB00091_DB00199	dcterms:title	"DDI between Cyclosporine and Erythromycin - The macrolide, erythromycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00199 .
ns1:DB00091_DB00207	dcterms:title	"DDI between Cyclosporine and Azithromycin - The macrolide, azithromycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00207 .
ns1:DB00091_DB00208	dcterms:title	"DDI between Cyclosporine and Ticlopidine - Ticlopidine decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00208 .
ns1:DB00091_DB00220	dcterms:title	"DDI between Cyclosporine and Nelfinavir - The protease inhibitor, nelfinavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00220 .
ns1:DB00091_DB00222	dcterms:title	"DDI between Cyclosporine and Glimepiride - The sulfonylurea, glimepiride, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00222 .
ns1:DB00091_DB00224	dcterms:title	"DDI between Cyclosporine and Indinavir - The protease inhibitor, indinavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00224 .
ns1:DB00091_DB00227	dcterms:title	"DDI between Cyclosporine and Lovastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00227 .
ns1:DB00091_DB00237	dcterms:title	"DDI between Cyclosporine and Butabarbital - The barbiturate, butabarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00237 .
ns1:DB00091_DB00241	dcterms:title	"DDI between Cyclosporine and Butalbital - The barbiturate, butalbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00241 .
ns1:DB00091_DB00252	dcterms:title	"DDI between Cyclosporine and Phenytoin - The hydantoin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00252 .
ns1:DB00091_DB00306	dcterms:title	"DDI between Cyclosporine and Talbutal - The sulfonamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00306 .
ns1:DB00091_DB00312	dcterms:title	"DDI between Cyclosporine and Pentobarbital - The barbiturate, pentobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00312 .
ns1:DB00091_DB00328	dcterms:title	"DDI between Cyclosporine and Indomethacin - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00328 .
ns1:DB00091_DB00338	dcterms:title	"DDI between Cyclosporine and Omeprazole - Omeprazole increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00338 .
ns1:DB00091_DB00339	dcterms:title	"DDI between Cyclosporine and Pyrazinamide - Pyrazinamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00339 ,
		ns3:DB00091 .
ns1:DB00091_DB00343	dcterms:title	"DDI between Cyclosporine and Diltiazem - Diltiazem may increase the effect and toxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00343 ,
		ns3:DB00091 .
ns1:DB00091_DB00359	dcterms:title	"DDI between Cyclosporine and Sulfadiazine - The sulfonamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00359 ,
		ns3:DB00091 .
ns1:DB00091_DB00390	dcterms:title	"DDI between Cyclosporine and Digoxin - Cyclosporine may increase the effect of digoxin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00390 ,
		ns3:DB00091 .
ns1:DB00091_DB00400	dcterms:title	"DDI between Cyclosporine and Griseofulvin - Griseofulvin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00400 ,
		ns3:DB00091 .
ns1:DB00091_DB00418	dcterms:title	"DDI between Cyclosporine and Secobarbital - The barbiturate, secobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00418 ,
		ns3:DB00091 .
ns1:DB00091_DB00422	dcterms:title	"DDI between Cyclosporine and Methylphenidate - Methylphenidate increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00422 ,
		ns3:DB00091 .
ns1:DB00091_DB00437	dcterms:title	"DDI between Cyclosporine and Allopurinol - Allopurinol increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00437 ,
		ns3:DB00091 .
ns1:DB00091_DB00439	dcterms:title	"DDI between Cyclosporine and Cerivastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00439 ,
		ns3:DB00091 .
ns1:DB00091_DB00446	dcterms:title	"DDI between Cyclosporine and Chloramphenicol - Chloramphenicol may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00446 ,
		ns3:DB00091 .
ns1:DB00091_DB00461	dcterms:title	"DDI between Cyclosporine and Nabumetone - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00461 ,
		ns3:DB00091 .
ns1:DB00091_DB00469	dcterms:title	"DDI between Cyclosporine and Tenoxicam - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00469 ,
		ns3:DB00091 .
ns1:DB00091_DB00472	dcterms:title	"DDI between Cyclosporine and Fluoxetine - The antidepressant increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00472 ,
		ns3:DB00091 .
ns1:DB00091_DB00474	dcterms:title	"DDI between Cyclosporine and Methohexital - The barbiturate, methohexital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00474 ,
		ns3:DB00091 .
ns1:DB00091_DB00500	dcterms:title	"DDI between Cyclosporine and Tolmetin - Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00500 ,
		ns3:DB00091 .
ns1:DB00091_DB00503	dcterms:title	"DDI between Cyclosporine and Ritonavir - The protease inhibitor, ritonavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00503 ,
		ns3:DB00091 .
ns1:DB00091_DB00519	dcterms:title	"DDI between Cyclosporine and Trandolapril - The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00519 .
ns1:DB00091_DB00520	dcterms:title	"DDI between Cyclosporine and Caspofungin - Cyclosporine increases the effect and toxicity of caspofungin"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00520 .
ns1:DB00091_DB00529	dcterms:title	"DDI between Cyclosporine and Foscarnet - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00529 .
ns1:DB00091_DB00532	dcterms:title	"DDI between Cyclosporine and Mephenytoin - The hydantoin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00532 .
ns1:DB00091_DB00537	dcterms:title	"DDI between Cyclosporine and Ciprofloxacin - Ciprofloxacin may increase the effect and toxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00537 .
ns1:DB00091_DB00554	dcterms:title	"DDI between Cyclosporine and Piroxicam - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00554 .
ns1:DB00091_DB00559	dcterms:title	"DDI between Cyclosporine and Bosentan - Cyclosporine may increase the effect and toxicity of bosentan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00559 .
ns1:DB00091_DB00563	dcterms:title	"DDI between Cyclosporine and Methotrexate - Cyclosporine may increase the effect and toxicity of methotrexate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00563 .
ns1:DB00091_DB00564	dcterms:title	"DDI between Cyclosporine and Carbamazepine - Carbamazepine may decrease the therapeutic effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00564 .
ns1:DB00091_DB00573	dcterms:title	"DDI between Cyclosporine and Fenoprofen - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00573 .
ns1:DB00091_DB00582	dcterms:title	"DDI between Cyclosporine and Voriconazole - Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00582 .
ns1:DB00091_DB00586	dcterms:title	"DDI between Cyclosporine and Diclofenac - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00586 .
ns1:DB00091_DB00599	dcterms:title	"DDI between Cyclosporine and Thiopental - Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00599 .
ns1:DB00091_DB00605	dcterms:title	"DDI between Cyclosporine and Sulindac - The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00605 .
ns1:DB00091_DB00607	dcterms:title	"DDI between Cyclosporine and Nafcillin - Nafcillin alters serum levels of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00607 .
ns1:DB00091_DB00608	dcterms:title	"DDI between Cyclosporine and Chloroquine - Chloroquine may increase the therapeutic and adverse effects of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00608 .
ns1:DB00091_DB00615	dcterms:title	"DDI between Cyclosporine and Rifabutin - The rifamycin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00615 .
ns1:DB00091_DB00619	dcterms:title	"DDI between Cyclosporine and Imatinib - Imatinib increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00619 .
ns1:DB00091_DB00622	dcterms:title	"DDI between Cyclosporine and Nicardipine - Nicardipine increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00622 .
ns1:DB00091_DB00624	dcterms:title	"DDI between Cyclosporine and Testosterone - The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00624 .
ns1:DB00091_DB00625	dcterms:title	"DDI between Cyclosporine and Efavirenz - Efavirenz decreases the levels of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00625 .
ns1:DB00091_DB00641	dcterms:title	"DDI between Cyclosporine and Simvastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00641 .
ns1:DB00091_DB00656	dcterms:title	"DDI between Cyclosporine and Trazodone - The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00656 .
ns1:DB00091_DB00658	dcterms:title	"DDI between Cyclosporine and Sevelamer - Sevelamer decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00658 .
ns1:DB00091_DB00661	dcterms:title	"DDI between Cyclosporine and Verapamil - Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00661 .
ns1:DB00091_DB00681	dcterms:title	"DDI between Cyclosporine and Amphotericin B - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00681 .
ns1:DB00091_DB00684	dcterms:title	"DDI between Cyclosporine and Tobramycin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00684 .
ns1:DB00091_DB00701	dcterms:title	"DDI between Cyclosporine and Amprenavir - The protease inhibitor, amprenavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00701 .
ns1:DB00091_DB00706	dcterms:title	"DDI between Cyclosporine and Tamsulosin - Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00706 .
ns1:DB00091_DB00712	dcterms:title	"DDI between Cyclosporine and Flurbiprofen - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00712 .
ns1:DB00091_DB00745	dcterms:title	"DDI between Cyclosporine and Modafinil - Modafinil decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00745 .
ns1:DB00091_DB00749	dcterms:title	"DDI between Cyclosporine and Etodolac - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00749 .
ns1:DB00091_DB00754	dcterms:title	"DDI between Cyclosporine and Ethotoin - The hydantoin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00091 .
ns1:DB00091_DB00773	dcterms:title	"DDI between Cyclosporine and Etoposide - Cyclosporine may increase the therapeutic and adverse effects of etoposide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00773 ,
		ns3:DB00091 .
ns1:DB00091_DB00776	dcterms:title	"DDI between Cyclosporine and Oxcarbazepine - Oxcarbazepine decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00776 ,
		ns3:DB00091 .
ns1:DB00091_DB00778	dcterms:title	"DDI between Cyclosporine and Roxithromycin - The macrolide, roxithromycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00778 ,
		ns3:DB00091 .
ns1:DB00091_DB00784	dcterms:title	"DDI between Cyclosporine and Mefenamic acid - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00784 ,
		ns3:DB00091 .
ns1:DB00091_DB00788	dcterms:title	"DDI between Cyclosporine and Naproxen - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00788 ,
		ns3:DB00091 .
ns1:DB00091_DB00794	dcterms:title	"DDI between Cyclosporine and Primidone - The barbiturate, primidone, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00794 ,
		ns3:DB00091 .
ns1:DB00091_DB00795	dcterms:title	"DDI between Cyclosporine and Sulfasalazine - The sulfonamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00795 ,
		ns3:DB00091 .
ns1:DB00091_DB00819	dcterms:title	"DDI between Cyclosporine and Acetazolamide - Acetazolamide may increase the effect and toxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00819 ,
		ns3:DB00091 .
ns1:DB00091_DB00849	dcterms:title	"DDI between Cyclosporine and Methylphenobarbital - The barbiturate, methylphenobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00849 ,
		ns3:DB00091 .
ns1:DB00091_DB00857	dcterms:title	"DDI between Cyclosporine and Terbinafine - Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00857 ,
		ns3:DB00091 .
ns1:DB00091_DB00864	dcterms:title	"DDI between Cyclosporine and Tacrolimus - Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00091 .
ns1:DB00091_DB00877	dcterms:title	"DDI between Cyclosporine and Sirolimus - Increases the effect and toxicity of sirolimus"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00877 ,
		ns3:DB00091 .
ns1:DB00091_DB00894	dcterms:title	"DDI between Cyclosporine and Testolactone - The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00894 ,
		ns3:DB00091 .
ns1:DB00091_DB00912	dcterms:title	"DDI between Cyclosporine and Repaglinide - Cyclosporine may increase the therapeutic and adverse effects of repaglinide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00912 ,
		ns3:DB00091 .
ns1:DB00091_DB00932	dcterms:title	"DDI between Cyclosporine and Tipranavir - Tipranavir may affect the efficacy/toxicity of Cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00932 .
ns1:DB00091_DB00939	dcterms:title	"DDI between Cyclosporine and Meclofenamic acid - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00939 .
ns1:DB00091_DB00973	dcterms:title	"DDI between Cyclosporine and Ezetimibe - Cyclosporine may increase the therapeutic and adverse effects of ezetimibe."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00973 .
ns1:DB00091_DB00976	dcterms:title	"DDI between Cyclosporine and Telithromycin - Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00976 .
ns1:DB00091_DB00977	dcterms:title	"DDI between Cyclosporine and Ethinyl Estradiol - The contraceptive increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00977 .
ns1:DB00091_DB00991	dcterms:title	"DDI between Cyclosporine and Oxaprozin - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB00991 .
ns1:DB00091_DB01009	dcterms:title	"DDI between Cyclosporine and Ketoprofen - The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01009 .
ns1:DB00091_DB01015	dcterms:title	"DDI between Cyclosporine and Sulfamethoxazole - The sulfonamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01015 .
ns1:DB00091_DB01016	dcterms:title	"DDI between Cyclosporine and Glyburide - The sulfonylurea, glibenclamide, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01016 .
ns1:DB00091_DB01026	dcterms:title	"DDI between Cyclosporine and Ketoconazole - Ketoconazole may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01026 .
ns1:DB00091_DB01030	dcterms:title	"DDI between Cyclosporine and Topotecan - The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01030 .
ns1:DB00091_DB01036	dcterms:title	"DDI between Cyclosporine and Tolterodine - Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01036 .
ns1:DB00091_DB01042	dcterms:title	"DDI between Cyclosporine and Melphalan - Melphalan increases toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01042 .
ns1:DB00091_DB01045	dcterms:title	"DDI between Cyclosporine and Rifampicin - The rifamycin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01045 .
ns1:DB00091_DB01050	dcterms:title	"DDI between Cyclosporine and Ibuprofen - Monitor for nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01050 .
ns1:DB00091_DB01059	dcterms:title	"DDI between Cyclosporine and Norfloxacin - Norfloxacin may increase the effect and toxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01059 .
ns1:DB00091_DB01067	dcterms:title	"DDI between Cyclosporine and Glipizide - The sulfonylurea, glipizide, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01067 .
ns1:DB00091_DB01072	dcterms:title	"DDI between Cyclosporine and Atazanavir - Atazanavir may increase the therapeutic and adverse effects of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01072 .
ns1:DB00091_DB01076	dcterms:title	"DDI between Cyclosporine and Atorvastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01076 .
ns1:DB00091_DB01083	dcterms:title	"DDI between Cyclosporine and Orlistat - Orlistat decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01083 .
ns1:DB00091_DB01095	dcterms:title	"DDI between Cyclosporine and Fluvastatin - Possible myopathy and rhabdomyolysis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01095 .
ns1:DB00091_DB01098	dcterms:title	"DDI between Cyclosporine and Rosuvastatin - Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01098 .
ns1:DB00091_DB01105	dcterms:title	"DDI between Cyclosporine and Sibutramine - Sibutramine increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01105 .
ns1:DB00091_DB01115	dcterms:title	"DDI between Cyclosporine and Nifedipine - Increased risk of gingivitis"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01115 .
ns1:DB00091_DB01118	dcterms:title	"DDI between Cyclosporine and Amiodarone - Amiodarone may increase the therapeutic and adverse effects of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01118 .
ns1:DB00091_DB01136	dcterms:title	"DDI between Cyclosporine and Carvedilol - Carvedilol may increase the therapeutic and adverse effects of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01136 .
ns1:DB00091_DB01138	dcterms:title	"DDI between Cyclosporine and Sulfinpyrazone - Sulfinpyrazone decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01138 .
ns1:DB00091_DB01149	dcterms:title	"DDI between Cyclosporine and Nefazodone - The antidepressant increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01149 .
ns1:DB00091_DB01156	dcterms:title	"DDI between Cyclosporine and Bupropion - Bupropion may decrease the therapeutic effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01156 .
ns1:DB00091_DB01167	dcterms:title	"DDI between Cyclosporine and Itraconazole - Itraconazole may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01167 .
ns1:DB00091_DB01174	dcterms:title	"DDI between Cyclosporine and Phenobarbital - The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01174 .
ns1:DB00091_DB01182	dcterms:title	"DDI between Cyclosporine and Propafenone - Propafenone increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01182 .
ns1:DB00091_DB01190	dcterms:title	"DDI between Cyclosporine and Clindamycin - Clindamycin may decrease the therapeutic effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01190 .
ns1:DB00091_DB01211	dcterms:title	"DDI between Cyclosporine and Clarithromycin - The macrolide, clarithromycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01211 .
ns1:DB00091_DB01232	dcterms:title	"DDI between Cyclosporine and Saquinavir - The protease inhibitor, saquinavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01232 .
ns1:DB00091_DB01233	dcterms:title	"DDI between Cyclosporine and Metoclopramide - Metoclopramide increases serum levels of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01233 .
ns1:DB00091_DB01263	dcterms:title	"DDI between Cyclosporine and Posaconazole - Increased level of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01263 .
ns1:DB00091_DB01319	dcterms:title	"DDI between Cyclosporine and Fosamprenavir - The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01319 .
ns1:DB00091_DB01320	dcterms:title	"DDI between Cyclosporine and Fosphenytoin - The hydantoin decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01320 .
ns1:DB00091_DB01321	dcterms:title	"DDI between Cyclosporine and Josamycin - The macrolide, josamycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01321 .
ns1:DB00091_DB01323	dcterms:title	"DDI between Cyclosporine and St. John's Wort - St. John's Wort decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01323 .
ns1:DB00091_DB01341	dcterms:title	"DDI between Cyclosporine and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01341 .
ns1:DB00091_DB01346	dcterms:title	"DDI between Cyclosporine and Quinidine barbiturate - The barbiturate, quinidine barbiturate, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01346 .
ns1:DB00091_DB01351	dcterms:title	"DDI between Cyclosporine and Amobarbital - The barbiturate, amobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01351 .
ns1:DB00091_DB01352	dcterms:title	"DDI between Cyclosporine and Aprobarbital - The barbiturate, aprobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01352 .
ns1:DB00091_DB01353	dcterms:title	"DDI between Cyclosporine and Butethal - The barbiturate, butethal, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01353 .
ns1:DB00091_DB01354	dcterms:title	"DDI between Cyclosporine and Heptabarbital - The barbiturate, heptabarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01354 .
ns1:DB00091_DB01355	dcterms:title	"DDI between Cyclosporine and Hexobarbital - The barbiturate, hexobarbital, increases the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01355 .
ns1:DB00091_DB01357	dcterms:title	"DDI between Cyclosporine and Mestranol - The contraceptive increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01357 .
ns1:DB00091_DB01361	dcterms:title	"DDI between Cyclosporine and Troleandomycin - The macrolide, troleandomycin, may increase the effect of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01361 .
ns1:DB00091_DB01369	dcterms:title	"DDI between Cyclosporine and Quinupristin - Synercid increases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01369 .
ns1:DB00091_DB01393	dcterms:title	"DDI between Cyclosporine and Bezafibrate - Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01393 .
ns1:DB00091_DB01394	dcterms:title	"DDI between Cyclosporine and Colchicine - Increased toxicity of both drugs"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01394 .
ns1:DB00091_DB01406	dcterms:title	"DDI between Cyclosporine and Danazol - The androgen, danazol, may increase the effect and toxicity of cyclosporine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01406 .
ns1:DB00091_DB01420	dcterms:title	"DDI between Cyclosporine and Testosterone Propionate - The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01420 .
ns1:DB00091_DB01582	dcterms:title	"DDI between Cyclosporine and Sulfamethazine - The sulfonamide decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01582 .
ns1:DB00091_DB01586	dcterms:title	"DDI between Cyclosporine and Ursodeoxycholic acid - Ursodiol increases the levels of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01586 .
ns1:DB00091_DB01597	dcterms:title	"DDI between Cyclosporine and Cilastatin - Imipenem increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01597 .
ns1:DB00091_DB01598	dcterms:title	"DDI between Cyclosporine and Imipenem - Imipenem increases the effect and toxicity of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01598 .
ns1:DB00091_DB01599	dcterms:title	"DDI between Cyclosporine and Probucol - Probucol decreases the effect of cyclosporine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01599 .
ns1:DB00091_DB01600	dcterms:title	"DDI between Cyclosporine and Tiaprofenic acid - Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB01600 .
ns1:DB00091_DB04855	dcterms:title	"DDI between Cyclosporine and Dronedarone - Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB04855 .
ns1:DB00091_DB05275	dcterms:title	"DDI between Cyclosporine and transdermal testosterone gel - The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB05275 .
ns1:DB00091_DB05521	dcterms:title	"DDI between Cyclosporine and Telaprevir - Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB05521 .
ns1:DB00091_DB06372	dcterms:title	"DDI between Cyclosporine and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB06372 .
ns1:DB00091_DB08860	dcterms:title	"DDI between Cyclosporine and Pitavastatin - Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB08860 .
ns1:DB00091_DB08874	dcterms:title	"DDI between Cyclosporine and Fidaxomicin - Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB08874 .
ns1:DB00091_DB08895	dcterms:title	"DDI between Cyclosporine and Tofacitinib - Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00091 ,
		ns3:DB08895 .
ns1:DB00092_DB06168	dcterms:title	"DDI between Alefacept and Canakinumab - Increases immunosuppressive effects and risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00092 ,
		ns3:DB06168 .
ns1:DB00092_DB06372	dcterms:title	"DDI between Alefacept and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00092 ,
		ns3:DB06372 .
ns1:DB00095_DB01253	dcterms:title	"DDI between Efalizumab and Ergonovine - The antiretroviral agent may increase the ergot derivative"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00095 ,
		ns3:DB01253 .
ns1:DB00095_DB06372	dcterms:title	"DDI between Efalizumab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00095 ,
		ns3:DB06372 .
ns1:DB00098_DB06168	dcterms:title	"DDI between Antithymocyte globulin and Canakinumab - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00098 ,
		ns3:DB06168 .
ns1:DB00098_DB06372	dcterms:title	"DDI between Antithymocyte globulin and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00098 ,
		ns3:DB06372 .
ns1:DB00099_DB01030	dcterms:title	"DDI between Filgrastim and Topotecan - Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00099 ,
		ns3:DB01030 .
ns1:DB00104_DB00246	dcterms:title	"DDI between Octreotide and Ziprasidone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00246 ,
		ns3:DB00104 .
ns1:DB00104_DB00539	dcterms:title	"DDI between Octreotide and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00539 ,
		ns3:DB00104 .
ns1:DB00104_DB00582	dcterms:title	"DDI between Octreotide and Voriconazole - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00582 ,
		ns3:DB00104 .
ns1:DB00104_DB00726	dcterms:title	"DDI between Octreotide and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00726 ,
		ns3:DB00104 .
ns1:DB00104_DB00864	dcterms:title	"DDI between Octreotide and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00104 .
ns1:DB00104_DB01369	dcterms:title	"DDI between Octreotide and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB01369 .
ns1:DB00104_DB01551	dcterms:title	"DDI between Octreotide and Dihydrocodeine - Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB01551 .
ns1:DB00104_DB01623	dcterms:title	"DDI between Octreotide and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB01623 .
ns1:DB00104_DB01624	dcterms:title	"DDI between Octreotide and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB01624 .
ns1:DB00104_DB02546	dcterms:title	"DDI between Octreotide and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB02546 .
ns1:DB00104_DB06697	dcterms:title	"DDI between Octreotide and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB06697 .
ns1:DB00104_DB06708	dcterms:title	"DDI between Octreotide and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB06708 .
ns1:DB00104_DB08919	dcterms:title	"DDI between Octreotide and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB08919 .
ns1:DB00104_DB08920	dcterms:title	"DDI between Octreotide and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00104 ,
		ns3:DB08920 .
ns1:DB00105_DB00277	dcterms:title	"DDI between Interferon Alfa-2b, Recombinant and Theophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00277 ,
		ns3:DB00105 .
ns1:DB00105_DB00651	dcterms:title	"DDI between Interferon Alfa-2b, Recombinant and Dyphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00651 ,
		ns3:DB00105 .
ns1:DB00105_DB01223	dcterms:title	"DDI between Interferon Alfa-2b, Recombinant and Aminophylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00105 ,
		ns3:DB01223 .
ns1:DB00105_DB01303	dcterms:title	"DDI between Interferon Alfa-2b, Recombinant and Oxtriphylline - Interferon increases the effect and toxicity of theophylline"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00105 ,
		ns3:DB01303 .
ns1:DB00106_DB00246	dcterms:title	"DDI between Abarelix and Ziprasidone - Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB00246 .
ns1:DB00106_DB00539	dcterms:title	"DDI between Abarelix and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB00539 .
ns1:DB00106_DB00582	dcterms:title	"DDI between Abarelix and Voriconazole - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB00582 .
ns1:DB00106_DB00726	dcterms:title	"DDI between Abarelix and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB00726 .
ns1:DB00106_DB00864	dcterms:title	"DDI between Abarelix and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB00864 .
ns1:DB00106_DB01623	dcterms:title	"DDI between Abarelix and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB01623 .
ns1:DB00106_DB01624	dcterms:title	"DDI between Abarelix and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB01624 .
ns1:DB00106_DB02546	dcterms:title	"DDI between Abarelix and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB02546 .
ns1:DB00106_DB08919	dcterms:title	"DDI between Abarelix and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB08919 .
ns1:DB00106_DB08920	dcterms:title	"DDI between Abarelix and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00106 ,
		ns3:DB08920 .
ns1:DB00107_DB00388	dcterms:title	"DDI between Oxytocin and Phenylephrine - Possible marked increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00107 ,
		ns3:DB00388 .
ns1:DB00107_DB00668	dcterms:title	"DDI between Oxytocin and Epinephrine - Possible marked increase of arterial pressure"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00107 ,
		ns3:DB00668 .
ns1:DB00108_DB00242	dcterms:title	"DDI between Natalizumab and Cladribine - Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00242 ,
		ns3:DB00108 .
ns1:DB00108_DB00262	dcterms:title	"DDI between Natalizumab and Carmustine - Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00262 ,
		ns3:DB00108 .
ns1:DB00108_DB00290	dcterms:title	"DDI between Natalizumab and Bleomycin - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00108 ,
		ns3:DB00290 .
ns1:DB00108_DB00291	dcterms:title	"DDI between Natalizumab and Chlorambucil - Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00108 ,
		ns3:DB00291 .
ns1:DB00108_DB00352	dcterms:title	"DDI between Natalizumab and Thioguanine - The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00352 ,
		ns3:DB00108 .
ns1:DB00108_DB00361	dcterms:title	"DDI between Natalizumab and Vinorelbine - Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00361 ,
		ns3:DB00108 .
ns1:DB00108_DB00385	dcterms:title	"DDI between Natalizumab and Valrubicin - Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00385 ,
		ns3:DB00108 .
ns1:DB00108_DB00444	dcterms:title	"DDI between Natalizumab and Teniposide - The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00108 .
ns1:DB00108_DB00515	dcterms:title	"DDI between Natalizumab and Cisplatin - Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00515 ,
		ns3:DB00108 .
ns1:DB00108_DB00541	dcterms:title	"DDI between Natalizumab and Vincristine - Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00541 ,
		ns3:DB00108 .
ns1:DB00108_DB00570	dcterms:title	"DDI between Natalizumab and Vinblastine - Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00570 ,
		ns3:DB00108 .
ns1:DB00108_DB00631	dcterms:title	"DDI between Natalizumab and Clofarabine - Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00631 ,
		ns3:DB00108 .
ns1:DB00108_DB00755	dcterms:title	"DDI between Natalizumab and Tretinoin - Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00755 ,
		ns3:DB00108 .
ns1:DB00108_DB00853	dcterms:title	"DDI between Natalizumab and Temozolomide - The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00853 ,
		ns3:DB00108 .
ns1:DB00108_DB00864	dcterms:title	"DDI between Natalizumab and Tacrolimus - Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00108 .
ns1:DB00108_DB00958	dcterms:title	"DDI between Natalizumab and Carboplatin - Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00958 ,
		ns3:DB00108 .
ns1:DB00108_DB01030	dcterms:title	"DDI between Natalizumab and Topotecan - The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01030 ,
		ns3:DB00108 .
ns1:DB00108_DB01041	dcterms:title	"DDI between Natalizumab and Thalidomide - Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01041 ,
		ns3:DB00108 .
ns1:DB00108_DB01229	dcterms:title	"DDI between Natalizumab and Paclitaxel - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01229 ,
		ns3:DB00108 .
ns1:DB00108_DB04572	dcterms:title	"DDI between Natalizumab and Thiotepa - The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04572 ,
		ns3:DB00108 .
ns1:DB00108_DB04865	dcterms:title	"DDI between Natalizumab and Homoharringtonine - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB04865 ,
		ns3:DB00108 .
ns1:DB00108_DB05773	dcterms:title	"DDI between Natalizumab and ado-trastuzumab emtansine - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05773 ,
		ns3:DB00108 .
ns1:DB00108_DB06168	dcterms:title	"DDI between Natalizumab and Canakinumab - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06168 ,
		ns3:DB00108 .
ns1:DB00108_DB06287	dcterms:title	"DDI between Natalizumab and Temsirolimus - Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06287 ,
		ns3:DB00108 .
ns1:DB00108_DB06674	dcterms:title	"DDI between Natalizumab and golimumab - Avoid combination due to the increased chance of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06674 ,
		ns3:DB00108 .
ns1:DB00108_DB08870	dcterms:title	"DDI between Natalizumab and Brentuximab vedotin - Avoid combination due to the increased risk of concurrent infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08870 ,
		ns3:DB00108 .
ns1:DB00108_DB08880	dcterms:title	"DDI between Natalizumab and Teriflunomide - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08880 ,
		ns3:DB00108 .
ns1:DB00108_DB08895	dcterms:title	"DDI between Natalizumab and Tofacitinib - Avoid combination due to the increased risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08895 ,
		ns3:DB00108 .
ns1:DB00108_DB08904	dcterms:title	"DDI between Natalizumab and Certolizumab pegol - Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08904 ,
		ns3:DB00108 .
ns1:DB00111_DB06372	dcterms:title	"DDI between Daclizumab and Rilonacept - results in increased immunosuppressive effects; increases the risk of infection."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06372 ,
		ns3:DB00111 .
ns1:DB00112_DB01268	dcterms:title	"DDI between Bevacizumab and Sunitinib - Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00112 ,
		ns3:DB01268 .
ns1:DB00118_DB00193	dcterms:title	"DDI between S-Adenosylmethionine and Tramadol - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00193 .
ns1:DB00118_DB00285	dcterms:title	"DDI between S-Adenosylmethionine and Venlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00285 ,
		ns3:DB00118 .
ns1:DB00118_DB00315	dcterms:title	"DDI between S-Adenosylmethionine and Zolmitriptan - Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00315 ,
		ns3:DB00118 .
ns1:DB00118_DB00605	dcterms:title	"DDI between S-Adenosylmethionine and Sulindac - S-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00605 .
ns1:DB00118_DB00656	dcterms:title	"DDI between S-Adenosylmethionine and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00656 .
ns1:DB00118_DB00682	dcterms:title	"DDI between S-Adenosylmethionine and Warfarin - Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00682 .
ns1:DB00118_DB00726	dcterms:title	"DDI between S-Adenosylmethionine and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00726 .
ns1:DB00118_DB00752	dcterms:title	"DDI between S-Adenosylmethionine and Tranylcypromine - Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00118 ,
		ns3:DB00752 .
ns1:DB00118_DB01009	dcterms:title	"DDI between S-Adenosylmethionine and Ketoprofen - Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01009 ,
		ns3:DB00118 .
ns1:DB00118_DB01381	dcterms:title	"DDI between S-Adenosylmethionine and Ginkgo biloba - Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01381 ,
		ns3:DB00118 .
ns1:DB00118_DB06700	dcterms:title	"DDI between S-Adenosylmethionine and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00118 .
ns1:DB00443_DB00474	dcterms:title	"DDI between Betamethasone and Methohexital - The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00474 ,
		ns3:DB00443 .
ns1:DB00443_DB00532	dcterms:title	"DDI between Betamethasone and Mephenytoin - The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00532 .
ns1:DB00443_DB00545	dcterms:title	"DDI between Betamethasone and Pyridostigmine - The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00545 ,
		ns3:DB00443 .
ns1:DB00443_DB00682	dcterms:title	"DDI between Betamethasone and Warfarin - The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00682 .
ns1:DB00443_DB00754	dcterms:title	"DDI between Betamethasone and Ethotoin - The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00754 .
ns1:DB00443_DB00794	dcterms:title	"DDI between Betamethasone and Primidone - The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00794 .
ns1:DB00443_DB00849	dcterms:title	"DDI between Betamethasone and Methylphenobarbital - The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB00849 .
ns1:DB00443_DB00945	dcterms:title	"DDI between Betamethasone and Acetylsalicylic acid - The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00945 ,
		ns3:DB00443 .
ns1:DB00443_DB01010	dcterms:title	"DDI between Betamethasone and Edrophonium - The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB01010 .
ns1:DB00443_DB01045	dcterms:title	"DDI between Betamethasone and Rifampicin - The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00443 .
ns1:DB00443_DB01122	dcterms:title	"DDI between Betamethasone and Ambenonium - The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB01122 .
ns1:DB00443_DB01125	dcterms:title	"DDI between Betamethasone and Anisindione - The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00443 .
ns1:DB00443_DB01174	dcterms:title	"DDI between Betamethasone and Phenobarbital - The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01174 ,
		ns3:DB00443 .
ns1:DB00443_DB01294	dcterms:title	"DDI between Betamethasone and Bismuth Subsalicylate - The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01294 ,
		ns3:DB00443 .
ns1:DB00443_DB01320	dcterms:title	"DDI between Betamethasone and Fosphenytoin - The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00443 .
ns1:DB00443_DB01339	dcterms:title	"DDI between Betamethasone and Vecuronium - Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01339 ,
		ns3:DB00443 .
ns1:DB00443_DB01341	dcterms:title	"DDI between Betamethasone and Dihydroquinidine barbiturate - The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01341 ,
		ns3:DB00443 .
ns1:DB00443_DB01346	dcterms:title	"DDI between Betamethasone and Quinidine barbiturate - The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01346 ,
		ns3:DB00443 .
ns1:DB00443_DB01351	dcterms:title	"DDI between Betamethasone and Amobarbital - The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01351 ,
		ns3:DB00443 .
ns1:DB00443_DB01352	dcterms:title	"DDI between Betamethasone and Aprobarbital - The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01352 ,
		ns3:DB00443 .
ns1:DB00443_DB01353	dcterms:title	"DDI between Betamethasone and Butethal - The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01353 ,
		ns3:DB00443 .
ns1:DB00443_DB01354	dcterms:title	"DDI between Betamethasone and Heptabarbital - The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01354 ,
		ns3:DB00443 .
ns1:DB00443_DB01355	dcterms:title	"DDI between Betamethasone and Hexobarbital - The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01355 ,
		ns3:DB00443 .
ns1:DB00443_DB01397	dcterms:title	"DDI between Betamethasone and Magnesium salicylate - The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01397 ,
		ns3:DB00443 .
ns1:DB00443_DB01398	dcterms:title	"DDI between Betamethasone and Salicylate-sodium - The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01398 ,
		ns3:DB00443 .
ns1:DB00443_DB01399	dcterms:title	"DDI between Betamethasone and Salsalate - The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00443 ,
		ns3:DB01399 .
ns1:DB00443_DB01401	dcterms:title	"DDI between Betamethasone and Trisalicylate-choline - The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01401 ,
		ns3:DB00443 .
ns1:DB00443_DB01418	dcterms:title	"DDI between Betamethasone and Acenocoumarol - The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00443 .
ns1:DB00443_DB05039	dcterms:title	"DDI between Betamethasone and Indacaterol - Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB05039 ,
		ns3:DB00443 .
ns1:DB00444_DB00503	dcterms:title	"DDI between Teniposide and Ritonavir - The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00503 .
ns1:DB00444_DB00582	dcterms:title	"DDI between Teniposide and Voriconazole - The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00582 .
ns1:DB00444_DB00619	dcterms:title	"DDI between Teniposide and Imatinib - The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Imatinib is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00619 .
ns1:DB00444_DB00622	dcterms:title	"DDI between Teniposide and Nicardipine - The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00622 .
ns1:DB00444_DB00701	dcterms:title	"DDI between Teniposide and Amprenavir - The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Amprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00444 ,
		ns3:DB00701 .
ns1:DB00444_DB00705	dcterms:title	"DDI between Teniposide and Delavirdine - The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Delavirdine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00705 ,
		ns3:DB00444 .
ns1:DB00444_DB00872	dcterms:title	"DDI between Teniposide and Conivaptan - The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Conivaptan is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00872 ,
		ns3:DB00444 .
ns1:DB00444_DB00908	dcterms:title	"DDI between Teniposide and Quinidine - The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00444 .
ns1:DB00444_DB00951	dcterms:title	"DDI between Teniposide and Isoniazid - The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00444 .
ns1:DB00444_DB00976	dcterms:title	"DDI between Teniposide and Telithromycin - The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00976 ,
		ns3:DB00444 .
ns1:DB00444_DB01026	dcterms:title	"DDI between Teniposide and Ketoconazole - The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01026 ,
		ns3:DB00444 .
ns1:DB00444_DB01072	dcterms:title	"DDI between Teniposide and Atazanavir - The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01072 ,
		ns3:DB00444 .
ns1:DB00444_DB01110	dcterms:title	"DDI between Teniposide and Miconazole - The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Miconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01110 ,
		ns3:DB00444 .
ns1:DB00444_DB01149	dcterms:title	"DDI between Teniposide and Nefazodone - The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nefazodone is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01149 ,
		ns3:DB00444 .
ns1:DB00444_DB01167	dcterms:title	"DDI between Teniposide and Itraconazole - The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01167 ,
		ns3:DB00444 .
ns1:DB00444_DB01211	dcterms:title	"DDI between Teniposide and Clarithromycin - The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Clarithromycin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01211 ,
		ns3:DB00444 .
ns1:DB00444_DB01232	dcterms:title	"DDI between Teniposide and Saquinavir - The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01232 ,
		ns3:DB00444 .
ns1:DB00444_DB01263	dcterms:title	"DDI between Teniposide and Posaconazole - The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Posaconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01263 ,
		ns3:DB00444 .
ns1:DB00444_DB01264	dcterms:title	"DDI between Teniposide and Darunavir - The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Darunavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01264 ,
		ns3:DB00444 .
ns1:DB00444_DB01319	dcterms:title	"DDI between Teniposide and Fosamprenavir - The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Fosamprenavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01319 ,
		ns3:DB00444 .
ns1:DB00444_DB01369	dcterms:title	"DDI between Teniposide and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01369 ,
		ns3:DB00444 .
ns1:DB00444_DB01601	dcterms:title	"DDI between Teniposide and Lopinavir - The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Lopinavir is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01601 ,
		ns3:DB00444 .
ns1:DB00445_DB00501	dcterms:title	"DDI between Epirubicin and Cimetidine - Cimetidine can increase epirubicin levels"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00501 ,
		ns3:DB00445 .
ns1:DB00446_DB00532	dcterms:title	"DDI between Chloramphenicol and Mephenytoin - Increases phenytoin, modifies chloramphenicol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00532 ,
		ns3:DB00446 .
ns1:DB00446_DB00599	dcterms:title	"DDI between Chloramphenicol and Thiopental - Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00446 ,
		ns3:DB00599 .
ns1:DB00446_DB00672	dcterms:title	"DDI between Chloramphenicol and Chlorpropamide - Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00672 ,
		ns3:DB00446 .
ns1:DB00446_DB00754	dcterms:title	"DDI between Chloramphenicol and Ethotoin - Increases phenytoin, modifies chloramphenicol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00754 ,
		ns3:DB00446 .
ns1:DB00446_DB00839	dcterms:title	"DDI between Chloramphenicol and Tolazamide - Chloramphenicol may increase the effect of sulfonylurea, tolazamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00839 ,
		ns3:DB00446 .
ns1:DB00446_DB00864	dcterms:title	"DDI between Chloramphenicol and Tacrolimus - Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00864 ,
		ns3:DB00446 .
ns1:DB00446_DB01016	dcterms:title	"DDI between Chloramphenicol and Glyburide - Chloramphenicol may increase the effect of sulfonylurea, glibenclamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01016 ,
		ns3:DB00446 .
ns1:DB00446_DB01045	dcterms:title	"DDI between Chloramphenicol and Rifampicin - Rifampin decreases the effect of chloramphenicol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01045 ,
		ns3:DB00446 .
ns1:DB00446_DB01067	dcterms:title	"DDI between Chloramphenicol and Glipizide - Chloramphenicol may increase the effect of sulfonylurea, glipizide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01067 ,
		ns3:DB00446 .
ns1:DB00446_DB01120	dcterms:title	"DDI between Chloramphenicol and Gliclazide - Chloramphenicol may increase the effect of sulfonylurea, gliclazide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01120 ,
		ns3:DB00446 .
ns1:DB00446_DB01124	dcterms:title	"DDI between Chloramphenicol and Tolbutamide - Chloramphenicol may increase the effect of sulfonylurea, tolbutamide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01124 ,
		ns3:DB00446 .
ns1:DB00446_DB01289	dcterms:title	"DDI between Chloramphenicol and Glisoxepide - Chloramphenicol may increase the effect of sulfonylurea, glisoxepide."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01289 ,
		ns3:DB00446 .
ns1:DB00446_DB01320	dcterms:title	"DDI between Chloramphenicol and Fosphenytoin - Increases phenytoin, modifies chloramphenicol"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01320 ,
		ns3:DB00446 .
ns1:DB00446_DB01382	dcterms:title	"DDI between Chloramphenicol and Glycodiazine - Chloramphenicol may increase the effect of sulfonylurea, glycodiazine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01382 ,
		ns3:DB00446 .
ns1:DB00446_DB06207	dcterms:title	"DDI between Chloramphenicol and Silodosin - Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06207 ,
		ns3:DB00446 .
ns1:DB00446_DB08815	dcterms:title	"DDI between Chloramphenicol and Lurasidone - Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08815 ,
		ns3:DB00446 .
ns1:DB00447_DB01032	dcterms:title	"DDI between Loracarbef and Probenecid - Probenecid may increase the serum level of loracarbef."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00447 ,
		ns3:DB01032 .
ns1:DB00448_DB00467	dcterms:title	"DDI between Lansoprazole and Enoxacin - Lansoprazole may decrease the absorption of enoxacin."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00467 ,
		ns3:DB00448 .
ns1:DB00448_DB00758	dcterms:title	"DDI between Lansoprazole and Clopidogrel - Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB00758 .
ns1:DB00448_DB01026	dcterms:title	"DDI between Lansoprazole and Ketoconazole - The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB01026 .
ns1:DB00448_DB01066	dcterms:title	"DDI between Lansoprazole and Cefditoren - Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB01066 .
ns1:DB00448_DB01072	dcterms:title	"DDI between Lansoprazole and Atazanavir - This gastric pH modifier decreases the levels/effects of atazanavir"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB01072 .
ns1:DB00448_DB01167	dcterms:title	"DDI between Lansoprazole and Itraconazole - The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB01167 .
ns1:DB00448_DB06209	dcterms:title	"DDI between Lansoprazole and Prasugrel - Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06209 ,
		ns3:DB00448 .
ns1:DB00448_DB06616	dcterms:title	"DDI between Lansoprazole and Bosutinib - Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00448 ,
		ns3:DB06616 .
ns1:DB00448_DB08864	dcterms:title	"DDI between Lansoprazole and Rilpivirine - Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB08864 ,
		ns3:DB00448 .
ns1:DB00449_DB06700	dcterms:title	"DDI between Dipivefrin and Desvenlafaxine - Desvenlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06700 ,
		ns3:DB00449 .
ns1:DB00450_DB00484	dcterms:title	"DDI between Droperidol and Brimonidine - Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00484 .
ns1:DB00450_DB00539	dcterms:title	"DDI between Droperidol and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00539 .
ns1:DB00450_DB00582	dcterms:title	"DDI between Droperidol and Voriconazole - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00582 .
ns1:DB00450_DB00611	dcterms:title	"DDI between Droperidol and Butorphanol - Droperidol may enhance the CNS depressant effect of butorphanol. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00611 .
ns1:DB00450_DB00662	dcterms:title	"DDI between Droperidol and Trimethobenzamide - Trimethobenzamide and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00662 .
ns1:DB00450_DB00726	dcterms:title	"DDI between Droperidol and Trimipramine - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00726 .
ns1:DB00450_DB00864	dcterms:title	"DDI between Droperidol and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00864 .
ns1:DB00450_DB00921	dcterms:title	"DDI between Droperidol and Buprenorphine - Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB00921 .
ns1:DB00450_DB01369	dcterms:title	"DDI between Droperidol and Quinupristin - This combination presents an increased risk of toxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB01369 .
ns1:DB00450_DB01551	dcterms:title	"DDI between Droperidol and Dihydrocodeine - Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB01551 .
ns1:DB00450_DB01623	dcterms:title	"DDI between Droperidol and Thiothixene - May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB01623 .
ns1:DB00450_DB01624	dcterms:title	"DDI between Droperidol and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB01624 .
ns1:DB00450_DB02546	dcterms:title	"DDI between Droperidol and Vorinostat - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB02546 .
ns1:DB00450_DB04844	dcterms:title	"DDI between Droperidol and Tetrabenazine - May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB04844 .
ns1:DB00450_DB06697	dcterms:title	"DDI between Droperidol and Artemether - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB06697 .
ns1:DB00450_DB06708	dcterms:title	"DDI between Droperidol and Lumefantrine - Additive QTc-prolongation may occur. Concomitant therapy should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB06708 .
ns1:DB00450_DB08919	dcterms:title	"DDI between Droperidol and Zuclopenthixol acetate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB08919 .
ns1:DB00450_DB08920	dcterms:title	"DDI between Droperidol and Zuclopenthixol decanoate - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00450 ,
		ns3:DB08920 .
ns1:DB00451_DB00481	dcterms:title	"DDI between Levothyroxine and Raloxifene - Raloxifene decreases absorption of levothyroxine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00451 ,
		ns3:DB00481 .
ns1:DB00451_DB00682	dcterms:title	"DDI between Levothyroxine and Warfarin - Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00682 ,
		ns3:DB00451 .
ns1:DB00451_DB00893	dcterms:title	"DDI between Levothyroxine and Iron Dextran - Iron decreases the absorption of levothyroxine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00893 ,
		ns3:DB00451 .
ns1:DB00451_DB01125	dcterms:title	"DDI between Levothyroxine and Anisindione - The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01125 ,
		ns3:DB00451 .
ns1:DB00451_DB01164	dcterms:title	"DDI between Levothyroxine and Calcium Chloride - Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00451 ,
		ns3:DB01164 .
ns1:DB00451_DB01373	dcterms:title	"DDI between Levothyroxine and Calcium - Calcium decreases absorption of levothyroxine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01373 ,
		ns3:DB00451 .
ns1:DB00451_DB01418	dcterms:title	"DDI between Levothyroxine and Acenocoumarol - The thyroid hormone, levothyroxine, increase the anticoagulant effect of acenocoumarol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01418 ,
		ns3:DB00451 .
ns1:DB00451_DB01432	dcterms:title	"DDI between Levothyroxine and Cholestyramine - The resin, cholestyramine, decreases the absorption of the thyroid hormone, levothyroxine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01432 ,
		ns3:DB00451 .
ns1:DB00451_DB01592	dcterms:title	"DDI between Levothyroxine and Iron - Iron decreases absorption of levothyroxine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01592 ,
		ns3:DB00451 .
ns1:DB00454_DB00477	dcterms:title	"DDI between Pethidine and Chlorpromazine - Increased sedation and hypotension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00477 .
ns1:DB00454_DB00503	dcterms:title	"DDI between Pethidine and Ritonavir - Ritonavir increases the levels of analgesic"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00503 .
ns1:DB00454_DB00656	dcterms:title	"DDI between Pethidine and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00656 .
ns1:DB00454_DB00674	dcterms:title	"DDI between Pethidine and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00674 ,
		ns3:DB00454 .
ns1:DB00454_DB00726	dcterms:title	"DDI between Pethidine and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00726 .
ns1:DB00454_DB00752	dcterms:title	"DDI between Pethidine and Tranylcypromine - Increased risk of serotonin syndrome. Concomitant use should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00752 .
ns1:DB00454_DB00780	dcterms:title	"DDI between Pethidine and Phenelzine - Potentially fatal adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00780 ,
		ns3:DB00454 .
ns1:DB00454_DB00843	dcterms:title	"DDI between Pethidine and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00843 ,
		ns3:DB00454 .
ns1:DB00454_DB00932	dcterms:title	"DDI between Pethidine and Tipranavir - Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB00932 .
ns1:DB00454_DB00951	dcterms:title	"DDI between Pethidine and Isoniazid - Possible episodes of hypotension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00951 ,
		ns3:DB00454 .
ns1:DB00454_DB00989	dcterms:title	"DDI between Pethidine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00454 .
ns1:DB00454_DB01037	dcterms:title	"DDI between Pethidine and Selegiline - Potentially fatal adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01037 ,
		ns3:DB00454 .
ns1:DB00454_DB01105	dcterms:title	"DDI between Pethidine and Sibutramine - Possible serotoninergic syndrome"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB01105 .
ns1:DB00454_DB01171	dcterms:title	"DDI between Pethidine and Moclobemide - Increased CNS toxicity (can cause death)"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB01171 .
ns1:DB00454_DB01247	dcterms:title	"DDI between Pethidine and Isocarboxazid - Potentially fatal adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01247 ,
		ns3:DB00454 .
ns1:DB00454_DB01367	dcterms:title	"DDI between Pethidine and Rasagiline - Increased risk of serotonin syndrome. Concomitant use should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB01367 .
ns1:DB00454_DB06210	dcterms:title	"DDI between Pethidine and Eltrombopag - Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB06210 .
ns1:DB00454_DB06274	dcterms:title	"DDI between Pethidine and Alvimopan - Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB06274 .
ns1:DB00454_DB06700	dcterms:title	"DDI between Pethidine and Desvenlafaxine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00454 ,
		ns3:DB06700 .
ns1:DB00455_DB00662	dcterms:title	"DDI between Loratadine and Trimethobenzamide - Trimethobenzamide and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00455 ,
		ns3:DB00662 .
ns1:DB00455_DB01149	dcterms:title	"DDI between Loratadine and Nefazodone - Increased risk of cardiotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00455 ,
		ns3:DB01149 .
ns1:DB00456_DB00479	dcterms:title	"DDI between Cefalotin and Amikacin - Increased risk of nephrotoxicity"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00456 ,
		ns3:DB00479 .
ns1:DB00457_DB00489	dcterms:title	"DDI between Prazosin and Sotalol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00489 .
ns1:DB00457_DB00521	dcterms:title	"DDI between Prazosin and Carteolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00521 .
ns1:DB00457_DB00571	dcterms:title	"DDI between Prazosin and Propranolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00571 .
ns1:DB00457_DB00598	dcterms:title	"DDI between Prazosin and Labetalol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00598 .
ns1:DB00457_DB00612	dcterms:title	"DDI between Prazosin and Bisoprolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00612 .
ns1:DB00457_DB00661	dcterms:title	"DDI between Prazosin and Verapamil - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00661 .
ns1:DB00457_DB00706	dcterms:title	"DDI between Prazosin and Tamsulosin - Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00706 .
ns1:DB00457_DB00820	dcterms:title	"DDI between Prazosin and Tadalafil - Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00820 .
ns1:DB00457_DB00862	dcterms:title	"DDI between Prazosin and Vardenafil - Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00862 ,
		ns3:DB00457 .
ns1:DB00457_DB00960	dcterms:title	"DDI between Prazosin and Pindolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB00960 .
ns1:DB00457_DB01136	dcterms:title	"DDI between Prazosin and Carvedilol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01136 .
ns1:DB00457_DB01193	dcterms:title	"DDI between Prazosin and Acebutolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01193 .
ns1:DB00457_DB01203	dcterms:title	"DDI between Prazosin and Nadolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01203 .
ns1:DB00457_DB01295	dcterms:title	"DDI between Prazosin and Bevantolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01295 .
ns1:DB00457_DB01297	dcterms:title	"DDI between Prazosin and Practolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01297 .
ns1:DB00457_DB01359	dcterms:title	"DDI between Prazosin and Penbutolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01359 .
ns1:DB00457_DB01580	dcterms:title	"DDI between Prazosin and Oxprenolol - Risk of hypotension at the beginning of therapy"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00457 ,
		ns3:DB01580 .
ns1:DB00457_DB06695	dcterms:title	"DDI between Prazosin and Dabigatran etexilate - P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB06695 ,
		ns3:DB00457 .
ns1:DB00458_DB00472	dcterms:title	"DDI between Imipramine and Fluoxetine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00472 .
ns1:DB00458_DB00476	dcterms:title	"DDI between Imipramine and Duloxetine - Possible increase in the levels of this agent when used with duloxetine"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00476 .
ns1:DB00458_DB00488	dcterms:title	"DDI between Imipramine and Altretamine - Risk of severe hypotension"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00488 .
ns1:DB00458_DB00501	dcterms:title	"DDI between Imipramine and Cimetidine - Cimetidine may increase the effect of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if cimetidine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00501 .
ns1:DB00458_DB00503	dcterms:title	"DDI between Imipramine and Ritonavir - Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00503 .
ns1:DB00458_DB00539	dcterms:title	"DDI between Imipramine and Toremifene - Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00539 .
ns1:DB00458_DB00564	dcterms:title	"DDI between Imipramine and Carbamazepine - Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00564 .
ns1:DB00458_DB00575	dcterms:title	"DDI between Imipramine and Clonidine - The tricyclic antidepressant, imipramine, decreases the effect of clonidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00575 .
ns1:DB00458_DB00582	dcterms:title	"DDI between Imipramine and Voriconazole - Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00582 .
ns1:DB00458_DB00604	dcterms:title	"DDI between Imipramine and Cisapride - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00604 .
ns1:DB00458_DB00610	dcterms:title	"DDI between Imipramine and Metaraminol - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00610 .
ns1:DB00458_DB00615	dcterms:title	"DDI between Imipramine and Rifabutin - The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00615 .
ns1:DB00458_DB00656	dcterms:title	"DDI between Imipramine and Trazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00656 .
ns1:DB00458_DB00662	dcterms:title	"DDI between Imipramine and Trimethobenzamide - Trimethobenzamide and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00662 .
ns1:DB00458_DB00668	dcterms:title	"DDI between Imipramine and Epinephrine - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of epinephrine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00668 .
ns1:DB00458_DB00674	dcterms:title	"DDI between Imipramine and Galantamine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00674 .
ns1:DB00458_DB00675	dcterms:title	"DDI between Imipramine and Tamoxifen - Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00675 .
ns1:DB00458_DB00679	dcterms:title	"DDI between Imipramine and Thioridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00679 .
ns1:DB00458_DB00706	dcterms:title	"DDI between Imipramine and Tamsulosin - Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00706 .
ns1:DB00458_DB00723	dcterms:title	"DDI between Imipramine and Methoxamine - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00723 .
ns1:DB00458_DB00726	dcterms:title	"DDI between Imipramine and Trimipramine - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00726 .
ns1:DB00458_DB00752	dcterms:title	"DDI between Imipramine and Tranylcypromine - Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00752 .
ns1:DB00458_DB00780	dcterms:title	"DDI between Imipramine and Phenelzine - Possibility of severe adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00780 .
ns1:DB00458_DB00816	dcterms:title	"DDI between Imipramine and Orciprenaline - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00816 .
ns1:DB00458_DB00841	dcterms:title	"DDI between Imipramine and Dobutamine - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00841 .
ns1:DB00458_DB00843	dcterms:title	"DDI between Imipramine and Donepezil - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00843 .
ns1:DB00458_DB00852	dcterms:title	"DDI between Imipramine and Pseudoephedrine - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pseudoephedrine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00852 ,
		ns3:DB00458 .
ns1:DB00458_DB00857	dcterms:title	"DDI between Imipramine and Terbinafine - Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if terbinafine is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00857 .
ns1:DB00458_DB00864	dcterms:title	"DDI between Imipramine and Tacrolimus - Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB00864 .
ns1:DB00458_DB00871	dcterms:title	"DDI between Imipramine and Terbutaline - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of terbutaline."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00871 ,
		ns3:DB00458 .
ns1:DB00458_DB00908	dcterms:title	"DDI between Imipramine and Quinidine - Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00908 ,
		ns3:DB00458 .
ns1:DB00458_DB00933	dcterms:title	"DDI between Imipramine and Mesoridazine - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00933 ,
		ns3:DB00458 .
ns1:DB00458_DB00988	dcterms:title	"DDI between Imipramine and Dopamine - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dopamine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00988 ,
		ns3:DB00458 .
ns1:DB00458_DB00989	dcterms:title	"DDI between Imipramine and Rivastigmine - Possible antagonism of action"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00989 ,
		ns3:DB00458 .
ns1:DB00458_DB01001	dcterms:title	"DDI between Imipramine and Salbutamol - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of salbutamol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01001 ,
		ns3:DB00458 .
ns1:DB00458_DB01026	dcterms:title	"DDI between Imipramine and Ketoconazole - Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB01026 .
ns1:DB00458_DB01045	dcterms:title	"DDI between Imipramine and Rifampicin - The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB01045 .
ns1:DB00458_DB01064	dcterms:title	"DDI between Imipramine and Isoprenaline - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of isoproterenol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01064 ,
		ns3:DB00458 .
ns1:DB00458_DB01072	dcterms:title	"DDI between Imipramine and Atazanavir - Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB01072 .
ns1:DB00458_DB01105	dcterms:title	"DDI between Imipramine and Sibutramine - Increased risk of CNS adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 ,
		ns3:DB01105 .
ns1:DB00458_DB01170	dcterms:title	"DDI between Imipramine and Guanethidine - The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01170 ,
		ns3:DB00458 .
ns1:DB00458_DB01171	dcterms:title	"DDI between Imipramine and Moclobemide - Possible severe adverse reaction with this combination"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01171 ,
		ns3:DB00458 .
ns1:DB00458_DB01208	dcterms:title	"DDI between Imipramine and Sparfloxacin - Increased risk of cardiotoxicity and arrhythmias"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01208 ,
		ns3:DB00458 .
ns1:DB00458_DB01247	dcterms:title	"DDI between Imipramine and Isocarboxazid - Possibility of severe adverse effects"@en ;
	ns2:Drug-Drug-Interaction	ns3:DB01247 ,
		ns3:DB00458 .
ns1:DB00458_DB01288	dcterms:title	"DDI between Imipramine and Fenoterol - The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of fenoterol."@en ;
	ns2:Drug-Drug-Interaction	ns3:DB00458 .